Tolerogenic Synthetic Nanocarriers

Abstract

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Description

RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 13/458,021, filed Apr. 27, 2012, pending, which claims the benefit under 35 U.S.C. .sctn.119 of U.S. provisional application 61/480,946, filed Apr. 29, 2011, 61/513,514, filed Jul. 29, 2011, 61/531,147, filed Sep. 6, 2011, 61/531,153, filed Sep. 6, 2011, 61/531,164, filed Sep. 6, 2011, 61/531,168, filed Sep. 6, 2011, 61/531,175, filed Sep. 6, 2011, 61/531,180, filed Sep. 6, 2011, 61/531,194, filed Sep. 6, 2011, 61/531,204, filed Sep. 6, 2011, 61/531,209, filed Sep. 6, 2011, and 61/531,215, filed Sep. 6, 2011, the entire contents of each of which are incorporated herein by reference.

FIELD OF THE INVENTION

[0002] This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressant that can provide antigen-specific immune suppression, preferably, tolerogenic immune responses.

BACKGROUND OF THE INVENTION

[0003] Conventional strategies for generating immunosuppression associated with an undesired immune response are based on broad-acting immunosuppressive drugs. Additionally, in order to maintain immunosuppression, immunosuppressant drug therapy is generally a life-long proposition. Unfortunately, the use of broad-acting immunosuppressants are associated with a risk of severe side effects, such as tumors, infections, nephrotoxicity and metabolic disorders. Accordingly, new immunosuppressant therapies would be beneficial.

SUMMARY OF THE INVENTION

[0004] In one aspect, a composition comprising (i) a first population of synthetic nanocarriers coupled to an immunosuppressant, and (ii) an APC presentable antigen are provided. In one embodiment, the immunosuppressant in the composition is in an amount effective to generate a tolerogenic immune response to the APC presentable antigen. In one embodiment, the APC presentable antigen is coupled to synthetic nanocarriers of the first population of synthetic nanocarriers. In another embodiment, the APC presentable antigen is coupled to synthetic nanocarriers of a second population of synthetic nanocarriers.

[0005] In one embodiment, the first population and the second population are the same.

[0006] In one embodiment, the mean of a particle size distribution obtained using dynamic light scattering of the synthetic nanocarriers of the first and/or second population is a diameter of greater than 100 nm. In another embodiment, the diameter is greater than 150 nm. In another embodiment, the diameter is greater than 200 nm. In another embodiment, the diameter is greater than 250 nm. In another embodiment, the diameter is greater than 300 nm.

[0007] In one embodiment, the immunosuppressant comprises a statin, an mTOR inhibitor, a TGF-.beta. signaling agent, a corticosteroid, an inhibitor of mitochondrial function, a P38 inhibitor, an NF-.kappa..beta. inhibitor, an adenosine receptor agonist, a prostaglandin E2 agonist, a phosphodiesterasse 4 inhibitor, an HDAC inhibitor or a proteasome inhibitor. In another embodiment, the mTOR inhibitor is rapamycin or an analog thereof.

[0008] In one embodiment, the APC presentable antigen comprises an MHC class I-restricted and/or MHC class II-restricted and/or a B cell epitope. In another embodiment, the APC presentable antigen is a protein. In another embodiment, the APC presentable antigen is a polypeptide or peptide comprising an MHC class I-restricted and/or MHC class II-restricted and/or a B cell epitope. In another embodiment, the APC presentable antigen is a lipid that binds to CD1d. In one embodiment, the APC presentable antigen is a therapeutic protein or portion thereof, an autoantigen or an allergen or is associated with an autoimmune disease, an inflammatory disease, an allergy, organ or tissue rejection or graft versus host disease.

[0009] In one embodiment, the load of the immunosuppressant and/or APC presentable antigen on average across the population of first and/or second synthetic nanocarriers is between 0.0001% and 50% (weight/weight). In another embodiment, the load of the immunosuppressant and/or APC presentable antigen on average across the population of first and/or second synthetic nanocarriers is between 0.1% and 10% (weight/weight).

[0010] In one embodiment, the synthetic nanocarriers of the first and/or second population of synthetic nanocarriers comprise lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles or peptide or protein particles.

[0011] In one embodiment, when the synthetic nanocarriers of the first and/or second population of synthetic nanocarriers comprise polymeric nanoparticles, the polymeric nanoparticles comprise polymer that is a non-methoxy-terminated, pluronic polymer. In another embodiment, the polymeric nanoparticles comprise a polyester, a polyester coupled to a polyether, polyamino acid, polycarbonate, polyacetal, polyketal, polysaccharide, polyethyloxazoline or polyethyleneimine. In another embodiment, the polyester comprises a poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) or polycaprolactone. In another embodiment, the polymeric nanoparticles comprise a polyester and a polyester coupled to a polyether. In another embodiment, the polyether comprises polyethylene glycol or polypropylene glycol.

[0012] In another embodiment, the aspect ratios of the synthetic nanocarriers of the first and/or second population of synthetic nanocarriers is greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7 or 1:10.

[0013] In another embodiment, the composition further comprises a pharmaceutically acceptable excipient.

[0014] In another aspect, a dosage form comprising any of the compositions provided is provided.

[0015] In another aspect, a method comprising administering any of the compositions or dosage forms provided herein to a subject is provided. In one embodiment, the subject is in need of antigen-specific tolerance. In another embodiment, the subject has an autoimmune disease, an inflammatory disease, an allergy, graft versus host disease, organ or tissue rejection or has undergone or will undergo transplantation. In another embodiment, the subject has received, is receiving or will receive a therapeutic protein against which they have experienced, are experiencing or are expected to experience an undesired immune response.

[0016] In another embodiment, any of the compositions or dosage forms provided may be in or administered in an amount effective to result in a tolerogenic immune response specific to the APC presentable antigen. In another embodiment, the dosage form is administered to the subject according to a protocol that was previously shown to result in a tolerogenic immune response specific to the APC presentable in one or more test subjects.

[0017] In another embodiment of any of the compositions or dosage forms provided, the composition may generate a desired immune response or reduce an undesired immune response, for example, in a subject.

[0018] In one embodiment, the method further comprises providing or identifying the subject. In another embodiment, the method further comprises assessing the generation of the tolerogenic immune response specific to the APC presentable antigen in the subject.

[0019] In one embodiment, the dosage form is administered by intravenous, transmucosal, intraperitoneal, oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular administration. In another embodiment, the administering is by inhalation or intravenous, subcutaneous or transmucosal administration.

[0020] In another aspect, any of the compositions or dosage forms provided may be for use in therapy or prophylaxis.

[0021] In another aspect, any of the compositions or dosage forms provided may be for use in therapy or prophylaxis in a subject who has undergone or will undergo transplantation, or has received, is receiving or will receive a therapeutic protein against which they have experienced, are experiencing or are expected to experience an undesired immune response.

[0022] In another aspect, any of the compositions or dosage forms provided may be for use in any of the methods provided.

[0023] In another aspect, any of the compositions or dosage forms provided may be for use in a method of inducing a tolerogenic immune response.

[0024] In another aspect, any of the compositions or dosage forms provided may be for use in a method of prophylaxis or treatment of an autoimmune disease, an inflammatory disease, an allergy, organ or tissue rejection, graft versus host disease or an undesired immune response.

[0025] In another aspect, any of the compositions or dosage forms provided may be for use in a method of therapy or prophylaxis comprising administration by any of the routes provided herein.

[0026] In another aspect, a use of any of the compositions or dosage forms provided for the manufacture of a medicament for use in any of the methods provided is provided.

[0027] In an embodiment of any of the compositions and methods provided herein, the antigens are peptides. Such antigens, in some embodiments, comprise at least an epitope as described anywhere herein but may also comprise additional amino acids that flank one or both ends of the epitope. In embodiments, the antigens comprise a whole antigenic protein. These antigens may be coupled to synthetic nanocarriers.

BRIEF DESCRIPTION OF THE FIGURES

[0028] FIG. 1 provides a representative example of a flow cytometric analysis of Treg cells.

[0029] FIG. 2 demonstrates the antigen-specific induction of FoxP3.sup.+ in CD4.sup.+CD25high Treg cells by tDC treated with nanocarrier encapsulated rapamycin plus free ovalbumin peptide (323-339).

[0030] FIG. 3 shows antigen-specific induction of FoxP3.sup.+ in CD4.sup.+CD25high Treg cells.

[0031] FIG. 4 shows an effect on the number of antigen-specific effector T cells and percentage of FoxP3+ cells with synthetic nanocarriers of the invention comprising immunosuppressant (rapamycin or simvastatin).

[0032] FIG. 5 shows a decrease in the number of popliteal lymph node cells with synthetic nanocarriers of the invention comprising immunosuppressant (rapamycin or simvastatin).

[0033] FIG. 6 demonstrates a reduction in CD69, a marker of T cell activation, with synthetic nanocarrier delivery of the immunosuppressant rapamycin.

DETAILED DESCRIPTION OF THE INVENTION

[0034] Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified materials or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting of the use of alternative terminology to describe the present invention.

[0035] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety for all purposes.

[0036] As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a polymer" includes a mixture of two or more such molecules or a mixture of differing molecular weights of a single polymer species, reference to "a synthetic nanocarrier" includes a mixture of two or more such synthetic nanocarriers or a plurality of such synthetic nanocarriers, reference to "a DNA molecule" includes a mixture of two or more such DNA molecules or a plurality of such DNA molecules, reference to "an immunosuppressant" includes a mixture of two or more such materials or a plurality of immunosuppressant molecules, and the like.

[0037] As used herein, the term "comprise" or variations thereof such as "comprises" or "comprising" are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein, the term "comprising" is inclusive and does not exclude additional, unrecited integers or method/process steps.

[0038] In embodiments of any of the compositions and methods provided herein, "comprising" may be replaced with "consisting essentially of" or "consisting of". The phrase "consisting essentially of" is used herein to require the specified integer(s) or steps as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term "consisting" is used to indicate the presence of the recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) alone.

A. INTRODUCTION

[0039] As previously mentioned, current conventional immunosuppressants are broad acting and generally result in an overall systemic down regulation of the immune system. The compositions and methods provided herein allow for more targeted immune effects by, for example, allowing for the targeted delivery to immune cells of interest. Thus, the compositions and methods can achieve immune suppression in a more directed manner. As shown in the Examples, compositions of the invention were used successfully to result in the generation of regulatory cells and to reduce T cell activation as evidenced by reduction of CD69.

[0040] The inventors have unexpectedly and surprisingly discovered that the problems and limitations noted above can be overcome by practicing the invention disclosed herein. In particular, the inventors have unexpectedly discovered that it is possible to provide compositions, and related methods, that provide immune suppression and, in some embodiments, antigen-specific tolerogenic effects. The compositions described herein are compositions that comprise 1) a population of synthetic nanocarriers to which an immunosuppressant is coupled and 2) an antigen presenting cell (APC) presentable antigen. The efficient uptake by APCs of such compositions is a convenient way in vivo and in vitro to shift the immune response in favor of immune suppressive effects (e.g., tolerogenic effects), such as regulatory T (Treg) cell development specific to the APC presentable antigen.

[0041] In one embodiment, the APC presentable antigen is coupled to the same synthetic nanocarriers to which the immunosuppressant is coupled. In another embodiment, the APC presentable antigen is coupled to different synthetic nanocarriers. In still another embodiment, the APC presentable antigen is not coupled to a synthetic nanocarrier. In another embodiment, the immunosuppressant in the composition is in an amount effective to generate a tolerogenic immune response to the APC presentable antigen.

[0042] In still another embodiment, the load of the immunosuppressant on average across the population of synthetic nanocarriers is between 0.0001% and 50% (weight/weight). In a further embodiment, the load of the APC presentable antigen on average across a population of synthetic nanocarriers is between 0.0001% and 50% (weight/weight). Preferably, in some embodiments, the load of the immunosuppressant on average across the population of synthetic nanocarriers is between 0.1% and 10% (weight/weight) and/or the load of the APC presentable antigen on average across a population of synthetic nanocarriers is between 0.1% and 10% (weight/weight).

[0043] In another aspect, dosage forms of any of the compositions herein are provided. Such dosage forms can be administered to a subject in need thereof, such as subjects in need of antigen-specific tolerance. In one embodiment, the subject is one that has or is at risk of having an autoimmune disease, an inflammatory disease, organ or tissue rejection, graft versus host disease or an allergy. In another embodiment, the subject is one that has undergone or will undergo transplantation. In still another embodiment, the subject is one that has been or will be treated with a therapeutic agent that stimulates an undesired immune response.

[0044] The invention will now be described in more detail below.

B. DEFINITIONS

[0045] "Administering" or "administration" means providing a material to a subject in a manner that is pharmacologically useful.

[0046] "Allergens" are any substances that can cause an undesired (e.g., a Type 1 hypersensitive) immune response (i.e., an allergic response or reaction) in a subject. Allergens include, but are not limited to, plant allergens (e.g., pollen, ragweed allergen), insect allergens, insect sting allergens (e.g., bee sting allergens), animal allergens (e.g., pet allergens, such as animal dander or cat Fel d 1 antigen), latex allergens, mold allergens, fungal allergens, cosmetic allergens, drug allergens, food allergens, dust, insect venom, viruses, bacteria, etc. Food allergens include, but are not limited to milk allergens, egg allergens, nut allergens (e.g., peanut or tree nut allergens, etc. (e.g., walnuts, cashews, etc.)), fish allergens, shellfish allergens, soy allergens, legume allergens, seed allergens and wheat allergens. Insect sting allergens include allergens that are or are associated with bee stings, wasp stings, hornet stings, yellow jacket stings, etc. Insect allergens also include house dust mite allergens (e.g., Der P1 antigen) and cockroach allergens. Drug allergens include allergens that are or are associated with antibiotics, NSAIDs, anaesthetics, etc. Pollen allergens include grass allergens, tree allergens, weed allergens, flower allergens, etc. Subjects that develop or are at risk of developing an undesired immune response to any of the allergens provided herein may be treated with any of the compositions and methods provided herein. Subjects that may be treated with any of the compositions and methods provided also include those who have or are at risk of having an allergy to any of the allergens provided.

[0047] An "allergy" also referred to herein as an "allergic condition," is any condition where there is an undesired (e.g., a Type 1 hypersensitive) immune response (i.e., allergic response or reaction) to a substance. Such substances are referred to herein as allergens. Allergies or allergic conditions include, but are not limited to, allergic asthma, hay fever, hives, eczema, plant allergies, bee sting allergies, pet allergies, latex allergies, mold allergies, cosmetic allergies, food allergies, allergic rhinitis or coryza, topic allergic reactions, anaphylaxis, atopic dermatitis, hypersensitivity reactions and other allergic conditions. The allergic reaction may be the result of an immune reaction to any allergen. In some embodiments, the allergy is a food allergy. Food allergies include, but are not limited to, milk allergies, egg allergies, nut allergies, fish allergies, shellfish allergies, soy allergies or wheat allergies.

[0048] "Amount effective" in the context of a composition or dosage form for administration to a subject refers to an amount of the composition or dosage form that produces one or more desired immune responses in the subject, for example, the generation of a tolerogenic immune response. Therefore, in some embodiments, an amount effective is any amount of a composition provided herein that produces one or more of these desired immune responses. This amount can be for in vitro or in vivo purposes. For in vivo purposes, the amount can be one that a clinician would believe may have a clinical benefit for a subject in need of antigen-specific tolerization. Such subjects include those that have or are at risk of having an inflammatory disease, an autoimmune disease, an allergy, organ or tissue rejection or graft versus host disease. Such subjects also include those that have undergone or will undergo transplantation. Such subjects further include those that have experienced, are experiencing or are expected to experience an undesired immune response against a therapeutic protein.

[0049] Amounts effective can involve only reducing the level of an undesired immune response, although in some embodiments, it involves preventing an undesired immune response altogether. Amounts effective can also involve delaying the occurrence of an undesired immune response. An amount that is effective can also be an amount of a composition provided herein that produces a desired therapeutic endpoint or a desired therapeutic result. Amounts effective, preferably, result in a tolerogenic immune response in a subject to an antigen. The achievement of any of the foregoing can be monitored by routine methods.

[0050] In some embodiments of any of the compositions and methods provided, the amount effective is one in which the desired immune response persists in the subject for at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 9 months, at least 1 year, at least 2 years, at least 5 years, or longer. In other embodiments of any of the compositions and methods provided, the amount effective is one which produces a measurable desired immune response, for example, a measurable decrease in an immune response (e.g., to a specific antigen), for at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 9 months, at least 1 year, at least 2 years, at least 5 years, or longer.

[0051] Amounts effective will depend, of course, on the particular subject being treated; the severity of a condition, disease or disorder; the individual patient parameters including age, physical condition, size and weight; the duration of the treatment; the nature of concurrent therapy (if any); the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reason.

[0052] In general, doses of the immunosuppressants and/or antigens in the compositions of the invention can range from about 10 .mu.g/kg to about 100,000 .mu.g/kg. In some embodiments, the doses can range from about 0.1 mg/kg to about 100 mg/kg. In still other embodiments, the doses can range from about 0.1 mg/kg to about 25 mg/kg, about 25 mg/kg to about 50 mg/kg, about 50 mg/kg to about 75 mg/kg or about 75 mg/kg to about 100 mg/kg. Alternatively, the dose can be administered based on the number of synthetic nanocarriers that provide the desired amount of immunosuppressants and/or antigens. For example, useful doses include greater than 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9 or 10.sup.10 synthetic nanocarriers per dose. Other examples of useful doses include from about 1.times.10.sup.6 to about 1.times.10.sup.10, about 1.times.10.sup.7 to about 1.times.10.sup.9 or about 1.times.10.sup.8 to about 1.times.10.sup.9 synthetic nanocarriers per dose.

[0053] "Antigen" means a B cell antigen or T cell antigen. "Type(s) of antigens" means molecules that share the same, or substantially the same, antigenic characteristics. In some embodiments, antigens may be proteins, polypeptides, peptides, lipoproteins, glycolipids, polynucleotides, polysaccharides or are contained or expressed in cells. In some embodiments, such as when the antigens are not well defined or characterized, the antigens may be contained within a cell or tissue preparation, cell debris, cell exosomes, conditioned media, etc. An antigen can be combined with the synthetic nanocarriers in the same form as what a subject is exposed to that causes an undesired immune response but may also be a fragment or derivative thereof. When a fragment or derivative, however, a desired immune response to the form encountered by such a subject is the preferable result with the compositions and methods provided.

[0054] "Antigen-specific" refers to any immune response that results from the presence of the antigen, or portion thereof, or that generates molecules that specifically recognize or bind the antigen. For example, where the immune response is antigen-specific antibody production, antibodies are produced that specifically bind the antigen. As another example, where the immune response is antigen-specific B cell or T cell proliferation and/or activity, the proliferation and/or activity results from recognition of the antigen, or portion thereof, alone or in complex with MHC molecules, by B cells, etc.

[0055] "Antigens associated" with a disease, disorder or condition provided herein are antigens that can generate an undesired immune response against, as a result of, or in conjunction with the disease, disorder or condition; the cause of the disease, disorder or condition (or a symptom or effect thereof); and/or can generate an undesired immune response that is a symptom, result or effect of the disease, disorder or condition. Preferably, in some embodiments, the use of an antigen associated with a disease, disorder or condition, etc. in the compositions and methods provided herein will lead to a tolerogenic immune response against the antigen and/or the cells, by, on or in which the antigen is expressed. The antigens can be in the same form as expressed in a subject with the disease, disorder or condition but may also be a fragment or derivative thereof. When a fragment or derivative, however, a desired immune response to the form expressed in such a subject is the preferable result with the compositions and methods provided. The antigens associated with a disease, disorder or condition, etc. in some embodiments, comprise MHC Class I-restricted epitopes and/or MHC Class II-restricted epitopes and/or B cell epitopes and/or comprise a lipid that binds to and forms a CD1d complex.

[0056] In one embodiment, the antigen is an antigen associated with an inflammatory disease, autoimmune disease, organ or tissue rejection or graft versus host disease. Such antigens include autoantigens, such as myelin basic protein, collagen (e.g., collagen type 11), human cartilage gp 39, chromogranin A, gp130-RAPS, proteolipid protein, fibrillarin, nuclear proteins, nucleolar proteins (e.g., small nucleolar protein), thyroid stimulating factor receptor, histones, glycoprotein gp 70, ribosomal proteins, pyruvate dehydrogenase dehydrolipoamide acetyltransferase, hair follicle antigens, human tropomyosin isoform 5, mitochondrial proteins, pancreatic .beta.-cell proteins, myelin oligodendrocyte glycoprotein, insulin, glutamic acid decarboxylase (GAD), gluten, and fragments or derivatives thereof. Other autoantigens are provided in Table 1 below.

[0057] Antigens also include those associated with organ or tissue rejection. Examples of such antigens include, but are not limited to, antigens from allogeneic cells, e.g., antigens from an allogeneic cell extract and antigens from other cells, such as endothelial cell antigens.

[0058] Antigens also include those associated with an allergy. Such antigens include the allergens described elsewhere herein.

[0059] Antigens also include those associated with a transplantable graft. Such antigens are associated with a transplantable graft, or an undesired immune response in a recipient of a transplantable graft that is generated as a result of the introduction of the transplantable graft in the recipient, that can be presented for recognition by cells of the immune system and that can generate an undesired immune response. Transplant antigens include those associated with organ or tissue rejection or graft versus host disease. Transplant antigens may be obtained or derived from cells of a biological material or from information related to a transplantable graft. Transplant antigens generally include proteins, polypeptides, peptides, lipoproteins, glycolipids, polynucleotides or are contained or expressed in cells. Information related to a transplantable graft is any information about a transplantable graft that can be used to obtain or derive transplant antigens. Such information includes information about antigens that would be expected to be present in or on cells of a transplantable graft such as, for example, sequence information, types or classes of antigens and/or their MHC Class I, MHC Class II or B cell presentation restrictions. Such information may also include information about the type of transplantable graft (e.g., autograft, allograft, xenograft), the molecular and cellular composition of the graft, the bodily location from which the graft is derived or to which the graft is to be transplanted (e.g., whole or partial organ, skin, bone, nerves, tendon, neurons, blood vessels, fat, cornea, etc.).

[0060] Antigens also include antigens associated with a therapeutic protein that can be presented for recognition by cells of the immune system and that can generate an undesired immune response against the therapeutic protein. Therapeutic protein antigens generally include proteins, polypeptides, peptides, lipoproteins, or are contained or expressed in, by or on cells.

[0061] Antigens, can be antigens that are fully defined or characterized. However, in some embodiments, an antigen is not fully defined or characterized. Antigens, therefore, also include those that are contained within a cell or tissue preparation, cell debris, cell exosome or conditioned media and can be delivered in such form in some embodiments.

[0062] "APC presentable antigen" means an antigen that can be presented for recognition by cells of the immune system, such as presented by antigen presenting cells, including but not limited to dendritic cells, B cells or macrophages. The APC presentable antigen can be presented for recognition by, for example, T cells. Such antigens may be recognized by and trigger an immune response in a T cell via presentation of the antigen or portion thereof bound to a Class I or Class II major histocompatability complex molecule (MHC), or bound to a CD1d molecule. CD1d is an antigen-presenting molecule that binds self and foreign lipids and glycolipids, and is often found on antigen presenting cells. It is also found on non-hematopoietic cells such as hepatocytes. CD1d contains a hydrophobic groove which binds hydrophobic lipids, usually for presentation to iNKT cells. Preferably, one or more tolerogenic immune responses specific to the APC presentable antigen results with the compositions provided herein. Such immune responses can be affected, for example, via the stimulation, production, induction or recruitment of regulatory cells, such as CD4.sup.+ Treg cells and/or CD8.sup.+ Treg cells.

[0063] APC presentable antigens generally include peptides, polypeptides, whole proteins or whole cell lysates. In one embodiment, the APC presentable antigen comprises an MHC class I-restricted epitope. In another embodiment, the APC presentable antigen comprises an MHC class II-restricted epitope. In another embodiment, the APC presentable antigen comprises a B cell epitope. In another embodiment, however, the APC presentable antigen is a lipid that binds to or forms a CD1d complex.

[0064] In further embodiments, the APC presentable antigens in the inventive compositions are provided in the form of a nucleic acid that encodes the peptide, polypeptide or protein. The nucleic acid may be DNA or RNA, such as mRNA. In embodiments, the inventive compositions comprise a complement, such as a full-length complement, or a degenerate (due to degeneracy of the genetic code) of any of the nucleic acids provided herein. In embodiments, the nucleic acid is an expression vector that can be transcribed when transfected into a cell line. In embodiments, the expression vector may comprise a plasmid, retrovirus, or an adenovirus amongst others.

[0065] In one embodiment, the antigen is associated with a disease, disorder or condition described herein and can in combination with an immunosuppressant lead to a tolerogenic immune response specific to the disease, disorder or condition.

[0066] "Assessing an immune response" refers to any measurement or determination of the level, presence or absence, reduction, increase in, etc. of an immune response in vitro or in vivo. Such measurements or determinations may be performed on one or more samples obtained from a subject. Such assessing can be performed with any of the methods provided herein or otherwise known in the art.

[0067] An "at risk" subject is one in which a health practitioner believes has a chance of having a disease, disorder or condition as provided herein or is one a health practitioner believes has a chance of experiencing an undesired immune response as provided herein.

[0068] An "autoimmune disease" is any disease where the immune system mounts an undesired immune response against self (e.g., one or more autoantigens). In some embodiments, an autoimmune disease comprises an aberrant destruction of cells of the body as part of the self-targeted immune response. In some embodiments, the destruction of self manifests in the malfunction of an organ, for example, the colon or pancreas. Examples of autoimmune diseases are described elsewhere herein. Additional autoimmune diseases will be known to those of skill in the art and the invention is not limited in this respect.

[0069] "Average", as used herein, refers to the arithmetic mean unless otherwise noted.

[0070] "B cell antigen" means any antigen that triggers an immune response in a B cell (e.g., an antigen that is specifically recognized by a B cell or a receptor thereon). In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other embodiments, the T cell antigen is not also a B cell antigen. B cell antigens include, but are not limited to proteins, peptides, small molecules, and carbohydrates. In some embodiments, the B cell antigen comprises a non-protein antigen (i.e., not a protein or peptide antigen). In some embodiments, the B cell antigen comprises a autoantigen. In other embodiments, the B cell antigen is obtained or derived from an allergen, autoantigen, therapeutic protein, or transplantable graft.

[0071] "Concomitantly" means administering two or more substances to a subject in a manner that is correlated in time, preferably sufficiently correlated in time so as to provide a modulation in an immune response. In embodiments, concomitant administration may occur through administration of two or more substances in the same dosage form. In other embodiments, concomitant administration may encompass administration of two or more substances in different dosage forms, but within a specified period of time, preferably within 1 month, more preferably within 1 week, still more preferably within 1 day, and even more preferably within 1 hour.

[0072] "Couple" or "Coupled" or "Couples" (and the like) means to chemically associate one entity (for example a moiety) with another. In some embodiments, the coupling is covalent, meaning that the coupling occurs in the context of the presence of a covalent bond between the two entities. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. In embodiments, encapsulation is a form of coupling.

[0073] "Dosage form" means a pharmacologically and/or immunologically active material in a medium, carrier, vehicle, or device suitable for administration to a subject.

[0074] "Encapsulate" means to enclose at least a portion of a substance within a synthetic nanocarrier. In some embodiments, a substance is enclosed completely within a synthetic nanocarrier. In other embodiments, most or all of a substance that is encapsulated is not exposed to the local environment external to the synthetic nanocarrier. In other embodiments, no more than 50%, 40%, 30%, 20%, 10% or 5% (weight/weight) is exposed to the local environment. Encapsulation is distinct from absorption, which places most or all of a substance on a surface of a synthetic nanocarrier, and leaves the substance exposed to the local environment external to the synthetic nanocarrier.

[0075] "Epitope", also known as an antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by, for example, antibodies, B cells, or T cells. As used herein, "MHC Class I-restricted epitopes" are epitopes that are presented to immune cells by MHC class I molecules found on nucleated cells. "MHC Class II-restricted epitopes" are epitopes that are presented to immune cells by MHC class II molecules found on antigen presenting cells (APCs), for example, on professional antigen-presenting immune cells, such as on macrophages, B cells, and dendritic cells, or on non-hematopoietic cells, such as hepatocytes. "B cell epitopes" are molecular structures that are recognized by antibodies or B cells. In some embodiments, the epitope itself is an antigen.

[0076] A number of epitopes are known to those of skill in the art, and exemplary epitopes suitable according to some aspects of this invention include, but are not limited to those listed in the Immune Epitope Database (www.immuneepitope.org, Vita R, Zarebski L, Greenbaum J A, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B. The immune epitope database 2.0. Nucleic Acids Res. 2010 January; 38 (Database issue):D854-62; the entire contents of which as well as all database entries of IEDB version 2.4, August 2011, and particularly all epitopes disclosed therein, are incorporated herein by reference). Epitopes can also be identified with publicly available algorithms, for example, the algorithms described in Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. 2010. peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010, 11:568; Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4(4):e1000048; Nielsen M, Lund O. 2009. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 10:296; Nielsen M, Lundegaard C, Lund O. 2007. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 8:238; Bui H H, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton K A, Motile B R, Chisari F V, Watkins D I, Sette A. 2005. Immunogenetics. 57:304-314; Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti M P, Sinigaglia F, Hammer J. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 17(6):555-561; Nielsen M, Lundegaard C, Worning P, Lauemoller S L, Lamberth K, Buus S, Brunak S, Lund O. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12:1007-1017; Bui H H, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton K A, Mothe B R, Chisari F V, Watkins D I, Sette A. 2005. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57:304-314; Peters B, Sette A. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6:132; Chou P Y, Fasman G D. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 47:45-148; Emini E A, Hughes J V, Perlow D S, Boger J. 1985. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55:836-839; Karplus P A, Schulz G E. 1985. Prediction of chain flexibility in proteins. Naturwissenschaften 72:212-213; Kolaskar A S, Tongaonkar P C. 1990. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276:172-174; Parker J M, Guo D, Hodges R S. 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425-5432; Larsen J E, Lund O, Nielsen M. 2006. Improved method for predicting linear B-cell epitopes. Immunome Res 2:2; Ponomarenko J V, Bourne P E. 2007. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol 7:64; Haste Andersen P, Nielsen M, Lund O. 2006. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 15:2558-2567; Ponomarenko J V, Bui H, Li W, Fusseder N, Bourne P E, Sette A, Peters B. 2008. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 9:514; Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, Buus S, and Lund O. 2008. PLoS Comput Biol. 4(7)e1000107. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan; the entire contents of each of which are incorporated herein by reference for disclosure of methods and algorithms for the identification of epitopes.

[0077] Other examples of epitopes that can be coupled to synthetic nanocarriers provided herein include any of the MHC Class I-restricted, MHC Class II-restricted and B cell epitopes as provided as SEQ ID NOs: 1-943. Without wishing to being bound by any particular theory, MHC Class I-restricted epitopes include those set forth in SEQ ID NOs: 1-186, MHC Class II-restricted epitopes include those set forth in SEQ ID NOs: 187-537, and B cell epitopes include those set forth in SEQ ID NOs: 538-943. These epitopes include MHC Class I-restricted autoantigens, MHC Class II-restricted epitopes of allergens and B cell epitopes of autoantigens and allergens.

[0078] "Generating" means causing an action, such as an immune response (e.g., a tolerogenic immune response) to occur, either directly oneself or indirectly, such as, but not limited to, an unrelated third party that takes an action through reliance on one's words or deeds.

[0079] "Identifying" is any action or set of actions that allows a clinician to recognize a subject as one who may benefit from the methods and compositions provided herein. Preferably, the identified subject is one who is in need of a tolerogenic immune response as provided herein. The action or set of actions may be either directly oneself or indirectly, such as, but not limited to, an unrelated third party that takes an action through reliance on one's words or deeds.

[0080] "Immunosuppressant" means a compound that causes an APC to have an immunosuppressive (e.g., tolerogenic effect). An immunosuppressive effect generally refers to the production or expression of cytokines or other factors by the APC that reduces, inhibits or prevents an undesired immune response or that promotes a desired immune response. When the APC results in an immunosuppressive effect on immune cells that recognize an antigen presented by the APC, the immunosuppressive effect is said to be specific to the presented antigen. Such effect is also referred to herein as a tolerogenic effect. Without being bound by any particular theory, it is thought that the immunosuppressive is a result of the immunosuppressant being delivered to the APC, preferably in the presence of an antigen (e.g., an administered antigen or one that is already present in vivo). Accordingly, the immunosuppressant includes compounds that provide a tolerogenic immune response to an antigen that may or may not be provided in the same composition or a different composition. In one embodiment, the immunosuppressant is one that causes an APC to promote a regulatory phenotype in one or more immune effector cells. For example, the regulatory phenotype may be characterized by the production, induction, stimulation or recruitment of regulatory immune cells. This may be the result of the conversion of CD4+ T cells (e.g., CD4+CD25highFoxP3+ Treg cells) to a regulatory phenotype. This may also be the result of induction of FoxP3 in other immune cells, such as CD8+ T cells, macrophages and iNKT cells. In one embodiment, the immunosuppressant is one that affects the response of the APC after it processes an antigen. In another embodiment, the immunosuppressant is not one that interferes with the processing of the antigen. In a further embodiment, the immunosuppressant is not an apoptotic-signaling molecule. In another embodiment, the immunosuppressant is not a phospholipid.

[0081] Immunosuppressants include, but are not limited to, statins; mTOR inhibitors, such as rapamycin or a rapamycin analog; TGF-.beta. signaling agents; TGF-.beta. receptor agonists; histone deacetylase inhibitors, such as Trichostatin A; corticosteroids; inhibitors of mitochondrial function, such as rotenone; P38 inhibitors; NF-.kappa..beta. inhibitors, such as 6Bio, Dexamethasone, TCPA-1, IKK VII; adenosine receptor agonists; prostaglandin E2 agonists (PGE2), such as Misoprostol; phosphodiesterase inhibitors, such as phosphodiesterase 4 inhibitor (PDE4), such as Rolipram; proteasome inhibitors; kinase inhibitors; G-protein coupled receptor agonists; G-protein coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors; PI3 KB inhibitors, such as TGX-221; autophagy inhibitors, such as 3-Methyladenine; aryl hydrocarbon receptor inhibitors; proteasome inhibitor I (PSI); and oxidized ATPs, such as P2X receptor blockers. Immunosuppressants also include IDO, vitamin D3, cyclosporins, such as cyclosporine A, aryl hydrocarbon receptor inhibitors, resveratrol, azathiopurine (Aza), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), FK506, sanglifehrin A, salmeterol, mycophenolate mofetil (MMF), aspirin and other COX inhibitors, niflumic acid, estriol and triptolide. In embodiments, the immunosuppressant may comprise any of the agents provided herein.

[0082] The immunosuppressant can be a compound that directly provides the immunosuppressive (e.g., tolerogenic) effect on APCs or it can be a compound that provides the immunosuppressive (e.g., tolerogenic) effect indirectly (i.e., after being processed in some way after administration). Immunosuppressants, therefore, include prodrug forms of any of the compounds provided herein.

[0083] Immunosuppressants also include nucleic acids that encode the peptides, polypeptides or proteins provided herein that result in an immunosuppressive (e.g., tolerogenic) immune response. In embodiments, therefore, the immunosuppressant is a nucleic acid that encodes a peptide, polypeptide or protein that results in an immunosuppressive (e.g., tolerogenic) immune response, and it is the nucleic acid that is coupled to the synthetic nanocarrier.

[0084] The nucleic acid may be DNA or RNA, such as mRNA. In embodiments, the inventive compositions comprise a complement, such as a full-length complement, or a degenerate (due to degeneracy of the genetic code) of any of the nucleic acids provided herein. In embodiments, the nucleic acid is an expression vector that can be transcribed when transfected into a cell line. In embodiments, the expression vector may comprise a plasmid, retrovirus, or an adenovirus amongst others. Nucleic acids can be isolated or synthesized using standard molecular biology approaches, for example by using a polymerase chain reaction to produce a nucleic acid fragment, which is then purified and cloned into an expression vector. Additional techniques useful in the practice of this invention may be found in Current Protocols in Molecular Biology 2007 by John Wiley and Sons, Inc.; Molecular Cloning: A Laboratory Manual (Third Edition) Joseph Sambrook, Peter MacCallum Cancer Institute, Melbourne, Australia; David Russell, University of Texas Southwestern Medical Center, Dallas, Cold Spring Harbor.

[0085] In embodiments, the immunosuppressants provided herein are coupled to synthetic nanocarriers. In preferable embodiments, the immunosuppressant is an element that is in addition to the material that makes up the structure of the synthetic nanocarrier. For example, in one embodiment, where the synthetic nanocarrier is made up of one or more polymers, the immunosuppressant is a compound that is in addition and coupled to the one or more polymers. As another example, in one embodiment, where the synthetic nanocarrier is made up of one or more lipids, the immunosuppressant is again in addition and coupled to the one or more lipids. In embodiments, such as where the material of the synthetic nanocarrier also results in an immunosuppressive (e.g., tolerogenic) effect, the immunosuppressant is an element present in addition to the material of the synthetic nanocarrier that results in an immunosuppressive (e.g., tolerogenic) effect.

[0086] Other exemplary immunosuppressants include, but are not limited, small molecule drugs, natural products, antibodies (e.g., antibodies against CD20, CD3, CD4), biologics-based drugs, carbohydrate-based drugs, nanoparticles, liposomes, RNAi, antisense nucleic acids, aptamers, methotrexate, NSAIDs; fingolimod; natalizumab; alemtuzumab; anti-CD3; tacrolimus (FK506), etc. Further immunosuppressants, are known to those of skill in the art, and the invention is not limited in this respect.

[0087] "Inflammatory disease" means any disease, disorder or condition in which undesired inflammation occurs.

[0088] "Load" of the immunosuppressant or antigen is the amount of the immunosuppressant or antigen coupled to a synthetic nanocarrier based on the total weight of materials in an entire synthetic nanocarrier (weight/weight). Generally, the load is calculated as an average across a population of synthetic nanocarriers. In one embodiment, the load of the immunosuppressant on average across the first population of synthetic nanocarriers is between 0.0001% and 50%. In another embodiment, the load of the antigen on average across the first and/or second population of synthetic nanocarriers is between 0.0001% and 50%. In yet another embodiment, the load of the immunosuppressant and/or antigen is between 0.01% and 20%. In a further embodiment, the load of the immunosuppressant and/or antigen is between 0.1% and 10%. In still a further embodiment, the load of the immunosuppressant and/or antigen is between 1% and 10%. In yet another embodiment, the load of the immunosuppressant and/or the antigen is at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19% or at least 20% on average across a population of synthetic nanocarriers. In yet a further embodiment, the load of the immunosuppressant and/or the antigen is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% on average across a population of synthetic nanocarriers. In some embodiments of the above embodiments, the load of the immunosuppressant and/or the antigen is no more than 25% on average across a population of synthetic nanocarriers. In embodiments, the load is calculated as described in the Examples.

[0089] In embodiments of any of the compositions and methods provided, the load is calculated as follows: Approximately 3 mg of synthetic nanocarriers are collected and centrifuged to separate supernatant from synthetic nanocarrier pellet. Acetonitrile is added to the pellet, and the sample is sonicated and centrifuged to remove any insoluble material. The supernatant and pellet are injected on RP-HPLC and absorbance is read at 278 nm. The .mu.g found in the pellet is used to calculate % entrapped (load), .mu.g in supernatant and pellet are used to calculate total .mu.g recovered.

[0090] "Maintenance dose" refers to a dose that is administered to a subject, after an initial dose has resulted in an immunosuppressive (e.g., tolerogenic) response in a subject, to sustain a desired immunosuppressive (e.g., tolerogenic) response. A maintenance dose, for example, can be one that maintains the tolerogenic effect achieved after the initial dose, prevents an undesired immune response in the subject, or prevents the subject becoming a subject at risk of experiencing an undesired immune response, including an undesired level of an immune response. In some embodiments, the maintenance dose is one that is sufficient to sustain an appropriate level of a desired immune response.

[0091] "Maximum dimension of a synthetic nanocarrier" means the largest dimension of a nanocarrier measured along any axis of the synthetic nanocarrier. "Minimum dimension of a synthetic nanocarrier" means the smallest dimension of a synthetic nanocarrier measured along any axis of the synthetic nanocarrier. For example, for a spheroidal synthetic nanocarrier, the maximum and minimum dimension of a synthetic nanocarrier would be substantially identical, and would be the size of its diameter. Similarly, for a cuboidal synthetic nanocarrier, the minimum dimension of a synthetic nanocarrier would be the smallest of its height, width or length, while the maximum dimension of a synthetic nanocarrier would be the largest of its height, width or length. In an embodiment, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or greater than 100 nm. In an embodiment, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or less than 5 nm. Preferably, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is greater than 110 nm, more preferably greater than 120 nm, more preferably greater than 130 nm, and more preferably still greater than 150 nm. Aspects ratios of the maximum and minimum dimensions of inventive synthetic nanocarriers may vary depending on the embodiment. For instance, aspect ratios of the maximum to minimum dimensions of the synthetic nanocarriers may vary from 1:1 to 1,000,000:1, preferably from 1:1 to 100,000:1, more preferably from 1:1 to 10,000:1, more preferably from 1:1 to 1000:1, still more preferably from 1:1 to 100:1, and yet more preferably from 1:1 to 10:1. Preferably, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample is equal to or less than 3 .mu.m, more preferably equal to or less than 2 .mu.m, more preferably equal to or less than 1 .mu.m, more preferably equal to or less than 800 nm, more preferably equal to or less than 600 nm, and more preferably still equal to or less than 500 nm. In preferred embodiments, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or greater than 100 nm, more preferably equal to or greater than 120 nm, more preferably equal to or greater than 130 nm, more preferably equal to or greater than 140 nm, and more preferably still equal to or greater than 150 nm. Measurement of synthetic nanocarrier dimensions (e.g., diameter) is obtained by suspending the synthetic nanocarriers in a liquid (usually aqueous) media and using dynamic light scattering (DLS) (e.g. using a Brookhaven ZetaPALS instrument). For example, a suspension of synthetic nanocarriers can be diluted from an aqueous buffer into purified water to achieve a final synthetic nanocarrier suspension concentration of approximately 0.01 to 0.1 mg/mL. The diluted suspension may be prepared directly inside, or transferred to, a suitable cuvette for DLS analysis. The cuvette may then be placed in the DLS, allowed to equilibrate to the controlled temperature, and then scanned for sufficient time to acquire a stable and reproducible distribution based on appropriate inputs for viscosity of the medium and refractive indices of the sample. The effective diameter, or mean of the distribution, is then reported. "Dimension" or "size" or "diameter" of synthetic nanocarriers means the mean of a particle size distribution obtained using dynamic light scattering.

[0092] "MHC" refers to major histocompatibility complex, a large genomic region or gene family found in most vertebrates that encodes MHC molecules that display fragments or epitopes of processed proteins on the cell surface. The presentation of MHC:peptide on cell surfaces allows for surveillance by immune cells, usually a T cell. There are two general classes of MHC molecules: Class I and Class II. Generally, Class I MHC molecules are found on nucleated cells and present peptides to cytotoxic T cells. Class II MHC molecules are found on certain immune cells, chiefly macrophages, B cells and dendritic cells, collectively known as professional APCs. The best-known genes in the MHC region are the subset that encodes antigen-presenting proteins on the cell surface. In humans, these genes are referred to as human leukocyte antigen (HLA) genes.

[0093] "Non-methoxy-terminated polymer" means a polymer that has at least one terminus that ends with a moiety other than methoxy. In some embodiments, the polymer has at least two termini that ends with a moiety other than methoxy. In other embodiments, the polymer has no termini that ends with methoxy. "Non-methoxy-terminated, pluronic polymer" means a polymer other than a linear pluronic polymer with methoxy at both termini. Polymeric nanoparticles as provided herein can comprise non-methoxy-terminated polymers or non-methoxy-terminated, pluronic polymers.

[0094] "Pharmaceutically acceptable excipient" means a pharmacologically inactive material used together with the recited synthetic nanocarriers to formulate the inventive compositions. Pharmaceutically acceptable excipients comprise a variety of materials known in the art, including but not limited to saccharides (such as glucose, lactose, and the like), preservatives such as antimicrobial agents, reconstitution aids, colorants, saline (such as phosphate buffered saline), and buffers.

[0095] "Protocol" refers to any dosing regimen of one or more substances to a subject. A dosing regimen may include the amount, frequency and/or mode of administration. In some embodiments, such a protocol may be used to administer one or more compositions of the invention to one or more test subjects. Immune responses in these test subject can then be assessed to determine whether or not the protocol was effective in reducing an undesired immune response or generating a desired immune response (e.g., the promotion of a tolerogenic effect). Any other therapeutic and/or prophylactic effect may also be assessed instead of or in addition to the aforementioned immune responses. Whether or not a protocol had a desired effect can be determined using any of the methods provided herein or otherwise known in the art. For example, a population of cells may be obtained from a subject to which a composition provided herein has been administered according to a specific protocol in order to determine whether or not specific immune cells, cytokines, antibodies, etc. were reduced, generated, activated, etc. Useful methods for detecting the presence and/or number of immune cells include, but are not limited to, flow cytometric methods (e.g., FACS) and immunohistochemistry methods. Antibodies and other binding agents for specific staining of immune cell markers, are commercially available. Such kits typically include staining reagents for multiple antigens that allow for FACS-based detection, separation and/or quantitation of a desired cell population from a heterogeneous population of cells.

[0096] "Providing a subject" is any action or set of actions that causes a clinician to come in contact with a subject and administer a composition provided herein thereto or to perform a method provided herein thereupon. Preferably, the subject is one who is in need of a tolerogenic immune response as provided herein. The action or set of actions may be either directly oneself or indirectly, such as, but not limited to, an unrelated third party that takes an action through reliance on one's words or deeds.

[0097] "Subject" means animals, including warm blooded mammals such as humans and primates; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish; reptiles; zoo and wild animals; and the like.

[0098] "Synthetic nanocarrier(s)" means a discrete object that is not found in nature, and that possesses at least one dimension that is less than or equal to 5 microns in size. Albumin nanoparticles are generally included as synthetic nanocarriers, however in certain embodiments the synthetic nanocarriers do not comprise albumin nanoparticles. In embodiments, inventive synthetic nanocarriers do not comprise chitosan. In other embodiments, inventive synthetic nanocarriers are not lipid-based nanoparticles. In further embodiments, inventive synthetic nanocarriers do not comprise a phospholipid.

[0099] A synthetic nanocarrier can be, but is not limited to, one or a plurality of lipid-based nanoparticles (also referred to herein as lipid nanoparticles, i.e., nanoparticles where the majority of the material that makes up their structure are lipids), polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles (i.e., particles that are primarily made up of viral structural proteins but that are not infectious or have low infectivity), peptide or protein-based particles (also referred to herein as protein particles, i.e., particles where the majority of the material that makes up their structure are peptides or proteins) (such as albumin nanoparticles) and/or nanoparticles that are developed using a combination of nanomaterials such as lipid-polymer nanoparticles. Synthetic nanocarriers may be a variety of different shapes, including but not limited to spheroidal, cuboidal, pyramidal, oblong, cylindrical, toroidal, and the like. Synthetic nanocarriers according to the invention comprise one or more surfaces. Exemplary synthetic nanocarriers that can be adapted for use in the practice of the present invention comprise: (1) the biodegradable nanoparticles disclosed in U.S. Pat. No. 5,543,158 to Gref et al., (2) the polymeric nanoparticles of Published US Patent Application 20060002852 to Saltzman et al., (3) the lithographically constructed nanoparticles of Published US Patent Application 20090028910 to DeSimone et al., (4) the disclosure of WO 2009/051837 to von Andrian et al., (5) the nanoparticles disclosed in Published US Patent Application 2008/0145441 to Penades et al., (6) the protein nanoparticles disclosed in Published US Patent Application 20090226525 to de los Rios et al., (7) the virus-like particles disclosed in published US Patent Application 20060222652 to Sebbel et al., (8) the nucleic acid coupled virus-like particles disclosed in published US Patent Application 20060251677 to Bachmann et al., (9) the virus-like particles disclosed in WO2010047839A1 or WO2009106999A2, (10) the nanoprecipitated nanoparticles disclosed in P. Paolicelli et al., "Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010), or (11) apoptotic cells, apoptotic bodies or the synthetic or semisynthetic mimics disclosed in U.S. Publication 2002/0086049. In embodiments, synthetic nanocarriers may possess an aspect ratio greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7, or greater than 1:10.

[0100] Synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface with hydroxyl groups that activate complement or alternatively comprise a surface that consists essentially of moieties that are not hydroxyl groups that activate complement. In a preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface that substantially activates complement or alternatively comprise a surface that consists essentially of moieties that do not substantially activate complement. In a more preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface that activates complement or alternatively comprise a surface that consists essentially of moieties that do not activate complement. In embodiments, synthetic nanocarriers exclude virus-like particles. In embodiments, synthetic nanocarriers may possess an aspect ratio greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7, or greater than 1:10.

[0101] "T cell antigen" means a CD4+ T-cell antigen, CD8+ cell antigen or a CD1d-restricted antigen. "CD4+ T-cell antigen" means any antigen that is recognized by and triggers an immune response in a CD4+ T-cell e.g., an antigen that is specifically recognized by a T-cell receptor on a CD4+T cell via presentation of the antigen or portion thereof bound to a Class II major histocompatability complex molecule (MHC). "CD8+ T cell antigen" means any antigen that is recognized by and triggers an immune response in a CD8+ T-cell e.g., an antigen that is specifically recognized by a T-cell receptor on a CD8+T cell via presentation of the antigen or portion thereof bound to a Class I major histocompatability complex molecule (MHC). "CD1d-restricted antigen" means an antigen that comprise one or more epitopes that bind to, complex to or are presented by CD1d molecules. Generally, CD1d-restricted T cell antigens are lipids presented to invariant NKT cells. CD1d-restricted T cell antigens may comprise one or more lipids, or glycolipids, including but not limited to: .alpha.-galactosylceramide (.alpha.-GalCer), .alpha.-linked glycosphingolipids (from Sphingomonas spp.), galactosyl diacylglycerols (from Borrelia burgdorferi), lypophosphoglycan (from Leishmania donovani), endogenous or exogenous .beta.-glucosylceramide, and phosphatidylinositol tetramannoside (PIM4) (from Mycobacterium leprae). For additional lipids and/or glycolipids useful as a CD1d-restricted antigens, see V. Cerundolo et al., "Harnessing invariant NKT cells in vaccination strategies." Nature Rev Immun, 9:28-38 (2009). In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other embodiments, the T cell antigen is not also a B cell antigen. T cell antigens generally are proteins or peptides, but may be other molecules such as lipids and glycolipids.

[0102] A "therapeutic protein" refers to any protein or protein-based therapy that may be administered to a subject and have a therapeutic effect. Such therapies include protein replacement and protein supplementation therapies. Such therapies also include the administration of exogenous or foreign protein, antibody therapies, and cell or cell-based therapies. Therapeutic proteins include enzymes, enzyme cofactors, hormones, blood clotting factors, cytokines, growth factors, monoclonal antibodies and polyclonal antibodies. Examples of other therapeutic proteins are provided elsewhere herein. Therapeutic proteins may be produced in, on or by cells and may be obtained from such cells or administered in the form of such cells. In embodiments, the therapeutic protein is produced in, on or by mammalian cells, insect cells, yeast cells, bacteria cells, plant cells, transgenic animal cells, transgenic plant cells, etc. The therapeutic protein may be recombinantly produced in such cells. The therapeutic protein may be produced in, on or by a virally transformed cell. The therapeutic protein may also be produced in, on or by autologous cells that have been transfected, transduced or otherwise manipulated to express it. Alternatively, the therapeutic protein may be administered as a nucleic acid or by introducing a nucleic acid into a virus, VLP, liposome, etc. Alternatively, the therapeutic protein may be obtained from such forms and administered as the therapeutic protein itself. Subjects, therefore, include any subject that has received, is receiving or will receive any of the foregoing. Such subject includes subjects that have received, is receiving or will receive gene therapy; autologous cells that have been transfected, transduced or otherwise manipulated to express a therapeutic protein, polypeptide or peptide; or cells that express a therapeutic protein, polypeptide or peptide.

[0103] "Therapeutic protein antigen" means an antigen that is associated with a therapeutic protein that can be, or a portion of which can be, presented for recognition by cells of the immune system and can generate an undesired immune response (e.g., the production of therapeutic protein-specific antibodies) against the therapeutic protein. Therapeutic protein antigens generally include proteins, polypeptides, peptides, lipoproteins, or are contained or expressed in, on or by cells.

[0104] "Tolerogenic immune response" means any immune response that can lead to immune suppression specific to an antigen or a cell, tissue, organ, etc. that expresses such an antigen. Such immune responses include any reduction, delay or inhibition in an undesired immune response specific to the antigen or cell, tissue, organ, etc. that expresses such antigen. Such immune responses also include any stimulation, production, induction, promotion or recruitment in a desired immune response specific to the antigen or cell, tissue, organ, etc. that expresses such antigen. Tolerogenic immune responses, therefore, include the absence of or reduction in an undesired immune response to an antigen that can be mediated by antigen reactive cells as well as the presence or promotion of suppressive cells. Tolerogenic immune responses as provided herein include immunological tolerance. To "generate a tolerogenic immune response" refers to the generation of any of the foregoing immune responses specific to an antigen or cell, tissue, organ, etc. that expresses such antigen. The tolerogenic immune response can be the result of MHC Class I-restricted presentation and/or MHC Class II-restricted presentation and/or B cell presentation and/or presentation by CD1d, etc.

[0105] Tolerogenic immune responses include any reduction, delay or inhibition in CD4+ T cell, CD8+ T cell or B cell proliferation and/or activity. Tolerogenic immune responses also include a reduction in antigen-specific antibody production. Tolerogenic immune responses can also include any response that leads to the stimulation, induction, production or recruitment of regulatory cells, such as CD4+ Treg cells, CD8+ Treg cells, Breg cells, etc. In some embodiments, the tolerogenic immune response, is one that results in the conversion to a regulatory phenotype characterized by the production, induction, stimulation or recruitment of regulatory cells.

[0106] Tolerogenic immune responses also include any response that leads to the stimulation, production or recruitment of CD4+ Treg cells and/or CD8+ Treg cells. CD4+ Treg cells can express the transcription factor FoxP3 and inhibit inflammatory responses and auto-immune inflammatory diseases (Human regulatory T cells in autoimmune diseases. Cvetanovich G L, Hafler D A. Curr Opin Immunol. 2010 December; 22(6):753-60. Regulatory T cells and autoimmunity. Vila J, Isaacs J D, Anderson A E.Curr Opin Hematol. 2009 July; 16(4):274-9). Such cells also suppress T-cell help to B-cells and induce tolerance to both self and foreign antigens (Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. Miyara M, Wing K, Sakaguchi S. J Allergy Clin Immunol. 2009 April; 123(4):749-55). CD4+ Treg cells recognize antigen when presented by Class II proteins on APCs. CD8+ Treg cells, which recognize antigen presented by Class I (and Qa-1), can also suppress T-cell help to B-cells and result in activation of antigen-specific suppression inducing tolerance to both self and foreign antigens. Disruption of the interaction of Qa-1 with CD8+ Treg cells has been shown to dysregulate immune responses and results in the development of auto-antibody formation and an auto-immune lethal systemic-lupus-erythematosus (Kim et al., Nature. 2010 Sep. 16, 467 (7313): 328-32). CD8+ Treg cells have also been shown to inhibit models of autoimmune inflammatory diseases including rheumatoid arthritis and colitis (CD4+CD25+ regulatory T cells in autoimmune arthritis. Oh S, Rankin A L, Caton A J. Immunol Rev. 2010 January; 233(1):97-111. Regulatory T cells in inflammatory bowel disease. Boden E K, Snapper S B. Curr Opin Gastroenterol. 2008 November; 24(6):733-41). In some embodiments, the compositions provided can effectively result in both types of responses (CD4+ Treg and CD8+ Treg). In other embodiments, FoxP3 can be induced in other immune cells, such as macrophages, iNKT cells, etc., and the compositions provided herein can result in one or more of these responses as well.

[0107] Tolerogenic immune responses also include, but are not limited to, the induction of regulatory cytokines, such as Treg cytokines; induction of inhibitory cytokines; the inhibition of inflammatory cytokines (e.g., IL-4, IL-1b, IL-5, TNF-.alpha., IL-6, GM-CSF, IFN-.gamma., IL-2, IL-9, IL-12, IL-17, IL-18, IL-21, IL-22, IL-23, M-CSF, C reactive protein, acute phase protein, chemokines (e.g., MCP-1, RANTES, MIP-1.alpha., MIP-1.beta., MIG, ITAC or IP-10), the production of anti-inflammatory cytokines (e.g., IL-4, IL-13, IL-10, etc.), chemokines (e.g., CCL-2, CXCL8), proteases (e.g., MMP-3, MMP-9), leukotrienes (e.g., CysLT-1, CysLT-2), prostaglandins (e.g., PGE2) or histamines; the inhibition of polarization to a Th17, Th1 or Th2 immune response; the inhibition of effector cell-specific cytokines: Th17 (e.g., IL-17, IL-25), Th1 (IFN-.gamma.), Th2 (e.g., IL-4, IL-13); the inhibition of Th1-, Th2- or TH17-specific transcription factors; the inhibition of proliferation of effector T cells; the induction of apoptosis of effector T cells; the induction of tolerogenic dendritic cell-specific genes, the induction of FoxP3 expression, the inhibition of IgE induction or IgE-mediated immune responses; the inhibition of antibody responses (e.g., antigen-specific antibody production); the inhibition of T helper cell response; the production of TGF-.beta. and/or IL-10; the inhibition of effector function of autoantibodies (e.g., inhibition in the depletion of cells, cell or tissue damage or complement activation); etc.

[0108] Any of the foregoing may be measured in vivo in one or more animal models or may be measured in vitro. One of ordinary skill in the art is familiar with such in vivo or in vitro measurements. Undesired immune responses or tolerogenic immune responses can be monitored using, for example, methods of assessing immune cell number and/or function, tetramer analysis, ELISPOT, flow cytometry-based analysis of cytokine expression, cytokine secretion, cytokine expression profiling, gene expression profiling, protein expression profiling, analysis of cell surface markers, PCR-based detection of immune cell receptor gene usage (see T. Clay et al., "Assays for Monitoring Cellular Immune Response to Active Immunotherapy of Cancer" Clinical Cancer Research 7:1127-1135 (2001)), etc. Undesired immune responses or tolerogenic immune responses may also be monitored using, for example, methods of assessing protein levels in plasma or serum, immune cell proliferation and/or functional assays, etc. In some embodiments, tolerogenic immune responses can be monitored by assessing the induction of FoxP3. In addition, specific methods are described in more detail in the Examples.

[0109] Preferably, tolerogenic immune responses lead to the inhibition of the development, progression or pathology of the diseases, disorders or conditions described herein. Whether or not the inventive compositions can lead to the inhibition of the development, progression or pathology of the diseases, disorders or conditions described herein can be measured with animal models of such diseases, disorders or conditions.

[0110] In some embodiments, the reduction of an undesired immune response or generation of a tolerogenic immune response may be assessed by determining clinical endpoints, clinical efficacy, clinical symptoms, disease biomarkers and/or clinical scores. Undesired immune responses or tolerogenic immune responses can also be assessed with diagnostic tests to assess the presence or absence of a disease, disorder or condition as provided herein. Undesired immune responses can further be assessed by methods of measuring therapeutic proteins levels and/or function in a subject. In embodiments, methods for monitoring or assessing undesired allergic responses include assessing an allergic response in a subject by skin reactivity and/or allergen-specific antibody production.

[0111] In some embodiments, monitoring or assessing the generation of an undesired immune response or a tolerogenic immune response in a subject can be prior to the administration of a composition of synthetic nanocarriers provided herein and/or prior to administration of a transplantable graft or therapeutic protein or exposure to an allergen. In other embodiments, assessing the generation of an undesired immune response or tolerogenic immune response can be after administration of a composition of synthetic nanocarriers provided herein and/or after administration of a transplantable graft or therapeutic protein or exposure to an allergen. In some embodiments, the assessment is done after administration of the composition of synthetic nanocarriers, but prior to administration of a transplantable graft or therapeutic protein or exposure to an allergen. In other embodiments, the assessment is done after administration of a transplantable graft or therapeutic protein or exposure to an allergen, but prior to administration of the composition. In still other embodiments, the assessment is performed prior to both the administration of the synthetic nanocarriers and administration of a transplantable graft or therapeutic protein or exposure to an allergen, while in yet other embodiments the assessment is performed after both the administration of synthetic nanocarriers and the administration of a transplantable graft or therapeutic protein or exposure to an allergen. In further embodiments, the assessment is performed both prior to and after the administration of the synthetic nanocarriers and/or administration of a transplantable graft or therapeutic protein or exposure to an allergen. In still other embodiments, the assessment is performed more than once on the subject to determine that a desirable immune state is maintained in the subject, such as a subject that has or is at risk of having an inflammatory disease, an autoimmune disease, an allergy, organ or tissue rejection or graft verus host disease. Other subjects include those that have undergone or will undergo transplantation as well as those that have received, are receiving or will receive a therapeutic protein against which they have experienced, are experiencing or are expected to experience an undesired immune response.

[0112] An antibody response can be assessed by determining one or more antibody titers. "Antibody titer" means a measurable level of antibody production. Methods for measuring antibody titers are known in the art and include Enzyme-linked Immunosorbent Assay (ELISA). In embodiments, the antibody response can be quantitated, for example, as the number of antibodies, concentration of antibodies or titer. The values can be absolute or they can be relative. Assays for quantifying an antibody response include antibody capture assays, enzyme-linked immunosorbent assays (ELISAs), inhibition liquid phase absorption assays (ILPAAs), rocket immunoelectrophoresis (RIE) assays and line immunoelectrophoresis (LIE) assays. When an antibody response is compared to another antibody response the same type of quantitative value (e.g., titer) and method of measurement (e.g., ELISA) is preferably used to make the comparison.

[0113] An ELISA method for measuring an antibody titer, for example, a typical sandwich ELISA, may consist of the following steps (i) preparing an ELISA-plate coating material such that the antibody target of interest is coupled to a substrate polymer or other suitable material (ii) preparing the coating material in an aqueous solution (such as PBS) and delivering the coating material solution to the wells of a multiwell plate for overnight deposition of the coating onto the multiwell plate (iii) thoroughly washing the multiwell plate with wash buffer (such as 0.05% Tween-20 in PBS) to remove excess coating material (iv) blocking the plate for nonspecific binding by applying a diluent solution (such as 10% fetal bovine serum in PBS), (v) washing the blocking/diluent solution from the plate with wash buffer (vi) diluting the serum sample(s) containing antibodies and appropriate standards (positive controls) with diluent as required to obtain a concentration that suitably saturates the ELISA response (vii) serially diluting the plasma samples on the multiwell plate such to cover a range of concentrations suitable for generating an ELISA response curve (viii) incubating the plate to provide for antibody-target binding (ix) washing the plate with wash buffer to remove antibodies not bound to antigen (x) adding an appropriate concentration of a secondary detection antibody in same diluent such as a biotin-coupled detection antibody capable of binding the primary antibody (xi) incubating the plate with the applied detection antibody, followed by washing with wash buffer (xii) adding an enzyme such as streptavidin-HRP (horse radish peroxidase) that will bind to biotin found on biotinylated antibodies and incubating (xiii) washing the multiwell plate (xiv) adding substrate(s) (such as TMB solution) to the plate (xv) applying a stop solution (such as 2N sulfuric acid) when color development is complete (xvi) reading optical density of the plate wells at a specific wavelength for the substrate (450 nm with subtraction of readings at 570 nm) (xvi) applying a suitable multiparameter curve fit to the data and defining half-maximal effective concentration (EC50) as the concentration on the curve at which half the maximum OD value for the plate standards is achieved.

[0114] A "transplantable graft" refers to a biological material, such as cells, tissues and organs (in whole or in part) that can be administered to a subject. Transplantable grafts may be autografts, allografts, or xenografts of, for example, a biological material such as an organ, tissue, skin, bone, nerves, tendon, neurons, blood vessels, fat, cornea, pluripotent cells, differentiated cells (obtained or derived in vivo or in vitro), etc. In some embodiments, a transplantable graft is formed, for example, from cartilage, bone, extracellular matrix, or collagen matrices. Transplantable grafts may also be single cells, suspensions of cells and cells in tissues and organs that can be transplanted. Transplantable cells typically have a therapeutic function, for example, a function that is lacking or diminished in a recipient subject. Some non-limiting examples of transplantable cells are .beta.-cells, hepatocytes, hematopoietic stem cells, neuronal stem cells, neurons, glial cells, or myelinating cells. Transplantable cells can be cells that are unmodified, for example, cells obtained from a donor subject and usable in transplantation without any genetic or epigenetic modifications. In other embodiments, transplantable cells can be modified cells, for example, cells obtained from a subject having a genetic defect, in which the genetic defect has been corrected, or cells that are derived from reprogrammed cells, for example, differentiated cells derived from cells obtained from a subject.

[0115] "Transplantation" refers to the process of transferring (moving) a transplantable graft into a recipient subject (e.g., from a donor subject, from an in vitro source (e.g., differentiated autologous or heterologous native or induced pluripotent cells)) and/or from one bodily location to another bodily location in the same subject.

[0116] "Undesired immune response" refers to any undesired immune response that results from exposure to an antigen, promotes or exacerbates a disease, disorder or condition provided herein (or a symptom thereof), or is symptomatic of a disease, disorder or condition provided herein. Such immune responses generally have a negative impact on a subject's health or is symptomatic of a negative impact on a subject's health.

C. INVENTIVE COMPOSITIONS

[0117] Provided herein are compositions of synthetic nanocarriers and immunosuppressants that when administered to a subject can result in immunosuppressive effects. Preferably, the compositions also comprise antigen, and the immunosuppressive effect is specific to the antigen and, thus, a tolerogenic effect. Such compositions can result in any of the tolerogenic responses provided herein, such as the stimulation, induction, production or recruitment of regulatory cells (e.g., CD4.sup.+ Treg cells and/or CD8.sup.+ Treg cells). In some embodiments, the tolerogenic immune response, is one that results in the conversion to a regulatory phenotype characterized by the production, induction, stimulation or recruitment of regulatory cells (e.g., Treg cells).

[0118] As mentioned above, the synthetic nanocarriers are designed to comprise immunosuppressants and, in some embodiments, antigen against which a tolerogenic effect is desired. A wide variety of synthetic nanocarriers can be used according to the invention. In some embodiments, synthetic nanocarriers are spheres or spheroids. In some embodiments, synthetic nanocarriers are flat or plate-shaped. In some embodiments, synthetic nanocarriers are cubes or cubic. In some embodiments, synthetic nanocarriers are ovals or ellipses. In some embodiments, synthetic nanocarriers are cylinders, cones, or pyramids.

[0119] In some embodiments, it is desirable to use a population of synthetic nanocarriers that is relatively uniform in terms of size, shape, and/or composition so that each synthetic nanocarrier has similar properties. For example, at least 80%, at least 90%, or at least 95% of the synthetic nanocarriers, based on the total number of synthetic nanocarriers, may have a minimum dimension or maximum dimension that falls within 5%, 10%, or 20% of the average diameter or average dimension of the synthetic nanocarriers. In some embodiments, a population of synthetic nanocarriers may be heterogeneous with respect to size, shape, and/or composition.

[0120] Synthetic nanocarriers can be solid or hollow and can comprise one or more layers. In some embodiments, each layer has a unique composition and unique properties relative to the other layer(s). To give but one example, synthetic nanocarriers may have a core/shell structure, wherein the core is one layer (e.g. a polymeric core) and the shell is a second layer (e.g. a lipid bilayer or monolayer). Synthetic nanocarriers may comprise a plurality of different layers.

[0121] In some embodiments, synthetic nanocarriers may optionally comprise one or more lipids. In some embodiments, a synthetic nanocarrier may comprise a liposome. In some embodiments, a synthetic nanocarrier may comprise a lipid bilayer. In some embodiments, a synthetic nanocarrier may comprise a lipid monolayer. In some embodiments, a synthetic nanocarrier may comprise a micelle. In some embodiments, a synthetic nanocarrier may comprise a core comprising a polymeric matrix surrounded by a lipid layer (e.g., lipid bilayer, lipid monolayer, etc.). In some embodiments, a synthetic nanocarrier may comprise a non-polymeric core (e.g., metal particle, quantum dot, ceramic particle, bone particle, viral particle, proteins, nucleic acids, carbohydrates, etc.) surrounded by a lipid layer (e.g., lipid bilayer, lipid monolayer, etc.).

[0122] In some embodiments, synthetic nanocarriers do not comprise a polymeric component. In some embodiments, synthetic nanocarriers may comprise metal particles, quantum dots, ceramic particles, etc. In some embodiments, a non-polymeric synthetic nanocarrier is an aggregate of non-polymeric components, such as an aggregate of metal atoms (e.g., gold atoms).

[0123] In some embodiments, synthetic nanocarriers may optionally comprise one or more amphiphilic entities. In some embodiments, an amphiphilic entity can promote the production of synthetic nanocarriers with increased stability, improved uniformity, or increased viscosity. In some embodiments, amphiphilic entities can be associated with the interior surface of a lipid membrane (e.g., lipid bilayer, lipid monolayer, etc.). Many amphiphilic entities known in the art are suitable for use in making synthetic nanocarriers in accordance with the present invention. Such amphiphilic entities include, but are not limited to, phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (Span.RTM.85) glycocholate; sorbitan monolaurate (Span.RTM.20); polysorbate 20 (Tween.RTM.20); polysorbate 60 (Tween.RTM.60); polysorbate 65 (Tween.RTM.65); polysorbate 80 (Tween.RTM.80); polysorbate 85 (Tween.RTM.85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipids; synthetic and/or natural detergents having high surfactant properties; deoxycholates; cyclodextrins; chaotropic salts; ion pairing agents; and combinations thereof. An amphiphilic entity component may be a mixture of different amphiphilic entities. Those skilled in the art will recognize that this is an exemplary, not comprehensive, list of substances with surfactant activity. Any amphiphilic entity may be used in the production of synthetic nanocarriers to be used in accordance with the present invention.

[0124] In some embodiments, synthetic nanocarriers may optionally comprise one or more carbohydrates. Carbohydrates may be natural or synthetic. A carbohydrate may be a derivatized natural carbohydrate. In certain embodiments, a carbohydrate comprises monosaccharide or disaccharide, including but not limited to glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid. In certain embodiments, a carbohydrate is a polysaccharide, including but not limited to pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, N,O-carboxylmethylchitosan, algin and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan. In embodiments, the inventive synthetic nanocarriers do not comprise (or specifically exclude) carbohydrates, such as a polysaccharide. In certain embodiments, the carbohydrate may comprise a carbohydrate derivative such as a sugar alcohol, including but not limited to mannitol, sorbitol, xylitol, erythritol, maltitol, and lactitol.

[0125] In some embodiments, synthetic nanocarriers can comprise one or more polymers. In some embodiments, the synthetic nanocarriers comprise one or more polymers that is a non-methoxy-terminated, pluronic polymer. In some embodiments, at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% (weight/weight) of the polymers that make up the synthetic nanocarriers are non-methoxy-terminated, pluronic polymers. In some embodiments, all of the polymers that make up the synthetic nanocarriers are non-methoxy-terminated, pluronic polymers. In some embodiments, the synthetic nanocarriers comprise one or more polymers that is a non-methoxy-terminated polymer. In some embodiments, at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% (weight/weight) of the polymers that make up the synthetic nanocarriers are non-methoxy-terminated polymers. In some embodiments, all of the polymers that make up the synthetic nanocarriers are non-methoxy-terminated polymers. In some embodiments, the synthetic nanocarriers comprise one or more polymers that does not comprise pluronic polymer. In some embodiments, at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% (weight/weight) of the polymers that make up the synthetic nanocarriers do not comprise pluronic polymer. In some embodiments, all of the polymers that make up the synthetic nanocarriers do not comprise pluronic polymer. In some embodiments, such a polymer can be surrounded by a coating layer (e.g., liposome, lipid monolayer, micelle, etc.). In some embodiments, various elements of the synthetic nanocarriers can be coupled with the polymer.

[0126] The immunosuppressants and/or antigens can be coupled to the synthetic nanocarriers by any of a number of methods. Generally, the coupling can be a result of bonding between the immunosuppressants and/or antigens and the synthetic nanocarriers. This bonding can result in the immunosuppressants and/or antigens being attached to the surface of the synthetic nanocarrierss and/or contained within (encapsulated) the synthetic nanocarriers. In some embodiments, however, the immunosuppressants and/or antigens are encapsulated by the synthetic nanocarriers as a result of the structure of the synthetic nanocarriers rather than bonding to the synthetic nanocarriers. In preferable embodiments, the synthetic nanocarriers comprise a polymer as provided herein, and the immunosuppressants and/or antigens are coupled to the polymer.

[0127] When coupling occurs as a result of bonding between the immunosuppressants and/or antigens and synthetic nanocarriers, the coupling may occur via a coupling moiety. A coupling moiety can be any moiety through which an immunosuppressant and/or antigen is bonded to a synthetic nanocarrier. Such moieties include covalent bonds, such as an amide bond or ester bond, as well as separate molecules that bond (covalently or non-covalently) the immunosuppressant and/or antigen to the synthetic nanocarrier. Such molecules include linkers or polymers or a unit thereof. For example, the coupling moiety can comprise a charged polymer to which an immunosuppressant and/or antigen electrostatically binds. As another example, the coupling moiety can comprise a polymer or unit thereof to which it is covalently bonded.

[0128] In preferred embodiments, the synthetic nanocarriers comprise a polymer as provided herein. These synthetic nanocarriers can be completely polymeric or they can be a mix of polymers and other materials.

[0129] In some embodiments, the polymers of a synthetic nanocarrier associate to form a polymeric matrix. In some of these embodiments, a component, such as an immunosuppressant or antigen, can be covalently associated with one or more polymers of the polymeric matrix. In some embodiments, covalent association is mediated by a linker. In some embodiments, a component can be noncovalently associated with one or more polymers of the polymeric matrix. For example, in some embodiments, a component can be encapsulated within, surrounded by, and/or dispersed throughout a polymeric matrix. Alternatively or additionally, a component can be associated with one or more polymers of a polymeric matrix by hydrophobic interactions, charge interactions, van der Waals forces, etc. A wide variety of polymers and methods for forming polymeric matrices therefrom are known conventionally.

[0130] Polymers may be natural or unnatural (synthetic) polymers. Polymers may be homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers may be random, block, or comprise a combination of random and block sequences. Typically, polymers in accordance with the present invention are organic polymers.

[0131] In some embodiments, the polymer comprises a polyester, polycarbonate, polyamide, or polyether, or unit thereof. In other embodiments, the polymer comprises poly(ethylene glycol) (PEG), polypropylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), or a polycaprolactone, or unit thereof. In some embodiments, it is preferred that the polymer is biodegradable. Therefore, in these embodiments, it is preferred that if the polymer comprises a polyether, such as poly(ethylene glycol) or polypropylene glycol or unit thereof, the polymer comprises a block-co-polymer of a polyether and a biodegradable polymer such that the polymer is biodegradable. In other embodiments, the polymer does not solely comprise a polyether or unit thereof, such as poly(ethylene glycol) or polypropylene glycol or unit thereof.

[0132] Other examples of polymers suitable for use in the present invention include, but are not limited to polyethylenes, polycarbonates (e.g. poly(1,3-dioxan-2one)), polyanhydrides (e.g. poly(sebacic anhydride)), polypropylfumerates, polyamides (e.g. polycaprolactam), polyacetals, polyethers, polyesters (e.g., polylactide, polyglycolide, polylactide-co-glycolide, polycaprolactone, polyhydroxyacid (e.g. poly(.beta.-hydroxyalkanoate))), poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polyureas, polystyrenes, and polyamines, polylysine, polylysine-PEG copolymers, and poly(ethyleneimine), poly(ethylene imine)-PEG copolymers.

[0133] In some embodiments, polymers in accordance with the present invention include polymers which have been approved for use in humans by the U.S. Food and Drug Administration (FDA) under 21 C.F.R. .sctn.177.2600, including but not limited to polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, poly(1,3-dioxan-2one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates.

[0134] In some embodiments, polymers can be hydrophilic. For example, polymers may comprise anionic groups (e.g., phosphate group, sulphate group, carboxylate group); cationic groups (e.g., quaternary amine group); or polar groups (e.g., hydroxyl group, thiol group, amine group). In some embodiments, a synthetic nanocarrier comprising a hydrophilic polymeric matrix generates a hydrophilic environment within the synthetic nanocarrier. In some embodiments, polymers can be hydrophobic. In some embodiments, a synthetic nanocarrier comprising a hydrophobic polymeric matrix generates a hydrophobic environment within the synthetic nanocarrier. Selection of the hydrophilicity or hydrophobicity of the polymer may have an impact on the nature of materials that are incorporated (e.g., coupled) within the synthetic nanocarrier.

[0135] In some embodiments, polymers may be modified with one or more moieties and/or functional groups. A variety of moieties or functional groups can be used in accordance with the present invention. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides (Papisov, 2001, ACS Symposium Series, 786:301). Certain embodiments may be made using the general teachings of U.S. Pat. No. 5,543,158 to Gref et al., or WO publication WO2009/051837 by Von Andrian et al.

[0136] In some embodiments, polymers may be modified with a lipid or fatty acid group. In some embodiments, a fatty acid group may be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid. In some embodiments, a fatty acid group may be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linoleic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.

[0137] In some embodiments, polymers may be polyesters, including copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as "PLGA"; and homopolymers comprising glycolic acid units, referred to herein as "PGA," and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as "PLA." In some embodiments, exemplary polyesters include, for example, polyhydroxyacids; PEG copolymers and copolymers of lactide and glycolide (e.g., PLA-PEG copolymers, PGA-PEG copolymers, PLGA-PEG copolymers, and derivatives thereof. In some embodiments, polyesters include, for example, poly(caprolactone), poly(caprolactone)-PEG copolymers, poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[.alpha.-(4-aminobutyl)-L-glycolic acid], and derivatives thereof.

[0138] In some embodiments, a polymer may be PLGA. PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA are characterized by the ratio of lactic acid:glycolic acid. Lactic acid can be L-lactic acid, D-lactic acid, or D,L-lactic acid. The degradation rate of PLGA can be adjusted by altering the lactic acid:glycolic acid ratio. In some embodiments, PLGA to be used in accordance with the present invention is characterized by a lactic acid:glycolic acid ratio of approximately 85:15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85.

[0139] In some embodiments, polymers may be one or more acrylic polymers. In certain embodiments, acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, polycyanoacrylates, and combinations comprising one or more of the foregoing polymers. The acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.

[0140] In some embodiments, polymers can be cationic polymers. In general, cationic polymers are able to condense and/or protect negatively charged strands of nucleic acids (e.g. DNA, or derivatives thereof). Amine-containing polymers such as poly(lysine) (Zauner et al., 1998, Adv. Drug Del. Rev., 30:97; and Kabanov et al., 1995, Bioconjugate Chem., 6:7), poly(ethylene imine) (PEI; Boussif et al., 1995, Proc. Natl. Acad. Sci., USA, 1995, 92:7297), and poly(amidoamine) dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci., USA, 93:4897; Tang et al., 1996, Bioconjugate Chem., 7:703; and Haensler et al., 1993, Bioconjugate Chem., 4:372) are positively-charged at physiological pH, form ion pairs with nucleic acids, and mediate transfection in a variety of cell lines. In embodiments, the inventive synthetic nanocarriers may not comprise (or may exclude) cationic polymers.

[0141] In some embodiments, polymers can be degradable polyesters bearing cationic side chains (Putnam et al., 1999, Macromolecules, 32:3658; Barrera et al., 1993, J. Am. Chem. Soc., 115:11010; Kwon et al., 1989, Macromolecules, 22:3250; Lim et al., 1999, J. Am. Chem. Soc., 121:5633; and Zhou et al., 1990, Macromolecules, 23:3399). Examples of these polyesters include poly(L-lactide-co-L-lysine) (Barrera et al., 1993, J. Am. Chem. Soc., 115:11010), poly(serine ester) (Zhou et al., 1990, Macromolecules, 23:3399), poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633), and poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633).

[0142] The properties of these and other polymers and methods for preparing them are well known in the art (see, for example, U.S. Pat. Nos. 6,123,727; 5,804,178; 5,770,417; 5,736,372; 5,716,404; 6,095,148; 5,837,752; 5,902,599; 5,696,175; 5,514,378; 5,512,600; 5,399,665; 5,019,379; 5,010,167; 4,806,621; 4,638,045; and 4,946,929; Wang et al., 2001, J. Am. Chem. Soc., 123:9480; Lim et al., 2001, J. Am. Chem. Soc., 123:2460; Langer, 2000, Acc. Chem. Res., 33:94; Langer, 1999, J. Control. Release, 62:7; and Uhrich et al., 1999, Chem. Rev., 99:3181). More generally, a variety of methods for synthesizing certain suitable polymers are described in Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, Ed. by Goethals, Pergamon Press, 1980; Principles of Polymerization by Odian, John Wiley & Sons, Fourth Edition, 2004; Contemporary Polymer Chemistry by Allcock et al., Prentice-Hall, 1981; Deming et al., 1997, Nature, 390:386; and in U.S. Pat. Nos. 6,506,577, 6,632,922, 6,686,446, and 6,818,732.

[0143] In some embodiments, polymers can be linear or branched polymers. In some embodiments, polymers can be dendrimers. In some embodiments, polymers can be substantially cross-linked to one another. In some embodiments, polymers can be substantially free of cross-links. In some embodiments, polymers can be used in accordance with the present invention without undergoing a cross-linking step. It is further to be understood that inventive synthetic nanocarriers may comprise block copolymers, graft copolymers, blends, mixtures, and/or adducts of any of the foregoing and other polymers. Those skilled in the art will recognize that the polymers listed herein represent an exemplary, not comprehensive, list of polymers that can be of use in accordance with the present invention.

[0144] Compositions according to the invention comprise synthetic nanocarriers in combination with pharmaceutically acceptable excipients, such as preservatives, buffers, saline, or phosphate buffered saline. The compositions may be made using conventional pharmaceutical manufacturing and compounding techniques to arrive at useful dosage forms. In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative.

[0145] In embodiments, when preparing synthetic nanocarriers as carriers, methods for coupling components to the synthetic nanocarriers may be useful. If the component is a small molecule it may be of advantage to attach the component to a polymer prior to the assembly of the synthetic nanocarriers. In embodiments, it may also be an advantage to prepare the synthetic nanocarriers with surface groups that are used to couple the components to the synthetic nanocarrier through the use of these surface groups rather than attaching the components to a polymer and then using this polymer conjugate in the construction of synthetic nanocarriers.

[0146] In certain embodiments, the coupling can be a covalent linker. In embodiments, peptides according to the invention can be covalently coupled to the external surface via a 1,2,3-triazole linker formed by the 1,3-dipolar cycloaddition reaction of azido groups on the surface of the nanocarrier with antigen or immunosuppressant containing an alkyne group or by the 1,3-dipolar cycloaddition reaction of alkynes on the surface of the nanocarrier with antigens or immunosuppressants containing an azido group. Such cycloaddition reactions are preferably performed in the presence of a Cu(I) catalyst along with a suitable Cu(I)-ligand and a reducing agent to reduce Cu(II) compound to catalytic active Cu(I) compound. This Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) can also be referred as the click reaction.

[0147] Additionally, the covalent coupling may comprise a covalent linker that comprises an amide linker, a disulfide linker, a thioether linker, a hydrazone linker, a hydrazide linker, an imine or oxime linker, an urea or thiourea linker, an amidine linker, an amine linker, and a sulfonamide linker.

[0148] An amide linker is formed via an amide bond between an amine on one component such as the antigen or immunosuppressant with the carboxylic acid group of a second component such as the nanocarrier. The amide bond in the linker can be made using any of the conventional amide bond forming reactions with suitably protected amino acids and activated carboxylic acid such N-hydroxysuccinimide-activated ester.

[0149] A disulfide linker is made via the formation of a disulfide (S--S) bond between two sulfur atoms of the form, for instance, of R.sub.1--S--S--R.sub.2. A disulfide bond can be formed by thiol exchange of an antigen or immunosuppressant containing thiol/mercaptan group (--SH) with another activated thiol group on a polymer or nanocarrier or a nanocarrier containing thiol/mercaptan groups with an antigen or immunosuppressant containing activated thiol group.

[0150] A triazole linker, specifically a 1,2,3-triazole of the form

##STR00001##

wherein R.sub.1 and R.sub.2 may be any chemical entities, is made by the 1,3-dipolar cycloaddition reaction of an azide attached to a first component such as the nanocarrier with a terminal alkyne attached to a second component such as the immunosuppressant or antigen. The 1,3-dipolar cycloaddition reaction is performed with or without a catalyst, preferably with Cu(I)-catalyst, which links the two components through a 1,2,3-triazole function. This chemistry is described in detail by Sharpless et al., Angew. Chem. Int. Ed. 41(14), 2596, (2002) and Meldal, et al, Chem. Rev., 2008, 108(8), 2952-3015 and is often referred to as a "click" reaction or CuAAC.

[0151] In embodiments, a polymer containing an azide or alkyne group, terminal to the polymer chain is prepared. This polymer is then used to prepare a synthetic nanocarrier in such a manner that a plurality of the alkyne or azide groups are positioned on the surface of that nanocarrier. Alternatively, the synthetic nanocarrier can be prepared by another route, and subsequently functionalized with alkyne or azide groups. The component is prepared with the presence of either an alkyne (if the polymer contains an azide) or an azide (if the polymer contains an alkyne) group. The component is then allowed to react with the nanocarrier via the 1,3-dipolar cycloaddition reaction with or without a catalyst which covalently couples the component to the particle through the 1,4-disubstituted 1,2,3-triazole linker.

[0152] A thioether linker is made by the formation of a sulfur-carbon (thioether) bond in the form, for instance, of R.sub.1--S--R.sub.2. Thioether can be made by either alkylation of a thiol/mercaptan (--SH) group on one component with an alkylating group such as halide or epoxide on a second component. Thioether linkers can also be formed by Michael addition of a thiol/mercaptan group on one component to an electron-deficient alkene group on a second component containing a maleimide group or vinyl sulfone group as the Michael acceptor. In another way, thioether linkers can be prepared by the radical thiol-ene reaction of a thiol/mercaptan group on one component with an alkene group on a second component.

[0153] A hydrazone linker is made by the reaction of a hydrazide group on one component with an aldehyde/ketone group on the second component.

[0154] A hydrazide linker is formed by the reaction of a hydrazine group on one component with a carboxylic acid group on the second component. Such reaction is generally performed using chemistry similar to the formation of amide bond where the carboxylic acid is activated with an activating reagent.

[0155] An imine or oxime linker is formed by the reaction of an amine or N-alkoxyamine (or aminooxy) group on one component with an aldehyde or ketone group on the second component.

[0156] An urea or thiourea linker is prepared by the reaction of an amine group on one component with an isocyanate or thioisocyanate group on the second component.

[0157] An amidine linker is prepared by the reaction of an amine group on one component with an imidoester group on the second component.

[0158] An amine linker is made by the alkylation reaction of an amine group on one component with an alkylating group such as halide, epoxide, or sulfonate ester group on the second component. Alternatively, an amine linker can also be made by reductive amination of an amine group on one component with an aldehyde or ketone group on the second component with a suitable reducing reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride.

[0159] A sulfonamide linker is made by the reaction of an amine group on one component with a sulfonyl halide (such as sulfonyl chloride) group on the second component.

[0160] A sulfone linker is made by Michael addition of a nucleophile to a vinyl sulfone. Either the vinyl sulfone or the nucleophile may be on the surface of the nanocarrier or attached to a component.

[0161] The component can also be conjugated to the nanocarrier via non-covalent conjugation methods. For example, a negative charged antigen or immunosuppressant can be conjugated to a positive charged nanocarrier through electrostatic adsorption. A component containing a metal ligand can also be conjugated to a nanocarrier containing a metal complex via a metal-ligand complex.

[0162] In embodiments, the component can be attached to a polymer, for example polylactic acid-block-polyethylene glycol, prior to the assembly of the synthetic nanocarrier or the synthetic nanocarrier can be formed with reactive or activatible groups on its surface. In the latter case, the component may be prepared with a group which is compatible with the attachment chemistry that is presented by the synthetic nanocarriers' surface. In other embodiments, a peptide component can be attached to VLPs or liposomes using a suitable linker. A linker is a compound or reagent that capable of coupling two molecules together. In an embodiment, the linker can be a homobifuntional or heterobifunctional reagent as described in Hermanson 2008. For example, an VLP or liposome synthetic nanocarrier containing a carboxylic group on the surface can be treated with a homobifunctional linker, adipic dihydrazide (ADH), in the presence of EDC to form the corresponding synthetic nanocarrier with the ADH linker. The resulting ADH linked synthetic nanocarrier is then conjugated with a peptide component containing an acid group via the other end of the ADH linker on NC to produce the corresponding VLP or liposome peptide conjugate.

[0163] For detailed descriptions of available conjugation methods, see Hermanson G T "Bioconjugate Techniques", 2nd Edition Published by Academic Press, Inc., 2008. In addition to covalent attachment the component can be coupled by adsorption to a pre-formed synthetic nanocarrier or it can be coupled by encapsulation during the formation of the synthetic nanocarrier.

[0164] Any immunosuppressant as provided herein can be coupled to the synthetic nanocarrier. Immunosuppressants include, but are not limited to, statins; mTOR inhibitors, such as rapamycin or a rapamycin analog; TGF-.beta. signaling agents; TGF-.beta. receptor agonists; histone deacetylase (HDAC) inhibitors; corticosteroids; inhibitors of mitochondrial function, such as rotenone; P38 inhibitors; NF-.kappa..beta. inhibitors; adenosine receptor agonists; prostaglandin E2 agonists; phosphodiesterase inhibitors, such as phosphodiesterase 4 inhibitor; proteasome inhibitors; kinase inhibitors; G-protein coupled receptor agonists; G-protein coupled receptor antagonists; glucocorticoids; retinoids; cytokine inhibitors; cytokine receptor inhibitors; cytokine receptor activators; peroxisome proliferator-activated receptor antagonists; peroxisome proliferator-activated receptor agonists; histone deacetylase inhibitors; calcineurin inhibitors; phosphatase inhibitors and oxidized ATPs. Immunosuppressants also include IDO, vitamin D3, cyclosporine A, aryl hydrocarbon receptor inhibitors, resveratrol, azathiopurine, 6-mercaptopurine, aspirin, niflumic acid, estriol, tripolide, interleukins (e.g., IL-1, IL-10), cyclosporine A, siRNAs targeting cytokines or cytokine receptors and the like.

[0165] Examples of statins include atorvastatin (LIPITOR.RTM., TORVAST.RTM.), cerivastatin, fluvastatin (LESCOL.RTM., LESCOL.RTM. XL), lovastatin (MEVACOR.RTM., ALTOCOR.RTM., ALTOPREV.RTM.), mevastatin (COMPACTIN.RTM.), pitavastatin (LIVALO.RTM., PIAVA.RTM.), rosuvastatin (PRAVACHOL.RTM., SELEKTINE.RTM., LIPOSTAT.RTM.), rosuvastatin (CRESTOR.RTM.), and simvastatin (ZOCOR.RTM., LIPEX.RTM.).

[0166] Examples of mTOR inhibitors include rapamycin and analogs thereof (e.g., CCL-779, RAD001, AP23573, C20-methallylrapamycin (C20-Marap), C16-(S)-butylsulfonamidorapamycin (C16-BSrap), C16-(S)-3-methylindolerapamycin (C16-iRap) (Bayle et al. Chemistry & Biology 2006, 13:99-107)), AZD8055, BEZ235 (NVP-BEZ235), chrysophanic acid (chrysophanol), deforolimus (MK-8669), everolimus (RAD0001), KU-0063794, PI-103, PP242, temsirolimus, and WYE-354 (available from Selleck, Houston, Tex., USA).

[0167] Examples of TGF-.beta. signaling agents include TGF-.beta. ligands (e.g., activin A, GDF1, GDF11, bone morphogenic proteins, nodal, TGF-.beta.s) and their receptors (e.g., ACVR1B, ACVR1C, ACVR2A, ACVR2B, BMPR2, BMPR1A, BMPR1B, TGF.beta.RI, TGF.beta.RII), R-SMADS/co-SMADS (e.g., SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD8), and ligand inhibitors (e.g, follistatin, noggin, chordin, DAN, lefty, LTBP1, THBS1, Decorin).

[0168] Examples of inhibitors of mitochondrial function include atractyloside (dipotassium salt), bongkrekic acid (triammonium salt), carbonyl cyanide m-chlorophenylhydrazone, carboxyatractyloside (e.g., from Atractylis gummifera), CGP-37157, (-)-Deguelin (e.g., from Mundulea sericea), F16, hexokinase II VDAC binding domain peptide, oligomycin, rotenone, Ru360, SFK1, and valinomycin (e.g., from Streptomyces fulvissimus) (EMD4Biosciences, USA).

[0169] Examples of P38 inhibitors include SB-203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole)- , SB-239063 (trans-1-(4hydroxycyclohexyl)-4-(fluorophenyl)-5-(2-methoxy-pyrimidin-4-y- l) imidazole), SB-220025 (5-(2amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole))- , and ARRY-797.

[0170] Examples of NF (e.g., NK-.kappa..beta.) inhibitors include IFRD1, 2-(1,8-naphthyridin-2-yl)-Phenol, 5-aminosalicylic acid, BAY 11-7082, BAY 11-7085, CAPE (Caffeic Acid Phenethylester), diethylmaleate, IKK-2 Inhibitor IV, IMD 0354, lactacystin, MG-132 [Z-Leu-Leu-Leu-CHO], NF.kappa.B Activation Inhibitor III, NF-.kappa.B Activation Inhibitor II, JSH-23, parthenolide, Phenylarsine Oxide (PAO), PPM-18, pyrrolidinedithiocarbamic acid ammonium salt, QNZ, RO 106-9920, rocaglamide, rocaglamide AL, rocaglamide C, rocaglamide I, rocaglamide J, rocaglaol, (R)-MG-132, sodium salicylate, triptolide (PG490), wedelolactone.

[0171] Examples of adenosine receptor agonists include CGS-21680 and ATL-146e.

[0172] Examples of prostaglandin E2 agonists include E-Prostanoid 2 and E-Prostanoid 4.

[0173] Examples of phosphodiesterase inhibitors (non-selective and selective inhibitors) include caffeine, aminophylline, IBMX (3-isobutyl-1-methylxanthine), paraxanthine, pentoxifylline, theobromine, theophylline, methylated xanthines, vinpocetine, EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine), anagrelide, enoximone (PERFAN), milrinone, levosimendon, mesembrine, ibudilast, piclamilast, luteolin, drotaverine, roflumilast (DAXAS.TM., DALIRESP.TM.), sildenafil (REVATION.RTM., VIAGRA.RTM.), tadalafil (ADCIRCA.RTM., CIALIS.RTM.), vardenafil (LEVITRA.RTM., STAXYN.RTM.), udenafil, avanafil, icariin, 4-methylpiperazine, and pyrazolo pyrimidin-7-1.

[0174] Examples of proteasome inhibitors include bortezomib, disulfiram, epigallocatechin-3-gallate, and salinosporamide A.

[0175] Examples of kinase inhibitors include bevacizumab, BIBW 2992, cetuximab (ERBITUX.RTM.), imatinib (GLEEVEC.RTM.), trastuzumab (HERCEPTIN.RTM.), gefitinib (IRESSA.RTM.), ranibizumab (LUCENTIS.RTM.), pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, pazopanib, mubritinib.

[0176] Examples of glucocorticoids include hydrocortisone (cortisol), cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate (DOCA), and aldosterone.

[0177] Examples of retinoids include retinol, retinal, tretinoin (retinoic acid, RETIN-A.RTM.), isotretinoin (ACCUTANE.RTM., AMNESTEEM.RTM., CLARAVIS, SOTRET.RTM.), alitretinoin (PANRETIN.RTM.), etretinate (TEGISON) and its metabolite acitretin (SORIATANE.RTM.), tazarotene (TAZORAC.RTM., AVAGE.RTM., ZORAC.RTM.), bexarotene (TARGRETIN.RTM.), and adapalene (DIFFERIN.RTM.).

[0178] Examples of cytokine inhibitors include IL1ra, IL1 receptor antagonist, IGFBP, TNF-BF, uromodulin, Alpha-2-Macroglobulin, Cyclosporin A, Pentamidine, and Pentoxifylline (PENTOPAK.RTM., PENTOXIL.RTM., TRENTAL.RTM.).

[0179] Examples of peroxisome proliferator-activated receptor antagonists include GW9662, PPAR.gamma. antagonist III, G335, T0070907 (EMD4Biosciences, USA).

[0180] Examples of peroxisome proliferator-activated receptor agonists include pioglitazone, ciglitazone, clofibrate, GW1929, GW7647, L-165,041, LY 171883, PPAR.gamma. activator, Fmoc-Leu, troglitazone, and WY-14643 (EMD4Biosciences, USA).

[0181] Examples of histone deacetylase inhibitors include hydroxamic acids (or hydroxamates) such as trichostatin A, cyclic tetrapeptides (such as trapoxin B) and depsipeptides, benzamides, electrophilic ketones, aliphatic acid compounds such as phenylbutyrate and valproic acid, hydroxamic acids such as vorinostat (SAHA), belinostat (PXD101), LAQ824, and panobinostat (LBH589), benzamides such as entinostat (MS-275), CI994, and mocetinostat (MGCD0103), nicotinamide, derivatives of NAD, dihydrocoumarin, naphthopyranone, and 2-hydroxynaphaldehydes.

[0182] Examples of calcineurin inhibitors include cyclosporine, pimecrolimus, voclosporin, and tacrolimus.

[0183] Examples of phosphatase inhibitors include BN82002 hydrochloride, CP-91149, calyculin A, cantharidic acid, cantharidin, cypermethrin, ethyl-3,4-dephostatin, fostriecin sodium salt, MAZ51, methyl-3,4-dephostatin, NSC 95397, norcantharidin, okadaic acid ammonium salt from prorocentrum concavum, okadaic acid, okadaic acid potassium salt, okadaic acid sodium salt, phenylarsine oxide, various phosphatase inhibitor cocktails, protein phosphatase 1C, protein phosphatase 2A inhibitor protein, protein phosphatase 2A1, protein phosphatase 2A2, sodium orthovanadate.

[0184] In some embodiments, APC presentable antigens as described herein are also coupled to synthetic nanocarriers. In some embodiments, the APC presentable antigens are coupled to the same or different synthetic nanocarriers as to which the immunosuppressants are coupled. In other embodiments, the APC presentable antigens are not coupled to any synthetic nanocarriers. APC presentable antigens include any of the antigens provided herein. Such antigens include antigens associated with inflammatory, autoimmune diseases, allergy, graft versus host disease, organ or tissue rejection, transplant antigens and therapeutic protein antigens.

[0185] Therapeutic proteins include, but are not limited to, infusible therapeutic proteins, enzymes, enzyme cofactors, hormones, blood clotting factors, cytokines and interferons, growth factors, monoclonal antibodies, and polyclonal antibodies (e.g., that are administered to a subject as a replacement therapy), and proteins associated with Pompe's disease (e.g., alglucosidase alfa, rhGAA (e.g., Myozyme and Lumizyme (Genzyme)). Therapeutic proteins also include proteins involved in the blood coagulation cascade. Therapeutic proteins include, but are not limited to, Factor VIII, Factor VII, Factor IX, Factor V, von Willebrand Factor, von Heldebrant Factor, tissue plasminogen activator, insulin, growth hormone, erythropoietin alfa, VEGF, thrombopoietin, lysozyme, antithrombin and the like. Therapeutic proteins also include adipokines, such as leptin and adiponectin. Other examples of therapeutic proteins are as described below and elsewhere herein. Also included are fragments or derivatives of any of the therapeutic proteins provided as the antigen.

[0186] Examples of therapeutic proteins used in enzyme replacement therapy of subjects having a lysosomal storage disorder include, but are not limited to, imiglucerase for the treatment of Gaucher's disease (e.g., CEREZYME.TM.), .alpha.-galactosidase A (a-gal A) for the treatment of Fabry disease (e.g., agalsidase beta, FABRYZYME.TM.), acid a-glucosidase (GAA) for the treatment of Pompe disease (e.g., alglucosidase alfa, LUMIZYME.TM., MYOZYME.TM.), arylsulfatase B for the treatment of Mucopolysaccharidoses (e.g., laronidase, ALDURAZYME.TM., idursulfase, ELAPRASE.TM., arylsulfatase B, NAGLAZYME.TM.).

[0187] Examples of enzymes include oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases.

[0188] Examples of hormones include Melatonin (N-acetyl-5-methoxytryptamine), Serotonin, Thyroxine (or tetraiodothyronine) (a thyroid hormone), Triiodothyronine (a thyroid hormone), Epinephrine (or adrenaline), Norepinephrine (or noradrenaline), Dopamine (or prolactin inhibiting hormone), Antimullerian hormone (or mullerian inhibiting factor or hormone), Adiponectin, Adrenocorticotropic hormone (or corticotropin), Angiotensinogen and angiotensin, Antidiuretic hormone (or vasopressin, arginine vasopressin), Atrial-natriuretic peptide (or atriopeptin), Calcitonin, Cholecystokinin, Corticotropin-releasing hormone, Erythropoietin, Follicle-stimulating hormone, Gastrin, Ghrelin, Glucagon, Glucagon-like peptide (GLP-1), GIP, Gonadotropin-releasing hormone, Growth hormone-releasing hormone, Human chorionic gonadotropin, Human placental lactogen, Growth hormone, Inhibin, Insulin, Insulin-like growth factor (or somatomedin), Leptin, Luteinizing hormone, Melanocyte stimulating hormone, Orexin, Oxytocin, Parathyroid hormone, Prolactin, Relaxin, Secretin, Somatostatin, Thrombopoietin, Thyroid-stimulating hormone (or thyrotropin), Thyrotropin-releasing hormone, Cortisol, Aldosterone, Testosterone, Dehydroepiandrosterone, Androstenedione, Dihydrotestosterone, Estradiol, Estrone, Estriol, Progesterone, Calcitriol (1,25-dihydroxyvitamin D3), Calcidiol (25-hydroxyvitamin D3), Prostaglandins, Leukotrienes, Prostacyclin, Thromboxane, Prolactin releasing hormone, Lipotropin, Brain natriuretic peptide, Neuropeptide Y, Histamine, Endothelin, Pancreatic polypeptide, Renin, and Enkephalin.

[0189] Examples of blood and blood coagulation factors include Factor I (fibrinogen), Factor II (prothrombin), tissue factor, Factor V (proaccelerin, labile factor), Factor VII (stable factor, proconvertin), Factor VIII (antihemophilic globulin), Factor IX (Christmas factor or plasma thromboplastin component), Factor X (Stuart-Prower factor), Factor Xa, Factor XI, Factor XII (Hageman factor), Factor XIII (fibrin-stabilizing factor), von Willebrand factor, prekallikrein (Fletcher factor), high-molecular weight kininogen (HMWK) (Fitzgerald factor), fibronectin, fibrin, thrombin, antithrombin III, heparin cofactor II, protein C, protein S, protein Z, protein Z-related protease inhibitot (ZPI), plasminogen, alpha 2-antiplasmin, tissue plasminogen activator (tPA), urokinase, plasminogen activator inhibitor-1 (PAI1), plasminogen activator inhibitor-2 (PAI2), cancer procoagulant, and epoetin alfa (Epogen, Procrit).

[0190] Examples of cytokines include lymphokines, interleukins, and chemokines, type 1 cytokines, such as IFN-.gamma., TGF-.beta., and type 2 cytokines, such as IL-4, IL-10, and IL-13.

[0191] Examples of growth factors include Adrenomedullin (AM), Angiopoietin (Ang), Autocrine motility factor, Bone morphogenetic proteins (BMPs), Brain-derived neurotrophic factor (BDNF), Epidermal growth factor (EGF), Erythropoietin (EPO), Fibroblast growth factor (FGF), Glial cell line-derived neurotrophic factor (GDNF), Granulocyte colony-stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Growth differentiation factor-9 (GDF9), Hepatocyte growth factor (HGF), Hepatoma-derived growth factor (HDGF), Insulin-like growth factor (IGF), Migration-stimulating factor, Myostatin (GDF-8), Nerve growth factor (NGF) and other neurotrophins, Platelet-derived growth factor (PDGF), Thrombopoietin (TPO), Transforming growth factor alpha(TGF-.alpha.), Transforming growth factor beta(TGF-.beta.), Tumour_necrosis_factor-alpha(TNF-.alpha.), Vascular endothelial growth factor (VEGF), Wnt Signaling Pathway, placental growth factor (P1GF), [(Foetal Bovine Somatotrophin)] (FBS), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, and IL-7.

[0192] Examples of monoclonal antibodies include Abagovomab, Abciximab, Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD, Alemtuzumab, Altumomab pentetate, Anatumomab mafenatox, Anrukinzumab, Anti-thymocyte globin, Apolizumab, Arcitumomab, Aselizumab, Atlizumab (tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab, Biciromab, Bivatuzumab mertansine, Blinatumomab, Brentuximab vedotin, Briakinumab, Canakinumab, Cantuzumab mertansine, Capromab pendetide, Catumaxomab, Cedelizumab, Certolizumab pegol, Cetuximab, Citatuzumab bogatox, Cixutumumab, Clenoliximab, Clivatuzumab tetraxetan, Conatumumab, Dacetuzumab, Daclizumab, Daratumumab, Denosumab, Detumomab, Dorlimomab aritox, Dorlixizumab, Ecromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab, Efungumab, Elotuzumab, Elsilimomab, Enlimomab pegol, Epitumomab cituxetan, Epratuzumab, Erlizumab, Ertumaxomab, Etaracizumab, Exbivirumab, Fanolesomab, Faralimomab, Farletuzumab, Felvizumab, Fezakinumab, Figitumumab, Fontolizumab, Foravirumab, Fresolimumab, Galiximab, Gantenerumab, Gavilimomab, Gemtuzumab ozogamicin, GC1008, Girentuximab, Glembatumumab vedotin, Golimumab, Gomiliximab, lbalizumab, Ibritumomab tiuxetan, Igovomab, Imciromab, Infliximab, Intetumumab, Inolimomab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Keliximab, Labetuzumab, Lebrikizumab, Lemalesomab, Lerdelimumab, Lexatumumab, Libivirumab, Lintuzumab, Lorvotuzumab mertansine, Lucatumumab, Lumiliximab, Mapatumumab, Maslimomab, Matuzumab, Mepolizumab, Metelimumab, Milatuzumab, Minretumomab, Mitumomab, Morolimumab, Motavizumab, Muromonab-CD3, Nacolomab tafenatox, Naptumomab estafenatox, Natalizumab, Nebacumab, Necitumumab, Nerelimomab, Nimotuzumab, Nofetumomab merpentan, Ocrelizumab, Odulimomab, Ofatumumab, Olaratumab, Omalizumab, Oportuzumab monatox, Oregovomab, Otelixizumab, Pagibaximab, Palivizumab, Panitumumab, Panobacumab, Pascolizumab, Pemtumomab, Pertuzumab, Pexelizumab, Pintumomab, Priliximab, Pritumumab, Rafivirumab, Ramucirumab, Ranibizumab, Raxibacumab, Regavirumab Reslizumab, Rilotumumab, Rituximab, Robatumumab, Rontalizumab, Rovelizumab, Ruplizumab, Satumomab pendetide, Sevirumab, Sibrotuzumab, Sifalimumab, Siltuximab, Siplizumab, Solanezumab, Sonepcizumab, Sontuzumab, Stamulumab, Sulesomab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tanezumab, Taplitumomab paptox, Tefibazumab, Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, Ticilimumab (tremelimumab), Tigatuzumab, Tocilizumab (atlizumab), Toralizumab, Tositumomab, Trastuzumab, Tremelimumab, Tucotuzumab celmoleukin, Tuvirumab, Urtoxazumab, Ustekinumab, Vapaliximab, Vedolizumab, Veltuzumab, Vepalimomab, Visilizumab, Volociximab, Votumumab, Zalutumumab, Zanolimumab, Ziralimumab, and Zolimomab aritox.

[0193] Examples of infusion therapy or injectable therapeutic proteins include, for example, Tocilizumab (Roche/Actemra.RTM.), alpha-1 antitrypsin (Kamada/AAT), Hematide.RTM. (Affymax and Takeda, synthetic peptide), albinterferon alfa-2b (Novartis/Zalbin.TM.) Rhucin.RTM. (Pharming Group, C1 inhibitor replacement therapy), tesamorelin (Theratechnologies/Egrifta, synthetic growth hormone-releasing factor), ocrelizumab (Genentech, Roche and Biogen), belimumab (GlaxoSmithKline/Benlysta.RTM.), pegloticase (Savient Pharmaceuticals/Krystexxa.TM.), taliglucerase alfa (Protalix/Uplyso), agalsidase alfa (Shire/Replagal.RTM.), velaglucerase alfa (Shire).

[0194] Additional therapeutic proteins useful in accordance to aspects of this invention will be apparent to those of skill in the art, and the invention is not limited in this respect.

[0195] In some embodiments, a component, such as an antigen or immunosuppressant, may be isolated. Isolated refers to the element being separated from its native environment and present in sufficient quantities to permit its identification or use. This means, for example, the element may be (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated elements may be, but need not be, substantially pure. Because an isolated element may be admixed with a pharmaceutically acceptable excipient in a pharmaceutical preparation, the element may comprise only a small percentage by weight of the preparation. The element is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other lipids or proteins. Any of the elements provided herein may be isolated. Any of the antigens provided herein can be included in the compositions in isolated form.

D. METHODS OF MAKING AND USING THE INVENTIVE COMPOSITIONS AND RELATED METHODS

[0196] Synthetic nanocarriers may be prepared using a wide variety of methods known in the art. For example, synthetic nanocarriers can be formed by methods as nanoprecipitation, flow focusing using fluidic channels, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, milling, microemulsion procedures, microfabrication, nanofabrication, sacrificial layers, simple and complex coacervation, and other methods well known to those of ordinary skill in the art. Alternatively or additionally, aqueous and organic solvent syntheses for monodisperse semiconductor, conductive, magnetic, organic, and other nanomaterials have been described (Pellegrino et al., 2005, Small, 1:48; Murray et al., 2000, Ann. Rev. Mat. Sci., 30:545; and Trindade et al., 2001, Chem. Mat., 13:3843). Additional methods have been described in the literature (see, e.g., Doubrow, Ed., "Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, 1992; Mathiowitz et al., 1987, J. Control. Release, 5:13; Mathiowitz et al., 1987, Reactive Polymers, 6:275; and Mathiowitz et al., 1988, J. Appl. Polymer Sci., 35:755; U.S. Pat. Nos. 5,578,325 and 6,007,845; P. Paolicelli et al., "Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010)).

[0197] Various materials may be encapsulated into synthetic nanocarriers as desirable using a variety of methods including but not limited to C. Astete et al., "Synthesis and characterization of PLGA nanoparticles" J. Biomater. Sci. Polymer Edn, Vol. 17, No. 3, pp. 247-289 (2006); K. Avgoustakis "Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery" Current Drug Delivery 1:321-333 (2004); C. Reis et al., "Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles" Nanomedicine 2:8-21 (2006); P. Paolicelli et al., "Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010). Other methods suitable for encapsulating materials into synthetic nanocarriers may be used, including without limitation methods disclosed in U.S. Pat. No. 6,632,671 to Unger Oct. 14, 2003.

[0198] In certain embodiments, synthetic nanocarriers are prepared by a nanoprecipitation process or spray drying. Conditions used in preparing synthetic nanocarriers may be altered to yield particles of a desired size or property (e.g., hydrophobicity, hydrophilicity, external morphology, "stickiness," shape, etc.). The method of preparing the synthetic nanocarriers and the conditions (e.g., solvent, temperature, concentration, air flow rate, etc.) used may depend on the materials to be coupled to the synthetic nanocarriers and/or the composition of the polymer matrix.

[0199] If particles prepared by any of the above methods have a size range outside of the desired range, particles can be sized, for example, using a sieve.

[0200] Components (i.e., elements) of the inventive synthetic nanocarriers (such as moieties of which an immunofeature surface is comprised, targeting moieties, polymeric matrices, antigens, immunosuppressants and the like) may be coupled to the overall synthetic nanocarrier, e.g., by one or more covalent bonds, or may be coupled by means of one or more linkers. Additional methods of functionalizing synthetic nanocarriers may be adapted from Published US Patent Application 2006/0002852 to Saltzman et al., Published US Patent Application 2009/0028910 to DeSimone et al., or Published International Patent Application WO/2008/127532 A1 to Murthy et al.

[0201] Alternatively or additionally, synthetic nanocarriers can be coupled to elements as provided herein directly or indirectly via non-covalent interactions. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. Such couplings may be arranged to be on an external surface or an internal surface of an inventive synthetic nanocarrier. In embodiments, encapsulation and/or absorption is a form of coupling. In embodiments, the inventive synthetic nanocarriers can be combined with an antigen by admixing in the same vehicle or delivery system.

[0202] Populations of synthetic nanocarriers may be combined to form pharmaceutical dosage forms according to the present invention using traditional pharmaceutical mixing methods. These include liquid-liquid mixing in which two or more suspensions, each containing one or more subsets of nanocarriers, are directly combined or are brought together via one or more vessels containing diluent. As synthetic nanocarriers may also be produced or stored in a powder form, dry powder-powder mixing could be performed as could the re-suspension of two or more powders in a common media. Depending on the properties of the nanocarriers and their interaction potentials, there may be advantages conferred to one or another route of mixing.

[0203] Typical inventive compositions that comprise synthetic nanocarriers may comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene 9-10 nonyl phenol, sodium desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity-adjustment agents (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol).

[0204] Compositions according to the invention comprise inventive synthetic nanocarriers in combination with pharmaceutically acceptable excipients. The compositions may be made using conventional pharmaceutical manufacturing and compounding techniques to arrive at useful dosage forms. Techniques suitable for use in practicing the present invention may be found in Handbook of Industrial Mixing: Science and Practice, Edited by Edward L. Paul, Victor A. Atiemo-Obeng, and Suzanne M. Kresta, 2004 John Wiley & Sons, Inc.; and Pharmaceutics: The Science of Dosage Form Design, 2nd Ed. Edited by M. E. Auten, 2001, Churchill Livingstone. In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative.

[0205] It is to be understood that the compositions of the invention can be made in any suitable manner, and the invention is in no way limited to compositions that can be produced using the methods described herein. Selection of an appropriate method may require attention to the properties of the particular moieties being associated.

[0206] In some embodiments, inventive synthetic nanocarriers are manufactured under sterile conditions or are terminally sterilized. This can ensure that resulting compositions are sterile and non-infectious, thus improving safety when compared to non-sterile compositions. This provides a valuable safety measure, especially when subjects receiving synthetic nanocarriers have immune defects, are suffering from infection, and/or are susceptible to infection. In some embodiments, inventive synthetic nanocarriers may be lyophilized and stored in suspension or as lyophilized powder depending on the formulation strategy for extended periods without losing activity.

[0207] The compositions of the invention can be administered by a variety of routes, including or not limited to subcutaneous, intranasal, oral, intravenous, intraperitoneal, intramuscular, transmucosal, transmucosal, sublingual, rectal, ophthalmic, pulmonary, intradermal, transdermal, transcutaneous or intradermal or by a combination of these routes. Routes of administration also include administration by inhalation or pulmonary aerosol. Techniques for preparing aerosol delivery systems are well known to those of skill in the art (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp. 1694-1712; incorporated by reference).

[0208] The transplantable grafts or therapeutic proteins provided as a cell-based therapy of the invention may be administered by parenteral, intraarterial, intranasal or intravenous administration or by injection to lymph nodes or anterior chamber of the eye or by local administration to an organ or tissue of interest. The administration may be by subcutaneous, intrathecal, intraventricular, intramuscular, intraperitoneal, intracoronary, intrapancreatic, intrahepatic or bronchial injection.

[0209] The compositions of the invention can be administered in effective amounts, such as the effective amounts described elsewhere herein. Doses of dosage forms contain varying amounts of populations of synthetic nanocarriers and/or varying amounts of antigens and/or immunosuppressants, according to the invention. The amount of synthetic nanocarriers and/or antigens and/or immunosuppressants present in the inventive dosage forms can be varied according to the nature of the antigens and/or immunosuppressants, the therapeutic benefit to be accomplished, and other such parameters. In embodiments, dose ranging studies can be conducted to establish optimal therapeutic amount of the population of synthetic nanocarriers and the amount of antigens and/or immunosuppressants to be present in the dosage form. In embodiments, the synthetic nanocarriers and/or the antigens and/or immunosuppressants are present in the dosage form in an amount effective to generate a tolerogenic immune response to the antigens upon administration to a subject. It may be possible to determine amounts of the antigens and/or immunosuppressants effective to generate a tolerogenic immune response using conventional dose ranging studies and techniques in subjects. Inventive dosage forms may be administered at a variety of frequencies. In a preferred embodiment, at least one administration of the dosage form is sufficient to generate a pharmacologically relevant response. In more preferred embodiments, at least two administrations, at least three administrations, or at least four administrations, of the dosage form are utilized to ensure a pharmacologically relevant response.

[0210] Prophylactic administration of the inventive compositions can be initiated prior to the onset of disease, disorder or condition or therapeutic administration can be initiated after a disorder, disorder or condition is established.

[0211] In some embodiments, administration of synthetic nanocarriers is undertaken e.g., prior to administration of a therapeutic protein, transplantable graft or exposure to an allergen. In exemplary embodiments, synthetic nanocarriers are administered at one or more times including, but not limited to, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 days prior to administration of a therapeutic protein, transplantable graft or exposure to an allergen. In addition or alternatively, synthetic nanocarriers can be administered to a subject following administration of a therapeutic protein, transplantable graft or exposure to an allergen. In exemplary embodiments, synthetic nanocarriers are administered at one or more times including, but not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, etc. days following administration of a therapeutic protein, transplantable graft or exposure to an allergen.

[0212] In some embodiments, a maintenance dose (e.g., of a synthetic nanocarrier composition provided herein) is administered to a subject after an initial administration has resulted in a tolerogenic response in the subject, for example to maintain the tolerogenic effect achieved after the initial dose, to prevent an undesired immune reaction in the subject, or to prevent the subject becoming a subject at risk of experiencing an undesired immune response or an undesired level of an immune response. In some embodiments, the maintenance dose is the same dose as the initial dose the subject received. In some embodiments, the maintenance dose is a lower dose than the initial dose. For example, in some embodiments, the maintenance dose is about 3/4, about 2/3, about 1/2, about 1/3, about 1/4, about 1/8, about 1/10, about 1/20, about 1/25, about 1/50, about 1/100, about 1/1,000, about 1/10,000, about 1/100,000, or about 1/1,000,000 (weight/weight) of the initial dose.

[0213] The compositions and methods described herein can be used to induce or enhance a tolerogenic immune response and/or to suppress, modulate, direct or redirect an undesired immune response for the purpose of immune suppression. The compositions and methods described herein can be used in the diagnosis, prophylaxis and/or treatment of diseases, disorders or conditions in which immune suppression (e.g., tolerogenic immune response) would confer a treatment benefit. Such diseases, disorders or conditions include autoimmune diseases, inflammatory diseases, allergies, organ or tissue rejection and graft versus host disease. The compositions and methods described herein can also be used in subjects who have undergone or will undergo transplantation. The compositions and methods described herein can also be used in subjects who have received, are receiving or will receive a therapeutic protein against which they have generated or are expected to generate an undesired immune response.

[0214] Autoimmune diseases include, but are not limited to, rheumatoid arthritis, multiple sclerosis, immune-mediated or Type I diabetes mellitus, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), systemic lupus erythematosus, psoriasis, scleroderma, autoimmune thyroid disease, alopecia areata, Grave's disease, Guillain-Barre syndrome, celiac disease, Sjogren's syndrome, rheumatic fever, gastritis, autoimmune atrophic gastritis, autoimmune hepatitis, insulitis, oophoritis, orchitis, uveitis, phacogenic uveitis, myasthenia gravis, primary myxoedema, pernicious anemia, autoimmune haemolytic anemia, Addison's disease, scleroderma, Goodpasture's syndrome, nephritis, for example, glomerulonephritis, psoriasis, pemphigus vulgaris, pemphigoid, sympathetic opthalmia, idiopathic thrombocylopenic purpura, idiopathic feucopenia, Wegener's granulomatosis and poly/dermatomyositis.

[0215] Some additional exemplary autoimmune diseases, associated autoantigens, and autoantibodies, which are contemplated for use in the invention, are described in Table 1 below:

TABLE-US-00001 Autoantibody Type Autoantibody Autoantigen Autoimmune disease or disorder Antinuclear Anti-SSA/Ro ribonucleoproteins Systemic lupus erythematosus, neonatal antibodies autoantibodies heart block, primary Sjogren's syndrome Anti-La/SS-B ribonucleoproteins Primary Sjogren's syndrome autoantibodies Anti-centromere centromere CREST syndrome antibodies Anti-neuronal Ri[disambiguation Opsoclonus nuclear antibody-2 needed] Anti-dsDNA double-stranded SLE DNA Anti-Jo1 histidine-tRNA Inflammatory myopathy ligase Anti-Smith snRNP core proteins SLE Anti- Type I Systemic sclerosis (anti-Scl-70 antibodies) topoisomerase topoisomerase antibodies Anti-histone histones SLE and Drug-induced LE[2] antibodies Anti-p62 nucleoporin 62 Primary biliary cirrhosis[3][4][5] antibodies[3] Anti-sp100 Sp100 nuclear antibodies [4] antigen Anti-glycoprotein- nucleoporin 210 kDa 210 antibodies[5] Anti- Anti-tTG Coeliac disease transglutaminase Anti-eTG Dermatitis herpetiformis antibodies Anti-ganglioside ganglioside GQ1B Miller-Fisher Syndrome antibodies ganglioside GD3 Acute motor axonal neuropathy (AMAN) ganglioside GM1 Multifocal motor neuropathy with conduction block (MMN) Anti-actin actin Coeliac disease anti-actin antibodies antibodies correlated with the level of intestinal damage [6][7] Liver kidney Autoimmune hepatitis.[8] microsomal type 1 antibody Lupus anticoagulant Anti-thrombin thrombin Systemic lupus erythematosus antibodies Anti-neutrophil phospholipid Antiphospholipid syndrome cytoplasmic c-ANCA proteins in Wegener's granulomatosis antibody neutrophil cytoplasm p-ANCA neutrophil Microscopic polyangiitis, Churg-Strauss perinuclear syndrome, systemic vasculitides (non- specific) Rheumatoid factor IgG Rheumatoid arthritis Anti-smooth muscle smooth muscle Chronic autoimmune hepatitis antibody Anti-mitochondrial mitochondria Primary biliary cirrhosis[9] antibody Anti-SRP signal recognition Polymyositis[10] particle exosome complex Scleromyositis nicotinic Myasthenia gravis acetylcholine receptor muscle-specific Myasthenia gravis kinase (MUSK) Anti-VGCC voltage-gated Lambert-Eaton myasthenic syndrome calcium channel (P/Q-type) thyroid peroxidase Hashimoto's thyroiditis (microsomal) TSH receptor Graves' disease Hu Paraneoplastic cerebellar syndrome Yo (cerebellar Paraneoplastic cerebellar syndrome Purkinje Cells) amphiphysin Stiff person syndrome, paraneoplastic cerebellar syndrome Anti-VGKC voltage-gated Limbic encephalitis, Isaac's Syndrome potassium channel (autoimmune neuromyotonia) (VGKC) basal ganglia Sydenham's chorea, paediatric autoimmune neurons neuropsychiatric disease associated with Streptococcus (PANDAS) N-methyl-D- Encephalitis aspartate receptor (NMDA) glutamic acid Diabetes mellitus type 1, stiff person decarboxylase syndrome (GAD) aquaporin-4 Neuromyelitis optica (Devic's syndrome)

[0216] Inflammatory diseases include, but are not limited to, Alzheimer's, arthritis, asthma, atherosclerosis, Crohn's disease, colitis, cystic fibrosis, dermatitis, diverticulitis, hepatitis, irritable bowel syndrome (IBS), lupus erythematous, muscular dystrophy, nephritis, Parkinson's, shingles and ulcerative colitis. Inflammatory diseases also include, for example, cardiovascular disease, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic cholecystitis, tuberculosis, Hashimoto's thyroiditis, sepsis, sarcoidosis, silicosis and other pneumoconioses, and an implanted foreign body in a wound, but are not so limited. As used herein, the term "sepsis" refers to a well-recognized clinical syndrome associated with a host's systemic inflammatory response to microbial invasion. The term "sepsis" as used herein refers to a condition that is typically signaled by fever or hypothermia, tachycardia, and tachypnea, and in severe instances can progress to hypotension, organ dysfunction, and even death.

[0217] In some embodiments, the inflammatory disease is non-autoimmune inflammatory bowel disease, post-surgical adhesions, coronary artery disease, hepatic fibrosis, acute respiratory distress syndrome, acute inflammatory pancreatitis, endoscopic retrograde cholangiopancreatography-induced pancreatitis, burns, atherogenesis of coronary, cerebral and peripheral arteries, appendicitis, cholecystitis, diverticulitis, visceral fibrotic disorders, wound healing, skin scarring disorders (keloids, hidradenitis suppurativa), granulomatous disorders (sarcoidosis, primary biliary cirrhosis), asthma, pyoderma gandrenosum, Sweet's syndrome, Behcet's disease, primary sclerosing cholangitis or an abscess. In some preferred embodiment the inflammatory disease is inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).

[0218] Inflammatory diseases include, but are not limited to, Alzheimer's, Ankylosing spondylitis, arthritis, asthma, atherosclerosis, Behcet's disease, chronic inflammatory demyelinating polyradiculoneuropathy, Crohn's disease, autoimmune inflammatory bowel disease, insulin-dependent diabetes mellitus, diabetes mellitus, juvenile diabetes, spontaneous autoimmune diabetes, gastritis, autoimmune atrophic gastritis, autoimmune hepatitis, thyroiditis, Hashimoto's thyroiditis, insulitis, oophoritis, orchitis, uveitis, phacogenic uveitis, multiple sclerosis, myasthenia gravis, primary myxoedema, thyrotoxicosis, pernicious anemia, autoimmune haemolytic anemia, Addison's disease, Anklosing spondylitis, sarcoidosis, scleroderma, Goodpasture's syndrome, Guillain-Barre syndrome, Graves' disease, glomerulonephritis, psoriasis, pemphigus vulgaris, pemphigoid, excema, bulous pemiphigous, sympathetic opthalmia, idiopathic thrombocylopenic purpura, idiopathic feucopenia, Sjogren's syndrome, systemic sclerosis, Wegener's granulomatosis, poly/dermatomyositis, primary biliary cirrhosis, primary sclerosing cholangitis, lupus or systemic lupus erythematosus.

[0219] Graft versus host disease (GVHD) is a complication that can occur after a pluripotent cell (e.g., stem cell) or bone marrow transplant in which the newly transplanted material results in an attack on the transplant recipient's body. In some instances, GVHD takes place after a blood transfusion. Graft-versus-host-disease can be divided into acute and chronic forms. The acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality. The chronic form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival.

EXAMPLES

Example 1

Mesoporous Silica Nanoparticles with Coupled Ibuprofen (Prophetic)

[0220] Mesoporous SiO2 nanoparticle cores are created through a sol-gel process. Hexadecyltrimethyl-ammonium bromide (CTAB) (0.5 g) is dissolved in deionized water (500 mL), and then 2 M aqueous NaOH solution (3.5 mL) is added to the CTAB solution. The solution is stirred for 30 min, and then Tetraethoxysilane (TEOS) (2.5 mL) is added to the solution. The resulting gel is stirred for 3 h at a temperature of 80.degree. C. The white precipitate which forms is captured by filtration, followed by washing with deionized water and drying at room temperature. The remaining surfactant is then extracted from the particles by suspension in an ethanolic solution of HCl overnight. The particles are washed with ethanol, centrifuged, and redispersed under ultrasonication. This wash procedure is repeated two additional times.

[0221] The SiO2 nanoparticles are then functionalized with amino groups using (3-aminopropyl)-triethoxysilane (APTMS). To do this, the particles are suspended in ethanol (30 mL), and APTMS (50 .mu.L) is added to the suspension. The suspension is allowed to stand at room temperature for 2 h and then is boiled for 4 h, keeping the volume constant by periodically adding ethanol. Remaining reactants are removed by five cycles of washing by centrifugation and redispersing in pure ethanol.

[0222] In a separate reaction, 1-4 nm diameter gold seeds are created. All water used in this reaction is first deionized and then distilled from glass. Water (45.5 mL) is added to a 100 mL round-bottom flask. While stirring, 0.2 M aqueous NaOH (1.5 mL) is added, followed by a 1% aqueous solution of tetrakis(hydroxymethyl)phosphonium chloride (THPC) (1.0 mL). Two minutes after the addition of THPC solution, a 10 mg/mL aqueous solution of chloroauric acid (2 mL), which has been aged at least 15 min, is added. The gold seeds are purified through dialysis against water.

[0223] To form the core-shell nanocarriers, the amino-functionalized SiO2 nanoparticles formed above are first mixed with the gold seeds for 2 h at room temperature. The gold-decorated SiO2 particles are collected through centrifugation and mixed with an aqueous solution of chloroauric acid and potassium bicarbonate to form the gold shell. The particles are then washed by centrifugation and redispersed in water. Ibuprofen is loaded by suspending the particles in a solution of sodium ibuprofen (1 mg/L) for 72 h. Free ibuprofen is then washed from the particles by centrifugation and redispersing in water.

Example 2

Liposomes Containing Cyclosporine A (Prophetic)

[0224] The liposomes are formed using thin film hydration. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (32 .mu.mol), cholesterol (32 .mu.mol), and cyclosporin A (6.4 .mu.mol) are dissolved in pure chloroform (3 mL). This lipid solution is added to a 50 mL round-bottom flask, and the solvent is evaporated on a rotary evaporator at a temperature of 60.degree. C. The flask is then flushed with nitrogen gas to remove remaining solvent. Phosphate buffered saline (2 mL) and five glass beads are added to the flask, and the lipid film is hydrated by shaking at 60.degree. C. for 1 h to form a suspension. The suspension is transferred to a small pressure tube and sonicated at 60.degree. C. for four cycles of 30 s pulses with a 30 s delay between each pulse. The suspension is then left undisturbed at room temperature for 2 h to allow for complete hydration. The liposomes are washed by centrifugation followed by resuspension in fresh phosphate buffered saline.

Example 3

Polymeric Nanocarrier Containing Polymer-Rapamycin Conjugate (Prophetic)

[0225] Preparation of PLGA-Rapamycin Conjugate:

[0226] PLGA polymer with acid end group (7525 DLG1A, acid number 0.46 mmol/g, Lakeshore Biomaterials; 5 g, 2.3 mmol, 1.0 eq) is dissolved in 30 mL of dichloromethane (DCM). N,N-Dicyclohexylcarbodimide (1.2 eq, 2.8 mmol, 0.57 g) is added followed by rapamycin (1.0 eq, 2.3 mmol, 2.1 g) and 4-dimethylaminopyridine (DMAP) (2.0 eq, 4.6 mmol, 0.56 g). The mixture is stirred at rt for 2 days. The mixture is then filtered to remove insoluble dicyclohexylurea. The filtrate is concentrated to ca. 10 mL in volume and added to 100 mL of isopropyl alcohol (IPA) to precipitate out the PLGA-rapamycin conjugate. The IPA layer is removed and the polymer is then washed with 50 mL of IPA and 50 mL of methyl t-butyl ether (MTBE). The polymer is then dried under vacuum at 35 C for 2 days to give PLGA-rapamycin as a white solid (ca. 6.5 g).

[0227] Preparation of Nanocarrier Containing PLGA-Rapamycin Conjugate and Ovalbumin peptide (323-339):

[0228] Nanocarrier Containing PLGA-Rapamycin is Prepared According to the Procedure Described in Example 1 as Follows:

[0229] Solutions for nanocarrier formation are prepared as follows:

[0230] Solution 1: Ovalbumin peptide 323-339 @ 20 mg/mL in dilute hydrochloric acid aqueous solution. The solution is prepared by dissolving ovalbumin peptide in 0.13 M hydrochloric acid solution at room temperature. Solution 2: PLGA-rapamycin @ 100 mg/mL in methylene chloride. The solution is prepared by dissolving PLGA-rapamycin in pure methylene chloride. Solution 3: PLA-PEG @ 100 mg/mL in methylene chloride. The solution is prepared by dissolving PLA-PEG in pure methylene chloride. Solution 4: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0231] A primary water-in-oil emulsion is prepared first. W1/O1 is prepared by combining solution 1 (0.2 mL), solution 2 (0.75 mL), and solution 3 (0.25 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) is then prepared by combining solution 4 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250. The W1/O1/W2 emulsion is added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers is washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600.times.g and 4.degree. C. for 35 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure is repeated, and the pellet is re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

Example 4

Preparation of Gold Nanocarriers (AuNCs) Containing Rapamycin (Prophetic)

[0232] Preparation of HS-PEG-Rapamycin:

[0233] A solution of PEG acid disulfide (1.0 eq), rapamycin (2.0-2.5 eq), DCC (2.5 eq) and DMAP (3.0 eq) in dry DMF is stirred at rt overnight. The insoluble dicyclohexylurea is removed by filtration and the filtrate is added to isopropyl alcohol (IPA) to precipitate out the PEG-disulfide-di-rapamycin ester and washed with IPA and dried. The polymer is then treated with tris(2-carboxyethyl)phosphine hydrochloride in DMF to reduce the PEG disulfide to thiol PEG rapamycin ester (HS-PEG-rapamycin). The resulting polymer is recovered by precipitation from IPA and dried as previously described and analyzed by H NMR and GPC.

[0234] Formation of Gold NCs (AuNCs):

[0235] An aq. solution of 500 mL of 1 mM HAuCl4 is heated to reflux for 10 min with vigorous stirring in a 1 L round-bottom flask equipped with a condenser. A solution of 50 mL of 40 mM of trisodium citrate is then rapidly added to the stirring solution. The resulting deep wine red solution is kept at reflux for 25-30 min and the heat is withdrawn and the solution is cooled to room temperature. The solution is then filtered through a 0.8 .mu.m membrane filter to give the AuNCs solution. The AuNCs are characterized using visible spectroscopy and transmission electron microscopy. The AuNCs are ca. 20 nm diameter capped by citrate with peak absorption at 520 nm.

[0236] AuNCs Conjugate with HS-PEG-Rapamycin:

[0237] A solution of 150 .mu.l of HS-PEG-rapamycin (10 .mu.M in 10 mM pH 9.0 carbonate buffer) is added to 1 mL of 20 nm diameter citrate-capped gold nanocarriers (1.16 nM) to produce a molar ratio of thiol to gold of 2500:1. The mixture is stirred at room temperature under argon for 1 hour to allow complete exchange of thiol with citrate on the gold nanocarriers. The AuNCs with PEG-rapamycin on the surface is then purified by centrifuge at 12,000 g for 30 minutes. The supernatant is decanted and the pellet containing AuNC-S-PEG-rapamycin is then pellet washed with 1.times.PBS buffer. The purified Gold-PEG-rapamycin nanocarriers are then resuspend in suitable buffer for further analysis and bioassays.

Example 5

Immune Response of Synthetic Nanocarriers with Coupled Rapamycin with and without Ovalbumin Peptide (323-339)

Materials

[0238] Ovalbumin peptide 323-339, a 17 amino acid peptide known to be a T and B cell epitope of Ovalbumin protein, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505; Part #4065609). Rapamycin was purchased from TSZ CHEM (185 Wilson Street, Framingham, Mass. 01702; Product Catalogue # R1017). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0239] Solution 1: Ovalbumin peptide 323-339 @ 20 mg/mL in dilute hydrochloric acid aqueous solution. The solution was prepared by dissolving ovalbumin peptide in 0.13 M hydrochloric acid solution at room temperature. Solution 2: Rapamycin @ 50 mg/mL in methylene chloride. The solution was prepared by dissolving rapamycin in pure methylene chloride. Solution 3: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 4: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

Method for Preparing Synthetic Nanocarrier Containing Rapamycin and Ovalbumin (323-339)

[0240] A primary water-in-oil emulsion was prepared first. W1/O1 was prepared by combining solution 1 (0.2 mL), solution 2 (0.2 mL), and solution 3 (1.0 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) was then prepared by combining solution 4 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.

[0241] The W1/O1/W2 emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the synthetic nanocarriers to form. A portion of the synthetic nanocarriers were washed by transferring the synthetic nanocarrier suspension to a centrifuge tube and centrifuging at 21,000.times.g and 4.degree. C. for one hour, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final synthetic nanocarrier dispersion of about 10 mg/mL.

[0242] The amounts of peptide and rapamycin in the synthetic nanocarriers were determined by HPLC analysis. The total dry-synthetic nanocarrier mass per mL of suspension was determined by a gravimetric method.

Method for Producing Synthetic Nanocarrier Containing Rapamycin

[0243] A primary water-in-oil emulsion was prepared first. W1/O1 was prepared by combining 0.13 M hydrochloric acid solution (0.2 mL), solution 2 (0.2 mL), and solution 3 (1.0 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) was then prepared by combining solution 4 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.

[0244] The W1/O1/W2 emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the synthetic nanocarriers to form. A portion of the synthetic nanocarriers were washed by transferring the synthetic nanocarrier suspension to a centrifuge tube and centrifuging at 21,000.times.g and 4.degree. C. for one hour, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final synthetic nanocarrier dispersion of about 10 mg/mL.

[0245] The amount of rapamycin in the synthetic nanocarrier was determined by HPLC analysis. The total dry-synthetic nanocarrier mass per mL of suspension was determined by a gravimetric method.

Method for Measuring Rapamycin Load

[0246] Approximately 3 mg of synthetic nanocarriers were collected and centrifuged to separate supernatant from synthetic nanocarrier pellet. Acetonitrile was added to the pellet, and the sample was sonicated and centrifuged to remove any insoluble material. The supernatant and pellet were injected on RP-HPLC and absorbance was read at 278 nm. The .mu.g found in the pellet were used to calculate % entrapped (load), .mu.g in supernatant and pellet were used to calculate total .mu.g recovered.

Method for Measuring Ovalbumin (323-339) Load

[0247] Approximately 3 mg of synthetic nanocarriers were collected and centrifuged to separate supernatant from synthetic nanocarrier pellet. Trifluoroethanol was added to the pellet and the sample was sonicated to dissolve the polymer, 0.2% trifluoroacetic acid was added and sample was sonicated and then centrifuged to remove any insoluble material. The supernatant and pellet were injected on RP-HPLC and absorbance was read at 215 nm. The .mu.g found in the pellet were used to calculate % entrapped (load), .mu.g in supernatant and pellet were used to calculate total .mu.g recovered.

Antigen-Specific Tolerogenic Dendritic Cells (tDC) Activity on Treg Cell Development

[0248] The assay included the use of OTII mice which have a transgenic T cell receptor specific for an immune-dominant ovalbumin peptide (323-339). In order to create antigen-specific tDCs, CD11c.sup.+ splenocytes were isolated, and the ovalbumin peptide (323-339) added in vitro at 1 .mu.g/ml or no antigen. Soluble or nanocarrier-encapsulated rapamycin was then added to the DCs for 2 hours which were then washed extensively to remove free rapamycin from the culture. Purified responder CD4.sup.+CD25.sup.- cells were isolated from OTII mice and added to tDC at a 10:1 T to DC ratio. The mixture of tDC and OTII T cells were then cultured for 4-5 days, and the frequency of Treg cells (CD4.sup.+CD25highFoxP3.sup.+) were analyzed by flow cytometry as shown in FIG. 1. Regions were selected based on isotype controls.

Method of Determining Nanocarrier Dimensions

[0249] Measurement of synthetic nanocarrier dimensions was obtained by dynamic light scattering (DLS). A suspension of the synthetic nanocarriers was diluted with purified water to achieve a final synthetic nanocarrier suspension concentration of approximately 0.01 to 0.1 mg/mL. The diluted suspension was prepared directly inside a suitable cuvette for DLS analysis. The cuvette was then placed in a Brookhaven Instruments Corp. ZetaPALS, allowed to equilibrate to 25.degree. C., and then scanned for sufficient time to acquire a stable and reproducible distribution based on appropriate inputs for viscosity of the medium and refractive indicies of the sample. The effective diameter, or mean of the distribution, was then reported.

Results

[0250] For proof of concept experiments, the tolerance inducing drug rapamycin was used in combination with the class II binding ovalbumin peptide 323-339. Rapamycin is an immunosuppressant used to suppress allogeneic transplantation rejection and is an inhibitor of mTOR, which is a regulator of several cellular functions including APC and T cell behavior. The synthetic nanocarriers were prepared according to the above, representative examples of which are described in more detail in the following tables (Tables 2-4).

TABLE-US-00002 TABLE 2 Synthetic Nanocarriers Containing both Rapamycin and Low Level Concentration of Ovalbumin (323-339) Washed Rapa Ova Synthetic Diameter Yield Load Load Nanocarrier Key Attributes (nm) (%) (%) (%) 1 7525 DLG 7A, 10% 265.6 85 9.6 0.6 Rapa, 4% Ova 2 7525 DLG 7A, 2% 257.0 82 1.2 1.8 Rapa, 4% Ova 3 5050 DLG 2.5A, 10% 192.8 71 12.8 0.4 Rapa, 4% Ova 4 5050 DLG 2.5A, 2% 165.3 64 1.0 0.7 Rapa, 4% Ova 5 7525 DLG 7A, 4% Ova 220.7 76 -- 1.1 6 5050 DLG 2.5A, 4% 161.8 60 -- 0.4 Ova 7 7525 DLG 7A, 10% 247.3 80 10.1 -- Rapa 8 5050 DLG 2.5A, 10% 198.9 74 12.6 -- Rapa

TABLE-US-00003 TABLE 3 Synthetic Nanocarriers Containing both Rapamycin and High Level Concentration of Ovalbumin (323-339) Washed Rapa Ova Synthetic Diameter Yield Load Load Nanocarrier Key Attributes (nm) (%) (%) (%) 9 7525 DLG 7A, 10% Rapa; increase 270 87 8.8 2.4 target Ova load to 12.5% by increasing Ova concentration in W1 10 7525 DLG 7A, 10% Rapa; increase 194 67 7.0 0.3 target Ova load to 8% by halving polymer concentration in O phase 11 7525 DLG 7A, 25% PLA-PEG, 227 77 9.3 2.5 10% Rapa, 4% Ova 12 7525 DLG 7A, 10% Rapa, 4% 239 84 7.9 0.6 Ova; gentler secondary sonication process

TABLE-US-00004 TABLE 4 Synthetic Nanocarriers Containing Rapamycin Washed Rapa Ova Synthetic Diameter Yield Load Load Nanocarrier Key Attributes (nm) (%) (%) (%) 13 PLA-PEG(5k)-OMe 254 75 7.5 N/A 14 100 DL 2A 204 76 7.6 N/A 15 7525 DLG 7A 263 84 8.4 N/A 16 50% 7525 DLG 7A, 50% 190 53 29.8 N/A 5050 DLG 2.5A

[0251] The results from a representative flow cytometric analysis show an increase in the number of CD4.sup.+CD25highFoxP3.sup.+ cells (FIG. 1) when DCs were treated with free rapamycin and free Ovalbumin (323-339).

[0252] Free rapamycin or synthetic nanocarriers containing rapamycin were combined with free soluble Ovalbumin (323-339) to evaluate induction of tDC (FIG. 2). It was found that nanocarriers containing rapamycin combined with free ovalbumin (323-339) induces Treg development. Briefly, antigen specific tDC were obtained by isolating dendritic cells (CD11c.sup.+ splenocytes) and culturing them in combination with the Ovalbumin (323-339) peptide plus soluble or nanocarrier encapsulated rapamycin (Synthetic Nanocarrier #s 13, 14, 15 and 16) for 2 hours followed by extensive washing. Purified responder CD4.sup.+CD25.sup.- cells were isolated from OTII mice and added to the tDC. The mixture of tDC and OTII T cells were then cultured for 4-5 days, and the frequency of Treg cells (CD4.sup.+CD25highFoxP3.sup.+) were analyzed by flow cytometry. The data show a dose dependent increase in CD4.sup.+CD25highFoxP3.sup.+ for both free rapamycin and nanocarrier encapsulated rapamycin suggesting induction of Treg by rapamycin nanocarrier treated DC.

[0253] Various nanocarrier compositions were used to evaluate induction of tDC (FIG. 3), and the induction of Treg was demonstrated. It was found that nanocarriers with co-encapsulated rapamycin and Ovalbumin (323-339) peptide resulted in higher induction of FoxP3 expressing cells (6.5%) than either unstimulated (1.3%) or rapamycin alone (2.7%). Interestingly, two separate nanocarrier compositions containing rapamycin alone (Synthetic Nanocarrier #s 7 and 8) demonstrated superior induction of FoxP3 expressing cells (22.4% and 27.2%, respectively) when combined with a population of synthetic nanocarriers containing Ovalbumin (323-339) as compared to an admixture with free Ovalbumin (323-339) peptide (12.7% and 17.7%, respectively). Overall, the data show an increase in CD4.sup.+CD25highFoxP3.sup.+ when using nanocarrier encapsulated rapamycin with superior responses seen with either co-encapsulated Ovalbumin (323-339) peptide or with admixed Ovalbumin (323-339) peptide containing nanocarrier.

Example 6

Evaluating Tolerogenic Immune Response by T Cell Phenotypic Analysis (Prophetic)

[0254] A composition of the invention is dissolved in phosphate-buffered saline (PBS) and injected into female Lewis rats intramuscularly in 0.1-0.2 ml containing 50014 of the composition. A control group of rats receives 0.1-0.2 ml of PBS. Nine to ten days after the injection, spleen and lymph nodes are harvested from the rats and single cell suspensions obtained by macerating tissues through a 40 .mu.m nylon cell strainer. Samples are stained in PBS (1% FCS) with the appropriate dilution of relevant monoclonal antibodies. Propidum iodide staining cells are excluded from analysis. Samples are acquired on an LSR2 flow cytometer (BD Biosciences, USA) and analyzed using FACS Diva software. The expression of markers CD4, CD25high and FoxP3 is analyzed on the cells. The presence of CD4.sup.+CD25highFoxP3.sup.+ cells suggests an induction of CD4+ Treg cells.

Example 7

Evaluating Tolerogenic Immune Response to APC Presentable Antigen In Vivo (Prophetic)

[0255] Balb/c mice are immunized with an APC presentable antigen in incomplete Freunds adjuvant to induce T cell proliferation (e.g., CD4.sup.+ T cell), the level of which is assessed. Subsequently, a composition of the invention comprising the APC presentable antigen and an immunosuppressant is administered subcutaneously in a dose-dependent manner. The same mice are then again exposed to the APC presentable antigen, and the level of T cell proliferation is again assessed. Changes in the T cell population are then monitored with a reduction in T cell proliferation upon subsequent challenge with the APC presentable antigen indicating a tolerogenic immune response.

Example 8

Evaluating Tolerogenic Immune Responses with Synthetic Nanocarriers Comprising Immunosuppressant and APC Presentable Antigen In Vivo

Materials and Methods of Synthetic Nanocarrier Production

Nanocarrier 1

[0256] Rapamycin was purchased from TSZ CHEM (185 Wilson Street, Framingham, Mass. 01702; Product Catalogue # R1017). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). PLA-PEG block co-polymer with a PEG block of approximately 5,000 Da and PLA block of approximately 20,000 Da was synthesized. Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0257] Solutions were prepared as follows:

[0258] Solution 1: Rapamycin @ 50 mg/mL in methylene chloride. The solution was prepared by dissolving rapamycin in pure methylene chloride. Solution 2: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 3: PLA-PEG @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLA-PEG in pure methylene chloride. Solution 4: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0259] An oil-in-water emulsion was used to prepare the nanocarriers. The O/W emulsion was prepared by combining solution 1 (0.2 mL), solution 2 (0.75 mL), solution 3 (0.25 mL), and solution 4 (3 mL) in a small pressure tube and sonicating at 30% amplitude for 60 seconds using a Branson Digital Sonifier 250. The O/W emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers was washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 21,000.times.g and 4.degree. C. for 45 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

[0260] Nanocarrier size was determined by dynamic light scattering. The amount of rapamycin in the nanocarrier was determined by HPLC analysis. The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method.

TABLE-US-00005 Effective Diameter Rapamycin Content Nanocarrier ID (nm) (% w/w) Nanocarrier 1 215 9.5

Nanocarrier 2

[0261] Ovalbumin peptide 323-339, a 17 amino acid peptide known to be a T and B cell epitope of Ovalbumin protein, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505; Part #4065609). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). PLA-PEG block co-polymer with a PEG block of approximately 5,000 Da and PLA block of approximately 20,000 Da was synthesized. Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0262] Solutions were prepared as follows:

[0263] Solution 1: Ovalbumin peptide 323-339 @ 20 mg/mL in dilute hydrochloric acid aqueous solution. The solution was prepared by dissolving ovalbumin peptide in 0.13 M hydrochloric acid solution at room temperature. Solution 2: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 3: PLA-PEG @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLA-PEG in pure methylene chloride. Solution 4: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0264] A primary water-in-oil emulsion was prepared first. W1/O1 was prepared by combining solution 1 (0.2 mL), solution 2 (0.75 mL), and solution 3 (0.25 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) was then prepared by combining solution 4 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.

[0265] The W1/O1/W2 emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers were washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600.times.g and 4.degree. C. for 35 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

[0266] Nanocarrier size was determined by dynamic light scattering. The amount of peptide in the nanocarrier was determined by HPLC analysis. The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method.

TABLE-US-00006 Effective Diameter Peptide Content Nanocarrier ID (nm) (% w/w) Nanocarrier 2 234 2.1

Nanocarrier 3

[0267] Simvastatin was purchased from LKT Laboratories, Inc. (2233 University Avenue West, St. Paul, Minn. 55114; Product Catalogue # S3449). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). PLA-PEG block co-polymer with a PEG block of approximately 5,000 Da and PLA block of approximately 20,000 Da was synthesized. Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0268] Solutions were prepared as follows:

[0269] Solution 1: Simvastatin @ 50 mg/mL in methylene chloride. The solution was prepared by dissolving simvastatin in pure methylene chloride. Solution 2: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 3: PLA-PEG @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLA-PEG in pure methylene chloride. Solution 4: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0270] An oil-in-water emulsion was used to prepare the nanocarriers. The O/W emulsion was prepared by combining solution 1 (0.15 mL), solution 2 (0.75 mL), solution 3 (0.25 mL), and solution 4 (3 mL) in a small pressure tube and sonicating at 30% amplitude for 60 seconds using a Branson Digital Sonifier 250. The O/W emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers was washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600.times.g and 4.degree. C. for 35 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

[0271] Nanocarrier size was determined by dynamic light scattering. The amount of simvastatin in the nanocarrier was determined by HPLC analysis. The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method.

TABLE-US-00007 Effective Diameter Simvastatin Content Nanocarrier ID (nm) (% w/w) Nanocarrier 3 196 8.0

Nanocarrier 4

[0272] Ovalbumin peptide 323-339, a 17 amino acid peptide known to be a T and B cell epitope of Ovalbumin protein, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505; Part #4065609). Rapamycin was purchased from TSZ CHEM (185 Wilson Street, Framingham, Mass. 01702; Product Catalogue # R1017). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). PLA-PEG block co-polymer with a PEG block of approximately 5,000 Da and PLA block of approximately 20,000 Da was synthesized. Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0273] Solutions were prepared as follows:

[0274] Solution 1: Ovalbumin peptide 323-339 @ 20 mg/mL in dilute hydrochloric acid aqueous solution. The solution was prepared by dissolving ovalbumin peptide in 0.13 M hydrochloric acid solution at room temperature. Solution 2: Rapamycin @ 50 mg/mL in methylene chloride. The solution was prepared by dissolving rapamycin in pure methylene chloride. Solution 3: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 4: PLA-PEG @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLA-PEG in pure methylene chloride. Solution 5: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0275] A primary water-in-oil emulsion was prepared first. W1/O1 was prepared by combining solution 1 (0.2 mL), solution 2 (0.2 mL), solution 3 (0.75 mL), and solution 4 (0.25 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) was then prepared by combining solution 5 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.

[0276] The W1/O1/W2 emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers were washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 21,000.times.g and 4.degree. C. for 45 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

[0277] Nanocarrier size was determined by dynamic light scattering. The amounts of peptide and rapamycin in the nanocarrier were determined by HPLC analysis. The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method.

TABLE-US-00008 Peptide Effective Diameter Rapamycin Content Content Nanocarrier ID (nm) (% w/w) (% w/w) 4 227 9.0 2.5

Nanocarrier 5

[0278] Ovalbumin peptide 323-339, a 17 amino acid peptide known to be a T and B cell epitope of Ovalbumin protein, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance Calif. 90505; Part #4065609). Simvastatin was purchased from LKT Laboratories, Inc. (2233 University Avenue West, St. Paul, Minn. 55114; Product Catalogue # S3449). PLGA with a lactide:glycolide ratio of 3:1 and an inherent viscosity of 0.75 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 7525 DLG 7A). PLA-PEG block co-polymer with a PEG block of approximately 5,000 Da and PLA block of approximately 20,000 Da was synthesized. Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0279] Solutions were prepared as follows:

[0280] Solution 1: Ovalbumin peptide 323-339 @ 20 mg/mL in dilute hydrochloric acid aqueous solution. The solution was prepared by dissolving ovalbumin peptide in 0.13 M hydrochloric acid solution at room temperature. Solution 2: Simvastatin @ 50 mg/mL in methylene chloride. The solution was prepared by dissolving simvastatin in pure methylene chloride. Solution 3: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLGA in pure methylene chloride. Solution 4: PLA-PEG @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving PLA-PEG in pure methylene chloride. Solution 5: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0281] A primary water-in-oil emulsion was prepared first. W1/O1 was prepared by combining solution 1 (0.2 mL), solution 2 (0.15 mL), solution 3 (0.75 mL), and solution 4 (0.25 mL) in a small pressure tube and sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary emulsion (W1/O1/W2) was then prepared by combining solution 5 (3.0 mL) with the primary W1/O1 emulsion, vortexing for 10 s, and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.

[0282] The W1/O1/W2 emulsion was added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers were washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600.times.g and 4.degree. C. for 35 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

[0283] Nanocarrier size was determined by dynamic light scattering. The amounts of peptide and simvastatin in the nanocarrier were determined by HPLC analysis. The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method.

TABLE-US-00009 Peptide Effective Diameter Simvastatin Content Content Nanocarrier ID (nm) (% w/w) (% w/w) Nanocarrier 5 226 2.7 1.9

In Vivo Administration 1

[0284] Spleens from B6.Cg-Tg(TcraTcrb)425Cbn/J (DTII) and C57BL/6 (B6) mice were harvested, mechanically dissociated and filtered separately through a 70 .mu.M sieve to yield a single-cell suspension. Purified CD4.sup.+CD25- cells were then extracted in a 2-step process. Using a Miltenyi Biotec AutoMACS magnetic cell sorter spleen cells were first labeled with CD4.sup.+ T-cell isolation kit II and the unlabeled fraction was depleted of CD25.sup.+ cells with CD25 depletion kit. The purified B6 cells were stained with an intracellular dye, Carboxyfluorescein Succinimidyl Ester (CFSE), before being admixed at equal concentrations with the purified OTII cells. They were then injected intravenously (i.v.) into B6.SJL-Ptprc.sup.a/BoyAi (CD45.1) recipient mice.

[0285] The next day the recipient CD45.1 mice were treated with targeted tolerogenic synthetic vaccine particles (t.sup.2SVP). They were loaded with combinations of ovalbumin peptide (323-339) (OVA.sup.323-339), Rapamycin (Rapa) and/or Simvastatin (Simva) and were administered subcutaneously (s.c.).

[0286] The injection constitutes a tolerogenic treatment and was followed by 4 more injections each spaced 2 weeks apart. After the treatment schedule was completed the recipient CD45.1 animals were killed and their spleens and popliteal lymph nodes were harvested, mechanically dissociated and filtered separately through a 70 .mu.M sieve to yield a single-cell suspension. The spleen cells were depleted of red blood cells (RBCs) by incubation with RBC lysis buffer (Stem Cell Technologies) and cell counts were performed on both the spleens and lymph nodes.

[0287] Spleen or lymph node cells were cultured in CM (complete media) supplemented with 10 U/ml IL-2, restimulated with OPII at 0.3.times.10.sup.6cells/well in 96-well round bottom (RB) plates and incubated at 37.degree. C., 5% CO.sub.2. Cells were split at Day 2 and harvested on Day 5. Supernatants were collected and frozen while cells were stained for phenotypic analysis by flow cytometry. The cells were analyzed on a Becton Dickinson FacsCanto flow cytometer.

In Vivo Administration 2

[0288] Spleens from B6.Cg-Tg(TcraTcrb)425Cbn/J (OTII) and C57BL/6 (B6) mice were harvested, mechanically dissociated and filtered separately through a 70 .mu.M sieve to yield a single-cell suspension. Purified CD4.sup.+CD25- cells were then extracted in a 2-step process using a Miltenyi Biotec AutoMACS magnetic cell sorter. Spleen cells were labeled using Miltenyi's CD4.sup.+ T-cell isolation kit II. The unlabeled CD4+ T-cell fraction was then depleted of CD25.sup.+ cells with CD25 depletion kit. The purified CD4 cells from B6 mice were then stained with an intracellular dye, Carboxyfluorescein Succinimidyl Ester (CFSE), before being admixed at equal concentrations with the purified OTII cells. They were then injected intravenously (i.v.) into B6.SJL-Ptprc.sup.a/BoyAi (CD45.1) recipient mice.

[0289] The next day the recipient CD45.1 mice were treated with targeted tolerogenic synthetic vaccine particles. They comprised combinations of ovalbumin peptide (323-339) (OVA.sup.323-339), Rapamycin (Rapa) and Simvastatin (Simva) and were administered subcutaneously (s.c.) or intravenously (i.v.).

[0290] After the treatment schedule was completed the recipient CD45.1 animals were killed and their spleens and popliteal lymph nodes were harvested, mechanically dissociated and filtered separately through a 70 .mu.M sieve to yield a single-cell suspension. The spleen cells were depleted of red blood cells (RBCs) by incorporation with RBC lysis buffer (Stem Cell Technologies) and cell counts were performed on both the spleens and lymph nodes.

[0291] Spleen or lymph node cells were cultured in CM supplemented with 10 U/ml IL-2, restimulated with 1 .mu.M OPII at 0.3.times.10.sup.6cells/well in 96-well round bottom (RB) plates and incubated at 37.degree. C., 5% CO.sub.2. Cells were split at Day 2 and harvested on Day 5. Supernatants were collected and frozen while cells were stained for phenotypic analysis by flow cytometry. The cells were analyzed on a Becton Dickinson FacsCanto flow cytometer.

Results

[0292] The results are shown in FIGS. 4 and 5 (Immunomodulator 1: rapamycin; immunomodulator 2: simvastatin). The figures shows in vivo effects and demonstrates that the number of immune cells is reduced by synthetic nanocarriers comprising antigen and immunosuppressants when compared to antigen-only nanocarrier. FIG. 5 demonstrates an increase in the percentage of immune cells that express FoxP3 with synthetic nanocarriers comprising antigen and immunosuppressant.

Example 9

Evaluating CD69 Activation with Synthetic Nanocarriers Comprising Immunosuppressant

Nanocarriers

[0293] .alpha.-Galactosyl Ceramide (KRN7000) was purchased from Avanti Polar Lipids, Inc. (700 Industrial Park Drive Alabaster, Ala. 35007-9105; Catalog number 867000P). PLGA with a lactide:glycolide ratio of 1:1 and an inherent viscosity of 0.45 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, Ala. 35211; Product Code 5050 DLG 4.5A). Polyvinyl alcohol (85-89% hydrolyzed) was purchased from EMD Chemicals (Product Number 1.41350.1001).

[0294] Solutions were prepared as follows:

[0295] Solution 1: KRN7000 @ 2 mg/mL in dimethylsulfoxide (DMSO). The solution was prepared by dissolving the dry lipid in pure DMSO. Solution 2: PLGA @ 100 mg/mL in methylene chloride. The solution was prepared by dissolving the PLGA in pure methylene chloride. Solution 3: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer.

[0296] A water-in-oil emulsion, (W/O) was prepared by combining solution 1 (1 mL), solution 2 (1 mL), solution 3 (3 mL) in a small pressure tube and sonicating at 30% amplitude for 60 seconds using a Branson Digital Sonifier model 250, with the pressure tube immersed in an ice water bath. The W/O emulsion was then added to a beaker containing 70 mM pH 8 phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the methylene chloride to evaporate and for the nanocarriers to form. A portion of the nanocarriers were washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600.times.g at 4.degree. C. for 45 min, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. The washing procedure was repeated, and the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL. Nanocarrier size was determined by dynamic light scattering. The amount of KRN7000 in the nanocarrier is reported as the theoretical loading given no loss on processing. The total dry-nanocarrier mass per mL of suspension (NP concentration), was determined by a gravimetric method.

TABLE-US-00010 KRN7000 Content NP Effective Diameter (Theoretical % concentration Nanocarrier (nm) wt/wt) (mg/mL) 212 2.0 9.0

Immunization

[0297] Mice were designated to groups that received PBS alone, sol aGC+solRAPA, sol aGC+NP RAPA. Mice were injected at 9 am and at 9.30 AM received BrefeldinA i.v. to prevent release of intracellular cytokines produced. At 1 pm, mice were sacrificed and the liver was perfused with PBS and processed to obtain a single cell suspension enriched for lymphocytes. Cells were stained with cell surface markers for iNKT cells (agc-loaded CD1d tetramers) and T cells receptor (TCRb) and activation marker CD69. Cells were acquired on a FacsCanto flow cytometer and analyzed on by FlowJo.

Results

[0298] iNKT cells from mice that received aGC were activated as seen by cytokine production and up regulation of CD69 on their surface. Both soluble and nanocarrier Rapamycin caused a significant decrease in surface levels of CD69 on iNKT cells, suggesting the cells were less activated following treatment compared to PBS treatment control. The results are shown in FIG. 6.

Example 10

Mesoporous Silica-Gold Core-Shell Nanocarriers Containing Ovalbumin (Prophetic)

[0299] Mesoporous SiO2 nanoparticle cores are created through a sol-gel process. Hexadecyltrimethyl-ammonium bromide (CTAB) (0.5 g) is dissolved in deionized water (500 mL), and then 2 M aqueous NaOH solution (3.5 mL) is added to the CTAB solution. The solution is stirred for 30 min, and then Tetraethoxysilane (TEOS) (2.5 mL) is added to the solution. The resulting gel is stirred for 3 h at a temperature of 80.degree. C. The white precipitate which forms is captured by filtration, followed by washing with deionized water and drying at room temperature. The remaining surfactant is then extracted from the particles by suspension in an ethanolic solution of HCl overnight. The particles are washed with ethanol, centrifuged, and redispersed under ultrasonication. This wash procedure is repeated two additional times.

[0300] The SiO2 nanoparticles are then functionalized with amino groups using (3-aminopropyl)-triethoxysilane (APTMS). To do this, the particles are suspended in ethanol (30 mL), and APTMS (50 .mu.L) is added to the suspension. The suspension is allowed to stand at room temperature for 2 h and then is boiled for 4 h, keeping the volume constant by periodically adding ethanol. Remaining reactants are removed by five cycles of washing by centrifugation and redispersing in pure ethanol.

[0301] In a separate reaction, 1-4 nm diameter gold seeds are created. All water used in this reaction is first deionized and then distilled from glass. Water (45.5 mL) is added to a 100 mL round-bottom flask. While stirring, 0.2 M aqueous NaOH (1.5 mL) is added, followed by a 1% aqueous solution of tetrakis(hydroxymethyl)phosphonium chloride (THPC) (1.0 mL). Two minutes after the addition of THPC solution, a 10 mg/mL aqueous solution of chloroauric acid (2 mL), which has been aged at least 15 min, is added. The gold seeds are purified through dialysis against water.

[0302] To form the core-shell nanocarriers, the amino-functionalized SiO2 nanoparticles formed above are first mixed with the gold seeds for 2 h at room temperature. The gold-decorated SiO2 particles are collected through centrifugation and mixed with an aqueous solution of chloroauric acid and potassium bicarbonate to form the gold shell. The particles are then washed by centrifugation and redispersed in water. Thiolated Ovalbumin (made by treating Ovalbumin with 2-iminothiolane hydrochloride) is loaded by suspending the particles in a solution of thiolated Ovalbumin (1 mg/L) for 72 h. The particles is then pellet washed with 1.times.PBS (pH 7.4) to remove free protein. The resulting silica-gold core-shell nanocarriers containing Ovalbumin are then re-suspended in 1.times.PBS for further analysis and assays.

Example 11

Liposomes Containing Rapamycin and Ovalbumin (Prophetic)

[0303] The liposomes are formed by thin film hydration. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (32 .mu.mol), cholesterol (32 .mu.mol), and rapamycin (6.4 .mu.mol) are dissolved in pure chloroform (3 mL). This lipid solution is added to a 10 mL glass tube and the solvent is removed under nitrogen gas stream and desiccated for 6 hr. under vacuum. Multilamellar vesicles are obtained by hydration of the film with 2.0 ml of 25 mM MOPS buffer pH 8.5, containing excess amount of Ovalbumin. The tube is vortexed until the lipid film is peeled of from the tube surface. To break the multilamellar vesicles into monolamellar, ten cycles of freezing (liquid nitrogen) and thawing (30.degree. C. water bath) are applied. The sample is then diluted to 1 ml in 25 mM MOPS buffer pH 8.5. Size of the resulting liposome is homogenized by extrusion by passing the sample 10 fold through a 200 nm pore polycarbonate filters. The resulting liposomes are then used for further analysis and bioassays.

Example 12

Polymeric Nanocarriers Composed of Modified Polyamino Acid with Surface Conjugated Ovalbumin (Prophetic)

[0304] Step-1. Preparation of Poly(.gamma.-glutamic acid) (.gamma.-PGA) modified with L-phenylalanine ethyl ester (L-PAE): 4.7 unit mmol of .gamma.-PGA (Mn=300 kD) is dissolved in 0.3 N--NaHCO3 aqueous solution (50 mL). L-PAE (4.7 mmol) and EDC.HCl (4.7 mmol) are added to the solution and stirred for 30 min at 4 C. The solution is then maintained at room temperature with stirring for 24 h. Low-molecular-weight chemicals are removed by dialysis using dialysis membrane with MWCO 50 kD. The resulting .gamma.-PGA-graft-L-PAE is obtained by freeze-drying.

[0305] Step-2. Preparation of nanoparticles from .gamma.-PGA-graft-L-PAE polymer: Nanoparticles composed of .gamma.-PGA-graft-L-PAE are prepared by a precipitation and dialysis method. .gamma.-PGA-graft-L-PAE (20 mg) was dissolved in 2 ml of DMSO followed by addition of 2 mL of water to form a translucent solution. The solution is then dialyzed against distilled water using cellulose membrane tubing (50,000 MWCO) to form the nanoparticles and to remove the organic solvents for 72 h at room temperature. The distilled water is exchanged at intervals of 12 h. The resulting nanoparticle solution (10 mg/mL in water) is then used for antigen conjugation.

[0306] Step-3. Ovalbumin conjugation to .gamma.-PGA nanoparticles: Surface carboxylic acid groups of the .gamma.-PGA nanoparticles (10 mg/ml) are first activated by EDC and NHS (10 mg/mL each in phosphate buffer, pH 5.8) for 2 h at ambient temperature. After pellet washing to remove excess EDC/NHS, the activated nanoparticles are mixed with 1 mL of Ovalbumin (10 mg/ml) in phosphate-buffered saline (PBS, pH 7.4) and the mixture is incubated at 4-8 C for 24 h. The resulting Ovalbumin conjugated .gamma.-PGA nanoparticles are washed twice with PBS and resuspended at 5 mg/mL in PBS for further analysis and bioassays.

Example 13

Erythropoietin (EPO)-Encapsulated .gamma.-PGA Nanoparticles (Prophetic)

[0307] To prepare the EPO-encapsulated 7-PGA nanoparticles, 0.25-4 mg of EPO is dissolved in 1 mL of PBS (pH 7.4) and 1 mL of the .gamma.-PGA-graft-L-PAE (10 mg/mL in DMSO) is added to the EPO solution. The resulting solution is centrifuged at 14,000.times.g for 15 min and repeatedly rinsed with PBS. The resulting EPO-encapsulated .gamma.-PGA nanoparticles are then resuspended in PBS (5 mg/mL) for further analysis and bioassay.

Example 14

Preparation of Gold Nanocarriers (AuNCs) Containing Ovalbumin (Prophetic)

[0308] Step-1. Formation of Gold NCs (AuNCs): An aq. solution of 500 mL of 1 mM HAuCl4 is heated to reflux for 10 min with vigorous stirring in a 1 L round-bottom flask equipped with a condenser. A solution of 50 mL of 40 mM of trisodium citrate is then rapidly added to the stirring solution. The resulting deep wine red solution is kept at reflux for 25-30 min and the heat is withdrawn and the solution is cooled to room temperature. The solution is then filtered through a 0.8 .mu.m membrane filter to give the AuNCs solution. The AuNCs are characterized using visible spectroscopy and transmission electron microscopy. The AuNCs are ca. 20 nm diameter capped by citrate with peak absorption at 520 nm.

[0309] Step-2. Conjugation of Ovalbumin to AuNCs: A solution of 150 .mu.l of thiolated Ovalbumin (10 .mu.M in 10 mM pH 9.0 carbonate buffer) is added to 1 mL of 20 nm diameter citrate-capped gold nanocarriers (1.16 nM) to produce a molar ratio of thiol to gold of 2500:1. The mixture is stirred at room temperature under argon for 1 hour to allow complete exchange of thiol with citrate on the gold nanocarriers. The AuNCs with Ovalbumin on the surface is then purified by centrifuge at 12,000 g for 30 minutes. The supernatant is decanted and the pellet containing AuNC-Ovalbumin is then pellet washed with 1.times.PBS buffer. The purified Gold-Ovalbumin nanocarriers are then resuspend in suitable buffer for further analysis and bioassays.

F. REFERENCES

[0310] Listing of any reference herein is not an admission that the reference or its teachings is/are prior art. [0311] Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Zeiser R, Leveson-Gower D B, Zambricki E A, Kambham N, Beilhack A, Loh J, Hou J Z, Negrin R S. Blood. 2008 Jan. 1; 111(1):453-62. [0312] Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. Zhang W, Zhang D, Shen M, Liu Y, Tian Y, Thomson A W, Lee W P, Zheng X X. J Immunol. 2010 Oct. 15; 185(8):4750-9. [0313] Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J. J Biomed Mater Res A. 2008 Mar. 15; 84(4):885-98. [0314] Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells. Das S, Haddadi A, Veniamin S, Samuel J. J Biomed Mater Res A. 2008 Jun. 15; 85(4):983-92. [0315] Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. Raimondi G, Sumpter T L, Matta B M, Pillai M, Corbitt N, Vodovotz Y, Wang Z, Thomson A W. J Immunol. 2010 Jan. 15; 184(2):624-36. [0316] mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Turnquist H R, Cardinal J, Macedo C, Rosborough B R, Sumpter T L, Geller D A, Metes D, Thomson A W. Blood. 2010 Jun. 10; 115(23):4758-69. [0317] Immunoregulatory functions of mTOR inhibition. Thomson A W, Turnquist H R, Raimondi G. Nat Rev Immunol. 2009 May; 9(5):324-37. [0318] Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. Pothoven K L, Kheradmand T, Yang Q, Houlihan J L, Zhang H, Degutes M, Miller S D, Luo X. Am J Transplant. 2010 August; 10(8):1774-84. [0319] Yagiie, C.; Arruebo M.; Santamaria, J. NIR-enhanced drug release from porous Au/SiO.sub.2 nanoparticles. Chem. Commun. 46, 7513-7515 (2010). [0320] Zeng, W.; Qian, X.; Zhang, Y.; Yin, J.; Zhu, Z. Organic modified mesoporous MCM-41 through solvothermal process as drug delivery system. Mater. Res. Bull. 40, 766-772 (2005). [0321] Oldenburg, S. J.; Westcott, S. L.; Averitt, R. D.; Halas, N. J. Surface enhanced Raman scattering in the near infrared using metal nanoshell substrates. J. Chem. Phys. 111, 4729-4735 (1999). [0322] Duff, D. G.; Baiker, A. A new hydrosol of gold clusters. 1. Formation and particle size variation. Langmuir 9, 2301-2309 (1993). [0323] Gregoriadis, G.; McCormack B.; Obrenovic, M.; Saffie, R.; Brahim, Z.; Perrie, Y. Vaccine entrapment in liposomes. Methods 19, 156-162 (1999). [0324] Arulsudar, N.; Subramanian, N.; Mishra, P.; Sharma, R. K.; Murthy, R. S. R. Preparation, characterisation and biodistribution of .sup.99mTc-labeled liposome encapsulated cyclosporine. J. Drug Target. 11, 187-196 (2003).

Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 943 <210> SEQ ID NO 1 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 1 Ala Gly Met Asp Met Cys Ser Ala Gly Trp Leu Ala Asp Arg Ser Val 1 5 10 15 Arg Tyr <210> SEQ ID NO 2 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 2 Glu Asp Ser Glu Ala Thr Leu Glu Val Val Val Lys Gly Ile Val Phe 1 5 10 15 His Tyr <210> SEQ ID NO 3 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 3 Ser Arg Val Ser Lys Glu Lys Glu Val Val Leu Leu Val Ala Thr Glu 1 5 10 15 Gly Arg <210> SEQ ID NO 4 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 4 Val Val Leu Leu Val Ala Thr Glu Gly Arg Val Arg Val Asn Ser Ala 1 5 10 15 Tyr Gln <210> SEQ ID NO 5 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 5 Val Val Val Lys Gly Ile Val Phe His Tyr Arg Ala Ile Ser Thr Arg 1 5 10 15 Tyr Thr <210> SEQ ID NO 6 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha 2 type VI collagen isoform 2C2 precursor epitope <400> SEQUENCE: 6 Asp Arg Ala Ser Phe Ile Lys Asn Leu 1 5 <210> SEQ ID NO 7 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 7 Ala Ser Ser Thr Ile Ile Lys Glu Gly Ile Asp Arg Thr Val Leu Gly 1 5 10 15 Ile Leu Val Ser 20 <210> SEQ ID NO 8 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 8 Ala Ser Thr Pro Thr Lys Leu Gln Glu Ser Leu Leu Lys Lys Leu Gly 1 5 10 15 Ser Asn Thr Tyr 20 <210> SEQ ID NO 9 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 9 Asp Arg Thr Val Leu Gly Ile Leu Val Ser Tyr Gln Ile Lys Val Lys 1 5 10 15 Leu Thr Val Ser 20 <210> SEQ ID NO 10 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 10 Glu Phe Ala Arg His Asn Leu Lys Asp Ala Gly Glu Ala Glu Glu Gly 1 5 10 15 Lys Arg Asp Lys 20 <210> SEQ ID NO 11 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 11 Glu Pro Asn His Val Ile Phe Lys Lys Ile Ser Arg Asp Lys Ser Val 1 5 10 15 Thr Ile Tyr Leu 20 <210> SEQ ID NO 12 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 12 Phe Glu Val Lys Ala Phe Ala Thr Asp Ser Thr Asp Ala Glu Glu Asp 1 5 10 15 Lys Ile Pro Lys 20 <210> SEQ ID NO 13 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 13 Gly Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val Pro 1 5 10 15 Phe Arg Leu Met 20 <210> SEQ ID NO 14 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 14 Gly Lys Ile Lys His Glu Asp Thr Asn Leu Ala Ser Ser Thr Ile Ile 1 5 10 15 Lys Glu Gly Ile 20 <210> SEQ ID NO 15 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 15 Gly Asn Arg Asp Tyr Ile Asp His Val Ser Gln Val Gln Pro Val Asp 1 5 10 15 Gly Val Val Leu 20 <210> SEQ ID NO 16 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 16 Lys Pro Val Ala Met Glu Glu Ala Gln Glu Lys Val Pro Pro Asn Ser 1 5 10 15 Thr Leu Thr Lys 20 <210> SEQ ID NO 17 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 17 Lys Val Pro Pro Asn Ser Thr Leu Thr Lys Thr Leu Thr Leu Leu Pro 1 5 10 15 Leu Leu Ala Asn 20 <210> SEQ ID NO 18 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 18 Leu Leu Lys Lys Leu Gly Ser Asn Thr Tyr Pro Phe Leu Leu Thr Phe 1 5 10 15 Pro Asp Tyr Leu 20 <210> SEQ ID NO 19 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 19 Leu Thr Phe Arg Arg Asp Leu Tyr Phe Ser Arg Val Gln Val Tyr Pro 1 5 10 15 Pro Val Gly Ala 20 <210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 20 Met Ala Ala Ser Gly Lys Thr Ser Lys Ser Glu Pro Asn His Val Ile 1 5 10 15 Phe Lys Lys Ile 20 <210> SEQ ID NO 21 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 21 Asn Arg Glu Arg Arg Gly Ile Ala Leu Asp Gly Lys Ile Lys His Glu 1 5 10 15 Asp Thr Asn Leu 20 <210> SEQ ID NO 22 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 22 Pro Cys Ser Val Met Leu Gln Pro Ala Pro Gln Asp Ser Gly Lys Ser 1 5 10 15 Cys Gly Val Asp 20 <210> SEQ ID NO 23 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 23 Pro Phe Leu Leu Thr Phe Pro Asp Tyr Leu Pro Cys Ser Val Met Leu 1 5 10 15 Gln Pro Ala Pro 20 <210> SEQ ID NO 24 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 24 Gln Asp Ser Gly Lys Ser Cys Gly Val Asp Phe Glu Val Lys Ala Phe 1 5 10 15 Ala Thr Asp Ser 20 <210> SEQ ID NO 25 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 25 Gln Val Gln Pro Val Asp Gly Val Val Leu Val Asp Pro Asp Leu Val 1 5 10 15 Lys Gly Lys Lys 20 <210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 26 Arg Val Gln Val Tyr Pro Pro Val Gly Ala Ala Ser Thr Pro Thr Lys 1 5 10 15 Leu Gln Glu Ser 20 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 27 Ser Arg Asp Lys Ser Val Thr Ile Tyr Leu Gly Asn Arg Asp Tyr Ile 1 5 10 15 Asp His Val Ser 20 <210> SEQ ID NO 28 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 28 Thr Leu Thr Leu Leu Pro Leu Leu Ala Asn Asn Arg Glu Arg Arg Gly 1 5 10 15 Ile Ala Leu Asp 20 <210> SEQ ID NO 29 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 29 Val Ala Thr Glu Val Pro Phe Arg Leu Met His Pro Gln Pro Glu Asp 1 5 10 15 Pro Ala Lys Glu 20 <210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 30 Val Asp Pro Asp Leu Val Lys Gly Lys Lys Val Tyr Val Thr Leu Thr 1 5 10 15 Cys Ala Phe Arg 20 <210> SEQ ID NO 31 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 31 Val Val Leu Tyr Ser Ser Asp Tyr Tyr Val Lys Pro Val Ala Met Glu 1 5 10 15 Glu Ala Gln Glu 20 <210> SEQ ID NO 32 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 32 Tyr Gln Ile Lys Val Lys Leu Thr Val Ser Gly Phe Leu Gly Glu Leu 1 5 10 15 Thr Ser Ser Glu 20 <210> SEQ ID NO 33 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain B, Structure Of Insulin epitope <400> SEQUENCE: 33 Ala Leu Tyr Leu Val Cys Gly Glu Arg 1 5 <210> SEQ ID NO 34 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain B, Structure Of Insulin epitope <400> SEQUENCE: 34 Ser His Leu Val Glu Ala Leu Tyr Leu Val 1 5 10 <210> SEQ ID NO 35 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens chaperonin (HSP60) epitope <400> SEQUENCE: 35 Gln Met Arg Pro Val Ser Arg Val Leu 1 5 <210> SEQ ID NO 36 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-3(IV) chain epitope <400> SEQUENCE: 36 Gly Ser Pro Ala Thr Trp Thr Thr Arg 1 5 <210> SEQ ID NO 37 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 1 precursor epitope <400> SEQUENCE: 37 Ala Arg Gly Gln Pro Gly Val Met Gly 1 5 <210> SEQ ID NO 38 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase 1 epitope <400> SEQUENCE: 38 Lys Met Leu Asp His Glu Tyr Thr Thr 1 5 <210> SEQ ID NO 39 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ezrin epitope <400> SEQUENCE: 39 Glu Tyr Thr Ala Lys Ile Ala Leu Leu 1 5 <210> SEQ ID NO 40 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ezrin epitope <400> SEQUENCE: 40 Leu Asn Ile Tyr Glu Lys Asp Asp Lys Leu 1 5 10 <210> SEQ ID NO 41 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glial fibrillary acidic protein isoform 2 epitope <400> SEQUENCE: 41 Asn Leu Ala Gln Asp Leu Ala Thr Val 1 5 <210> SEQ ID NO 42 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glial fibrillary acidic protein isoform 2 epitope <400> SEQUENCE: 42 Gln Leu Ala Arg Gln Gln Val His Val 1 5 <210> SEQ ID NO 43 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glucagon receptor epitope <400> SEQUENCE: 43 Arg Arg Arg Trp His Arg Trp Arg Leu 1 5 <210> SEQ ID NO 44 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glucose-6-phosphatase, catalytic, related epitope <400> SEQUENCE: 44 Phe Leu Trp Ser Val Phe Trp Leu Ile 1 5 <210> SEQ ID NO 45 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 1 epitope <400> SEQUENCE: 45 Asn Met Phe Thr Tyr Glu Ile Ala Pro Val Phe Val Leu Met Glu 1 5 10 15 <210> SEQ ID NO 46 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 46 Ile Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys 1 5 10 <210> SEQ ID NO 47 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 47 Asn Phe Phe Arg Met Val Ile Ser Asn Pro Ala Ala Thr 1 5 10 <210> SEQ ID NO 48 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 48 Phe Leu Gln Asp Val Met Asn Ile Leu 1 5 <210> SEQ ID NO 49 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 49 Leu Leu Gln Glu Tyr Asn Trp Glu Leu 1 5 <210> SEQ ID NO 50 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 50 Arg Met Met Glu Tyr Gly Thr Thr Met Val 1 5 10 <210> SEQ ID NO 51 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 51 Val Met Asn Ile Leu Leu Gln Tyr Val Val 1 5 10 <210> SEQ ID NO 52 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 52 Ala Phe Thr Ser Glu His Ser His Phe Ser Leu 1 5 10 <210> SEQ ID NO 53 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 53 Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys 1 5 10 <210> SEQ ID NO 54 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 54 Phe Lys Met Phe Pro Glu Val Lys Glu Lys Gly 1 5 10 <210> SEQ ID NO 55 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 55 Phe Thr Ser Glu His Ser His Phe Ser Leu 1 5 10 <210> SEQ ID NO 56 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 56 Met Ile Ala Arg Phe Lys Met Phe Pro Glu Val Lys Glu Lys Gly 1 5 10 15 <210> SEQ ID NO 57 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 57 Arg Phe Lys Met Phe Pro Glu Val Lys 1 5 <210> SEQ ID NO 58 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 58 Arg Phe Lys Met Phe Pro Glu Val Lys Glu 1 5 10 <210> SEQ ID NO 59 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 59 Arg Phe Lys Met Phe Pro Glu Val Lys Glu Lys 1 5 10 <210> SEQ ID NO 60 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 60 Thr Ser Glu His Ser His Phe Ser Leu 1 5 <210> SEQ ID NO 61 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 61 Val Met Asn Ile Leu Leu Gln Tyr Val 1 5 <210> SEQ ID NO 62 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 62 Glu Leu Ala Glu Tyr Leu Tyr Asn Ile 1 5 <210> SEQ ID NO 63 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 63 Ile Leu Met His Cys Gln Thr Thr Leu 1 5 <210> SEQ ID NO 64 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens heat shock 27kDa protein 1 epitope <400> SEQUENCE: 64 Gln Leu Ser Ser Gly Val Ser Glu Ile Arg His 1 5 10 <210> SEQ ID NO 65 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-27 alpha chain precursor epitope <400> SEQUENCE: 65 Leu Arg Arg Tyr Leu Glu Asn Gly Lys 1 5 <210> SEQ ID NO 66 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-7 alpha chain precursor epitope <400> SEQUENCE: 66 Val Met Ala Pro Arg Thr Val Leu Leu 1 5 <210> SEQ ID NO 67 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-7 alpha chain precursor epitope <400> SEQUENCE: 67 Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr 1 5 10 <210> SEQ ID NO 68 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 68 Ala Leu Asn Glu Asp Leu Ser Ser Trp Thr Ala Ala Asp Thr 1 5 10 <210> SEQ ID NO 69 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 69 Leu Leu Arg Gly Tyr His Gln Asp Ala Tyr 1 5 10 <210> SEQ ID NO 70 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 70 Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Glu Cys Val 1 5 10 15 <210> SEQ ID NO 71 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 71 Trp Asp Arg Glu Thr Gln Ile Cys Lys Ala Lys Ala Gln 1 5 10 <210> SEQ ID NO 72 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 72 Ala Leu Trp Gly Pro Asp Pro Ala Ala Ala Phe 1 5 10 <210> SEQ ID NO 73 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 73 Leu Ala Leu Trp Gly Pro Asp Pro Ala Ala 1 5 10 <210> SEQ ID NO 74 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 74 Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu 1 5 10 <210> SEQ ID NO 75 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 75 Ala Leu Trp Met Arg Leu Leu Pro Leu 1 5 <210> SEQ ID NO 76 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 76 His Leu Val Glu Ala Leu Tyr Leu Val 1 5 <210> SEQ ID NO 77 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 77 Ser Leu Gln Lys Arg Gly Ile Val Glu Gln 1 5 10 <210> SEQ ID NO 78 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 78 Ser Leu Gln Pro Leu Ala Leu Glu Gly 1 5 <210> SEQ ID NO 79 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 79 Ser Leu Tyr Gln Leu Glu Asn Tyr Cys 1 5 <210> SEQ ID NO 80 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 80 Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr 1 5 10 <210> SEQ ID NO 81 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 81 Trp Gly Pro Asp Pro Ala Ala Ala 1 5 <210> SEQ ID NO 82 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 82 Phe Tyr Thr Pro Lys Thr Arg Arg Glu 1 5 <210> SEQ ID NO 83 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 83 Gly Glu Arg Gly Phe Phe Tyr Thr 1 5 <210> SEQ ID NO 84 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 84 Glu Arg Gly Phe Phe Tyr Thr Pro Lys 1 5 <210> SEQ ID NO 85 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 85 Leu Cys Gly Ser His Leu Val Glu Ala Leu 1 5 10 <210> SEQ ID NO 86 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 86 Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr 1 5 10 <210> SEQ ID NO 87 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 87 Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe 1 5 10 <210> SEQ ID NO 88 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 88 Phe Leu Ile Val Leu Ser Val Ala Leu 1 5 <210> SEQ ID NO 89 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 89 Lys Leu Gln Val Phe Leu Ile Val Leu 1 5 <210> SEQ ID NO 90 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein epitope <400> SEQUENCE: 90 Phe Leu Trp Ser Val Phe Met Leu Ile 1 5 <210> SEQ ID NO 91 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 91 Phe Leu Phe Ala Val Gly Phe Tyr Leu 1 5 <210> SEQ ID NO 92 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 92 Leu Asn Ile Asp Leu Leu Trp Ser Val 1 5 <210> SEQ ID NO 93 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 93 Val Leu Phe Gly Leu Gly Phe Ala Ile 1 5 <210> SEQ ID NO 94 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 94 Asn Leu Phe Leu Phe Leu Phe Ala Val 1 5 <210> SEQ ID NO 95 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 95 Tyr Leu Leu Leu Arg Val Leu Asn Ile 1 5 <210> SEQ ID NO 96 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 96 Ala Leu Gln Lys Ala Lys Gln Asp Leu 1 5 <210> SEQ ID NO 97 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 97 Asp Ala Lys Asn Lys Leu Glu Gly Leu 1 5 <210> SEQ ID NO 98 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 98 Gly Ala Ser Gly Val Gly Ser Gly Leu 1 5 <210> SEQ ID NO 99 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 99 Lys Ala Lys Gln Asp Leu Ala Arg Leu 1 5 <210> SEQ ID NO 100 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 100 Lys Leu Glu Gly Leu Glu Asp Ala Leu 1 5 <210> SEQ ID NO 101 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 101 Asn Met Gln Asp Leu Val Glu Asp Leu 1 5 <210> SEQ ID NO 102 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 102 Arg Leu Leu Lys Glu Tyr Gln Glu Leu 1 5 <210> SEQ ID NO 103 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 103 Trp Tyr Gln Thr Lys Tyr Glu Glu Leu 1 5 <210> SEQ ID NO 104 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 104 Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp Leu Glu 1 5 10 15 Met Gln Ile Glu 20 <210> SEQ ID NO 105 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 105 Ala Leu Glu Glu Ala Asn Ala Asp Leu 1 5 <210> SEQ ID NO 106 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 106 Ala Asn Ala Asp Leu Glu Val Lys Ile 1 5 <210> SEQ ID NO 107 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 107 Ala Arg Thr Asp Leu Glu Met Gln Ile 1 5 <210> SEQ ID NO 108 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 108 Ala Ser Tyr Leu Asp Lys Val Arg Ala 1 5 <210> SEQ ID NO 109 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 109 Asp Val Asn Gly Leu Arg Arg Val Leu 1 5 <210> SEQ ID NO 110 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 110 Gly Leu Arg Arg Val Leu Asp Glu Leu 1 5 <210> SEQ ID NO 111 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 111 Ile Ser Ser Val Leu Ala Gly Ala Ser Cys Pro Ala 1 5 10 <210> SEQ ID NO 112 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 112 Leu Asp Lys Val Arg Ala Leu Glu Glu 1 5 <210> SEQ ID NO 113 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 113 Gln Ile Glu Gly Leu Lys Glu Glu Leu 1 5 <210> SEQ ID NO 114 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 114 Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu Glu Val 1 5 10 <210> SEQ ID NO 115 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 115 Arg Leu Ala Ser Tyr Leu Asp Lys Val 1 5 <210> SEQ ID NO 116 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 116 Ser Tyr Leu Asp Lys Val Arg Ala 1 5 <210> SEQ ID NO 117 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 117 Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu 1 5 10 15 Glu Val Lys Ile 20 <210> SEQ ID NO 118 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 118 Gly Leu Glu Lys Ile Glu Lys Gln Leu 1 5 <210> SEQ ID NO 119 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 119 Met Gly Asn Ile Asp Ser Ile Asn Cys Lys 1 5 10 <210> SEQ ID NO 120 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 120 Tyr Ser Leu Lys Leu Ile Lys Arg Leu 1 5 <210> SEQ ID NO 121 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 121 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr 20 <210> SEQ ID NO 122 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 122 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 <210> SEQ ID NO 123 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 123 Val Val His Phe Phe Lys Asn Ile Val 1 5 <210> SEQ ID NO 124 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 124 Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 Thr Pro Pro <210> SEQ ID NO 125 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 125 His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser 1 5 10 15 His Gly Arg Thr 20 <210> SEQ ID NO 126 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 126 Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro 1 5 10 15 Ser Gln Gly Lys 20 <210> SEQ ID NO 127 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 127 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr Met 20 <210> SEQ ID NO 128 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 128 Phe Lys Gly Val Asp Ala Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu 1 5 10 15 Gly Gly Arg Asp 20 <210> SEQ ID NO 129 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 129 Arg Pro Gly Phe Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala 1 5 10 15 His Lys Gly <210> SEQ ID NO 130 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 130 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr Met Asp His Ala Arg His Gly Phe Leu Pro Arg His 20 25 30 Arg Asp Thr Gly Ile Leu 35 <210> SEQ ID NO 131 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 131 Lys Tyr Leu Ala Thr Ala Ser Thr Met 1 5 <210> SEQ ID NO 132 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 132 Gly Leu Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro 1 5 10 15 Gly Phe Gly Tyr 20 <210> SEQ ID NO 133 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 133 Phe Gly Gly Asp Arg Gly Ala Pro Lys Arg Gly Ser Gly Lys Asp Ser 1 5 10 15 His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser 20 25 30 His Gly Arg Thr Gln Asp Glu Asn Pro Val Val 35 40 <210> SEQ ID NO 134 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 134 Gly Leu Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro 1 5 10 15 Gly Phe Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala His Lys 20 25 30 Gly Phe Lys Gly Val Asp Ala Gln 35 40 <210> SEQ ID NO 135 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC class I related protein A epitope <400> SEQUENCE: 135 Ala Ala Ala Ala Ala Ile Phe Val Ile 1 5 <210> SEQ ID NO 136 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 136 Ser Leu Ser Arg Phe Ser Trp Gly Ala 1 5 <210> SEQ ID NO 137 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 137 Asp Tyr Lys Ser Ala His Lys Gly Phe 1 5 <210> SEQ ID NO 138 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin basic protein epitope <400> SEQUENCE: 138 Ser Lys Ile Phe Lys Leu Gly Gly Arg Asp Ser Arg Ser Gly Ser Pro 1 5 10 15 Met Ala Arg <210> SEQ ID NO 139 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin basic protein epitope <400> SEQUENCE: 139 Thr Pro Arg Thr Pro Pro Pro Gln 1 5 <210> SEQ ID NO 140 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 140 Phe Leu Tyr Gly Ala Leu Leu Leu Ala 1 5 <210> SEQ ID NO 141 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 141 Lys Leu Ile Glu Thr Tyr Phe Ser Lys 1 5 <210> SEQ ID NO 142 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 142 Leu Met Trp Ala Lys Ile Gly Pro Val 1 5 <210> SEQ ID NO 143 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 143 Ser Leu Leu Leu Glu Leu Glu Glu Val 1 5 <210> SEQ ID NO 144 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 144 Val Leu Phe Ser Ser Asp Phe Arg Ile 1 5 <210> SEQ ID NO 145 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin heavy chain, skeletal muscle, adult 2 (Myosin heavy chain IIa) (MyHC-IIa) epitope <400> SEQUENCE: 145 Glu Phe Gln Lys Met Arg Arg Asp Leu 1 5 <210> SEQ ID NO 146 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin heavy chain, skeletal muscle, adult 2 (Myosin heavy chain IIa) (MyHC-IIa) epitope <400> SEQUENCE: 146 Lys Met Arg Arg Asp Leu Glu Glu Ala 1 5 <210> SEQ ID NO 147 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens peroxiredoxin-2 isoform a epitope <400> SEQUENCE: 147 Glu Val Lys Leu Ser Asp Tyr Lys Gly Lys Tyr Val 1 5 10 <210> SEQ ID NO 148 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 148 His Leu Cys Gly Ser His Leu Val Glu Ala 1 5 10 <210> SEQ ID NO 149 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 149 Ala Leu Trp Gly Pro Asp Pro Ala Ala Ala 1 5 10 <210> SEQ ID NO 150 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 150 Arg Leu Leu Pro Leu Leu Ala Leu Leu 1 5 <210> SEQ ID NO 151 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 151 Ala Leu Trp Met Arg Leu Leu Pro Leu Leu 1 5 10 <210> SEQ ID NO 152 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 152 Trp Met Arg Leu Leu Pro Leu Leu Ala Leu 1 5 10 <210> SEQ ID NO 153 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 153 Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys 1 5 10 <210> SEQ ID NO 154 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 154 Pro Leu Leu Ala Leu Leu Ala Leu Trp Gly 1 5 10 <210> SEQ ID NO 155 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 155 Leu Leu Pro Pro Leu Leu Glu His Leu 1 5 <210> SEQ ID NO 156 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 156 Ser Leu Ala Ala Gly Val Lys Leu Leu 1 5 <210> SEQ ID NO 157 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 157 Ser Leu Ser Pro Leu Gln Ala Glu Leu 1 5 <210> SEQ ID NO 158 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 158 Ala Leu Thr Ala Val Ala Glu Glu Val 1 5 <210> SEQ ID NO 159 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 159 Ser Leu Tyr His Val Tyr Glu Val Asn Leu 1 5 10 <210> SEQ ID NO 160 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 160 Thr Ile Ala Asp Phe Trp Gln Met Val 1 5 <210> SEQ ID NO 161 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 161 Val Ile Val Met Leu Thr Pro Leu Val 1 5 <210> SEQ ID NO 162 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 162 Met Val Trp Glu Ser Gly Cys Thr Val 1 5 <210> SEQ ID NO 163 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 163 Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val 1 5 10 <210> SEQ ID NO 164 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 164 Phe Met Ser Asp Lys Pro Leu His Leu Ala Val Ser Leu Asn Lys Glu 1 5 10 15 Ile Tyr Phe His 20 <210> SEQ ID NO 165 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 165 Gly Glu Ala Glu Glu Gly Lys Arg Asp Lys Asn Asp Val Asp Glu 1 5 10 15 <210> SEQ ID NO 166 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 166 Gly Glu Pro Ile Pro Val Thr Val Thr Val Thr Asn Asn Thr Glu Lys 1 5 10 15 Thr Val Lys Lys 20 <210> SEQ ID NO 167 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 167 His Pro Gln Pro Glu Asp Pro Ala Lys Glu Ser Tyr Gln Asp Ala Asn 1 5 10 15 Leu Val Phe Glu 20 <210> SEQ ID NO 168 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 168 Ile Lys Ala Phe Val Glu Gln Val Ala Asn Val Val Leu Tyr Ser Ser 1 5 10 15 Asp Tyr Tyr Val 20 <210> SEQ ID NO 169 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 169 Lys Ser Ser Val Arg Leu Leu Ile Arg Lys Val Gln His Ala Pro Leu 1 5 10 15 Glu Met Gly Pro 20 <210> SEQ ID NO 170 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 170 Gln Pro Arg Ala Glu Ala Ala Trp Gln Phe Phe Met Ser Asp Lys Pro 1 5 10 15 Leu His Leu Ala 20 <210> SEQ ID NO 171 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 171 Ser Tyr Gln Asp Ala Asn Leu Val Phe Glu Glu Phe Ala Arg His Asn 1 5 10 15 Leu Lys Asp Ala 20 <210> SEQ ID NO 172 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 172 Thr Asp Ala Glu Glu Asp Lys Ile Pro Lys Lys Ser Ser Val Arg Leu 1 5 10 15 Leu Ile Arg Lys 20 <210> SEQ ID NO 173 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 173 Thr Asn Asn Thr Glu Lys Thr Val Lys Lys Ile Lys Ala Phe Val Glu 1 5 10 15 Gln Val Ala Asn 20 <210> SEQ ID NO 174 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 174 Val Gln His Ala Pro Leu Glu Met Gly Pro Gln Pro Arg Ala Glu Ala 1 5 10 15 Ala Trp Gln Phe 20 <210> SEQ ID NO 175 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 175 Val Ser Leu Asn Lys Glu Ile Tyr Phe His Gly Glu Pro Ile Pro Val 1 5 10 15 Thr Val Thr Val 20 <210> SEQ ID NO 176 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 176 Val Tyr Val Thr Leu Thr Cys Ala Phe Arg Tyr Gly Gln Glu Asp Ile 1 5 10 15 Asp Val Ile Gly 20 <210> SEQ ID NO 177 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 177 Tyr Gly Gln Glu Asp Ile Asp Val Ile Gly Leu Thr Phe Arg Arg Asp 1 5 10 15 Leu Tyr Phe Ser 20 <210> SEQ ID NO 178 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens SSA protein SS-56 epitope <400> SEQUENCE: 178 Tyr Thr Cys Pro Leu Cys Arg Ala Pro Val 1 5 10 <210> SEQ ID NO 179 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 179 Glu Pro Leu Ala Arg Leu Glu Leu 1 5 <210> SEQ ID NO 180 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 180 Glu Pro Leu Ala Arg Leu Glu Leu Phe Val Val Leu Thr Arg Leu Leu 1 5 10 15 Gln Ala Phe Thr 20 <210> SEQ ID NO 181 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 181 Ile Lys Asp Asp Asn Leu Met Pro Ala Tyr Tyr Lys Cys Ile Gln Glu 1 5 10 15 Val Leu Lys Thr 20 <210> SEQ ID NO 182 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 182 Ile Arg Asp Ser Met Glu Pro Val Val Glu Gln Leu Thr Gln Glu Phe 1 5 10 15 Cys Glu Arg Met 20 <210> SEQ ID NO 183 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor V beta chain 13.1 epitope <400> SEQUENCE: 183 Leu Gly Arg Ala Gly Leu Thr Tyr 1 5 <210> SEQ ID NO 184 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens transaldolase 1 epitope <400> SEQUENCE: 184 Leu Leu Phe Ser Phe Ala Gln Ala Val 1 5 <210> SEQ ID NO 185 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vasoactive intestinal polypeptide receptor 1 precursor epitope <400> SEQUENCE: 185 Arg Arg Lys Trp Arg Arg Trp His Leu 1 5 <210> SEQ ID NO 186 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vasoactive intestinal polypeptide receptor 1 precursor epitope <400> SEQUENCE: 186 Arg Arg Lys Trp Arg Arg Trp His Leu 1 5 <210> SEQ ID NO 187 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 187 Ala His Ala Ser Ala Arg Gln Gln Trp Glu Leu Gln Gly Asp Arg Arg 1 5 10 15 Cys Gln Ser Gln 20 <210> SEQ ID NO 188 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 188 Ala Lys Leu Thr Ile Leu Val Ala Leu Ala Leu Phe Leu Leu Ala Ala 1 5 10 15 His Ala Ser Ala 20 <210> SEQ ID NO 189 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 189 Ala Leu Gln Gln Ile Met Glu Asn Gln Ser Asp Arg Leu Gln Gly Arg 1 5 10 15 Gln Gln Glu <210> SEQ ID NO 190 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 190 Ala Asn Leu Arg Pro Cys Glu Gln His Leu Met Gln Lys Ile Gln Arg 1 5 10 15 Asp Glu Asp Ser 20 <210> SEQ ID NO 191 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 191 Cys Asn Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met Cys Glu 1 5 10 15 Ala Leu Gln Gln 20 <210> SEQ ID NO 192 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 5-hydroxytryptamine receptor 2C (5-HT-2C) (Serotonin receptor 2C) (5-HT2C) (5-HTR2C) (5HT-1C) epitope <400> SEQUENCE: 192 Pro Arg Gly Thr Met Gln Ala Ile Asn Asn Glu Arg Lys Ala Ser Lys 1 5 10 15 <210> SEQ ID NO 193 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 193 Asp Gln Gly Thr Cys Leu Leu Leu Thr Glu Val Ala 1 5 10 <210> SEQ ID NO 194 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 194 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val 1 5 10 <210> SEQ ID NO 195 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 195 Gly Glu Arg Ile Thr Lys Met Thr Glu Gly Leu Ala Lys 1 5 10 <210> SEQ ID NO 196 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 196 Pro Gly Glu Trp Arg Ile Ile Tyr Ala Ala Ala Asp Asn Lys 1 5 10 <210> SEQ ID NO 197 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 197 Arg Ile Glu Cys Ile Asn Asp Cys 1 5 <210> SEQ ID NO 198 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 198 Val Ala Lys Arg Gln Glu Gly Tyr Val Tyr Val Leu 1 5 10 <210> SEQ ID NO 199 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 199 Val Ser Glu Asn Met Leu Val Thr Tyr Val 1 5 10 <210> SEQ ID NO 200 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 200 Asp Gln Gly Thr Cys Leu Leu Leu Thr Glu Val Ala 1 5 10 <210> SEQ ID NO 201 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 201 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val 1 5 10 <210> SEQ ID NO 202 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 202 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val Pro Asn 1 5 10 15 <210> SEQ ID NO 203 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 203 Gly Glu Arg Ile Thr Lys Met Thr Glu Gly Leu Ala Lys 1 5 10 <210> SEQ ID NO 204 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 204 Pro Gly Glu Trp Arg Ile Ile Tyr Ala Ala Ala Asp Asn Lys 1 5 10 <210> SEQ ID NO 205 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 205 Arg Ile Glu Cys Ile Asn Asp Cys 1 5 <210> SEQ ID NO 206 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 206 Val Ala Lys Arg Gln Glu Gly Tyr Val Tyr Val Leu 1 5 10 <210> SEQ ID NO 207 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 207 Val Ser Glu Asn Met Leu Val Thr Tyr Val 1 5 10 <210> SEQ ID NO 208 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 208 Asp Ile Phe Ala Ser Lys Asn Phe His Leu Gln Lys Asn 1 5 10 <210> SEQ ID NO 209 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 209 Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys 1 5 10 <210> SEQ ID NO 210 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 210 Lys Leu Thr Ser Gly Lys Ile Ala Ser Cys Leu Asn 1 5 10 <210> SEQ ID NO 211 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 211 Gln Phe Ala Lys Leu Thr Gly Phe Thr Leu Met Gly 1 5 10 <210> SEQ ID NO 212 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 212 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 213 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 213 Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 15 <210> SEQ ID NO 214 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 214 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 <210> SEQ ID NO 215 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 215 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 216 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 216 Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 15 <210> SEQ ID NO 217 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 217 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 <210> SEQ ID NO 218 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 218 Thr Asn Lys Trp Glu Asp Lys 1 5 <210> SEQ ID NO 219 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 219 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys Arg 1 5 10 <210> SEQ ID NO 220 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 220 Pro Arg Leu Ser Trp His Gln Tyr Thr Lys Arg Asp Ser Arg Glu 1 5 10 15 <210> SEQ ID NO 221 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 221 Thr Val Asp Leu Ile Ser Pro Val Thr Lys Arg Ala Ser Leu Lys 1 5 10 15 <210> SEQ ID NO 222 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 222 Ala Trp Tyr Tyr Val Pro Leu Gly Thr Gln Tyr Thr Asp Ala Pro Ser 1 5 10 15 Phe Ser <210> SEQ ID NO 223 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 223 Asp Ala Tyr Pro Ser Gly Ala Trp Tyr Tyr Val Pro Leu Gly Thr Gln 1 5 10 15 Tyr Thr <210> SEQ ID NO 224 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 224 Asp Ile Gly Ser Glu Ser Thr Glu Asp Gln Ala Met Glu Asp Ile Lys 1 5 10 15 Gln Met <210> SEQ ID NO 225 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 225 Glu Asp Ile Lys Gln Met 1 5 <210> SEQ ID NO 226 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 226 Glu Pro Met Ile Gly Val Asn Gln Glu Leu Ala Tyr 1 5 10 <210> SEQ ID NO 227 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 227 Glu Pro Met Ile Gly Val Asn Gln Glu Leu Ala Tyr Phe Tyr Pro Glu 1 5 10 15 Leu Phe <210> SEQ ID NO 228 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 228 Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met Cys Glu Ala Leu 1 5 10 15 Gln <210> SEQ ID NO 229 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 229 Ser Gln Leu Glu Arg Ala Asn Leu Arg Pro Cys Glu Gln His Leu Met 1 5 10 15 <210> SEQ ID NO 230 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 230 Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn 1 5 10 15 <210> SEQ ID NO 231 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 231 Ile Phe Ser Gly Asn Met Asn Ile Lys Leu Lys Met Pro Met Tyr Ile 1 5 10 15 Ala Gly Tyr Lys 20 <210> SEQ ID NO 232 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 232 Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr Phe Asp Gly Arg Gly 1 5 10 15 Ala Gln Val Tyr 20 <210> SEQ ID NO 233 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 233 Leu Gly His Asp Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr 1 5 10 15 Val Ala Phe Asn 20 <210> SEQ ID NO 234 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 234 Ser Gly Lys Tyr Glu Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe 1 5 10 15 Asn Val Glu <210> SEQ ID NO 235 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 235 Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys 1 5 10 <210> SEQ ID NO 236 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 236 Gly Leu Phe Gly Arg Lys Thr Gly Ser Val Ala 1 5 10 <210> SEQ ID NO 237 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 237 Lys Ile Gly Pro Glu Leu His Gly Leu 1 5 <210> SEQ ID NO 238 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 238 Leu Lys Ala Gly Glu Gly Asn Lys Ile Gly Pro Glu 1 5 10 <210> SEQ ID NO 239 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 239 Leu Lys Lys Pro Lys Asp Arg Asn Asp Leu Ile 1 5 10 <210> SEQ ID NO 240 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 allergen epitope <400> SEQUENCE: 240 Gly Leu Glu Ile Asp Val Pro Gly Ile Asp Thr Asn Ala Cys His Phe 1 5 10 15 Val Lys <210> SEQ ID NO 241 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 allergen epitope <400> SEQUENCE: 241 Pro Gly Ile Asp Thr Asn Ala Cys His Phe Val Lys Cys Pro Leu Val 1 5 10 15 Lys Gly Gln Gln 20 <210> SEQ ID NO 242 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 242 Arg Phe Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn 1 5 10 15 Lys Ile Arg <210> SEQ ID NO 243 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 243 Ala Val Asn Ile Val Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr 1 5 10 15 <210> SEQ ID NO 244 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 244 Phe Ala Gly Lys Asp Leu Glu Ser Ile Lys Gly Thr Ala Pro Phe Glu 1 5 10 15 Thr His Ala Asn 20 <210> SEQ ID NO 245 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 245 Gly Thr Ala Pro Phe Glu Thr His Ala Asn Arg 1 5 10 <210> SEQ ID NO 246 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 246 Lys Gly Thr Ala Pro Phe Glu Thr His Ala Asn Arg Ile Val Gly Phe 1 5 10 15 Phe Ser Lys Ile Ile 20 <210> SEQ ID NO 247 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 247 Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr Leu 1 5 10 15 Asp Thr Phe Phe Gly 20 <210> SEQ ID NO 248 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 248 Phe Ala Gly Lys Asp Leu Glu Ser Ile Lys Gly Thr Ala Pro Phe Glu 1 5 10 15 Ile His Ala Asn 20 <210> SEQ ID NO 249 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 249 Val Asn Thr Phe Val Ala Ser His Lys Pro Arg Gly Val Thr His Asp 1 5 10 15 Gln Leu Asn Asn Phe 20 <210> SEQ ID NO 250 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 250 Ala Asp Pro Ser Ile Met Ala Lys 1 5 <210> SEQ ID NO 251 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 251 Ala Asp Pro Ser Ile Met Ala Lys Phe Thr Gln Phe Ala Gly Lys Asp 1 5 10 15 Leu Glu Ser Ile Lys 20 <210> SEQ ID NO 252 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 252 Ala Glu Ala Ala Trp 1 5 <210> SEQ ID NO 253 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 253 Ala Glu Ala Ala Trp Gly Ala Thr Leu Asp Thr Phe Phe Gly Met Ile 1 5 10 15 Phe Ser Lys Met 20 <210> SEQ ID NO 254 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 254 Ala Gly Phe Val Ser Tyr Met Lys 1 5 <210> SEQ ID NO 255 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phaseolus vulgaris Glycine-rich cell wall structural protein 1.8 precursor epitope <400> SEQUENCE: 255 Gly Gly Tyr Gly Asp Gly Gly Ala His Gly Gly Gly Tyr Gly Gly 1 5 10 15 <210> SEQ ID NO 256 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 256 Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser 1 5 10 15 <210> SEQ ID NO 257 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 257 Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile Lys Ala Gly 1 5 10 15 <210> SEQ ID NO 258 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 258 Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile 1 5 10 15 <210> SEQ ID NO 259 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 259 Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asn 1 5 10 15 <210> SEQ ID NO 260 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 260 Pro Lys Gly Gly Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser 1 5 10 15 <210> SEQ ID NO 261 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens KIAA1224 protein epitope <400> SEQUENCE: 261 Asp Leu Glu Ser Tyr Leu Gln Leu Asn Cys Glu Arg Gly Thr Trp Arg 1 5 10 15 <210> SEQ ID NO 262 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Lep D 2 precursor epitope <400> SEQUENCE: 262 Lys Gly Glu Ala Leu Asp Phe Asn Tyr Gly Met Thr Ile Pro Ala 1 5 10 15 <210> SEQ ID NO 263 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 263 Ala Gly Leu Pro Gly Lys Cys Gly Val Asn Ile Pro 1 5 10 <210> SEQ ID NO 264 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 264 Ala Lys Gly Ile Ala Gly Leu Asn Pro Asn Leu Ala 1 5 10 <210> SEQ ID NO 265 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 265 Cys Gly Val Asn Ile Pro Tyr Lys Ile Ser Pro Ser 1 5 10 <210> SEQ ID NO 266 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 266 Cys Lys Gly Val Arg Ala Val Asn Asp Ala Ser Arg 1 5 10 <210> SEQ ID NO 267 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 267 Cys Val Leu Tyr Leu Lys Asn Gly Gly Val Leu Pro 1 5 10 <210> SEQ ID NO 268 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Lipocalin 1 (tear prealbumin) epitope <400> SEQUENCE: 268 Lys Pro Val Arg Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn 1 5 10 15 <210> SEQ ID NO 269 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 269 Glu Phe Asn Thr Glu Phe Thr Ile His Ala Asp Lys Asn Asn Leu 1 5 10 15 <210> SEQ ID NO 270 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 270 Phe Thr Ile His Ala Asp Lys Asn Asn Leu Lys Met His Met Asp 1 5 10 15 <210> SEQ ID NO 271 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 271 Lys Met His Met Asp Phe Pro Asn Val Phe Gln Ala Asp Leu Thr 1 5 10 15 <210> SEQ ID NO 272 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 272 Ala Leu Phe Lys Ala Leu Glu Ala Tyr Leu Ile Ala Asn 1 5 10 <210> SEQ ID NO 273 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 273 Asp Ala Val Val Pro Glu Glu Asn Ile Lys Tyr Ala 1 5 10 <210> SEQ ID NO 274 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 274 Asp Ile Leu Leu Gly Phe Ile Glu Ser Ile Glu Asn 1 5 10 <210> SEQ ID NO 275 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 275 Gly Gly Ser Ile Cys Lys Thr Thr Ala Ile Phe His 1 5 10 <210> SEQ ID NO 276 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 276 Gly Val Gln Thr His Val Leu Glu Leu Thr Ser Ser 1 5 10 <210> SEQ ID NO 277 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 precursor epitope <400> SEQUENCE: 277 Phe Gly Asn Arg Pro Thr Met Glu Ala Val Gly Ala Tyr Asp Val 1 5 10 15 <210> SEQ ID NO 278 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 precursor epitope <400> SEQUENCE: 278 Met Glu Ala Val Gly Ala Tyr Asp Val Ile Val Asn Gly Asp Lys 1 5 10 15 <210> SEQ ID NO 279 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Canis lupus familiaris Major allergen Can f 1 precursor epitope <400> SEQUENCE: 279 Ala Leu Glu Asp Phe Arg Glu Phe Ser Arg Ala Lys Gly Leu Asn Gln 1 5 10 15 <210> SEQ ID NO 280 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Canis lupus familiaris Major allergen Can f 1 precursor epitope <400> SEQUENCE: 280 Asp Gln Glu Val Pro Glu Lys Pro Asp Ser Val Thr Pro Met Ile Leu 1 5 10 15 <210> SEQ ID NO 281 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 281 Ala Gly Lys Glu Lys Ala Ala Gly Leu Phe Lys Ala 1 5 10 <210> SEQ ID NO 282 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 282 Ala Gly Leu Phe Lys Ala Val Glu Ala Tyr Leu Leu 1 5 10 <210> SEQ ID NO 283 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 283 Ala Pro Gln His Phe Thr Ser Ala Glu Asn Leu Glu 1 5 10 <210> SEQ ID NO 284 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 284 Ala Arg Leu Phe Lys Ser Phe Val Leu Asp Ala Asp 1 5 10 <210> SEQ ID NO 285 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 285 Glu Ile Asp His Ala Asn Phe Lys Tyr Cys Tyr Ser 1 5 10 <210> SEQ ID NO 286 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Daucus carota Major allergen Dau c 1 epitope <400> SEQUENCE: 286 Ala Leu Phe Lys Ala Ile Glu Ala Tyr Leu Ile Ala Asn 1 5 10 <210> SEQ ID NO 287 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 287 Asp Gly Tyr Asn Val Phe Arg Ile Ser Glu Phe Glu Asn Asp Glu His 1 5 10 15 <210> SEQ ID NO 288 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 288 Asp Lys Asp Arg Pro Phe Gln Leu Phe Glu Phe Tyr Ala Arg Glu Pro 1 5 10 15 <210> SEQ ID NO 289 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 289 Asp Leu Thr Lys Ile Asp Arg Cys Phe Gln Leu Arg Gly Asn Gly Val 1 5 10 15 <210> SEQ ID NO 290 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 290 Asp Arg Pro Phe Gln Leu Phe Glu Phe Tyr Ala Arg Glu Pro Asp Val 1 5 10 15 <210> SEQ ID NO 291 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 291 Asp Val Ser Pro Glu Ile Lys Glu Glu Phe Val Lys Ile Val Gln Lys 1 5 10 15 <210> SEQ ID NO 292 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 292 Glu Asn Ala Arg Ile Leu Lys Asn Cys Val Asp Ala Lys Met Thr Glu 1 5 10 15 Glu <210> SEQ ID NO 293 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 293 Arg Asp Val Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu 1 5 10 15 Gln <210> SEQ ID NO 294 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 294 Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala 1 5 10 15 Leu <210> SEQ ID NO 295 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 295 Asp Val Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln 1 5 10 15 Val <210> SEQ ID NO 296 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 296 Glu Ile Cys Pro Ala Val Lys Arg Asp Val Asp Leu Phe Leu Thr Gly 1 5 10 15 Thr <210> SEQ ID NO 297 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 297 Glu Gln Val Ala Gln Tyr Lys Ala Leu Pro Val Val Leu Glu Asn Ala 1 5 10 15 <210> SEQ ID NO 298 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 298 Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys Asn Cys 1 5 10 15 Val <210> SEQ ID NO 299 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 299 Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln 1 5 10 15 Tyr <210> SEQ ID NO 300 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 300 Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys Ile Tyr Thr Ser Pro Leu 1 5 10 15 <210> SEQ ID NO 301 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 301 Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys 1 5 10 15 <210> SEQ ID NO 302 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica Major allergen Mal d 1 epitope <400> SEQUENCE: 302 Gly Leu Phe Lys Leu Ile Glu Ser Tyr Leu Lys Asp His Pro Asp 1 5 10 15 <210> SEQ ID NO 303 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus avium Major allergen Pru av 1 epitope <400> SEQUENCE: 303 Asn Leu Phe Lys Leu Ile Glu Thr Tyr Leu Lys Gly His Pro Asp 1 5 10 15 <210> SEQ ID NO 304 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 304 Ala Ala Pro Ala Glu Gly Glu Lys Pro Ala Glu Glu Glu Lys Pro Ile 1 5 10 15 Thr Glu Ala Ala 20 <210> SEQ ID NO 305 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 305 Ala Glu Glu Glu Lys Pro Ile Thr Glu Ala Ala Glu Thr Ala Thr Thr 1 5 10 15 Glu Val Pro Val 20 <210> SEQ ID NO 306 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 306 Ala Pro Ala Glu Pro Glu Ala Pro Ala Pro Glu Thr Glu Lys Ala Glu 1 5 10 15 Glu Val Glu Lys 20 <210> SEQ ID NO 307 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 307 Ala Pro Glu Ala Asp Gln Thr Thr Pro Glu Glu Lys Pro Ala Glu Pro 1 5 10 15 Glu Pro Val Ala 20 <210> SEQ ID NO 308 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 308 Ala Ser Glu Gln Glu Thr Ala Asp Ala Thr Pro Glu Lys Glu Glu Pro 1 5 10 15 Thr Ala Ala Pro 20 <210> SEQ ID NO 309 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope <400> SEQUENCE: 309 Tyr Ala Tyr Val Ala Arg Glu Gln Ser Cys Arg 1 5 10 <210> SEQ ID NO 310 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope <400> SEQUENCE: 310 Ala Leu Ala Gln Thr His Thr Ala Ile Ala Val Ile Ile Gly Ile Lys 1 5 10 15 Asp Leu Asp <210> SEQ ID NO 311 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 311 Glu Asp Ile Pro Gln Pro Pro Val Ser Gln Phe His Ile Gln Gly Gln 1 5 10 15 Val Tyr Cys Asp Thr Cys Arg Ala Gly Phe Ile Thr Glu Leu Ser Glu 20 25 30 Phe Ile Pro 35 <210> SEQ ID NO 312 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 312 Gly Ala Ser Leu Arg Leu Gln Cys Lys Asp Lys Glu Asn Gly Asp Val 1 5 10 15 Thr Phe Thr Glu Val Gly Tyr Thr Arg Ala Glu Gly Leu Tyr Ser 20 25 30 <210> SEQ ID NO 313 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 313 Gly Thr Thr Arg Thr Val Asn Pro Leu Gly Phe Phe Lys Lys Glu Ala 1 5 10 15 Leu Pro Lys Cys Ala Gln Val Tyr Asn Lys Leu Gly Met Tyr Pro Pro 20 25 30 Asn Met <210> SEQ ID NO 314 <211> LENGTH: 53 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 314 Leu Val Glu Arg Asp His Lys Asn Glu Phe Cys Glu Ile Thr Leu Ile 1 5 10 15 Ser Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp Ala 20 25 30 Lys Pro Ser Leu Lys Phe Lys Leu Asn Thr Val Asn Gly Thr Thr Arg 35 40 45 Thr Val Asn Pro Leu 50 <210> SEQ ID NO 315 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 315 Met Leu Val Glu Arg Asp His Lys Asn Glu Phe Cys Glu Ile Thr Leu 1 5 10 15 Ile Ser Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp 20 25 30 Ala <210> SEQ ID NO 316 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 316 Ala Gly Gly Ser Pro Ser Pro Pro Ala Asp Gly Gly 1 5 10 <210> SEQ ID NO 317 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 317 Ala Gly Ser Lys Leu Cys Glu Lys Thr Ser Lys Thr 1 5 10 <210> SEQ ID NO 318 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 318 Cys Asp Lys Lys Cys Ile Glu Trp Glu Lys Ala Gln 1 5 10 <210> SEQ ID NO 319 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 319 Asp Gly Gly Ser Pro Pro Pro Pro Ala Asp Gly Gly 1 5 10 <210> SEQ ID NO 320 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 320 Glu Lys Thr Ser Lys Thr Tyr Ser Gly Lys Cys Asp 1 5 10 <210> SEQ ID NO 321 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope> SEQUENCE: 321 Ala Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly 1 5 10 <210> SEQ ID NO 322 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 322 Ala Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly Asp Asn Leu 1 5 10 15 <210> SEQ ID NO 323 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 323 Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu 1 5 10 <210> SEQ ID NO 324 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 324 Ala Phe Ile Leu Asp Gly Asp Asn Leu Phe Pro Lys Val Ala Pro Gln 1 5 10 15 Ala Ile Ser Ser Val 20 <210> SEQ ID NO 325 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 325 Ala Ile Ser Ser Val Glu Asn Ile Glu Gly Asn Gly 1 5 10 <210> SEQ ID NO 326 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 326 Glu Thr Leu Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser 1 5 10 15 <210> SEQ ID NO 327 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-F/ I epitope <400> SEQUENCE: 327 Gly Glu Thr Leu Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser 1 5 10 15 <210> SEQ ID NO 328 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 328 Ala Asn Asn Asn Tyr Asp Pro Trp Ser Ile Tyr Ala Ile Gly Gly Ser 1 5 10 15 Ser Asn Pro Thr 20 <210> SEQ ID NO 329 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 329 Ala Ser Thr Gly Val Thr Ile Ser Asn Asn His Phe Phe Asn His His 1 5 10 15 Lys Val Met Leu 20 <210> SEQ ID NO 330 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 330 Cys Ala Asn Trp Val Trp Arg Ser Thr Gln Asp Ser Phe Asn Asn Gly 1 5 10 15 Ala Tyr Phe Val 20 <210> SEQ ID NO 331 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 331 Asp Ala Ile Thr Met Arg Asn Val Thr Asp Val Trp Ile Asp His Asn 1 5 10 15 Ser Leu Ser Asp 20 <210> SEQ ID NO 332 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 332 Asp Ala Asn Trp Asp Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val 1 5 10 15 Gly Phe Gly Ser 20 <210> SEQ ID NO 333 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 333 Ala Ile Gly Asp Lys Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asn 1 5 10 15 Lys Trp Leu Glu 20 <210> SEQ ID NO 334 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 334 Cys Tyr Glu Ile Lys Cys Lys Glu Pro Val Glu Cys Ser Gly Glu Pro 1 5 10 15 Val Leu Val Lys 20 <210> SEQ ID NO 335 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 335 Asp His Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys Pro Pro Phe 1 5 10 15 Asp Gly Met Thr 20 <210> SEQ ID NO 336 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 336 Glu Gly Gly Ala His Leu Val Gln Asp Asp Val Ile Pro Ala Asn Trp 1 5 10 15 Lys Pro Asp Thr 20 <210> SEQ ID NO 337 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 337 Phe Lys Asp Gly Leu Gly Cys Gly Ala Cys Tyr Glu Ile Lys Cys Lys 1 5 10 15 Glu Pro Val Glu 20 <210> SEQ ID NO 338 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 338 Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr Gln Pro Phe Pro Lys 1 5 10 15 <210> SEQ ID NO 339 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 339 Met Leu Leu Arg Lys Tyr Gly Ile Ala Ala Glu Asn Val Ile Asp 1 5 10 15 <210> SEQ ID NO 340 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 340 Asn Ser Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr 1 5 10 15 <210> SEQ ID NO 341 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 341 Ala Ser Asn Lys Arg Glu Lys Ile Glu Glu Asn Gly Ser Met Arg Val 1 5 10 15 Phe Met Gln His 20 <210> SEQ ID NO 342 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 342 Asp Ile Lys Glu Lys Phe Ala Lys Leu Cys Glu Ala His Gly Ile Thr 1 5 10 15 Arg Asp Asn Ile 20 <210> SEQ ID NO 343 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 343 Glu Glu Ala Ser Ser Thr Arg Gly Asn Leu Asp Val Ala Lys Leu Asn 1 5 10 15 Gly Asp Trp Phe 20 <210> SEQ ID NO 344 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 344 Glu Glu Asn Gly Ser Met Arg Val Phe Met Gln His Ile Asp Val Leu 1 5 10 15 Glu Asn Ser Leu 20 <210> SEQ ID NO 345 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 345 Glu Asn Ser Leu Gly Phe Lys Phe Arg Ile Lys Glu Asn Gly Glu Cys 1 5 10 15 Arg Glu Leu Tyr 20 <210> SEQ ID NO 346 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 346 Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys Ser Glu 1 5 10 15 Asn Val Val Val Thr 20 <210> SEQ ID NO 347 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 347 Asp Asn Gly Val Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile Arg 1 5 10 15 Asp <210> SEQ ID NO 348 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 348 Glu Ala Leu Phe Asp Ala Asn Gln Asn Thr Lys Thr Ala Lys Ile Glu 1 5 10 15 Ile Lys Ala Ser Leu 20 <210> SEQ ID NO 349 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 349 Gln Tyr Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys 1 5 10 15 Ser Glu Asn Val Val Val Thr Val Lys Leu Ile Gly Asp Asn Gly Val 20 25 30 Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile Arg Asp 35 40 45 <210> SEQ ID NO 350 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 350 Thr Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Leu Asp Gly Leu Glu 1 5 10 15 Ile Asp Val <210> SEQ ID NO 351 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 351 Ala Ser Ile Asp Gly Leu Gly Val Asp Val Pro Gly Ile Asp 1 5 10 <210> SEQ ID NO 352 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 352 Phe Glu Ala Val Gln Asn Thr Lys Thr Ala Lys Ile Glu Ile Lys 1 5 10 15 <210> SEQ ID NO 353 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 353 Arg Gly Lys Pro Pro Gln Leu Glu Ala Val Phe Glu Ala Val Gln Asn 1 5 10 15 Thr <210> SEQ ID NO 354 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 354 Cys His Gly Ser Glu Pro Cys Ile Ile His Arg Gly Lys Pro Phe 1 5 10 15 <210> SEQ ID NO 355 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 355 Cys Pro Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn 1 5 10 15 Val Pro Lys Ile Ala Pro Lys Ser Glu Asn Val 20 25 <210> SEQ ID NO 356 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 356 Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys Ser Glu 1 5 10 15 Asn Val Val Val Thr Val Lys Val Met Gly 20 25 <210> SEQ ID NO 357 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 357 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys 1 5 10 15 <210> SEQ ID NO 358 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 358 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys Val 1 5 10 15 Leu Val Pro Gly 20 <210> SEQ ID NO 359 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 359 Cys His Gly Ser Glu Pro Cys Ile Ile His Arg Gly Lys Pro Phe 1 5 10 15 <210> SEQ ID NO 360 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 360 Asp His Gly Val Met Ala Cys Gly Thr Val His Gly Gln Val Glu 1 5 10 15 <210> SEQ ID NO 361 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 361 Gly Cys Lys Phe Ile Lys Cys Pro Val Lys Lys Gly Glu Ala Leu 1 5 10 15 <210> SEQ ID NO 362 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 362 Gly Glu Lys Met Thr Leu Glu Ala Lys Phe Ala Ala Asn Gln Asp 1 5 10 15 <210> SEQ ID NO 363 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 363 Gly Glu Val Thr Glu Leu Asp Ile Thr Gly Cys Ser Gly Asp Thr 1 5 10 15 <210> SEQ ID NO 364 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 364 Gly Lys Met Thr Phe Lys Asp Cys Gly His Gly Glu Val Thr Glu 1 5 10 15 <210> SEQ ID NO 365 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Neurofilament heavy polypeptide (NF-H) (Neurofilament triplet H protein) (200 kDa neurofilament protein) epitope <400> SEQUENCE: 365 Tyr Gln Glu Ala Ile Gln Gln Leu Asp Ala Glu Leu Arg Asn Thr Lys 1 5 10 15 <210> SEQ ID NO 366 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 366 Ala Ala Ala Leu Pro Gly Lys Cys Gly Val 1 5 10 <210> SEQ ID NO 367 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 367 Ala Cys Cys Asn Gly Ile Arg Asn Val Asn 1 5 10 <210> SEQ ID NO 368 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 368 Ala Pro Cys Ile Pro Tyr Val Arg Gly Gly 1 5 10 <210> SEQ ID NO 369 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 369 Ile Arg Asn Val Asn Asn Leu Ala Arg Thr 1 5 10 <210> SEQ ID NO 370 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 370 Ile Ser Ala Ser Thr Asn Cys Ala Thr Val Lys 1 5 10 <210> SEQ ID NO 371 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 371 Asn Leu Ala Arg Thr Thr Pro Asp Arg Gln 1 5 10 <210> SEQ ID NO 372 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 372 Cys Phe Asp Val Phe Lys Glu Leu Lys Val 1 5 10 <210> SEQ ID NO 373 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 373 Gly Ser Ile Gly Ala Ala Ser Met Glu Phe 1 5 10 <210> SEQ ID NO 374 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 374 Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser Glu Lys Met Lys Ile 1 5 10 15 Leu Glu <210> SEQ ID NO 375 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 375 Ile Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val 1 5 10 15 Ser Pro <210> SEQ ID NO 376 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 376 Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys 1 5 10 <210> SEQ ID NO 377 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 377 Ala Glu Val Asp Cys Ser Arg Phe Pro Asn Ala Thr Asp Lys 1 5 10 <210> SEQ ID NO 378 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 378 Ala Thr Asp Lys Glu Gly Lys Asp Val Leu Val Cys Asn Lys 1 5 10 <210> SEQ ID NO 379 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 379 Ala Val Val Glu Ser Asn Gly Thr Leu Thr Leu Ser His Phe Gly Lys 1 5 10 15 Cys <210> SEQ ID NO 380 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 380 Cys Leu Leu Cys Ala Tyr Ser Ile Glu Phe Gly Thr Asn Ile Ser Lys 1 5 10 15 <210> SEQ ID NO 381 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 381 Asp Asn Glu Cys Leu Leu Cys Ala His Lys Val Glu Gln Gly Ala Ser 1 5 10 15 Val Asp Lys Arg 20 <210> SEQ ID NO 382 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata pectate lyase epitope <400> SEQUENCE: 382 Gly His Ser Asp Glu Leu Thr Ser Asp Lys Ser Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 383 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Zinnia violacea Pectate lyase precursor epitope <400> SEQUENCE: 383 Gly His Ser Asp Ser Tyr Thr Gln Asp Lys Asn Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 384 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 384 Asp Gly Arg Thr Ile Ile Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr 1 5 10 15 His Ala Val Asn Ile 20 <210> SEQ ID NO 385 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 385 Asp Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly 1 5 10 15 Cys Gly Ser <210> SEQ ID NO 386 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 386 Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser 1 5 10 15 Ala Tyr Leu <210> SEQ ID NO 387 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 387 Ile Arg Glu Ala Leu Thr Gln Thr His Thr Ala Ile Ala Val Ile Ile 1 5 10 15 Gly Ile Lys Asp Leu 20 <210> SEQ ID NO 388 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 388 Ile Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 1 5 10 15 Ala Ala Thr <210> SEQ ID NO 389 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 389 Phe Arg His Tyr Asp Gly Arg Thr Ile Met Gln His Asp Asn Gly Tyr 1 5 10 15 Gln Pro Asn <210> SEQ ID NO 390 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 390 Gly Arg Thr Ile Met Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His 1 5 10 15 Ala Val Asn <210> SEQ ID NO 391 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 391 His Ala Val Asn Ile Val Gly Tyr Gly Asn Thr Gln Gly Val Asp Tyr 1 5 10 15 Trp Ile Val <210> SEQ ID NO 392 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 392 Asn Lys Ile Arg Gln Ala Leu Thr Gln Thr His Thr Ala Val Ala Val 1 5 10 15 Ile Ile Gly <210> SEQ ID NO 393 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 393 Pro Tyr Val Ala Arg Glu Gln Ser Cys His Arg Pro Asn Ala Gln Arg 1 5 10 15 Tyr Gly Leu <210> SEQ ID NO 394 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 394 Ala Val Gln Val Thr Phe Thr Val Gln Lys Gly Ser Asp Pro Lys 1 5 10 15 <210> SEQ ID NO 395 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 395 Glu Glu Trp Glu Pro Leu Thr Lys Lys Gly Asn Val Trp Glu Val 1 5 10 15 <210> SEQ ID NO 396 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 396 Phe Thr Val Gln Lys Gly Ser Asp Pro Lys Lys Leu Val Leu Asp 1 5 10 15 <210> SEQ ID NO 397 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 397 Phe Thr Val Gln Lys Gly Ser Asp Pro Lys Lys Leu Val Leu Asn 1 5 10 15 <210> SEQ ID NO 398 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 398 Gly Ser Asp Pro Lys Lys Leu Val Leu Asp Ile Lys Tyr Thr Arg 1 5 10 15 <210> SEQ ID NO 399 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 399 Cys Asp Cys Asp Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala 1 5 10 15 <210> SEQ ID NO 400 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 400 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys 1 5 10 <210> SEQ ID NO 401 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 401 Cys Arg Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu 1 5 10 15 <210> SEQ ID NO 402 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 402 Asp Thr Ile Ser Ser Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile 1 5 10 15 Asp Thr <210> SEQ ID NO 403 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 403 Glu Arg Thr Glu Gly Arg Cys Leu His Tyr Thr Val Asp Lys Ser Lys 1 5 10 15 Pro Lys <210> SEQ ID NO 404 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Spiroplasma citri plectrovirus spv1-r8a2b orf 14 transmembrane protein epitope <400> SEQUENCE: 404 His Val Ile Glu Val Gln Gln Ile Asn Ser Glu Arg Ser Trp Phe Phe 1 5 10 15 <210> SEQ ID NO 405 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 405 Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly 1 5 10 15 Cys Gly Asn Thr 20 <210> SEQ ID NO 406 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 406 Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val 1 5 10 15 Asp Lys Ala Pro 20 <210> SEQ ID NO 407 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 407 Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser 1 5 10 15 Tyr Ser Ala Lys 20 <210> SEQ ID NO 408 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 408 Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr 1 5 10 15 Val Asp Gly Asp 20 <210> SEQ ID NO 409 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 409 Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys Gly Ser Asn 1 5 10 15 Pro Asn Tyr Leu 20 <210> SEQ ID NO 410 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.1 precursor epitope <400> SEQUENCE: 410 Gly Ala Gly Asp Glu Asn Ile Glu Asp Arg Gly Met Leu Ala Thr Val 1 5 10 15 <210> SEQ ID NO 411 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.1 precursor epitope <400> SEQUENCE: 411 Gly Ala Gly Asp Glu Asn Ile Glu Asp Arg Gly Met Leu Ala Thr Val 1 5 10 15 <210> SEQ ID NO 412 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 412 Gly Ala Ser Asp Thr His Phe Gln Asp Leu Lys Met His Val Thr Leu 1 5 10 15 <210> SEQ ID NO 413 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 413 Gly Ala Ser Asp Thr His Phe Gln Asp Leu Lys Met His Val Thr Leu 1 5 10 15 <210> SEQ ID NO 414 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 414 Glu Glu Ala Tyr His Ala Cys Asp Ile Lys Asp 1 5 10 <210> SEQ ID NO 415 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 415 Gly Lys Val Tyr Leu Val Gly Gly Pro Glu Leu Gly Gly Trp Lys 1 5 10 15 <210> SEQ ID NO 416 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 416 Leu Gly Gly Trp Lys Leu Gln Ser Asp Pro Arg Ala Tyr Ala Leu 1 5 10 15 <210> SEQ ID NO 417 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 417 Pro Gly Gly Pro Asp Arg Phe Thr Leu Leu Thr Pro Gly Ser His 1 5 10 15 <210> SEQ ID NO 418 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 418 Ala Tyr Cys Cys Ser Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val 1 5 10 15 <210> SEQ ID NO 419 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 419 Cys Gly Glu Lys Arg Ala Tyr Cys Cys Ser Asp Pro Gly Arg Tyr Cys 1 5 10 15 Pro Trp Gln Val 20 <210> SEQ ID NO 420 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 420 Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val Val Cys Tyr Glu Ser Ser 1 5 10 15 Glu <210> SEQ ID NO 421 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 421 Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val Val Cys Tyr Glu Ser Ser 1 5 10 15 Glu Ile Cys Ser 20 <210> SEQ ID NO 422 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 422 Gly Asn Val Cys Gly Glu Lys Arg Ala Tyr Cys Cys Ser Asp Pro 1 5 10 15 <210> SEQ ID NO 423 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 423 Leu Val Pro Cys Ala Trp Ala Gly Asn Val Cys Gly Glu Lys Arg 1 5 10 15 <210> SEQ ID NO 424 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 424 Leu Val Pro Cys Ala Trp Ala Gly Asn Val Cys Gly Glu Lys Arg Ala 1 5 10 15 Tyr Cys Cys Ser 20 <210> SEQ ID NO 425 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 425 Val Cys Tyr Glu Ser Ser Glu Ile Cys Ser Lys Lys Cys Gly Lys 1 5 10 15 <210> SEQ ID NO 426 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 426 Cys Gly Lys Val Gly Lys Tyr Cys Cys Ser Pro Ile Gly Lys Tyr Cys 1 5 10 15 Val Cys Tyr Asp 20 <210> SEQ ID NO 427 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 427 Asp Asp Gly Leu Cys Tyr Glu Gly Thr Asn Cys Gly Lys Val Gly Lys 1 5 10 15 Tyr Cys Cys Ser 20 <210> SEQ ID NO 428 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 428 Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile 1 5 10 <210> SEQ ID NO 429 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 429 Pro Ile Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile 1 5 10 <210> SEQ ID NO 430 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 430 Pro Ile Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile Cys Asn 1 5 10 15 Lys Asn Cys Thr 20 <210> SEQ ID NO 431 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 431 Val Cys Tyr Asp Ser Lys Ala Ile Cys Asn Lys Asn Cys Thr 1 5 10 <210> SEQ ID NO 432 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula pollen allergen Bet v 1 epitope <400> SEQUENCE: 432 His Glu Val Lys Ala Glu Gln Val Lys Ala Thr Lys Glu Met Gly 1 5 10 15 <210> SEQ ID NO 433 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 433 Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala Ser 1 5 10 15 Asn Lys Ala Phe 20 <210> SEQ ID NO 434 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 434 Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn 1 5 10 15 Asp Ala Ile Lys 20 <210> SEQ ID NO 435 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 435 Ala Ala Val Asp Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala 1 5 10 15 Ala Tyr Lys Leu 20 <210> SEQ ID NO 436 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 436 Ala Glu Glu Val Lys Ala Thr Pro Ala Gly Glu Leu Gln Val Ile Asp 1 5 10 15 Lys Val Asp Ala 20 <210> SEQ ID NO 437 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 437 Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp 1 5 10 15 Lys Phe Thr Val 20 <210> SEQ ID NO 438 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 438 Ala Phe Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Asn Val Arg Ser 1 5 10 15 Ala Gly Glu Leu 20 <210> SEQ ID NO 439 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 439 Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro 1 5 10 15 Asp Asp Thr Lys 20 <210> SEQ ID NO 440 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 440 Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp 1 5 10 15 Asn Gly Gly Ala 20 <210> SEQ ID NO 441 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 441 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala 1 5 10 15 Lys Lys Gly Glu 20 <210> SEQ ID NO 442 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 442 Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala 1 5 10 <210> SEQ ID NO 443 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 443 Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr Gln Ala Gln Lys Ala 1 5 10 15 Gly Lys Pro Ala 20 <210> SEQ ID NO 444 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 444 Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Ser 1 5 10 15 Ala Phe Asn Lys 20 <210> SEQ ID NO 445 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 445 Ala Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys 1 5 10 15 Gly Leu Leu Ala 20 <210> SEQ ID NO 446 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 446 Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser Ala Ala Lys 1 5 10 15 Ala Pro Gly Leu 20 <210> SEQ ID NO 447 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 447 Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Glu Val Lys Tyr Ala Val 1 5 10 15 Phe Glu Ala Ala 20 <210> SEQ ID NO 448 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 448 Ala Cys Ser Gly Glu Pro Val Val Val His Ile Thr 1 5 10 <210> SEQ ID NO 449 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 449 Ala Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp 1 5 10 <210> SEQ ID NO 450 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 450 Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val Lys 1 5 10 <210> SEQ ID NO 451 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 451 Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala 1 5 10 <210> SEQ ID NO 452 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 452 Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly 1 5 10 <210> SEQ ID NO 453 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 453 Phe Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser 1 5 10 <210> SEQ ID NO 454 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 454 Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ala 1 5 10 <210> SEQ ID NO 455 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 455 Glu Leu Lys Glu Ser Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro 1 5 10 15 <210> SEQ ID NO 456 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 456 Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe 1 5 10 15 <210> SEQ ID NO 457 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 457 Phe Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser Gly Glu Pro 1 5 10 15 <210> SEQ ID NO 458 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 458 Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly 1 5 10 15 <210> SEQ ID NO 459 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 11 epitope <400> SEQUENCE: 459 Arg Tyr Ala Asn Pro Ile Ala Phe Phe Arg Lys Glu Pro Leu Lys 1 5 10 15 <210> SEQ ID NO 460 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 460 Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly 1 5 10 15 <210> SEQ ID NO 461 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 461 Glu Trp Val Ala Met Thr Lys Gly Glu Gly Gly Val Trp Thr Phe 1 5 10 15 <210> SEQ ID NO 462 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 462 Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe 1 5 10 15 <210> SEQ ID NO 463 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 463 Lys Asn Val Phe Asp Asp Val Val Pro Glu Lys Tyr Thr Ile Gly 1 5 10 15 <210> SEQ ID NO 464 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 464 Leu Gln Gly Pro Phe Asn Phe Arg Phe Leu Thr Glu Lys Gly Met 1 5 10 15 <210> SEQ ID NO 465 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 465 Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr Glu Pro 1 5 10 15 <210> SEQ ID NO 466 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 466 Phe Pro Lys Glu Val Trp Glu Gln Ile Phe Ser Thr Trp Leu Leu 1 5 10 15 <210> SEQ ID NO 467 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 467 Phe Val His Leu Gly His Arg Asp Asn Ile Glu Asp Asp Leu Leu 1 5 10 15 <210> SEQ ID NO 468 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 468 Gly Ile Val Val Ala Trp Lys Val Arg Leu Leu Pro Val Pro Pro 1 5 10 15 <210> SEQ ID NO 469 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 469 Asn Arg Asn Asn Thr Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp 1 5 10 15 <210> SEQ ID NO 470 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5a epitope <400> SEQUENCE: 470 Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys 1 5 10 <210> SEQ ID NO 471 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5a epitope <400> SEQUENCE: 471 Asn Ala Gly Phe Lys Ala Ala Leu Ala Gly Ala Gly Val Gln Pro Ala 1 5 10 15 Asp Lys Tyr <210> SEQ ID NO 472 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 472 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 1 5 10 15 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala 20 25 <210> SEQ ID NO 473 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 473 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 1 5 10 15 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala 20 25 30 Ala <210> SEQ ID NO 474 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 474 Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala Ala Asp Lys Phe Lys 1 5 10 15 Thr Phe Glu <210> SEQ ID NO 475 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 475 Ala Lys Phe Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val 1 5 10 15 Ile Ala Gly Ala Leu Glu Val His Ala Val Lys 20 25 <210> SEQ ID NO 476 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 476 Ala Met Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala 1 5 10 15 Thr Val Ala <210> SEQ ID NO 477 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 477 Ala Arg Trp Lys Asn Ser Lys Ile Trp Leu Gln Phe Ala Gln Leu Thr 1 5 10 15 Asp Phe Asn Leu 20 <210> SEQ ID NO 478 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 478 Ala Val Leu Leu Val Pro Ala Asn Lys Lys Phe Phe Val Asn Asn Leu 1 5 10 15 Val Phe Arg Gly 20 <210> SEQ ID NO 479 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 479 Asp Gly Thr Ile Val Ala Gln Pro Asp Pro Ala Arg Trp Lys Asn Ser 1 5 10 15 Lys Ile Trp Leu 20 <210> SEQ ID NO 480 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 480 Phe Phe Val Asn Asn Leu Val Phe Arg Gly Pro Cys Gln Pro His Leu 1 5 10 15 Ser Phe Lys Val 20 <210> SEQ ID NO 481 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 481 Phe Gly Glu Cys Glu Gly Val Lys Ile Gln Gly Leu Lys Ile Lys Ala 1 5 10 15 Pro Arg Asp Ser 20 <210> SEQ ID NO 482 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 482 Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp 1 5 10 15 <210> SEQ ID NO 483 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 483 Ala Cys Lys Lys Pro Ser Ala Met Leu Leu Val Pro Gly Asn Lys 1 5 10 15 <210> SEQ ID NO 484 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 484 Ala Ile Lys Phe Asp Phe Ser Thr Gly Leu Ile Ile Gln Gly Leu 1 5 10 15 <210> SEQ ID NO 485 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 485 Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp 1 5 10 15 <210> SEQ ID NO 486 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 486 Ala Asn Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn 1 5 10 15 <210> SEQ ID NO 487 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arabidopsis thaliana Probable pectate lyase 18 precursor epitope <400> SEQUENCE: 487 Gly His Ser Asp Thr Tyr Ser Arg Asp Lys Asn Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 488 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Profilin-2/4 epitope <400> SEQUENCE: 488 Leu Gly His Asp Gly Thr Val Trp Ala Gln Ser Ala Asp Phe Pro 1 5 10 15 <210> SEQ ID NO 489 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 489 Asp Glu Tyr Cys Ser Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 1 5 10 15 Ser Gly Glu Gly 20 <210> SEQ ID NO 490 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 490 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln 20 <210> SEQ ID NO 491 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 491 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln Trp Gly Trp Cys Gly Ser Thr Asp Glu Tyr Cys Ser 20 25 30 Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 35 40 <210> SEQ ID NO 492 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 492 Lys Leu Cys Pro Asn Asn Leu Cys Cys Ser Gln Trp Gly Trp Cys Gly 1 5 10 15 Ser Thr Asp Glu 20 <210> SEQ ID NO 493 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 493 Asn Gly Gly Leu Asp Leu Asp Val Asn Val Phe Arg Gln Leu Asp Thr 1 5 10 15 Asp Gly Lys Gly 20 <210> SEQ ID NO 494 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 494 Gly Lys Cys Gly Val Ser Ile Pro Tyr Lys 1 5 10 <210> SEQ ID NO 495 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 495 Ile Thr Cys Gly Gln Val Ser Ser Ser Leu 1 5 10 <210> SEQ ID NO 496 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 496 Ser Ile Pro Tyr Lys Ile Ser Ala Ser Thr 1 5 10 <210> SEQ ID NO 497 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 497 Asp Arg Gln Ala Ala Cys Asn Cys Leu Lys Gln Leu Ser Ala Ser 1 5 10 15 <210> SEQ ID NO 498 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 498 Val Asn Pro Asn Asn Ala Ala Ala Leu Pro Gly Lys Cys Gly Val 1 5 10 15 <210> SEQ ID NO 499 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arabidopsis thaliana Putative pectate lyase 17 precursor epitope <400> SEQUENCE: 499 Gly His Asn Asp Asn Phe Val Lys Asp Val Lys Met Lys Val Thr Val 1 5 10 15 <210> SEQ ID NO 500 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens RAD51-like 1 isoform 1 epitope <400> SEQUENCE: 500 Thr Arg Leu Ile Leu Gln Tyr Leu Asp Ser Glu Arg Arg Gln Ile Leu 1 5 10 15 <210> SEQ ID NO 501 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 501 Asp Pro Gly Pro Ala Arg Val Ile Tyr Thr Tyr Pro Asn Lys Val Phe 1 5 10 15 <210> SEQ ID NO 502 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 502 Ala Thr Trp Thr Cys Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys 1 5 10 15 Trp Glu Asp Lys 20 <210> SEQ ID NO 503 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 503 His Tyr Leu Leu Glu Phe Pro Thr Phe Pro Asp Gly His Asp Tyr Lys 1 5 10 15 Phe Asp Ser Lys 20 <210> SEQ ID NO 504 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 504 Lys Phe Asp Ser Lys Lys Pro Lys Glu Asp Pro Gly Pro Ala Arg Val 1 5 10 15 Ile Tyr Thr Tyr 20 <210> SEQ ID NO 505 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 505 Leu Ile Lys Gly Arg Thr Pro Ile Lys Phe Gly Lys Ala Asp Cys Asp 1 5 10 15 Arg Pro Pro Lys 20 <210> SEQ ID NO 506 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 506 Ser Tyr Pro His Trp Phe Thr Asn Gly Tyr Asp Gly Asn Gly Lys Leu 1 5 10 15 Ile Lys Gly Arg 20 <210> SEQ ID NO 507 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 507 Ala Glu Asp Glu Asp Asn Gln Gln Gly Gln Gly Glu Gly Leu Lys Tyr 1 5 10 15 Leu Gly Phe <210> SEQ ID NO 508 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 508 Phe Ser Asn Val Tyr Leu Phe Ala Lys Asp Lys Ser Gly Pro Leu Gln 1 5 10 15 Pro Gly Val <210> SEQ ID NO 509 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 509 Lys Phe Val Asp Ser Thr Val Val Ala Ser Val Thr Ile Ile Asp Arg 1 5 10 15 Ser Leu Pro <210> SEQ ID NO 510 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 510 Gln Pro Gly Val Asp Ile Ile Glu Gly Pro Val Lys Asn Val Ala Val 1 5 10 15 Pro Leu Tyr <210> SEQ ID NO 511 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 511 Arg Ser Leu Pro Pro Ile Val Lys Asp Ala Ser Ile Gln Val Val Ser 1 5 10 15 Ala Ile Arg <210> SEQ ID NO 512 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 512 Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn Thr Leu 1 5 10 15 Cys <210> SEQ ID NO 513 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 513 Glu Lys Asp Ala Ile Pro Glu Asn Leu Pro Pro Leu Thr Ala Asp Phe 1 5 10 15 Ala Glu Asp Lys 20 <210> SEQ ID NO 514 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 514 Glu Ser His Ala Gly Cys Glu Lys Ser 1 5 <210> SEQ ID NO 515 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 515 His Pro Glu Tyr Ala Val Ser Val Leu Leu 1 5 10 <210> SEQ ID NO 516 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 516 Leu Ser Leu Ile Leu Asn Arg Leu Cys 1 5 <210> SEQ ID NO 517 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 517 Asp Phe Val Arg Ala Ala Gly Val Tyr Ala Val Asp 1 5 10 <210> SEQ ID NO 518 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 518 Lys Tyr Leu Asp Phe Val Arg Ala Ala Gly Val Tyr 1 5 10 <210> SEQ ID NO 519 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 519 Asn Val Val Lys Thr Val Val Thr Pro Val Tyr Tyr 1 5 10 <210> SEQ ID NO 520 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 520 Pro Arg Ile Val Leu Asp Val Ala Ser Ser Val Phe 1 5 10 <210> SEQ ID NO 521 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 521 Gln Gly Tyr Arg Val Ser Ser Tyr Leu Pro Leu Leu 1 5 10 <210> SEQ ID NO 522 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Stress-induced protein SAM22 epitope <400> SEQUENCE: 522 Ala Leu Phe Lys Ala Ile Glu Ala Tyr Leu Leu Ala His Pro Asp 1 5 10 15 <210> SEQ ID NO 523 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 523 Ala Phe Asn Val Glu Asn Gly Asn Ala Thr Pro Gln Leu Thr Lys 1 5 10 15 <210> SEQ ID NO 524 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 524 Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr Ala Ile Gly Gly 1 5 10 15 <210> SEQ ID NO 525 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 525 Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe Asn 1 5 10 15 <210> SEQ ID NO 526 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 526 Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr Gly Leu Val His Val 1 5 10 15 <210> SEQ ID NO 527 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 527 Cys Ser Asn Trp Val Trp Gln Ser Thr Gln Asp Val Phe Tyr Asn 1 5 10 15 <210> SEQ ID NO 528 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 528 Ala Asp Phe Ser Asn Tyr Gly Ala Val Val Asp Val Tyr Ala Pro Gly 1 5 10 15 Lys Asp Ile Thr 20 <210> SEQ ID NO 529 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 529 Ala Lys Gly Val Ser Leu Val Ala Val Lys Val Leu Asp Cys Asp Gly 1 5 10 15 Ser Gly Ser Asn 20 <210> SEQ ID NO 530 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 530 Ala Ser Asn Gln Ala Ala Lys Ala Ile Ser Asp Ala Gly Ile Phe Met 1 5 10 15 Ala Val Ala Ala 20 <210> SEQ ID NO 531 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 531 Asp Cys Asn Gly His Gly Thr His Val Ala Gly Thr Val Gly Gly Thr 1 5 10 15 Lys Tyr Gly Leu 20 <210> SEQ ID NO 532 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 532 Asp Pro Ser Ala Gly Lys Gly Val Thr Ala Tyr Ile Ile Asp Thr Gly 1 5 10 15 Ile Asp Ile Asp 20 <210> SEQ ID NO 533 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 533 Ala Cys Lys Tyr Gly Ser Leu Lys Pro Asn Cys Gly 1 5 10 <210> SEQ ID NO 534 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 534 Cys Asn Tyr Gly Pro Ser Gly Asn Phe Met Asn Glu 1 5 10 <210> SEQ ID NO 535 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 535 Asp Val Ala Lys Tyr Gln Val Gly Gln Asn Val Ala 1 5 10 <210> SEQ ID NO 536 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 536 Glu Lys Trp His Lys His Tyr Leu Val Cys Asn Tyr 1 5 10 <210> SEQ ID NO 537 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 537 Glu Leu Ala Tyr Val Ala Gln Val Trp Ala Asn Gln 1 5 10 <210> SEQ ID NO 538 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana 11S globulin-like protein epitope <400> SEQUENCE: 538 Ala Phe Gln Ile Ser Arg Glu Glu Ala Arg Arg Leu Lys Tyr Asn 1 5 10 15 <210> SEQ ID NO 539 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Carya illinoinensis 11S legumin protein epitope <400> SEQUENCE: 539 Glu Glu Ser Gln Arg Gln Ser Gln Gln Gly Gln Arg 1 5 10 <210> SEQ ID NO 540 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin epitope <400> SEQUENCE: 540 Asp Ala His Gln Pro Thr Arg Arg Val Arg Lys Gly Asp Val Val Ala 1 5 10 15 Leu Pro <210> SEQ ID NO 541 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin seed storage protein 1 precursor (Legumin-like protein 1) epitope <400> SEQUENCE: 541 Phe Lys Gln Asn Val Asn Arg Pro Ser Arg Ala Asp 1 5 10 <210> SEQ ID NO 542 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin seed storage protein 3 precursor (Legumin-like protein 3) (Allergen Fag e 1) epitope <400> SEQUENCE: 542 Asp Ile Ser Thr Lys Glu Ala Phe Arg Leu Lys Asn 1 5 10 <210> SEQ ID NO 543 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale 2s albumin epitope <400> SEQUENCE: 543 Cys Gln Arg Gln Phe Glu Glu Gln Gln Arg Phe Arg 1 5 10 <210> SEQ ID NO 544 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Sesamum indicum 2S seed storage protein 1 epitope <400> SEQUENCE: 544 His Phe Arg Glu Cys Cys Asn Glu Ile Arg 1 5 10 <210> SEQ ID NO 545 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Sesamum indicum 2S seed storage protein 1 precursor epitope <400> SEQUENCE: 545 Cys Met Gln Trp Met Arg Ser Met Arg Gly 1 5 10 <210> SEQ ID NO 546 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bertholletia excelsa 2S sulfur-rich seed storage protein precursor (Allergen Ber e 1) epitope <400> SEQUENCE: 546 Cys Arg Cys Glu Gly Leu Arg Met Met Met Met Arg Met Gln 1 5 10 <210> SEQ ID NO 547 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 52 kDa Ro protein epitope <400> SEQUENCE: 547 Leu Glu Lys Asp Glu Arg Glu Gln Leu Arg Ile Leu Gly Glu Lys Glu 1 5 10 15 Ala Lys Leu Ala Gln Gln Ser Gln Ala Leu Gln Glu Leu Ile Ser Glu 20 25 30 Leu Asp Arg Arg Cys His Ser Ser 35 40 <210> SEQ ID NO 548 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 52-kD SS-A/Ro autoantigen epitope <400> SEQUENCE: 548 Gln Glu Lys Leu Gln Val Ala Leu Gly Glu 1 5 10 <210> SEQ ID NO 549 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 5-hydroxytryptamine (serotonin) receptor 4 epitope <400> SEQUENCE: 549 Gly Ile Ile Asp Leu Ile Glu Lys Arg Lys Phe Asn Gln Asn Ser Asn 1 5 10 15 Ser Thr Tyr Cys Val 20 <210> SEQ ID NO 550 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60 kDa heat shock protein, mitochondrial precursor epitope <400> SEQUENCE: 550 Asp Gly Val Ala Val Leu Lys Val Gly Gly 1 5 10 <210> SEQ ID NO 551 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60 kDa SS-A/Ro ribonucleoprotein epitope <400> SEQUENCE: 551 Glu Leu Tyr Lys Glu Lys Ala Leu Ser Val Glu Thr Glu Lys Leu Leu 1 5 10 15 Lys Tyr Leu Glu Ala Val 20 <210> SEQ ID NO 552 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60S acidic ribosomal protein P0 epitope <400> SEQUENCE: 552 Ala Lys Val Glu Ala Lys Glu Glu Ser Glu Glu Ser Asp Glu Asp Met 1 5 10 15 Gly Phe Gly Leu Phe Asp 20 <210> SEQ ID NO 553 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60S acidic ribosomal protein P2 epitope <400> SEQUENCE: 553 Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 <210> SEQ ID NO 554 <211> LENGTH: 50 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 64 Kd autoantigen epitope <400> SEQUENCE: 554 Ala Thr Lys Lys Glu Glu Glu Lys Lys Gly Gly Asp Arg Asn Thr Gly 1 5 10 15 Leu Ser Arg Asp Lys Asp Lys Lys Arg Glu Glu Met Lys Glu Val Ala 20 25 30 Lys Lys Glu Asp Asp Glu Lys Val Lys Gly Glu Arg Arg Asn Thr Asp 35 40 45 Thr Arg 50 <210> SEQ ID NO 555 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 65 kDa heat shock protein epitope <400> SEQUENCE: 555 Ala Leu Leu Arg Cys Ile Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn 1 5 10 15 Glu Asp Cys <210> SEQ ID NO 556 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Acetylcholine receptor subunit alpha precursor epitope <400> SEQUENCE: 556 Ala Ile Asn Pro Glu Ser Asp Gln Pro Asp Leu Ser Asn Phe 1 5 10 <210> SEQ ID NO 557 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon acidic Cyn d 1 isoallergen isoform 1 precursor epitope <400> SEQUENCE: 557 Gln Asp Asp Val Ile Pro Glu Asp Trp Lys Pro Asp Thr Val Tyr Lys 1 5 10 15 Ser Lys Ile Gln Phe 20 <210> SEQ ID NO 558 <211> LENGTH: 50 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon acidic Cyn d 1 isoallergen isoform 3 precursor epitope <400> SEQUENCE: 558 Glu Glu Asp Lys Leu Arg Lys Ala Gly Glu Leu Met Leu Gln Phe Arg 1 5 10 15 Arg Val Lys Cys Glu Tyr Pro Ser Asp Thr Lys Ile Thr Phe His Val 20 25 30 Glu Lys Gly Ser Ser Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr Ala 35 40 45 Ala Gly 50 <210> SEQ ID NO 559 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P0) epitope <400> SEQUENCE: 559 Ala Ala Ala Ala Ala Pro Ala Lys 1 5 <210> SEQ ID NO 560 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P1) epitope <400> SEQUENCE: 560 Glu Ser Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 15 <210> SEQ ID NO 561 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P2) epitope <400> SEQUENCE: 561 Ala Pro Ala Ala Gly Ser Ala Pro Ala Ala Ala Glu Glu Lys Lys 1 5 10 15 <210> SEQ ID NO 562 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Adrenergic, beta-2-, receptor, surface epitope <400> SEQUENCE: 562 His Trp Tyr Arg Ala Thr His Gln Glu Ala Ile Asn Cys Tyr Ala Asn 1 5 10 15 <210> SEQ ID NO 563 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Alanyl-tRNA synthetase, cytoplasmic epitope <400> SEQUENCE: 563 Phe Ile Asp Glu Pro Arg Arg Arg Pro Ile 1 5 10 <210> SEQ ID NO 564 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus albumin epitope <400> SEQUENCE: 564 Pro Val Glu Ser Lys Val Thr 1 5 <210> SEQ ID NO 565 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia Albumin seed storage protein epitope <400> SEQUENCE: 565 Gly Leu Arg Gly Glu Glu Met Glu Glu Met Val Gln Ser 1 5 10 <210> SEQ ID NO 566 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus alcohol dehydrogenase epitope <400> SEQUENCE: 566 Ala Val Asn Gly Asp Trp Pro Leu Pro Thr Lys Leu Pro Leu Val Gly 1 5 10 15 Gly His <210> SEQ ID NO 567 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penicillium chrysogenum alkaline serine protease epitope <400> SEQUENCE: 567 Ala Asn Val Val Gln Arg Asn Ala Pro Ser Trp Gly Leu Ser Arg Ile 1 5 10 15 Ser Ser Lys Lys Ser Gly Ala Thr Asp Tyr Val Tyr Asp Ser Thr Ala 20 25 30 Gly Glu Gly Ile Val 35 <210> SEQ ID NO 568 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen epitope <400> SEQUENCE: 568 Asp Asp Gln Cys Gln Arg Gln Leu Gln Arg 1 5 10 <210> SEQ ID NO 569 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale allergen Ana o 2 epitope <400> SEQUENCE: 569 Glu Glu Ser Glu Asp Glu Lys Arg Arg Trp Gly Gln Arg Asp Asn 1 5 10 15 <210> SEQ ID NO 570 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Allergen Ara h 1, clone P41B precursor epitope <400> SEQUENCE: 570 Ala Lys Ser Ser Pro Tyr Gln Lys Lys Thr 1 5 10 <210> SEQ ID NO 571 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen Arah3/Arah4 epitope <400> SEQUENCE: 571 Ala Gly Val Ala Leu Ser Arg Leu Val Leu Arg Arg Asn Ala Leu 1 5 10 15 <210> SEQ ID NO 572 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen Arah6 epitope <400> SEQUENCE: 572 Asp Arg Gln Met Val Gln His Phe Lys Arg 1 5 10 <210> SEQ ID NO 573 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Periplaneta americana Allergen Cr-PI epitope <400> SEQUENCE: 573 Ile Pro Lys Gly Lys Lys Gly Gly Gln Ala Tyr 1 5 10 <210> SEQ ID NO 574 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 574 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 575 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Allergen II epitope <400> SEQUENCE: 575 Asp Arg Leu Gln Gly Arg Gln Gln Glu Gln 1 5 10 <210> SEQ ID NO 576 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lens culinaris allergen Len c 1.0101 epitope <400> SEQUENCE: 576 Ala Ile Asn Ala Ser Ser Asp Leu Asn Leu Ile Gly Phe Gly Ile 1 5 10 15 <210> SEQ ID NO 577 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 577 Asp Val Glu Leu Ser Leu Arg Ser Ser Asp Ile Ala 1 5 10 <210> SEQ ID NO 578 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penicillium chrysogenum Allergen Pen n 18 epitope <400> SEQUENCE: 578 Ala His Ile Lys Lys Ser Lys Lys Gly Asp Lys Lys Phe Lys Gly Ser 1 5 10 15 Val Ala Asn Met Ser Leu Gly Gly Gly Ser Ser Arg Thr Leu Asp 20 25 30 <210> SEQ ID NO 579 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Sinapis alba Allergen Sin a 1 epitope <400> SEQUENCE: 579 Gln Gly Pro His Val Ile Ser Arg Ile Tyr Gln Thr Ala Thr 1 5 10 <210> SEQ ID NO 580 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ziziphus mauritiana allergen Ziz m 1 epitope <400> SEQUENCE: 580 Lys Thr Asn Tyr Ser Ser Ser Ile Ile Leu Glu Tyr 1 5 10 <210> SEQ ID NO 581 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum tataricum allergenic protein epitope <400> SEQUENCE: 581 Asp Ile Ser Thr Glu Glu Ala Tyr Lys Leu Lys Asn Gly Arg Gln Glu 1 5 10 15 Val Glu Val Phe Arg Pro Phe Gln Ser Arg Tyr Glu Lys Glu Glu Glu 20 25 30 Lys Glu Arg Glu Arg 35 <210> SEQ ID NO 582 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha 2 interferon epitope <400> SEQUENCE: 582 Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser 1 5 10 <210> SEQ ID NO 583 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha S1 casein epitope <400> SEQUENCE: 583 Glu Asp Gln Ala Met Glu Asp Ile Lys Gln Met Glu Ala Glu Ser Ile 1 5 10 15 Ser Ser Ser Glu Glu Ile Val Pro Asn Ser Val Glu Gln Lys 20 25 30 <210> SEQ ID NO 584 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha/beta-gliadin A-II precursor epitope <400> SEQUENCE: 584 Gln Val Ser Phe Gln Gln Pro Gln Gln Gln 1 5 10 <210> SEQ ID NO 585 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha/beta-gliadin A-V epitope <400> SEQUENCE: 585 Leu Ala Leu Gln Thr Leu Pro Ala Met Cys 1 5 10 <210> SEQ ID NO 586 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-1 type IV collagen epitope <400> SEQUENCE: 586 Ser Arg Cys Gln Val Cys Met Arg Arg Thr 1 5 10 <210> SEQ ID NO 587 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha1A-voltage-dependent calcium channel epitope <400> SEQUENCE: 587 Glu Asp Ser Asp Glu Asp Glu Phe Gln Ile Thr Glu 1 5 10 <210> SEQ ID NO 588 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-2 type XI collagen epitope <400> SEQUENCE: 588 Gly Ser Leu Asp Ser Leu Arg Arg Glu Ile Glu Gln Met Arg Arg 1 5 10 15 <210> SEQ ID NO 589 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha2(I) collagen epitope <400> SEQUENCE: 589 Leu Pro Gly Leu Lys Gly His Asn Gly Leu Gln Gly Leu Pro Gly Leu 1 5 10 15 Ala Gly His His 20 <210> SEQ ID NO 590 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha-amylase inhibitor 0.28 precursor (CIII) (WMAI-1) epitope <400> SEQUENCE: 590 Ala Tyr Pro Asp Val 1 5 <210> SEQ ID NO 591 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Alpha-enolase epitope <400> SEQUENCE: 591 Lys Ile His Ala Arg Glu Ile Phe Asp Ser Arg Gly Asn Pro Thr Val 1 5 10 15 Glu <210> SEQ ID NO 592 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-fibrinogen precursor epitope <400> SEQUENCE: 592 Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser 1 5 10 15 <210> SEQ ID NO 593 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha-gliadin epitope <400> SEQUENCE: 593 Leu Gly Gln Gly Ser Phe Arg Pro Ser Gln Gln Asn 1 5 10 <210> SEQ ID NO 594 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-lactalbumin epitope <400> SEQUENCE: 594 Lys Asp Leu Lys Gly Tyr Gly Gly Val Ser 1 5 10 <210> SEQ ID NO 595 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-lactalbumin precursor epitope <400> SEQUENCE: 595 Lys Cys Glu Val Phe Arg Glu Leu Lys Asp Leu Lys Gly Tyr 1 5 10 <210> SEQ ID NO 596 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha-S1-casein epitope <400> SEQUENCE: 596 Leu Asn Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Gln Val 1 5 10 15 Phe Gly Lys Glu 20 <210> SEQ ID NO 597 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 597 Ala Met Glu Asp Ile Lys Gln Met Glu Ala 1 5 10 <210> SEQ ID NO 598 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S2-casein precursor epitope <400> SEQUENCE: 598 Glu Asn Leu Cys Ser Thr Phe Cys Lys Glu 1 5 10 <210> SEQ ID NO 599 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens anti-beta-amyloid peptide immunoglobulin heavy chain variable region epitope <400> SEQUENCE: 599 Ala His Ile Trp Trp Asn Asp 1 5 <210> SEQ ID NO 600 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aquaporin-4 epitope <400> SEQUENCE: 600 Phe Cys Pro Asp Val Glu Phe Lys Arg Arg Phe Lys Glu Ala Phe Ser 1 5 10 15 Lys Ala Ala Gln Gln Thr Lys Gly 20 <210> SEQ ID NO 601 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 601 Cys Cys Asn Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met 1 5 10 15 <210> SEQ ID NO 602 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ATP-dependent DNA helicase 2 subunit 2 epitope <400> SEQUENCE: 602 Glu Glu Ala Ser Gly Ser Ser Val Thr Ala Glu Glu Ala Lys Lys Phe 1 5 10 15 Leu Ala Pro Lys 20 <210> SEQ ID NO 603 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens autoantigen epitope <400> SEQUENCE: 603 Glu Ile Arg Val Arg Leu Gln Ser Ala Ser Pro Ser Thr Arg Trp Thr 1 5 10 15 Glu Leu Asp Asp Val Lys Arg Leu Leu Lys Gly Ser 20 25 <210> SEQ ID NO 604 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Band 3 anion transport protein epitope <400> SEQUENCE: 604 Leu Phe Lys Pro Pro Lys Tyr His Pro Asp Val Pro Tyr Val Lys Arg 1 5 10 15 <210> SEQ ID NO 605 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Bd 30K (34 kDa maturing seed protein) epitope <400> SEQUENCE: 605 Glu Asp Trp Gly Glu Asp Gly Tyr Ile Trp Ile Gln Arg Asn Thr 1 5 10 15 <210> SEQ ID NO 606 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Bence Jones protein HAG epitope <400> SEQUENCE: 606 Ala Trp His Gln Gln Gln Pro 1 5 <210> SEQ ID NO 607 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Bet v 4 epitope <400> SEQUENCE: 607 Phe Ala Arg Ala Asn Arg Gly Leu 1 5 <210> SEQ ID NO 608 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata beta-1, 3-glucananse epitope <400> SEQUENCE: 608 Gly Leu Phe Tyr Pro Asn Lys Gln Pro 1 5 <210> SEQ ID NO 609 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis beta-1,3-glucanase epitope <400> SEQUENCE: 609 Gly Leu Phe Phe Pro Asp Lys Arg Pro Lys Tyr Asn Leu Asn Phe 1 5 10 15 <210> SEQ ID NO 610 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea beta-1,3-glucanase-like protein epitope <400> SEQUENCE: 610 Ala Gly Arg Asn Ser Trp Asn Cys Asp Phe Ser Gln 1 5 10 <210> SEQ ID NO 611 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens beta-2-glycoprotein 1 precursor epitope <400> SEQUENCE: 611 Leu Lys Thr Pro Arg Val 1 5 <210> SEQ ID NO 612 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens beta-2-glycoprotein I epitope <400> SEQUENCE: 612 Thr Leu Arg Val Tyr Lys 1 5 <210> SEQ ID NO 613 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus beta-casein epitope <400> SEQUENCE: 613 Gln Ser Lys Val Leu Pro Val Pro Gln Lys Ala Val Pro 1 5 10 <210> SEQ ID NO 614 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-casein precursor epitope <400> SEQUENCE: 614 Asp Glu Leu Gln Asp Lys Ile His Pro Phe Ala Gln 1 5 10 <210> SEQ ID NO 615 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-lactoglobulin epitope <400> SEQUENCE: 615 Ala Gln Lys Lys Ile Ile Ala Glu Lys Thr 1 5 10 <210> SEQ ID NO 616 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-lactoglobulin precursor epitope <400> SEQUENCE: 616 Ala Ala Ser Asp Ile Ser Leu Leu Asp Ala Gln Ser Ala Pro Leu Arg 1 5 10 15 <210> SEQ ID NO 617 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Botulinum neurotoxin type E epitope <400> SEQUENCE: 617 Trp Lys Ala Pro Ser Ser Pro 1 5 <210> SEQ ID NO 618 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens bullous pemphigoid antigen epitope <400> SEQUENCE: 618 Lys Ser Thr Ala Lys Asp Cys Thr Phe Lys Pro Asp Phe Glu Met Thr 1 5 10 15 Val Lys Glu <210> SEQ ID NO 619 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Bullous pemphigoid antigen 1, isoforms 1/2/3/4/5/8 epitope <400> SEQUENCE: 619 Leu Thr Asp Thr Lys Thr Gly Leu His Phe Asn Ile Asn Glu Ala Ile 1 5 10 15 Glu Gln Gly Thr 20 <210> SEQ ID NO 620 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum BW 16kDa allergen epitope <400> SEQUENCE: 620 Glu Gly Val Arg Asp Leu Lys Glu 1 5 <210> SEQ ID NO 621 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens calcium channel, alpha 1A subunit isoform 3 epitope <400> SEQUENCE: 621 Gly Asn Ile Gly Ile Asp Val Glu Asp Glu Asp Ser Asp Glu Asp Glu 1 5 10 15 Phe <210> SEQ ID NO 622 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Calpastatin epitope <400> SEQUENCE: 622 Ala Val Cys Arg Thr Ser Met Cys Ser Ile Gln Ser Ala Pro Pro 1 5 10 15 <210> SEQ ID NO 623 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Calreticulin precursor epitope <400> SEQUENCE: 623 Lys Glu Gln Phe Leu Asp Gly Asp Gly Trp Thr Ser Arg Trp Ile Glu 1 5 10 15 Ser Lys <210> SEQ ID NO 624 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ca-sensing receptor epitope <400> SEQUENCE: 624 Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp 1 5 10 <210> SEQ ID NO 625 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Caspase-8 precursor epitope <400> SEQUENCE: 625 Asp Arg Asn Gly Thr His Leu Asp Ala 1 5 <210> SEQ ID NO 626 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein A isoform a epitope <400> SEQUENCE: 626 Gly Pro Ser Arg Arg Gly Pro Ser Leu Gly Ala Ser Ser His 1 5 10 <210> SEQ ID NO 627 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein B, 80kDa epitope <400> SEQUENCE: 627 Met Gly Pro Lys Arg Arg Gln Leu Thr Phe 1 5 10 <210> SEQ ID NO 628 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein-A epitope <400> SEQUENCE: 628 Glu Ala Pro Arg Arg Arg Ser Pro Ser Pro 1 5 10 <210> SEQ ID NO 629 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Chain A, Birch Pollen Profilin epitope <400> SEQUENCE: 629 Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu Ile Thr Gly 1 5 10 15 Ile <210> SEQ ID NO 630 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain A, Crystal Structure Of The Glycosylated Five-Domain Human Beta2-Glycoprotein I Purified From Blood Plasma epitope <400> SEQUENCE: 630 Arg Gly Gly Met Arg 1 5 <210> SEQ ID NO 631 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain H, Three-Dimensional Structure Of A Human Immunoglobulin With A Hinge Deletion epitope <400> SEQUENCE: 631 Ala Leu Pro Ala Pro Ile Glu 1 5 <210> SEQ ID NO 632 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens cholesterol side-chain cleavage enzyme P450scc (EC 1.14.15.67) epitope <400> SEQUENCE: 632 Phe Asp Pro Glu Asn Phe Asp Pro Thr Arg Trp Leu Ser Lys Asp Lys 1 5 10 15 Asn Ile Thr Tyr Phe Arg Asn Leu Gly Phe Gly 20 25 <210> SEQ ID NO 633 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens citrate synthase epitope <400> SEQUENCE: 633 Ala Leu Lys His Leu Pro Asn Asp Pro Met 1 5 10 <210> SEQ ID NO 634 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens claudin 11 epitope <400> SEQUENCE: 634 Ala His Arg Glu Thr 1 5 <210> SEQ ID NO 635 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Coagulation factor VIII precursor epitope <400> SEQUENCE: 635 Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr 1 5 10 <210> SEQ ID NO 636 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Oncorhynchus mykiss collagen a2(I) epitope <400> SEQUENCE: 636 Met Lys Gly Leu Arg Gly His Gly Gly Leu Gln Gly Met Pro Gly Pro 1 5 10 15 Asn Gly Pro Ser 20 <210> SEQ ID NO 637 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-1(II) chain epitope <400> SEQUENCE: 637 Ala Arg Gly Ala Gln Gly Pro Pro Gly Ala Thr Gly Phe Pro 1 5 10 <210> SEQ ID NO 638 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen alpha-1(VII) chain precursor epitope <400> SEQUENCE: 638 Gly Thr Leu His Val Val Gln Arg 1 5 <210> SEQ ID NO 639 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-1(XVII) chain epitope <400> SEQUENCE: 639 Arg Ser Ile Leu Pro Tyr Gly Asp Ser Met Asp Arg Ile Glu Lys Asp 1 5 10 15 Arg Leu Gln Gly Met Ala Pro 20 <210> SEQ ID NO 640 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-3(IV) chain epitope <400> SEQUENCE: 640 Thr Ala Ile Pro Ser Cys Pro Glu Gly Thr Val Pro Leu Tyr Ser 1 5 10 15 <210> SEQ ID NO 641 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen VII epitope <400> SEQUENCE: 641 Ile Ile Trp Arg Ser Thr Gln Gly 1 5 <210> SEQ ID NO 642 <211> LENGTH: 46 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus collagen, type I, alpha 2 epitope <400> SEQUENCE: 642 Ala Pro Gly Pro Asp Gly Asn Asn Gly Ala Gln Gly Pro Pro Gly Leu 1 5 10 15 Gln Gly Val Gln Gly Gly Lys Gly Glu Gln Gly Pro Ala Gly Pro Pro 20 25 30 Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Thr Ala Gly Glu 35 40 45 <210> SEQ ID NO 643 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 epitope <400> SEQUENCE: 643 Pro Pro Gly Pro Thr Gly Ala Ser Gly 1 5 <210> SEQ ID NO 644 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 1 precursor epitope <400> SEQUENCE: 644 Ala Arg Gly Leu Thr Gly Arg Pro Gly Asp Ala 1 5 10 <210> SEQ ID NO 645 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 2 precursor epitope <400> SEQUENCE: 645 Leu Val Gly Pro Arg Gly Glu Arg Gly Phe Pro 1 5 10 <210> SEQ ID NO 646 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Complement C1q subcomponent subunit A epitope <400> SEQUENCE: 646 Lys Gly Glu Gln Gly Glu Pro Gly Ala 1 5 <210> SEQ ID NO 647 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Condensin-2 complex subunit D3 epitope <400> SEQUENCE: 647 Pro Thr Pro Glu Thr Gly Pro Leu Gln Arg 1 5 10 <210> SEQ ID NO 648 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Conglutin-7 precursor epitope <400> SEQUENCE: 648 Ala Ala His Ala Ser Ala Arg Gln Gln Trp Glu Leu Gln Gly Asp 1 5 10 15 <210> SEQ ID NO 649 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Periplaneta americana Cr-PII allergen epitope <400> SEQUENCE: 649 Ile Arg Ser Trp Phe Gly Leu Pro 1 5 <210> SEQ ID NO 650 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 650 Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys 1 5 10 <210> SEQ ID NO 651 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Cytochrome P450 3A1 epitope <400> SEQUENCE: 651 Asp Met Val Leu Asn Glu Thr Leu Arg Leu 1 5 10 <210> SEQ ID NO 652 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens cytoskeleton-associated protein 5 isoform b epitope <400> SEQUENCE: 652 Cys Gln Ala Leu Val Arg Met Leu Ala Lys Lys Pro Gly Trp Lys 1 5 10 15 <210> SEQ ID NO 653 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 epitope <400> SEQUENCE: 653 Ile Ala Thr His Ala Lys Ile Arg Asp 1 5 <210> SEQ ID NO 654 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 7 allergen epitope <400> SEQUENCE: 654 His Ile Gly Gly Leu Ser Ile Leu Asp Pro Ile Phe Gly Val Leu 1 5 10 15 <210> SEQ ID NO 655 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 655 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val 35 40 <210> SEQ ID NO 656 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 7 allergen polypeptide epitope <400> SEQUENCE: 656 His Ile Gly Gly Leu Ser Ile Leu Asp Pro Ile Phe Ala Val Leu 1 5 10 15 <210> SEQ ID NO 657 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Desmoglein-1 epitope <400> SEQUENCE: 657 Arg Glu Trp Ile Lys Phe Ala Ala Ala Cys Arg Glu 1 5 10 <210> SEQ ID NO 658 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Desmoglein-3 precursor epitope <400> SEQUENCE: 658 Arg Glu Trp Val Lys Phe Ala Lys Pro Cys Arg Glu 1 5 10 <210> SEQ ID NO 659 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoglein-3 preproprotein epitope <400> SEQUENCE: 659 Ser Gln Glu Pro Ala Gly Thr Pro Met Phe Leu Leu Ser Arg Asn Thr 1 5 10 15 Gly Glu Val Arg Thr Leu Thr Asn Ser Leu Asp Arg Glu Gln 20 25 30 <210> SEQ ID NO 660 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoplakin epitope <400> SEQUENCE: 660 Gly Asn Ser Ser Tyr Ser Tyr Ser Tyr Ser Phe Ser 1 5 10 <210> SEQ ID NO 661 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoplakin isoform II epitope <400> SEQUENCE: 661 Leu Val Asp Arg Lys Thr Gly Ser Gln Tyr Asp Ile Gln Asp Ala Ile 1 5 10 15 Asp Lys Gly Leu 20 <210> SEQ ID NO 662 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens dihydrolipoamide S- acetyltransferase (E2 component of pyruvate dehydrogenase complex), isoform CRA_a epitope <400> SEQUENCE: 662 Ala Glu Ile Glu Thr Asp Lys Ala Thr Ile Gly Phe Glu Val Gln Glu 1 5 10 15 Glu Gly <210> SEQ ID NO 663 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase 1 epitope <400> SEQUENCE: 663 Gly Val Pro Ile Glu Lys Ile Tyr Asn Lys Thr Gln Arg Glu Lys Phe 1 5 10 15 Ala <210> SEQ ID NO 664 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase I epitope <400> SEQUENCE: 664 Glu Leu Asp Gly Gln Glu Tyr Val Val Glu Phe Asp Phe Leu Gly Lys 1 5 10 15 Asp Ser Ile Arg 20 <210> SEQ ID NO 665 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase II beta epitope <400> SEQUENCE: 665 His Pro Met Leu Pro Asn Tyr Lys Asn Phe Lys Gly Thr Ile Gln Glu 1 5 10 15 Leu Gly Gln Asn 20 <210> SEQ ID NO 666 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA-directed RNA polymerase II subunit RPB1 epitope <400> SEQUENCE: 666 Tyr Ser Pro Thr Ser Pro Ser 1 5 <210> SEQ ID NO 667 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens E3 ubiquitin-protein ligase TRIM9 isoform 2 epitope <400> SEQUENCE: 667 Ala Phe Asn Lys Thr Gly Val Ser Pro Tyr Ser Lys Thr Leu Val Leu 1 5 10 15 Gln Thr Ser Glu Gly Lys Ala Leu Gln Gln Tyr Pro Ser Glu Arg Glu 20 25 30 Leu Arg Gly Ile 35 <210> SEQ ID NO 668 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Candida albicans Enolase 1 (2-phosphoglycerate dehydratase) (2-phospho-D-glycerate hydro-lyase) epitope <400> SEQUENCE: 668 Gln Ala Ala Asn Asp Ser Tyr Ala Ala Gly Trp Gly Val Met Val Ser 1 5 10 15 His Arg Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Ser Val 20 25 30 Gly Leu Arg Ser Gly Gln Ile 35 <210> SEQ ID NO 669 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens enolase 1 variant epitope <400> SEQUENCE: 669 Lys Ile His Ala Arg Glu Ile Phe Asp Ser Arg Gly Asn Pro Thr Val 1 5 10 15 <210> SEQ ID NO 670 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis ENSP-like protein epitope <400> SEQUENCE: 670 Phe Pro Leu Ile Thr Cys Cys Gly Tyr Gly Gly Lys Tyr Asn Phe Ser 1 5 10 15 Val Thr Ala Pro Cys 20 <210> SEQ ID NO 671 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens envoplakin epitope <400> SEQUENCE: 671 Ala Gly Glu Thr Lys Pro Ser Ser Ser Leu Ser Ile Gly Ser Ile Ile 1 5 10 15 Ser Lys Ser Pro 20 <210> SEQ ID NO 672 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum Fag e 1 epitope <400> SEQUENCE: 672 Ala Val Val Leu Lys Ala Gly Asn Glu Gly Leu Glu 1 5 10 <210> SEQ ID NO 673 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fas AMA epitope <400> SEQUENCE: 673 Cys Val Pro 1 <210> SEQ ID NO 674 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens FGA protein epitope <400> SEQUENCE: 674 Ser Arg Ala Leu Ala Arg Glu Val Asp Leu Lys Asp Tyr Glu Asp Gln 1 5 10 15 Gln Lys <210> SEQ ID NO 675 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens FGB protein epitope <400> SEQUENCE: 675 Ala Arg Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser 1 5 10 15 Leu Arg Pro Ala 20 <210> SEQ ID NO 676 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrin beta epitope <400> SEQUENCE: 676 Ala Asn Lys Tyr Gln Ile Ser Val Asn Lys Tyr Arg Gly Thr Ala Gly 1 5 10 15 Asn Ala Leu <210> SEQ ID NO 677 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen alpha chain isoform alpha preproprotein epitope <400> SEQUENCE: 677 Asp Ser Pro Gly Ser Gly Asn Ala Arg Pro Asn Asn Pro Asp Trp 1 5 10 15 <210> SEQ ID NO 678 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fibrinogen alpha chain precursor epitope <400> SEQUENCE: 678 Phe Leu Ala Glu Gly Gly Gly Val Arg Gly Pro Arg Val Val Glu Arg 1 5 10 15 His <210> SEQ ID NO 679 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen alpha chain preproprotein, isoform alpha epitope <400> SEQUENCE: 679 Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala Lys Ser Arg 1 5 10 15 Pro Val Arg Gly 20 <210> SEQ ID NO 680 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain epitope <400> SEQUENCE: 680 Pro Arg Lys Gln Cys Ser Lys Glu Asp Gly Gly Gly Trp Trp Tyr 1 5 10 15 <210> SEQ ID NO 681 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain, isoform CRA_d epitope <400> SEQUENCE: 681 Asn Glu Glu Gly Phe Phe Ser Ala Arg Gly His Arg Pro Leu Asp Lys 1 5 10 15 Lys <210> SEQ ID NO 682 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain, isoform CRA_i epitope <400> SEQUENCE: 682 Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly 1 5 10 15 Gly Tyr Arg Ala Arg Pro Ala Lys 20 <210> SEQ ID NO 683 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fibronectin precursor epitope <400> SEQUENCE: 683 Leu Thr Ser Arg Pro Ala 1 5 <210> SEQ ID NO 684 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens filaggrin epitope <400> SEQUENCE: 684 Asp Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu 1 5 10 15 Gly His <210> SEQ ID NO 685 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Follistatin-related protein 1 epitope <400> SEQUENCE: 685 Leu Lys Phe Val Glu Gln Asn Glu 1 5 <210> SEQ ID NO 686 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Forkhead box protein E3 epitope <400> SEQUENCE: 686 Pro Thr Pro Ala Pro Gly Pro Gly Arg Arg 1 5 10 <210> SEQ ID NO 687 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens GAD65 autoantigen glutamic acid decarboxylase epitope <400> SEQUENCE: 687 Ala Pro Ala Met Ile Pro Pro 1 5 <210> SEQ ID NO 688 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Gamma-gliadin precursor epitope <400> SEQUENCE: 688 Leu Gln Pro Gln Gln Pro Phe Pro Gln Gln 1 5 10 <210> SEQ ID NO 689 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 689 Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr Leu 1 5 10 15 Asp Thr Phe Phe Gly 20 <210> SEQ ID NO 690 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 690 Gly Val Thr His Asp Gln Leu Asn Asn Phe Arg 1 5 10 <210> SEQ ID NO 691 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-IV precursor epitope <400> SEQUENCE: 691 Lys Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr 1 5 10 15 Leu Asp Ala Phe Phe Gly Met 20 <210> SEQ ID NO 692 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-VI precursor epitope <400> SEQUENCE: 692 Ile Val Ser Phe Leu Ser Glu Val Ile Ser Leu Ala Gly Ser Asp Ala 1 5 10 15 Asn Ile Pro Ala Ile Gln Asn Leu Ala Lys Glu Leu Ala Thr Ser His 20 25 30 Lys Pro Arg 35 <210> SEQ ID NO 693 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-VIII epitope <400> SEQUENCE: 693 Ile Val Gly Phe Phe Ser Glu Val Ile Gly Leu Ile Gly Asn Pro Glu 1 5 10 15 Asn Arg Pro Ala Leu Lys Thr Leu Ile Asp Gly Leu Ala Ser Ser His 20 25 30 Lys Ala Arg 35 <210> SEQ ID NO 694 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Glucan endo-1,3-beta- glucosidase, basic vacuolar isoform epitope <400> SEQUENCE: 694 Ala Trp Leu Ala Gln Phe Val Leu Pro 1 5 <210> SEQ ID NO 695 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutamate decarboxylase epitope <400> SEQUENCE: 695 Phe Arg Glu Arg Gln Ser Ser Lys Asn Leu Leu Ser Cys Glu Asn Ser 1 5 10 15 Asp Arg Asp Ala 20 <210> SEQ ID NO 696 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 1 epitope <400> SEQUENCE: 696 Met Ala Ser Ser Thr Pro Ser Ser Ser Ala Thr Ser Ser Asn Ala Gly 1 5 10 15 Ala Asp Pro Asn 20 <210> SEQ ID NO 697 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 697 Pro Gly Ser Gly Phe Trp Ser Phe Gly Ser Glu Asp Gly Ser Gly Asp 1 5 10 15 Ser Glu Asn <210> SEQ ID NO 698 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutamate receptor, ionotropic, N-methyl D-aspartate 2A epitope <400> SEQUENCE: 698 Ser Val Ser Tyr Asp Asp Trp Asp Tyr Ser Leu Glu Ala Arg Val 1 5 10 15 <210> SEQ ID NO 699 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutathione peroxidase-GI epitope <400> SEQUENCE: 699 Asn Glu His Pro Val Phe Ala Tyr Leu Lys Asp Lys Leu Pro 1 5 10 <210> SEQ ID NO 700 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, high molecular weight subunit DX5 epitope <400> SEQUENCE: 700 Ala Gln Gly Gln Gln Pro Gly Gln Gly Gln Gln Gly Gln Gln 1 5 10 <210> SEQ ID NO 701 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, high molecular weight subunit DX5 precursor epitope <400> SEQUENCE: 701 Gln Gln Pro Gly Gln 1 5 <210> SEQ ID NO 702 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, low molecular weight subunit precursor epitope <400> SEQUENCE: 702 Gln Gln Gln Pro Pro 1 5 <210> SEQ ID NO 703 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phaseolus vulgaris Glycine-rich cell wall structural protein 1.8 precursor epitope <400> SEQUENCE: 703 Gly Gly Tyr Gly Asp Gly Gly Ala His Gly Gly Gly Tyr Gly Gly 1 5 10 15 <210> SEQ ID NO 704 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Glycinin epitope <400> SEQUENCE: 704 Ala Leu Ser Arg Leu Val Leu Arg Arg Asn Ala Leu Arg Arg Pro 1 5 10 15 <210> SEQ ID NO 705 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Glycinin G1 precursor epitope <400> SEQUENCE: 705 Gly Ala Ile Val Thr Val Lys Gly Gly Leu Ser Val Ile 1 5 10 <210> SEQ ID NO 706 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Glycinin G2 precursor epitope <400> SEQUENCE: 706 Ala Leu Ser Arg Cys Thr Leu Asn Arg Asn Ala Leu Arg Arg Pro 1 5 10 15 <210> SEQ ID NO 707 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Holcus lanatus group V allergen epitope <400> SEQUENCE: 707 Ala Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr Phe Glu Ala Ala 1 5 10 15 <210> SEQ ID NO 708 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Gu protein epitope <400> SEQUENCE: 708 Ile Asp Ala Pro Lys Pro Lys Lys Met Lys Lys Glu Lys Glu Met Asn 1 5 10 15 Gly Glu Thr Arg Glu Lys Ser Pro Lys Leu Lys Asn Gly Phe Pro His 20 25 30 Pro Glu Pro Asp Cys Asn 35 <210> SEQ ID NO 709 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens H1 histone family, member 0 epitope <400> SEQUENCE: 709 Lys Glu Ile Lys Lys Val Ala Thr Pro Lys Lys Ala Ser Lys Pro Lys 1 5 10 15 Lys <210> SEQ ID NO 710 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens heat shock 60kDa protein 1 (chaperonin) epitope <400> SEQUENCE: 710 Ala Tyr Ala Lys Asp Val Lys Phe Gly Ala Asp Ala 1 5 10 <210> SEQ ID NO 711 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Heat shock protein HSP 90-beta epitope <400> SEQUENCE: 711 Gly Leu Glu Leu Pro Glu 1 5 <210> SEQ ID NO 712 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens high mobility group protein 17 epitope <400> SEQUENCE: 712 Lys Lys Ala Pro Ala Lys Lys Gly Glu Lys Val Pro Lys Gly Lys 1 5 10 15 <210> SEQ ID NO 713 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens High mobility group protein B1 epitope <400> SEQUENCE: 713 Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val Lys Ala Glu 1 5 10 15 Lys Ser Lys Lys Lys Lys 20 <210> SEQ ID NO 714 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens high-mobility group box 2 epitope <400> SEQUENCE: 714 Phe Glu Asp Met Ala Lys Ser Asp Lys Ala Arg Tyr Asp Arg Glu 1 5 10 15 <210> SEQ ID NO 715 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histidyl-tRNA synthetase, cytoplasmic epitope <400> SEQUENCE: 715 Ala Glu Arg Ala Ala Leu Glu Glu Leu Val Lys Leu Gln Gly Glu Arg 1 5 10 15 Val Arg Gly Leu Lys Gln Gln Lys Ala Ser Ala Glu Leu Ile Glu Glu 20 25 30 Glu Val Ala Lys Leu Leu Lys Leu Lys Ala Gln 35 40 <210> SEQ ID NO 716 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H1.4 epitope <400> SEQUENCE: 716 Ser Glu Thr Ala Pro Ala Ala Pro Ala Ala Pro Ala Pro Ala Glu Lys 1 5 10 15 <210> SEQ ID NO 717 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histone H1b epitope <400> SEQUENCE: 717 Lys Pro Lys Ala Ala Lys Pro Lys Lys Ala Ala Ala Lys Lys Lys 1 5 10 15 <210> SEQ ID NO 718 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H2A.Z epitope <400> SEQUENCE: 718 Gly Lys Ala Lys Thr Lys Ala Val Ser Arg Ser Gln Arg Ala Gly Leu 1 5 10 15 Gln Phe Pro Val 20 <210> SEQ ID NO 719 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histone H3 epitope <400> SEQUENCE: 719 Leu Pro Phe Gln Arg Leu Val Arg Glu Ile Ala Gln Asp Phe Lys 1 5 10 15 <210> SEQ ID NO 720 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H3-like centromeric protein A epitope <400> SEQUENCE: 720 Lys Pro Glu Ala Pro Arg Arg Arg Ser Pro 1 5 10 <210> SEQ ID NO 721 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-27 alpha chain precursor epitope <400> SEQUENCE: 721 Lys Ala Lys Ala Gln Thr Asp Arg 1 5 <210> SEQ ID NO 722 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 722 Ala Lys Ala Gln Thr Asp Arg Glu Asp Leu Arg Thr Leu Leu Arg Tyr 1 5 10 15 <210> SEQ ID NO 723 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-DR3 epitope <400> SEQUENCE: 723 Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln 1 5 10 15 Lys Arg Gly Arg 20 <210> SEQ ID NO 724 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HMG-17 epitope <400> SEQUENCE: 724 Asp Gly Lys Ala Lys Val Lys Asp Glu Pro Gln Arg Arg Ser Ala 1 5 10 15 <210> SEQ ID NO 725 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HNRNPA2B1 protein epitope <400> SEQUENCE: 725 Glu Thr Thr Glu Glu Ser Leu Arg Asn Tyr Tyr Glu Gln 1 5 10 <210> SEQ ID NO 726 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens hypothetical protein epitope <400> SEQUENCE: 726 Ala Asn Glu Asp Ala Ala Gln Gly Ile Ala Asn Trp Asp Ala Val Gln 1 5 10 15 Asp Ile Ala Asn Glu Asp Gly Phe His Gly Ile Asp Ile Glu Asp Ala 20 25 30 Ala Gln Gly 35 <210> SEQ ID NO 727 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Oryza sativa Japonica Group hypothetical protein epitope <400> SEQUENCE: 727 Ala Phe Asn His Phe Gly Ile Gln Leu Val Gln Arg 1 5 10 <210> SEQ ID NO 728 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig alpha-1 chain C region epitope <400> SEQUENCE: 728 Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr 1 5 10 15 Pro Ser Pro Ser 20 <210> SEQ ID NO 729 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig gamma-1 chain C region epitope <400> SEQUENCE: 729 Lys Phe Asn Trp Tyr Val Asp 1 5 <210> SEQ ID NO 730 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig gamma-3 chain C region epitope <400> SEQUENCE: 730 Asp Gly Ser Phe Phe Leu Tyr 1 5 <210> SEQ ID NO 731 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig heavy chain V-III region (ART) epitope <400> SEQUENCE: 731 Cys Ser Val Met His Glu Gly 1 5 <210> SEQ ID NO 732 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig lambda chain V-II region MGC epitope <400> SEQUENCE: 732 Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr 1 5 10 15 <210> SEQ ID NO 733 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig L-chain V-region epitope <400> SEQUENCE: 733 Ala Pro Ser Val Thr Leu Phe 1 5 <210> SEQ ID NO 734 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Immunoglobulin heavy chain epitope <400> SEQUENCE: 734 Asp Lys Ser Arg Trp Gln Glu 1 5 <210> SEQ ID NO 735 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens immunoglobulin light chain epitope <400> SEQUENCE: 735 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 1 5 10 15 <210> SEQ ID NO 736 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens immunoglobulin light chain variable region epitope <400> SEQUENCE: 736 Ala Gly Glu Lys Val Thr Met 1 5 <210> SEQ ID NO 737 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 737 Thr Ser Ile 1 <210> SEQ ID NO 738 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Integrin alpha-6 epitope <400> SEQUENCE: 738 Leu Lys Arg Asp Met Lys Ser Ala His Leu Leu Pro Glu His 1 5 10 <210> SEQ ID NO 739 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Integrin beta-3 precursor epitope <400> SEQUENCE: 739 Cys Ala Pro Glu Ser Ile Glu Phe Pro Val Ser Glu Ala Arg Val Leu 1 5 10 15 Glu Asp <210> SEQ ID NO 740 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon alpha 2 epitope <400> SEQUENCE: 740 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr 1 5 10 <210> SEQ ID NO 741 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon alpha A epitope <400> SEQUENCE: 741 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile 1 5 10 <210> SEQ ID NO 742 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon beta precursor epitope <400> SEQUENCE: 742 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr 1 5 10 <210> SEQ ID NO 743 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon-alpha 2 epitope <400> SEQUENCE: 743 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser 1 5 10 <210> SEQ ID NO 744 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 744 Met Gly Ile Leu Lys Leu Gln Val Phe Leu Ile Val Leu Ser Val Ala 1 5 10 15 Leu Asn His Leu Lys Ala Thr Pro Ile Glu Ser His Gln Val Glu Lys 20 25 30 Arg Lys Cys Asn Thr 35 <210> SEQ ID NO 745 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Kappa-casein precursor epitope <400> SEQUENCE: 745 Ala Lys Tyr Ile Pro Ile Gln Tyr Val Leu Ser Arg Tyr Pro 1 5 10 <210> SEQ ID NO 746 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ku antigen epitope <400> SEQUENCE: 746 Arg Gly Asp Gly Pro Phe Arg Leu Gly Gly 1 5 10 <210> SEQ ID NO 747 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens leukotriene B4 receptor 2 epitope <400> SEQUENCE: 747 Gly Arg Gly Asn Gly Asp Pro Gly Gly Gly Met Glu Lys Asp Gly 1 5 10 15 <210> SEQ ID NO 748 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens liver histone H1e epitope <400> SEQUENCE: 748 Ile Lys Lys Val Ala Thr Pro Lys Lys Ala Ser Pro Lys Lys 1 5 10 <210> SEQ ID NO 749 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Lupus La protein epitope <400> SEQUENCE: 749 Ala Gln Pro Gly Ser Gly Lys Gly Lys Val Gln Phe Gln Gly Lys Lys 1 5 10 15 Thr Lys Phe Ala Ser Asp Asp 20 <210> SEQ ID NO 750 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens lymphocyte activation gene 3 protein precursor epitope <400> SEQUENCE: 750 Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu Ala Pro Gly Pro His 1 5 10 15 Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro Arg Arg Tyr 20 25 30 <210> SEQ ID NO 751 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens m3 muscarinic cholinergic receptor epitope <400> SEQUENCE: 751 Glu Pro Thr Ile Thr Phe Gly Thr Ala Ile 1 5 10 <210> SEQ ID NO 752 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Alternaria alternata Major allergen Alt a 1 precursor epitope <400> SEQUENCE: 752 Ala Asp Pro Val Thr Thr Glu Gly Asp Tyr Val Val Lys Ile Ser Glu 1 5 10 15 Phe Tyr Gly Arg 20 <210> SEQ ID NO 753 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anisakis simplex Major allergen Ani s 1 epitope <400> SEQUENCE: 753 Cys Lys Met Pro Asp Arg Gly Ala Cys Ala Leu Gly Lys Lys Pro 1 5 10 15 <210> SEQ ID NO 754 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 1 epitope <400> SEQUENCE: 754 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys Arg Tyr 1 5 10 <210> SEQ ID NO 755 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 epitope <400> SEQUENCE: 755 Ala His Ile Leu Arg Trp Gly Asn Glu Ser 1 5 10 <210> SEQ ID NO 756 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus major allergen beta-lactoglobulin epitope <400> SEQUENCE: 756 Leu Gln Lys Trp Glu Asn Asp Glu Cys Ala Gln Lys Lys Ile Ile Ala 1 5 10 15 Glu Lys Thr Lys 20 <210> SEQ ID NO 757 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 757 Asp Ala Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser 1 5 10 <210> SEQ ID NO 758 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 2 precursor epitope <400> SEQUENCE: 758 Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Gln Asp Cys Tyr 1 5 10 <210> SEQ ID NO 759 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 759 Leu Leu Asp Lys Ile Tyr Thr Ser Pro Leu Cys 1 5 10 <210> SEQ ID NO 760 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Turbo cornutus major allergen Tur c1 - Turbo cornutus epitope <400> SEQUENCE: 760 Leu Glu Asp Glu Leu Leu Ala Glu Lys Glu Lys Tyr Lys Ala Ile Ser 1 5 10 15 Asp Glu Leu Asp Gln Thr Phe Ala Glu Leu Ala Gly Tyr 20 25 <210> SEQ ID NO 761 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus major house dust allergen epitope <400> SEQUENCE: 761 Leu Ala His Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val 1 5 10 15 Asp Cys Ala Ser Gln His Gly Cys His 20 25 <210> SEQ ID NO 762 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 762 Ala Pro Pro Ala Ser Glu Gln Glu Thr 1 5 <210> SEQ ID NO 763 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope <400> SEQUENCE: 763 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Pro Gln Arg Tyr Cys Arg His 35 40 <210> SEQ ID NO 764 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 764 Phe Thr Glu Val Gly Tyr Thr Arg Ala Glu Gly Leu 1 5 10 <210> SEQ ID NO 765 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 765 Asp Gly Asp Asn Leu Phe Pro Lys Val Ala 1 5 10 <210> SEQ ID NO 766 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 766 Trp Arg Ser Thr Gln Asp Ser Phe Asn Asn Gly 1 5 10 <210> SEQ ID NO 767 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana Major pollen allergen Cor a 1 epitope <400> SEQUENCE: 767 Tyr Val Leu Asp Gly Asp Lys Leu Leu Pro Lys Val Ala Pro Gln Ala 1 5 10 15 Leu <210> SEQ ID NO 768 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Holcus lanatus Major pollen allergen Hol l 1 precursor epitope <400> SEQUENCE: 768 Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp 1 5 10 15 Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp 20 25 <210> SEQ ID NO 769 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juniperus ashei Major pollen allergen Jun a 1 precursor epitope <400> SEQUENCE: 769 Ala Phe Asn Gln Phe Gly Pro Asn Ala Gly Gln Arg 1 5 10 <210> SEQ ID NO 770 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea major pollen allergen Ole e 1 epitope <400> SEQUENCE: 770 Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp Val Lys 1 5 10 15 Pro Ser Leu Lys Phe Ile Leu Asn Thr Val Asn Gly Thr Thr Arg Thr 20 25 30 Val Asn <210> SEQ ID NO 771 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica mal d 3 epitope <400> SEQUENCE: 771 Arg Thr Thr Ala Asp Arg Gln Thr Ala 1 5 <210> SEQ ID NO 772 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 772 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 <210> SEQ ID NO 773 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens melanin-concentrating hormone receptor 1, isoform CRA_a epitope <400> SEQUENCE: 773 Ala Glu His Ala Ser Arg Met Ser Val Leu Arg Ala Lys Pro Met Ser 1 5 10 15 Asn Ser Gln Arg Leu Leu Leu Leu Ser Pro Gly Ser Pro Pro 20 25 30 <210> SEQ ID NO 774 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Melanocyte protein Pmel 17 precursor epitope <400> SEQUENCE: 774 Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr Pro Gly Gln Ala Pro 1 5 10 15 <210> SEQ ID NO 775 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC classII HLA-DRB1 epitope <400> SEQUENCE: 775 Glu Gln Arg Arg Ala Ala 1 5 <210> SEQ ID NO 776 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC HLA-DR1-beta epitope <400> SEQUENCE: 776 Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln 1 5 10 15 Arg Arg Ala Ala 20 <210> SEQ ID NO 777 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Blomia tropicalis Mite allergen Blo t 5 epitope <400> SEQUENCE: 777 Glu Glu Ala Gln Thr Leu Ser Lys Ile Leu Leu Lys Asp Leu Lys Glu 1 5 10 15 <210> SEQ ID NO 778 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 778 Asp Pro Cys Ile Ile 1 5 <210> SEQ ID NO 779 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 779 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys 1 5 10 15 <210> SEQ ID NO 780 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 780 Ala Ala Asn Gln Asp Thr Ala Lys Val Thr Ile Lys Val Leu Ala Lys 1 5 10 15 Val Ala Gly Thr Thr Ile Gln Val Pro Gly Leu Glu Thr Asp Gly Cys 20 25 30 Lys <210> SEQ ID NO 781 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum monomeric alpha-amylase inhibitor epitope <400> SEQUENCE: 781 Ala Ala Ser Val Pro Glu 1 5 <210> SEQ ID NO 782 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Muscarinic acetylcholine receptor M1 epitope <400> SEQUENCE: 782 Gln Tyr Leu Val Gly Glu Arg Thr Val Leu Ala Gly Gln Cys Tyr Ile 1 5 10 15 Gln Phe Leu Ser Gln 20 <210> SEQ ID NO 783 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin associated glycoprotein epitope <400> SEQUENCE: 783 Asp Ser Tyr Thr Leu Thr Glu Glu Leu Ala Tyr Ala Glu Ile Arg Val 1 5 10 15 Lys <210> SEQ ID NO 784 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 784 Ile Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys 1 5 10 <210> SEQ ID NO 785 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin oligodendrocyte glycoprotein epitope <400> SEQUENCE: 785 Ala Leu Val Gly Asp Glu Val Glu Leu Pro Cys Arg Ile Ser Pro Gly 1 5 10 15 Lys Asn Ala Thr Gly Met Glu Leu Gly Trp 20 25 <210> SEQ ID NO 786 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin oligodendrocyte glycoprotein isoform alpha6 precursor epitope <400> SEQUENCE: 786 His Arg Thr Phe Glu 1 5 <210> SEQ ID NO 787 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 787 Ala Asp Ala Arg Met 1 5 <210> SEQ ID NO 788 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 788 Gly His Trp Gly Ala Trp Met Pro Ser Ser Ile Ser Ala Phe Glu Gly 1 5 10 15 Thr Cys Val Ser Ile 20 <210> SEQ ID NO 789 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-oligodendrocyte glycoprotein precursor epitope <400> SEQUENCE: 789 Gly Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val 1 5 10 15 Gly Asp Glu Val Glu Leu Pro Cys Arg Ile 20 25 <210> SEQ ID NO 790 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myeloblastin precursor epitope <400> SEQUENCE: 790 Ala His Arg Pro Pro Ser Pro Ala 1 5 <210> SEQ ID NO 791 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myeloperoxidase epitope <400> SEQUENCE: 791 Gly Ser Ala Ser Pro Met Glu Leu Leu Ser 1 5 10 <210> SEQ ID NO 792 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin-11 epitope <400> SEQUENCE: 792 Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Thr Gln 1 5 10 15 Gln Glu Leu Arg 20 <210> SEQ ID NO 793 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Neurofilament heavy polypeptide (NF-H) (Neurofilament triplet H protein) (200 kDa neurofilament protein) epitope <400> SEQUENCE: 793 Ala Lys Ser Pro Glu Lys Ala Lys 1 5 <210> SEQ ID NO 794 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens nicotinic acetylcholine receptor alpha subunit|AChR alpha subunit epitope <400> SEQUENCE: 794 Glu Val Asn Gln Ile Val Thr Thr Asn Val Arg Leu Lys Gln Gln Trp 1 5 10 15 <210> SEQ ID NO 795 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Non-histone chromosomal protein HMG-17 epitope <400> SEQUENCE: 795 Val Lys Asp Glu Pro Gln Arg Arg Ser Ala 1 5 10 <210> SEQ ID NO 796 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus armeniaca Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 796 Val Asn Pro Asn Asn Ala Ala Ala Leu 1 5 <210> SEQ ID NO 797 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus armeniaca Non-specific lipid-transfer protein 1 (LTP 1) (Major allergen Pru ar 3) epitope <400> SEQUENCE: 797 Leu Ala Arg Thr Thr Pro Asp Arg Arg Thr Ala Cys Asn Cys Leu 1 5 10 15 <210> SEQ ID NO 798 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus domestica Non-specific lipid-transfer protein 1 (LTP 1) (Major allergen Pru d 3) epitope <400> SEQUENCE: 798 Leu Ala Arg Thr Thr Ala Asp Arg Arg Ala Ala Cys Asn Cys Leu Lys 1 5 10 15 Gln Leu <210> SEQ ID NO 799 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica Non-specific lipid-transfer protein precursor (LTP) (Allergen Mal d 3) epitope <400> SEQUENCE: 799 Ala Asp Arg Gln Thr Ala Cys Asn Cys Leu Lys Asn Leu Ala Gly 1 5 10 15 <210> SEQ ID NO 800 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens NR2 subunit NMDA receptor epitope <400> SEQUENCE: 800 Asp Trp Glu Tyr Ser Val Trp Leu Ser Asn 1 5 10 <210> SEQ ID NO 801 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens nuclear autoantigen Sp-100 isoform 1 epitope <400> SEQUENCE: 801 Glu Val Phe Ile Ser Ala Pro Arg 1 5 <210> SEQ ID NO 802 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Ole e 1 protein epitope <400> SEQUENCE: 802 Glu Asp Val Pro Gln Pro Pro Val Ser Gln Phe His 1 5 10 <210> SEQ ID NO 803 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Ole e 1.0102 protein epitope <400> SEQUENCE: 803 Glu Asp Val Pro Gln Pro Pro Val Ser Gln Phe His Ile Gln Gly Gln 1 5 10 15 Val Tyr Cys Asp Thr Cys Arg Ala Gly 20 25 <210> SEQ ID NO 804 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Omega gliadin storage protein epitope <400> SEQUENCE: 804 Gln Gln Pro Gln Gln Ser Phe Pro Gln Gln 1 5 10 <210> SEQ ID NO 805 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum omega-5 gliadin epitope <400> SEQUENCE: 805 Gln Gln Phe His Gln Gln Gln 1 5 <210> SEQ ID NO 806 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Oryzin precursor epitope <400> SEQUENCE: 806 Ala Ser Asn Thr Ser Pro Ala Ser Ala Pro Asn Ala Leu Thr Val Ala 1 5 10 15 Ala Ile Asn Lys Ser Asn Ala Arg Ala Ser Phe Ser Asn Tyr Gly Ser 20 25 30 Val Val Asp 35 <210> SEQ ID NO 807 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 807 Cys Phe Asp Val Phe Lys Glu Leu Lys 1 5 <210> SEQ ID NO 808 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid epitope <400> SEQUENCE: 808 Cys Asn Phe Cys Asn Ala Val Val Glu Ser 1 5 10 <210> SEQ ID NO 809 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 809 Ala Glu Val Asp Cys Ser Arg Phe Pro Asn Ala Thr Asp Lys 1 5 10 <210> SEQ ID NO 810 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max P34 probable thiol protease precursor epitope <400> SEQUENCE: 810 Ala Ser Trp Asp Trp Arg Lys Lys Gly Val 1 5 10 <210> SEQ ID NO 811 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max P34 probable thiol protease precursor; Gly m 1 epitope <400> SEQUENCE: 811 Pro Gln Glu Phe Ser Lys Lys Thr Tyr Gln 1 5 10 <210> SEQ ID NO 812 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens p70 autoantigen epitope <400> SEQUENCE: 812 Glu Ala Leu Thr Lys His Phe Gln Asp 1 5 <210> SEQ ID NO 813 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens PADI-H protein epitope <400> SEQUENCE: 813 Lys Ala Ala Ser Gly Ser Thr Gly Asp Gln Lys Val Gln Ile Ser Tyr 1 5 10 15 Tyr Gly Pro Lys 20 <210> SEQ ID NO 814 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Par j epitope <400> SEQUENCE: 814 Gly Thr Ser Ser Cys Arg Leu Val Pro 1 5 <210> SEQ ID NO 815 <211> LENGTH: 47 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Blomia tropicalis Paramyosin epitope <400> SEQUENCE: 815 Glu Lys Leu Arg Asp Gln Lys Glu Ala Leu Ala Arg Glu Asn Lys Lys 1 5 10 15 Leu Ala Asp Asp Leu Ala Glu Ala Lys Ser Gln Leu Asn Asp Ala His 20 25 30 Arg Arg Ile His Glu Gln Glu Ile Glu Ile Lys Arg Leu Glu Asn 35 40 45 <210> SEQ ID NO 816 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gadus morhua callarias Parvalbumin beta epitope <400> SEQUENCE: 816 Ala Ala Glu Ala Ala Cys Phe Lys 1 5 <210> SEQ ID NO 817 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Salmo salar parvalbumin like 1 epitope <400> SEQUENCE: 817 Ala Asp Ile Lys Thr Ala Leu Glu Ala Arg Lys Ala Ala Asp Thr 1 5 10 15 <210> SEQ ID NO 818 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juniperus ashei Pathogenesis-related protein precursor epitope <400> SEQUENCE: 818 Ala Asp Ile Asn Ala Val Cys Pro Ser Glu Leu Lys 1 5 10 <210> SEQ ID NO 819 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Nicotiana tabacum Pectate lyase epitope <400> SEQUENCE: 819 Ala Tyr Asn His Phe Gly Lys Arg Leu Asp Gln Arg 1 5 10 <210> SEQ ID NO 820 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata AAA Group pectate lyase 2 epitope <400> SEQUENCE: 820 Ala Phe Asn His Phe Gly Glu Gly Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 821 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Farfantepenaeus aztecus Pen a 1 allergen epitope <400> SEQUENCE: 821 Ala Asn Ile Gln Leu Val Glu Lys Asp Lys Ala Leu Ser Asn Ala 1 5 10 15 <210> SEQ ID NO 822 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Peptidase 1 precursor (Major mite fecal allergen Der p 1) (Allergen Der p I) epitope <400> SEQUENCE: 822 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val 35 40 <210> SEQ ID NO 823 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens pericentriolar material 1 protein epitope <400> SEQUENCE: 823 Lys Asp Cys 1 <210> SEQ ID NO 824 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Periplakin epitope <400> SEQUENCE: 824 Ile His Asp Arg Lys Ser Gly Lys Lys Phe Ser Ile Glu Glu Ala Leu 1 5 10 15 Gln Ser Gly Arg 20 <210> SEQ ID NO 825 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 825 Leu Ile Asp Thr Lys Cys Tyr Lys Leu Glu His Pro Val Thr Gly Cys 1 5 10 15 Gly Glu Arg Thr Glu Gly Arg Cys Leu His Tyr Thr Val Asp Lys Ser 20 25 30 Lys Pro Lys Val Tyr Gln Trp Phe Asp Leu Arg Lys Tyr 35 40 45 <210> SEQ ID NO 826 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Myrmecia pilosula Pilosulin-1 precursor (Major allergen Myr p 1) (Myr p I) epitope <400> SEQUENCE: 826 Lys Glu Ala Ile Pro Met Ala Val Glu Met Ala Lys Ser Gln 1 5 10 <210> SEQ ID NO 827 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens plasma protease C1 inhibitor precursor epitope <400> SEQUENCE: 827 Ala Ser Ala Ile Ser Val Ala Arg 1 5 <210> SEQ ID NO 828 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens platelet glycoprotein IIIa epitope <400> SEQUENCE: 828 Arg Ala Arg Ala Lys Trp 1 5 <210> SEQ ID NO 829 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens plexin domain containing 1, isoform CRA_b epitope <400> SEQUENCE: 829 Asn Cys Ser Trp Cys His Val Leu Gln Arg Cys Ser 1 5 10 <210> SEQ ID NO 830 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens PM/Scl 100kD nucleolar protein epitope <400> SEQUENCE: 830 Cys Ile Ala Ala Lys Lys Ile Lys Gln Ser Val Gly Asn Lys Ser 1 5 10 15 <210> SEQ ID NO 831 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Polcalcin Bet v 4 epitope <400> SEQUENCE: 831 Phe Gly Arg Ala Asn Arg Gly Leu 1 5 <210> SEQ ID NO 832 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Polcalcin Phl p 7 (Calcium- binding pollen allergen Phl p 7) (P7) epitope <400> SEQUENCE: 832 Ala Asp Asp Met Glu Arg Ile Phe Lys Arg Phe Asp Thr Asn Gly Asp 1 5 10 15 Gly Lys Ile Ser Leu Ser Glu Leu Thr Asp Ala Leu Arg Thr Leu Gly 20 25 30 Ser Thr Ser Ala 35 <210> SEQ ID NO 833 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 833 Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp 1 5 10 15 Lys Ala Asp Thr Ser Tyr Ser Ala Lys 20 25 <210> SEQ ID NO 834 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.4 epitope <400> SEQUENCE: 834 Ala Phe Asn Lys Phe Thr Asp Asn Val Asp Gln Arg 1 5 10 <210> SEQ ID NO 835 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 835 Met Pro Arg Cys Arg Phe Gly Phe 1 5 <210> SEQ ID NO 836 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 836 Cys Asp Ile Lys Asp Pro Ile Arg Leu Glu Pro Gly Gly Pro Asp 1 5 10 15 <210> SEQ ID NO 837 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula pollen allergen Bet v 1 epitope <400> SEQUENCE: 837 Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu Leu 1 5 10 15 Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn 20 25 30 <210> SEQ ID NO 838 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 838 Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala Ser 1 5 10 15 Asn Lys Ala Phe 20 <210> SEQ ID NO 839 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 2-A (Lol p II-A) epitope <400> SEQUENCE: 839 Glu Lys Gly Met Arg Asn Val Phe Asp Asp Val Val Pro Ala Asp Phe 1 5 10 15 Lys Val Gly Thr Thr Tyr Lys Pro Glu 20 25 <210> SEQ ID NO 840 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 3 (Lol p III) epitope <400> SEQUENCE: 840 Lys Gly Gly Met Lys Asn Val Phe Asp Glu Val Ile Pro Thr Ala Phe 1 5 10 15 Thr Val Gly Lys Thr Tyr Thr Pro Glu Tyr Asn 20 25 <210> SEQ ID NO 841 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 841 Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp 1 5 10 <210> SEQ ID NO 842 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 842 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ala Met 1 5 10 15 <210> SEQ ID NO 843 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Zea mays pollen allergen Phl p 11 epitope <400> SEQUENCE: 843 Arg Asp Arg Ala Arg Val Pro Leu 1 5 <210> SEQ ID NO 844 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense pollen allergen Phl pI epitope <400> SEQUENCE: 844 Ile Pro Lys Val Pro Pro Gly Pro Asn Ile Thr Ala 1 5 10 <210> SEQ ID NO 845 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 845 Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg Asp 1 5 10 15 Arg Pro Thr Ala 20 <210> SEQ ID NO 846 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein epitope <400> SEQUENCE: 846 Gln Glu Thr Cys Gly Thr Met Val Arg Ala Leu Met Pro Cys Leu Pro 1 5 10 15 Phe Val Gln Gly Lys Glu Lys Glu Pro Ser Lys Gly Cys Cys 20 25 30 <210> SEQ ID NO 847 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein 2 epitope <400> SEQUENCE: 847 Ala Glu Val Pro Lys Lys Cys Asp Ile Lys 1 5 10 <210> SEQ ID NO 848 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein 2 precursor epitope <400> SEQUENCE: 848 Glu Ala Cys Gly Lys Val Val Gln Asp Ile Met Pro Cys Leu His Phe 1 5 10 15 Val Lys Gly Glu Glu Lys Glu Pro Ser Lys Glu Cys Cys Ser 20 25 30 <210> SEQ ID NO 849 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Solanum lycopersicum Probable pectate lyase P59 epitope <400> SEQUENCE: 849 Ala Phe Asn His Phe Gly Lys Arg Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 850 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens profilaggrin epitope <400> SEQUENCE: 850 Gly Gly Gln Gly Ser Arg His Gln Gln Ala Arg 1 5 10 <210> SEQ ID NO 851 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cucumis melo profilin epitope <400> SEQUENCE: 851 Ala Phe Arg Leu Glu Glu Ile Ala Ala Ile 1 5 10 <210> SEQ ID NO 852 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Profilin-1 epitope <400> SEQUENCE: 852 Trp Ala Gln Ser Thr Asp Phe Pro Gln Phe Lys Pro Glu Glu Ile Thr 1 5 10 15 Ala Ile Met Asn Asp Phe Asn Glu Pro Gly Ser Leu Ala Pro Thr Gly 20 25 30 Leu Tyr Leu Gly Gly Thr Lys Tyr Met Val Ile Gln Gly Glu Pro Gly 35 40 45 Ala Val Ile Arg Gly Lys Lys Gly 50 55 <210> SEQ ID NO 853 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 853 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln Trp Gly Trp Cys Gly Ser Thr Asp Glu Tyr Cys Ser 20 25 30 Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 35 40 <210> SEQ ID NO 854 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Proliferating cell nuclear antigen epitope <400> SEQUENCE: 854 Leu Lys Tyr Tyr Leu Ala Pro Lys Ile Glu Asp Glu Glu Gly Ser 1 5 10 15 <210> SEQ ID NO 855 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Proline-rich transmembrane protein 2 epitope <400> SEQUENCE: 855 His Ser Glu Ala Glu Thr Gly Pro Pro 1 5 <210> SEQ ID NO 856 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki), isoform CRA_a epitope <400> SEQUENCE: 856 Leu Asp Gly Pro Thr Tyr Lys Arg Arg Leu Asp Glu Cys Glu Glu 1 5 10 15 <210> SEQ ID NO 857 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens protein tyrosine phosphatase-like autoantigen epitope <400> SEQUENCE: 857 Gly Ala His Gly Asp Thr Thr Pro Glu Tyr Gln Asp Leu 1 5 10 <210> SEQ ID NO 858 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens protein-arginine deiminase type-4 epitope <400> SEQUENCE: 858 Ala Phe Phe Pro Asn Met Val Asn Met Leu Val Leu Gly Lys His Leu 1 5 10 15 Gly Ile Pro Lys 20 <210> SEQ ID NO 859 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proteinase 3 epitope <400> SEQUENCE: 859 Cys Ala Thr Arg Leu Phe Pro Asp Phe Phe Thr Arg Val Ala Leu 1 5 10 15 <210> SEQ ID NO 860 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 860 Gly Lys Cys Gly Val Ser Ile Pro Tyr Lys 1 5 10 <210> SEQ ID NO 861 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus dulcis prunin 1 precursor epitope <400> SEQUENCE: 861 Glu Glu Ser Gln Gln Ser Ser Gln Gln Gly Arg Gln Gln Glu Gln 1 5 10 15 <210> SEQ ID NO 862 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus dulcis prunin 2 precursor epitope <400> SEQUENCE: 862 Asp Ser Gln Pro Gln Gln Phe Gln Gln Gln Gln Gln Gln Gln Gln 1 5 10 15 <210> SEQ ID NO 863 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hesperocyparis arizonica putative allergen Cup a 1 epitope <400> SEQUENCE: 863 Trp Arg Phe Thr Arg Asp Ala Phe Thr Asn Gly 1 5 10 <210> SEQ ID NO 864 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Putative HTLV-1-related endogenous sequence (p25) epitope <400> SEQUENCE: 864 Pro Thr Arg Ala Pro Ser Gly Pro Arg Pro Pro 1 5 10 <210> SEQ ID NO 865 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Putative small nuclear ribonucleoprotein polypeptide E-like protein 1 epitope <400> SEQUENCE: 865 Glu Ile His Ser Lys Thr Lys Ser 1 5 <210> SEQ ID NO 866 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor tyrosine-protein kinase rbB-2 precursor epitope <400> SEQUENCE: 866 Pro Glu Ser Phe Asp Gly Asp Pro Ala Ser Asn Thr Ala Pro Leu Gln 1 5 10 15 Pro Glu <210> SEQ ID NO 867 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 867 Lys Glu Arg Leu Ala Ala Leu Gly Pro Glu Gly Ala His 1 5 10 <210> SEQ ID NO 868 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens recombinant IgG2 heavy chain epitope <400> SEQUENCE: 868 Glu Pro Gln Val Val Thr Leu Pro Pro Ser Arg 1 5 10 <210> SEQ ID NO 869 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Replication protein A 32 kDa subunit epitope <400> SEQUENCE: 869 Arg Ser Phe Gln Asn Lys Lys Ser Leu Val Ala Phe Lys Ile Met Pro 1 5 10 15 Leu Glu Asp Met 20 <210> SEQ ID NO 870 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 870 Phe Pro Thr Phe Pro Asp Gly His Asp Tyr 1 5 10 <210> SEQ ID NO 871 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ribosomal protein L7 epitope <400> SEQUENCE: 871 Glu Leu Lys Ile Lys Arg Leu Arg Lys Lys Phe Ala Gln Lys Met Leu 1 5 10 15 Arg Lys Ala Arg Arg Lys Leu 20 <210> SEQ ID NO 872 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ribosomal protein P2 epitope <400> SEQUENCE: 872 Ser Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 <210> SEQ ID NO 873 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Mangifera indica ripening-related pectate lyase epitope <400> SEQUENCE: 873 Ala Tyr Asn His Phe Gly Glu Gly Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 874 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse)), isoform CRA_c epitope <400> SEQUENCE: 874 Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1 5 10 15 Gly Gly Gly Ser Ser 20 <210> SEQ ID NO 875 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ro ribonucleoprotein epitope <400> SEQUENCE: 875 Asp Gly Tyr Val Trp Gln Val Thr Asp Met Asn Arg Leu His Arg Phe 1 5 10 15 Leu Cys Phe Gly Ser 20 <210> SEQ ID NO 876 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 876 Ala Glu Asp Glu Asp Asn Gln Gln Gly Gln 1 5 10 <210> SEQ ID NO 877 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 877 Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val 1 5 10 <210> SEQ ID NO 878 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia seed storage protein epitope <400> SEQUENCE: 878 Asp Asp Asn Gly Leu Glu Glu Thr Ile Cys Thr Leu Arg Leu Arg 1 5 10 15 <210> SEQ ID NO 879 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea seed storage protein SSP2 epitope <400> SEQUENCE: 879 Cys Gly Leu Arg Ala Pro Gln Arg Cys Asp Leu Asp Val Glu Ser 1 5 10 15 <210> SEQ ID NO 880 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 epitope <400> SEQUENCE: 880 Arg Pro Asn Ala Thr Tyr Ser Leu 1 5 <210> SEQ ID NO 881 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Serum albumin epitope <400> SEQUENCE: 881 Gln Ser Arg Ala Thr Leu Gly Ile 1 5 <210> SEQ ID NO 882 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 882 Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn Thr Leu 1 5 10 15 Cys <210> SEQ ID NO 883 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein epitope <400> SEQUENCE: 883 Pro Pro Pro Gly Ile Arg Gly Pro 1 5 <210> SEQ ID NO 884 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein B' epitope <400> SEQUENCE: 884 Pro Pro Pro Gly Met Arg Gly Pro 1 5 <210> SEQ ID NO 885 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein D1 polypeptide epitope <400> SEQUENCE: 885 Lys Met Thr Leu Lys Asn Arg Glu Pro Val Gln Leu Glu Thr Leu Ser 1 5 10 15 Ile Arg Gly Asn Arg Ile Arg Tyr 20 <210> SEQ ID NO 886 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein D2 isoform 1 epitope <400> SEQUENCE: 886 Gly Lys Lys Lys Ser Lys Pro Val Asn Lys Asp Arg Tyr Ile Ser Lys 1 5 10 15 Met Phe Leu Arg Gly Asp Ser 20 <210> SEQ ID NO 887 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein F epitope <400> SEQUENCE: 887 Glu Glu Glu Glu Asp Gly Glu Met 1 5 <210> SEQ ID NO 888 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein G epitope <400> SEQUENCE: 888 Trp Ser Lys Ala His Pro Pro Glu 1 5 <210> SEQ ID NO 889 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide A epitope <400> SEQUENCE: 889 Ala Met Lys Ile Ser Phe Ala Lys Lys 1 5 <210> SEQ ID NO 890 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide B epitope <400> SEQUENCE: 890 Pro Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 891 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide B/B' isoform B epitope <400> SEQUENCE: 891 Met Gly Arg Gly Ala Pro Pro Pro Gly Met Met Gly 1 5 10 <210> SEQ ID NO 892 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide C, isoform CRA_b epitope <400> SEQUENCE: 892 Ala Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 893 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide D3 epitope <400> SEQUENCE: 893 Ala Ala Arg Gly Arg Gly Arg Gly Met Gly Arg Gly Asn Ile Phe 1 5 10 15 <210> SEQ ID NO 894 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide N variant epitope <400> SEQUENCE: 894 Val Gly Arg Ala Thr Pro Pro Pro Gly Ile Met Ala 1 5 10 <210> SEQ ID NO 895 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein Sm D1 epitope <400> SEQUENCE: 895 Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg 1 5 10 15 Gly Arg Gly Gly Pro Arg Arg 20 <210> SEQ ID NO 896 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein Sm D2 epitope <400> SEQUENCE: 896 Glu Glu Leu Gln Lys Arg Glu Glu 1 5 <210> SEQ ID NO 897 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein- associated proteins B and B' epitope <400> SEQUENCE: 897 Arg Gly Val Gly Gly Pro Ser Gln 1 5 <210> SEQ ID NO 898 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 898 Ala Glu Glu Val Glu Glu Glu Arg Leu Lys 1 5 10 <210> SEQ ID NO 899 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Smoothelin epitope <400> SEQUENCE: 899 Gly Ser Thr Met Met Gln Thr Lys Thr Phe Ser Ser Ser Ser Ser Ser 1 5 10 15 Lys Lys Met Gly 20 <210> SEQ ID NO 900 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens snRNP polypeptide B epitope <400> SEQUENCE: 900 Pro Pro Gly Met Arg Pro Pro Met Gly Pro Met Gly Ile Pro Pro 1 5 10 15 <210> SEQ ID NO 901 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens spectrin, alpha, non-erythrocytic 1 (alpha-fodrin), isoform CRA_e epitope <400> SEQUENCE: 901 Phe Gln Phe Phe Gln Arg Asp Ala Glu Glu Leu Glu Lys Trp 1 5 10 <210> SEQ ID NO 902 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens steroid 17-alpha-hydroxylase/17,20 lyase epitope <400> SEQUENCE: 902 Glu Val Pro Asp Asp Gly Gln Leu Pro Ser Leu Glu Gly Ile Pro Lys 1 5 10 15 Val Val Phe Leu Ile Asp Ser Phe Lys Val Lys Ile Lys Val Arg Gln 20 25 30 Ala Trp Arg Glu Ala Gln Ala Glu Gly Ser Thr 35 40 <210> SEQ ID NO 903 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Sucrase-isomaltase, intestinal epitope <400> SEQUENCE: 903 Asp Phe Thr Tyr Asp Gln Val Ala Phe Asn Gly Leu Pro Gln Phe 1 5 10 15 <210> SEQ ID NO 904 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 904 Asp Ala Leu Thr Leu Arg Thr Ala Thr Asn Ile Trp 1 5 10 <210> SEQ ID NO 905 <211> LENGTH: 48 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Superoxide dismutase epitope <400> SEQUENCE: 905 Tyr Thr Leu Pro Pro Leu Pro Tyr Pro Tyr Asp Ala Leu Gln Pro Tyr 1 5 10 15 Ile Ser Gln Gln Ile Met Glu Leu His His Lys Lys His His Gln Thr 20 25 30 Tyr Val Asn Gly Leu Asn Ala Ala Leu Glu Ala Gln Lys Lys Ala Ala 35 40 45 <210> SEQ ID NO 906 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T cell receptor beta variable 20 epitope <400> SEQUENCE: 906 Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe 1 5 10 <210> SEQ ID NO 907 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T cell receptor beta variable 5 epitope <400> SEQUENCE: 907 Ala Leu Gly Gln Gly Pro Gln Phe Ile Phe Gln Tyr Tyr Glu Glu Glu 1 5 10 15 Glu Arg <210> SEQ ID NO 908 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Tax1-binding protein 1 epitope <400> SEQUENCE: 908 Glu Phe Lys Lys Arg Phe Ser Asp Ala Thr Ser Lys Ala His Gln 1 5 10 15 <210> SEQ ID NO 909 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain epitope <400> SEQUENCE: 909 Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu 1 5 10 15 <210> SEQ ID NO 910 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain C region epitope <400> SEQUENCE: 910 Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln Val 1 5 10 15 <210> SEQ ID NO 911 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain V region YT35 epitope <400> SEQUENCE: 911 Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr 1 5 10 15 <210> SEQ ID NO 912 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta-chain (V1-D- J-C) precursor epitope <400> SEQUENCE: 912 Ser Pro Arg Ser Gly Asp Leu Ser Val Tyr 1 5 10 <210> SEQ ID NO 913 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TCR V-beta 6.1 epitope <400> SEQUENCE: 913 Leu Gly Gln Gly Pro Glu Phe Leu Ile Tyr Phe Gln Gly Thr Gly Ala 1 5 10 15 Ala Asp Asp Ser Gly 20 <210> SEQ ID NO 914 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TCR V-beta 6.3 epitope <400> SEQUENCE: 914 Asp Pro Ile Ser Gly His Val Ser Leu Phe 1 5 10 <210> SEQ ID NO 915 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyroglobulin epitope <400> SEQUENCE: 915 Pro Pro Ala Arg Ala Leu Lys Arg Ser Leu Trp Val Glu Val Asp Leu 1 5 10 15 Leu Ile Gly Ser 20 <210> SEQ ID NO 916 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyroid peroxidase epitope <400> SEQUENCE: 916 Gly Leu Pro Arg Leu Glu Thr Pro Ala Asp Leu Ser Thr Ala Ile Ala 1 5 10 15 Ser Arg Ser <210> SEQ ID NO 917 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens thyroid stimulating hormone receptor epitope <400> SEQUENCE: 917 Glu Ile Ile Gly Phe Gly Gln Glu Leu Lys Asn Pro Gln Glu Glu 1 5 10 15 <210> SEQ ID NO 918 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens thyroid stimulating hormone receptor variant epitope <400> SEQUENCE: 918 Glu Glu Gln Glu Asp Glu Ile Ile Gly Phe Gly Gln Glu Leu Lys Asn 1 5 10 15 <210> SEQ ID NO 919 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyrotropin receptor epitope <400> SEQUENCE: 919 Gly Gln Glu Leu Lys Asn Pro Gln Glu Glu Thr Leu Gln Ala Phe Asp 1 5 10 15 Ser His Tyr Asp 20 <210> SEQ ID NO 920 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens transaldolase 1 epitope <400> SEQUENCE: 920 Ala Ala Ala Gln Met Pro Ala Tyr Gln Glu Leu Val Glu Glu Ala 1 5 10 15 <210> SEQ ID NO 921 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 921 Asp Cys Asn Gly His Gly Thr His Val Ala Gly Thr Val Gly Gly Thr 1 5 10 15 Lys Tyr Gly Leu 20 <210> SEQ ID NO 922 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens trinucleotide repeat containing 6A, isoform CRA_b epitope <400> SEQUENCE: 922 Ala Phe Leu Ser Val Asp His Leu Gly Gly Gly Gly Glu Ser Met 1 5 10 15 <210> SEQ ID NO 923 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens trinucleotide repeat containing 6A, isoform CRA_c epitope <400> SEQUENCE: 923 Trp Gly Ser Ser Ser Val Gly Pro Gln Ala Leu Ser Lys Ser Gly 1 5 10 15 <210> SEQ ID NO 924 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tripartite motif-containing 67 epitope <400> SEQUENCE: 924 Leu Gly Gly Gly Ala Gly Gly Gly Gly Asp His Ala Asp Lys Leu Ser 1 5 10 15 Leu Tyr Ser Glu Thr Asp Ser Gly Tyr Gly Ser Tyr Thr Pro Ser Leu 20 25 30 Lys Ser Pro Asn 35 <210> SEQ ID NO 925 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Triticum aestivum proteins epitope <400> SEQUENCE: 925 Leu Pro Gln Gln Gln Ile Pro Gln Gln Pro 1 5 10 <210> SEQ ID NO 926 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penaeus tropomyosin epitope <400> SEQUENCE: 926 Phe Leu Ala Glu Glu Ala Asp Arg Lys 1 5 <210> SEQ ID NO 927 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TSHR protein epitope <400> SEQUENCE: 927 Cys His Gln Glu Glu Asp Phe Arg Val Thr Cys Lys Asp Ile Gln Arg 1 5 10 15 Ile Pro Ser Leu 20 <210> SEQ ID NO 928 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tubulin beta-6 chain epitope <400> SEQUENCE: 928 Ala Ala Cys Asp Pro Arg His Gly Arg Tyr Leu Thr Val Ala 1 5 10 <210> SEQ ID NO 929 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tumor necrosis factor ligand superfamily member 6 epitope <400> SEQUENCE: 929 Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu 1 5 10 <210> SEQ ID NO 930 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Paralichthys olivaceus type 1 collagen alpha 2 epitope <400> SEQUENCE: 930 Met Lys Gly Leu Arg Gly His Pro Gly Leu Gln Gly Met Pro Gly Pro 1 5 10 15 Ser Gly Pro Ser 20 <210> SEQ ID NO 931 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum type 1 non-specific lipid transfer protein precursor epitope <400> SEQUENCE: 931 Ala Arg Gly Thr Pro Leu Lys Cys Gly Val 1 5 10 <210> SEQ ID NO 932 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa epitope <400> SEQUENCE: 932 Glu Arg Lys Arg Arg 1 5 <210> SEQ ID NO 933 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein A epitope <400> SEQUENCE: 933 Ala Gly Ala Ala Arg Asp Ala Leu Gln Gly Phe Lys Ile Thr Gln Asn 1 5 10 15 Asn Ala Met Lys Ile Ser Phe Ala Lys Lys 20 25 <210> SEQ ID NO 934 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein C epitope <400> SEQUENCE: 934 Pro Ala Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 935 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anisakis simplex UA3-recognized allergen epitope <400> SEQUENCE: 935 Met Cys Gln Cys Val Gln Lys Tyr Gly Thr Glu Phe Cys Lys Lys Arg 1 5 10 15 Leu Ala <210> SEQ ID NO 936 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens unnamed protein product epitope <400> SEQUENCE: 936 Ala Phe Gln Gln Gly Lys Ile Pro Pro 1 5 <210> SEQ ID NO 937 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans nigra vicilin seed storage protein epitope <400> SEQUENCE: 937 Ser Phe Glu Asp Gln Gly Arg Arg 1 5 <210> SEQ ID NO 938 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale Vicilin-like protein epitope <400> SEQUENCE: 938 Ala Ile Met Gly Pro Pro Thr Lys Phe Ser Phe Ser Leu Phe Leu 1 5 10 15 <210> SEQ ID NO 939 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia vicilin-like protein precursor epitope <400> SEQUENCE: 939 Asp Gln Arg Ser Gln Glu Glu Arg Glu Arg 1 5 10 <210> SEQ ID NO 940 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vimentin epitope <400> SEQUENCE: 940 Arg Leu Arg Ser Ser Val Pro Gly Val Arg Leu Leu Gln Asp Ser Val 1 5 10 15 Asp Phe Ser Leu 20 <210> SEQ ID NO 941 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens von Willebrand factor epitope <400> SEQUENCE: 941 His Cys Gln Ile Cys His Cys Asp Val Val Asn Leu Thr Cys Glu 1 5 10 15 <210> SEQ ID NO 942 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens von Willebrand factor-cleaving protease precursor epitope <400> SEQUENCE: 942 Pro Ser His Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala 1 5 10 15 Val Ser Ser Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro Pro 20 25 30 Ser Pro Gly Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg 35 40 45 <210> SEQ ID NO 943 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens XRCC4 protein epitope <400> SEQUENCE: 943 Val Ser Lys Asp Asp Ser Ile Ile Ser Ser Leu Asp Val Thr Asp 1 5 10 15

1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 943 <210> SEQ ID NO 1 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 1 Ala Gly Met Asp Met Cys Ser Ala Gly Trp Leu Ala Asp Arg Ser Val 1 5 10 15 Arg Tyr <210> SEQ ID NO 2 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 2 Glu Asp Ser Glu Ala Thr Leu Glu Val Val Val Lys Gly Ile Val Phe 1 5 10 15 His Tyr <210> SEQ ID NO 3 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 3 Ser Arg Val Ser Lys Glu Lys Glu Val Val Leu Leu Val Ala Thr Glu 1 5 10 15 Gly Arg <210> SEQ ID NO 4 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 4 Val Val Leu Leu Val Ala Thr Glu Gly Arg Val Arg Val Asn Ser Ala 1 5 10 15 Tyr Gln <210> SEQ ID NO 5 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aggrecan core protein precursor epitope <400> SEQUENCE: 5 Val Val Val Lys Gly Ile Val Phe His Tyr Arg Ala Ile Ser Thr Arg 1 5 10 15 Tyr Thr <210> SEQ ID NO 6 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha 2 type VI collagen isoform 2C2 precursor epitope <400> SEQUENCE: 6 Asp Arg Ala Ser Phe Ile Lys Asn Leu 1 5 <210> SEQ ID NO 7 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 7 Ala Ser Ser Thr Ile Ile Lys Glu Gly Ile Asp Arg Thr Val Leu Gly 1 5 10 15 Ile Leu Val Ser 20 <210> SEQ ID NO 8 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 8 Ala Ser Thr Pro Thr Lys Leu Gln Glu Ser Leu Leu Lys Lys Leu Gly 1 5 10 15 Ser Asn Thr Tyr 20 <210> SEQ ID NO 9 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 9 Asp Arg Thr Val Leu Gly Ile Leu Val Ser Tyr Gln Ile Lys Val Lys 1 5 10 15 Leu Thr Val Ser 20 <210> SEQ ID NO 10 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 10 Glu Phe Ala Arg His Asn Leu Lys Asp Ala Gly Glu Ala Glu Glu Gly 1 5 10 15 Lys Arg Asp Lys 20 <210> SEQ ID NO 11 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 11 Glu Pro Asn His Val Ile Phe Lys Lys Ile Ser Arg Asp Lys Ser Val 1 5 10 15 Thr Ile Tyr Leu 20 <210> SEQ ID NO 12 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 12 Phe Glu Val Lys Ala Phe Ala Thr Asp Ser Thr Asp Ala Glu Glu Asp 1 5 10 15 Lys Ile Pro Lys 20 <210> SEQ ID NO 13 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 13 Gly Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val Pro 1 5 10 15 Phe Arg Leu Met 20 <210> SEQ ID NO 14 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 14 Gly Lys Ile Lys His Glu Asp Thr Asn Leu Ala Ser Ser Thr Ile Ile 1 5 10 15 Lys Glu Gly Ile 20 <210> SEQ ID NO 15 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 15 Gly Asn Arg Asp Tyr Ile Asp His Val Ser Gln Val Gln Pro Val Asp 1 5 10 15 Gly Val Val Leu 20

<210> SEQ ID NO 16 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 16 Lys Pro Val Ala Met Glu Glu Ala Gln Glu Lys Val Pro Pro Asn Ser 1 5 10 15 Thr Leu Thr Lys 20 <210> SEQ ID NO 17 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 17 Lys Val Pro Pro Asn Ser Thr Leu Thr Lys Thr Leu Thr Leu Leu Pro 1 5 10 15 Leu Leu Ala Asn 20 <210> SEQ ID NO 18 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 18 Leu Leu Lys Lys Leu Gly Ser Asn Thr Tyr Pro Phe Leu Leu Thr Phe 1 5 10 15 Pro Asp Tyr Leu 20 <210> SEQ ID NO 19 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 19 Leu Thr Phe Arg Arg Asp Leu Tyr Phe Ser Arg Val Gln Val Tyr Pro 1 5 10 15 Pro Val Gly Ala 20 <210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 20 Met Ala Ala Ser Gly Lys Thr Ser Lys Ser Glu Pro Asn His Val Ile 1 5 10 15 Phe Lys Lys Ile 20 <210> SEQ ID NO 21 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 21 Asn Arg Glu Arg Arg Gly Ile Ala Leu Asp Gly Lys Ile Lys His Glu 1 5 10 15 Asp Thr Asn Leu 20 <210> SEQ ID NO 22 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 22 Pro Cys Ser Val Met Leu Gln Pro Ala Pro Gln Asp Ser Gly Lys Ser 1 5 10 15 Cys Gly Val Asp 20 <210> SEQ ID NO 23 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 23 Pro Phe Leu Leu Thr Phe Pro Asp Tyr Leu Pro Cys Ser Val Met Leu 1 5 10 15 Gln Pro Ala Pro 20 <210> SEQ ID NO 24 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 24 Gln Asp Ser Gly Lys Ser Cys Gly Val Asp Phe Glu Val Lys Ala Phe 1 5 10 15 Ala Thr Asp Ser 20 <210> SEQ ID NO 25 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 25 Gln Val Gln Pro Val Asp Gly Val Val Leu Val Asp Pro Asp Leu Val 1 5 10 15 Lys Gly Lys Lys 20 <210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 26 Arg Val Gln Val Tyr Pro Pro Val Gly Ala Ala Ser Thr Pro Thr Lys 1 5 10 15 Leu Gln Glu Ser 20 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 27 Ser Arg Asp Lys Ser Val Thr Ile Tyr Leu Gly Asn Arg Asp Tyr Ile 1 5 10 15 Asp His Val Ser 20 <210> SEQ ID NO 28 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 28 Thr Leu Thr Leu Leu Pro Leu Leu Ala Asn Asn Arg Glu Arg Arg Gly 1 5 10 15 Ile Ala Leu Asp 20 <210> SEQ ID NO 29 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 29 Val Ala Thr Glu Val Pro Phe Arg Leu Met His Pro Gln Pro Glu Asp 1 5 10 15 Pro Ala Lys Glu 20 <210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 30 Val Asp Pro Asp Leu Val Lys Gly Lys Lys Val Tyr Val Thr Leu Thr 1 5 10 15 Cys Ala Phe Arg 20 <210> SEQ ID NO 31 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 31 Val Val Leu Tyr Ser Ser Asp Tyr Tyr Val Lys Pro Val Ala Met Glu 1 5 10 15

Glu Ala Gln Glu 20 <210> SEQ ID NO 32 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens arrestin epitope <400> SEQUENCE: 32 Tyr Gln Ile Lys Val Lys Leu Thr Val Ser Gly Phe Leu Gly Glu Leu 1 5 10 15 Thr Ser Ser Glu 20 <210> SEQ ID NO 33 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain B, Structure Of Insulin epitope <400> SEQUENCE: 33 Ala Leu Tyr Leu Val Cys Gly Glu Arg 1 5 <210> SEQ ID NO 34 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain B, Structure Of Insulin epitope <400> SEQUENCE: 34 Ser His Leu Val Glu Ala Leu Tyr Leu Val 1 5 10 <210> SEQ ID NO 35 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens chaperonin (HSP60) epitope <400> SEQUENCE: 35 Gln Met Arg Pro Val Ser Arg Val Leu 1 5 <210> SEQ ID NO 36 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-3(IV) chain epitope <400> SEQUENCE: 36 Gly Ser Pro Ala Thr Trp Thr Thr Arg 1 5 <210> SEQ ID NO 37 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 1 precursor epitope <400> SEQUENCE: 37 Ala Arg Gly Gln Pro Gly Val Met Gly 1 5 <210> SEQ ID NO 38 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase 1 epitope <400> SEQUENCE: 38 Lys Met Leu Asp His Glu Tyr Thr Thr 1 5 <210> SEQ ID NO 39 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ezrin epitope <400> SEQUENCE: 39 Glu Tyr Thr Ala Lys Ile Ala Leu Leu 1 5 <210> SEQ ID NO 40 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ezrin epitope <400> SEQUENCE: 40 Leu Asn Ile Tyr Glu Lys Asp Asp Lys Leu 1 5 10 <210> SEQ ID NO 41 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glial fibrillary acidic protein isoform 2 epitope <400> SEQUENCE: 41 Asn Leu Ala Gln Asp Leu Ala Thr Val 1 5 <210> SEQ ID NO 42 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glial fibrillary acidic protein isoform 2 epitope <400> SEQUENCE: 42 Gln Leu Ala Arg Gln Gln Val His Val 1 5 <210> SEQ ID NO 43 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glucagon receptor epitope <400> SEQUENCE: 43 Arg Arg Arg Trp His Arg Trp Arg Leu 1 5 <210> SEQ ID NO 44 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glucose-6-phosphatase, catalytic, related epitope <400> SEQUENCE: 44 Phe Leu Trp Ser Val Phe Trp Leu Ile 1 5 <210> SEQ ID NO 45 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 1 epitope <400> SEQUENCE: 45 Asn Met Phe Thr Tyr Glu Ile Ala Pro Val Phe Val Leu Met Glu 1 5 10 15 <210> SEQ ID NO 46 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 46 Ile Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys 1 5 10 <210> SEQ ID NO 47 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 47 Asn Phe Phe Arg Met Val Ile Ser Asn Pro Ala Ala Thr 1 5 10 <210> SEQ ID NO 48 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 48 Phe Leu Gln Asp Val Met Asn Ile Leu 1 5 <210> SEQ ID NO 49 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:

<223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 49 Leu Leu Gln Glu Tyr Asn Trp Glu Leu 1 5 <210> SEQ ID NO 50 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 50 Arg Met Met Glu Tyr Gly Thr Thr Met Val 1 5 10 <210> SEQ ID NO 51 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 51 Val Met Asn Ile Leu Leu Gln Tyr Val Val 1 5 10 <210> SEQ ID NO 52 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 52 Ala Phe Thr Ser Glu His Ser His Phe Ser Leu 1 5 10 <210> SEQ ID NO 53 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 53 Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys 1 5 10 <210> SEQ ID NO 54 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 54 Phe Lys Met Phe Pro Glu Val Lys Glu Lys Gly 1 5 10 <210> SEQ ID NO 55 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 55 Phe Thr Ser Glu His Ser His Phe Ser Leu 1 5 10 <210> SEQ ID NO 56 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 56 Met Ile Ala Arg Phe Lys Met Phe Pro Glu Val Lys Glu Lys Gly 1 5 10 15 <210> SEQ ID NO 57 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 57 Arg Phe Lys Met Phe Pro Glu Val Lys 1 5 <210> SEQ ID NO 58 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 58 Arg Phe Lys Met Phe Pro Glu Val Lys Glu 1 5 10 <210> SEQ ID NO 59 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 59 Arg Phe Lys Met Phe Pro Glu Val Lys Glu Lys 1 5 10 <210> SEQ ID NO 60 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 60 Thr Ser Glu His Ser His Phe Ser Leu 1 5 <210> SEQ ID NO 61 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 61 Val Met Asn Ile Leu Leu Gln Tyr Val 1 5 <210> SEQ ID NO 62 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 62 Glu Leu Ala Glu Tyr Leu Tyr Asn Ile 1 5 <210> SEQ ID NO 63 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 63 Ile Leu Met His Cys Gln Thr Thr Leu 1 5 <210> SEQ ID NO 64 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens heat shock 27kDa protein 1 epitope <400> SEQUENCE: 64 Gln Leu Ser Ser Gly Val Ser Glu Ile Arg His 1 5 10 <210> SEQ ID NO 65 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-27 alpha chain precursor epitope <400> SEQUENCE: 65 Leu Arg Arg Tyr Leu Glu Asn Gly Lys 1 5 <210> SEQ ID NO 66 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-7 alpha chain precursor epitope <400> SEQUENCE: 66 Val Met Ala Pro Arg Thr Val Leu Leu 1 5 <210> SEQ ID NO 67 <211> LENGTH: 14

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-7 alpha chain precursor epitope <400> SEQUENCE: 67 Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr 1 5 10 <210> SEQ ID NO 68 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 68 Ala Leu Asn Glu Asp Leu Ser Ser Trp Thr Ala Ala Asp Thr 1 5 10 <210> SEQ ID NO 69 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 69 Leu Leu Arg Gly Tyr His Gln Asp Ala Tyr 1 5 10 <210> SEQ ID NO 70 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 70 Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Glu Cys Val 1 5 10 15 <210> SEQ ID NO 71 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 71 Trp Asp Arg Glu Thr Gln Ile Cys Lys Ala Lys Ala Gln 1 5 10 <210> SEQ ID NO 72 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 72 Ala Leu Trp Gly Pro Asp Pro Ala Ala Ala Phe 1 5 10 <210> SEQ ID NO 73 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 73 Leu Ala Leu Trp Gly Pro Asp Pro Ala Ala 1 5 10 <210> SEQ ID NO 74 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens insulin epitope <400> SEQUENCE: 74 Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu 1 5 10 <210> SEQ ID NO 75 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 75 Ala Leu Trp Met Arg Leu Leu Pro Leu 1 5 <210> SEQ ID NO 76 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 76 His Leu Val Glu Ala Leu Tyr Leu Val 1 5 <210> SEQ ID NO 77 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 77 Ser Leu Gln Lys Arg Gly Ile Val Glu Gln 1 5 10 <210> SEQ ID NO 78 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 78 Ser Leu Gln Pro Leu Ala Leu Glu Gly 1 5 <210> SEQ ID NO 79 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 79 Ser Leu Tyr Gln Leu Glu Asn Tyr Cys 1 5 <210> SEQ ID NO 80 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 80 Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr 1 5 10 <210> SEQ ID NO 81 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 81 Trp Gly Pro Asp Pro Ala Ala Ala 1 5 <210> SEQ ID NO 82 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 82 Phe Tyr Thr Pro Lys Thr Arg Arg Glu 1 5 <210> SEQ ID NO 83 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 83 Gly Glu Arg Gly Phe Phe Tyr Thr 1 5 <210> SEQ ID NO 84 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 84 Glu Arg Gly Phe Phe Tyr Thr Pro Lys 1 5 <210> SEQ ID NO 85 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 85 Leu Cys Gly Ser His Leu Val Glu Ala Leu 1 5 10 <210> SEQ ID NO 86 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 86 Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr 1 5 10 <210> SEQ ID NO 87 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 87 Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe 1 5 10 <210> SEQ ID NO 88 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 88 Phe Leu Ile Val Leu Ser Val Ala Leu 1 5 <210> SEQ ID NO 89 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 89 Lys Leu Gln Val Phe Leu Ile Val Leu 1 5 <210> SEQ ID NO 90 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein epitope <400> SEQUENCE: 90 Phe Leu Trp Ser Val Phe Met Leu Ile 1 5 <210> SEQ ID NO 91 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 91 Phe Leu Phe Ala Val Gly Phe Tyr Leu 1 5 <210> SEQ ID NO 92 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 92 Leu Asn Ile Asp Leu Leu Trp Ser Val 1 5 <210> SEQ ID NO 93 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 93 Val Leu Phe Gly Leu Gly Phe Ala Ile 1 5 <210> SEQ ID NO 94 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 94 Asn Leu Phe Leu Phe Leu Phe Ala Val 1 5 <210> SEQ ID NO 95 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens islet-specific glucose-6- phosphatase-related protein isoform 1 epitope <400> SEQUENCE: 95 Tyr Leu Leu Leu Arg Val Leu Asn Ile 1 5 <210> SEQ ID NO 96 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 96 Ala Leu Gln Lys Ala Lys Gln Asp Leu 1 5 <210> SEQ ID NO 97 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 97 Asp Ala Lys Asn Lys Leu Glu Gly Leu 1 5 <210> SEQ ID NO 98 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 98 Gly Ala Ser Gly Val Gly Ser Gly Leu 1 5 <210> SEQ ID NO 99 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 99 Lys Ala Lys Gln Asp Leu Ala Arg Leu 1 5 <210> SEQ ID NO 100 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 100 Lys Leu Glu Gly Leu Glu Asp Ala Leu 1 5 <210> SEQ ID NO 101 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 101 Asn Met Gln Asp Leu Val Glu Asp Leu 1 5 <210> SEQ ID NO 102 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 102 Arg Leu Leu Lys Glu Tyr Gln Glu Leu 1 5 <210> SEQ ID NO 103 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens keratin 6C epitope <400> SEQUENCE: 103 Trp Tyr Gln Thr Lys Tyr Glu Glu Leu 1 5 <210> SEQ ID NO 104 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 104 Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr Asp Leu Glu

1 5 10 15 Met Gln Ile Glu 20 <210> SEQ ID NO 105 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 105 Ala Leu Glu Glu Ala Asn Ala Asp Leu 1 5 <210> SEQ ID NO 106 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 106 Ala Asn Ala Asp Leu Glu Val Lys Ile 1 5 <210> SEQ ID NO 107 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 107 Ala Arg Thr Asp Leu Glu Met Gln Ile 1 5 <210> SEQ ID NO 108 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 108 Ala Ser Tyr Leu Asp Lys Val Arg Ala 1 5 <210> SEQ ID NO 109 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 109 Asp Val Asn Gly Leu Arg Arg Val Leu 1 5 <210> SEQ ID NO 110 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 110 Gly Leu Arg Arg Val Leu Asp Glu Leu 1 5 <210> SEQ ID NO 111 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 111 Ile Ser Ser Val Leu Ala Gly Ala Ser Cys Pro Ala 1 5 10 <210> SEQ ID NO 112 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 112 Leu Asp Lys Val Arg Ala Leu Glu Glu 1 5 <210> SEQ ID NO 113 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 113 Gln Ile Glu Gly Leu Lys Glu Glu Leu 1 5 <210> SEQ ID NO 114 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 114 Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu Glu Val 1 5 10 <210> SEQ ID NO 115 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 115 Arg Leu Ala Ser Tyr Leu Asp Lys Val 1 5 <210> SEQ ID NO 116 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 116 Ser Tyr Leu Asp Lys Val Arg Ala 1 5 <210> SEQ ID NO 117 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Keratin, type I cytoskeletal 17 (Cytokeratin 17) (K17) (CK 17) (Version 2) epitope <400> SEQUENCE: 117 Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu 1 5 10 15 Glu Val Lys Ile 20 <210> SEQ ID NO 118 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 118 Gly Leu Glu Lys Ile Glu Lys Gln Leu 1 5 <210> SEQ ID NO 119 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 119 Met Gly Asn Ile Asp Ser Ile Asn Cys Lys 1 5 10 <210> SEQ ID NO 120 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens maspin epitope <400> SEQUENCE: 120 Tyr Ser Leu Lys Leu Ile Lys Arg Leu 1 5 <210> SEQ ID NO 121 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope

<400> SEQUENCE: 121 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr 20 <210> SEQ ID NO 122 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 122 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 <210> SEQ ID NO 123 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 123 Val Val His Phe Phe Lys Asn Ile Val 1 5 <210> SEQ ID NO 124 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 124 Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 Thr Pro Pro <210> SEQ ID NO 125 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 125 His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser 1 5 10 15 His Gly Arg Thr 20 <210> SEQ ID NO 126 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 126 Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro 1 5 10 15 Ser Gln Gly Lys 20 <210> SEQ ID NO 127 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 127 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr Met 20 <210> SEQ ID NO 128 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 128 Phe Lys Gly Val Asp Ala Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu 1 5 10 15 Gly Gly Arg Asp 20 <210> SEQ ID NO 129 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 129 Arg Pro Gly Phe Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala 1 5 10 15 His Lys Gly <210> SEQ ID NO 130 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 130 Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly Ser Lys Tyr Leu Ala 1 5 10 15 Thr Ala Ser Thr Met Asp His Ala Arg His Gly Phe Leu Pro Arg His 20 25 30 Arg Asp Thr Gly Ile Leu 35 <210> SEQ ID NO 131 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 131 Lys Tyr Leu Ala Thr Ala Ser Thr Met 1 5 <210> SEQ ID NO 132 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 132 Gly Leu Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro 1 5 10 15 Gly Phe Gly Tyr 20 <210> SEQ ID NO 133 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 133 Phe Gly Gly Asp Arg Gly Ala Pro Lys Arg Gly Ser Gly Lys Asp Ser 1 5 10 15 His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser 20 25 30 His Gly Arg Thr Gln Asp Glu Asn Pro Val Val 35 40 <210> SEQ ID NO 134 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 134 Gly Leu Ser Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro 1 5 10 15 Gly Phe Gly Tyr Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala His Lys 20 25 30 Gly Phe Lys Gly Val Asp Ala Gln 35 40 <210> SEQ ID NO 135 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC class I related protein A epitope <400> SEQUENCE: 135 Ala Ala Ala Ala Ala Ile Phe Val Ile 1 5 <210> SEQ ID NO 136 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 136 Ser Leu Ser Arg Phe Ser Trp Gly Ala 1 5 <210> SEQ ID NO 137 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 137

Asp Tyr Lys Ser Ala His Lys Gly Phe 1 5 <210> SEQ ID NO 138 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin basic protein epitope <400> SEQUENCE: 138 Ser Lys Ile Phe Lys Leu Gly Gly Arg Asp Ser Arg Ser Gly Ser Pro 1 5 10 15 Met Ala Arg <210> SEQ ID NO 139 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin basic protein epitope <400> SEQUENCE: 139 Thr Pro Arg Thr Pro Pro Pro Gln 1 5 <210> SEQ ID NO 140 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 140 Phe Leu Tyr Gly Ala Leu Leu Leu Ala 1 5 <210> SEQ ID NO 141 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 141 Lys Leu Ile Glu Thr Tyr Phe Ser Lys 1 5 <210> SEQ ID NO 142 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 142 Leu Met Trp Ala Lys Ile Gly Pro Val 1 5 <210> SEQ ID NO 143 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 143 Ser Leu Leu Leu Glu Leu Glu Glu Val 1 5 <210> SEQ ID NO 144 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 144 Val Leu Phe Ser Ser Asp Phe Arg Ile 1 5 <210> SEQ ID NO 145 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin heavy chain, skeletal muscle, adult 2 (Myosin heavy chain IIa) (MyHC-IIa) epitope <400> SEQUENCE: 145 Glu Phe Gln Lys Met Arg Arg Asp Leu 1 5 <210> SEQ ID NO 146 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin heavy chain, skeletal muscle, adult 2 (Myosin heavy chain IIa) (MyHC-IIa) epitope <400> SEQUENCE: 146 Lys Met Arg Arg Asp Leu Glu Glu Ala 1 5 <210> SEQ ID NO 147 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens peroxiredoxin-2 isoform a epitope <400> SEQUENCE: 147 Glu Val Lys Leu Ser Asp Tyr Lys Gly Lys Tyr Val 1 5 10 <210> SEQ ID NO 148 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 148 His Leu Cys Gly Ser His Leu Val Glu Ala 1 5 10 <210> SEQ ID NO 149 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 149 Ala Leu Trp Gly Pro Asp Pro Ala Ala Ala 1 5 10 <210> SEQ ID NO 150 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 150 Arg Leu Leu Pro Leu Leu Ala Leu Leu 1 5 <210> SEQ ID NO 151 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 151 Ala Leu Trp Met Arg Leu Leu Pro Leu Leu 1 5 10 <210> SEQ ID NO 152 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 152 Trp Met Arg Leu Leu Pro Leu Leu Ala Leu 1 5 10 <210> SEQ ID NO 153 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 153 Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys 1 5 10 <210> SEQ ID NO 154 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proinsulin precursor epitope <400> SEQUENCE: 154 Pro Leu Leu Ala Leu Leu Ala Leu Trp Gly 1 5 10 <210> SEQ ID NO 155 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 155 Leu Leu Pro Pro Leu Leu Glu His Leu

1 5 <210> SEQ ID NO 156 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 156 Ser Leu Ala Ala Gly Val Lys Leu Leu 1 5 <210> SEQ ID NO 157 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 157 Ser Leu Ser Pro Leu Gln Ala Glu Leu 1 5 <210> SEQ ID NO 158 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 158 Ala Leu Thr Ala Val Ala Glu Glu Val 1 5 <210> SEQ ID NO 159 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 159 Ser Leu Tyr His Val Tyr Glu Val Asn Leu 1 5 10 <210> SEQ ID NO 160 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 160 Thr Ile Ala Asp Phe Trp Gln Met Val 1 5 <210> SEQ ID NO 161 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 161 Val Ile Val Met Leu Thr Pro Leu Val 1 5 <210> SEQ ID NO 162 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 162 Met Val Trp Glu Ser Gly Cys Thr Val 1 5 <210> SEQ ID NO 163 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 163 Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val 1 5 10 <210> SEQ ID NO 164 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 164 Phe Met Ser Asp Lys Pro Leu His Leu Ala Val Ser Leu Asn Lys Glu 1 5 10 15 Ile Tyr Phe His 20 <210> SEQ ID NO 165 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 165 Gly Glu Ala Glu Glu Gly Lys Arg Asp Lys Asn Asp Val Asp Glu 1 5 10 15 <210> SEQ ID NO 166 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 166 Gly Glu Pro Ile Pro Val Thr Val Thr Val Thr Asn Asn Thr Glu Lys 1 5 10 15 Thr Val Lys Lys 20 <210> SEQ ID NO 167 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 167 His Pro Gln Pro Glu Asp Pro Ala Lys Glu Ser Tyr Gln Asp Ala Asn 1 5 10 15 Leu Val Phe Glu 20 <210> SEQ ID NO 168 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 168 Ile Lys Ala Phe Val Glu Gln Val Ala Asn Val Val Leu Tyr Ser Ser 1 5 10 15 Asp Tyr Tyr Val 20 <210> SEQ ID NO 169 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 169 Lys Ser Ser Val Arg Leu Leu Ile Arg Lys Val Gln His Ala Pro Leu 1 5 10 15 Glu Met Gly Pro 20 <210> SEQ ID NO 170 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 170 Gln Pro Arg Ala Glu Ala Ala Trp Gln Phe Phe Met Ser Asp Lys Pro 1 5 10 15 Leu His Leu Ala 20 <210> SEQ ID NO 171 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 171 Ser Tyr Gln Asp Ala Asn Leu Val Phe Glu Glu Phe Ala Arg His Asn 1 5 10 15 Leu Lys Asp Ala 20 <210> SEQ ID NO 172 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:

<223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 172 Thr Asp Ala Glu Glu Asp Lys Ile Pro Lys Lys Ser Ser Val Arg Leu 1 5 10 15 Leu Ile Arg Lys 20 <210> SEQ ID NO 173 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 173 Thr Asn Asn Thr Glu Lys Thr Val Lys Lys Ile Lys Ala Phe Val Glu 1 5 10 15 Gln Val Ala Asn 20 <210> SEQ ID NO 174 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 174 Val Gln His Ala Pro Leu Glu Met Gly Pro Gln Pro Arg Ala Glu Ala 1 5 10 15 Ala Trp Gln Phe 20 <210> SEQ ID NO 175 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 175 Val Ser Leu Asn Lys Glu Ile Tyr Phe His Gly Glu Pro Ile Pro Val 1 5 10 15 Thr Val Thr Val 20 <210> SEQ ID NO 176 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 176 Val Tyr Val Thr Leu Thr Cys Ala Phe Arg Tyr Gly Gln Glu Asp Ile 1 5 10 15 Asp Val Ile Gly 20 <210> SEQ ID NO 177 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope <400> SEQUENCE: 177 Tyr Gly Gln Glu Asp Ile Asp Val Ile Gly Leu Thr Phe Arg Arg Asp 1 5 10 15 Leu Tyr Phe Ser 20 <210> SEQ ID NO 178 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens SSA protein SS-56 epitope <400> SEQUENCE: 178 Tyr Thr Cys Pro Leu Cys Arg Ala Pro Val 1 5 10 <210> SEQ ID NO 179 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 179 Glu Pro Leu Ala Arg Leu Glu Leu 1 5 <210> SEQ ID NO 180 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 180 Glu Pro Leu Ala Arg Leu Glu Leu Phe Val Val Leu Thr Arg Leu Leu 1 5 10 15 Gln Ala Phe Thr 20 <210> SEQ ID NO 181 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 181 Ile Lys Asp Asp Asn Leu Met Pro Ala Tyr Tyr Lys Cys Ile Gln Glu 1 5 10 15 Val Leu Lys Thr 20 <210> SEQ ID NO 182 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Steroid 21-hydroxylase epitope <400> SEQUENCE: 182 Ile Arg Asp Ser Met Glu Pro Val Val Glu Gln Leu Thr Gln Glu Phe 1 5 10 15 Cys Glu Arg Met 20 <210> SEQ ID NO 183 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor V beta chain 13.1 epitope <400> SEQUENCE: 183 Leu Gly Arg Ala Gly Leu Thr Tyr 1 5 <210> SEQ ID NO 184 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens transaldolase 1 epitope <400> SEQUENCE: 184 Leu Leu Phe Ser Phe Ala Gln Ala Val 1 5 <210> SEQ ID NO 185 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vasoactive intestinal polypeptide receptor 1 precursor epitope <400> SEQUENCE: 185 Arg Arg Lys Trp Arg Arg Trp His Leu 1 5 <210> SEQ ID NO 186 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vasoactive intestinal polypeptide receptor 1 precursor epitope <400> SEQUENCE: 186 Arg Arg Lys Trp Arg Arg Trp His Leu 1 5 <210> SEQ ID NO 187 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 187 Ala His Ala Ser Ala Arg Gln Gln Trp Glu Leu Gln Gly Asp Arg Arg 1 5 10 15 Cys Gln Ser Gln 20 <210> SEQ ID NO 188 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 188

Ala Lys Leu Thr Ile Leu Val Ala Leu Ala Leu Phe Leu Leu Ala Ala 1 5 10 15 His Ala Ser Ala 20 <210> SEQ ID NO 189 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 189 Ala Leu Gln Gln Ile Met Glu Asn Gln Ser Asp Arg Leu Gln Gly Arg 1 5 10 15 Gln Gln Glu <210> SEQ ID NO 190 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 190 Ala Asn Leu Arg Pro Cys Glu Gln His Leu Met Gln Lys Ile Gln Arg 1 5 10 15 Asp Glu Asp Ser 20 <210> SEQ ID NO 191 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea 2S protein 1 epitope <400> SEQUENCE: 191 Cys Asn Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met Cys Glu 1 5 10 15 Ala Leu Gln Gln 20 <210> SEQ ID NO 192 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 5-hydroxytryptamine receptor 2C (5-HT-2C) (Serotonin receptor 2C) (5-HT2C) (5-HTR2C) (5HT-1C) epitope <400> SEQUENCE: 192 Pro Arg Gly Thr Met Gln Ala Ile Asn Asn Glu Arg Lys Ala Ser Lys 1 5 10 15 <210> SEQ ID NO 193 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 193 Asp Gln Gly Thr Cys Leu Leu Leu Thr Glu Val Ala 1 5 10 <210> SEQ ID NO 194 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 194 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val 1 5 10 <210> SEQ ID NO 195 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 195 Gly Glu Arg Ile Thr Lys Met Thr Glu Gly Leu Ala Lys 1 5 10 <210> SEQ ID NO 196 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 196 Pro Gly Glu Trp Arg Ile Ile Tyr Ala Ala Ala Asp Asn Lys 1 5 10 <210> SEQ ID NO 197 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 197 Arg Ile Glu Cys Ile Asn Asp Cys 1 5 <210> SEQ ID NO 198 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 198 Val Ala Lys Arg Gln Glu Gly Tyr Val Tyr Val Leu 1 5 10 <210> SEQ ID NO 199 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 199 Val Ser Glu Asn Met Leu Val Thr Tyr Val 1 5 10 <210> SEQ ID NO 200 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 200 Asp Gln Gly Thr Cys Leu Leu Leu Thr Glu Val Ala 1 5 10 <210> SEQ ID NO 201 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 201 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val 1 5 10 <210> SEQ ID NO 202 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 202 Glu Leu Glu Lys Tyr Gln Gln Leu Asn Ser Glu Arg Gly Val Pro Asn 1 5 10 15 <210> SEQ ID NO 203 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 203 Gly Glu Arg Ile Thr Lys Met Thr Glu Gly Leu Ala Lys 1 5 10 <210> SEQ ID NO 204 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 204 Pro Gly Glu Trp Arg Ile Ile Tyr Ala Ala Ala Asp Asn Lys 1 5 10 <210> SEQ ID NO 205 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 205 Arg Ile Glu Cys Ile Asn Asp Cys 1 5

<210> SEQ ID NO 206 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 206 Val Ala Lys Arg Gln Glu Gly Tyr Val Tyr Val Leu 1 5 10 <210> SEQ ID NO 207 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Allergen Bos d 2 precursor epitope <400> SEQUENCE: 207 Val Ser Glu Asn Met Leu Val Thr Tyr Val 1 5 10 <210> SEQ ID NO 208 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 208 Asp Ile Phe Ala Ser Lys Asn Phe His Leu Gln Lys Asn 1 5 10 <210> SEQ ID NO 209 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 209 Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys 1 5 10 <210> SEQ ID NO 210 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 210 Lys Leu Thr Ser Gly Lys Ile Ala Ser Cys Leu Asn 1 5 10 <210> SEQ ID NO 211 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Allergen Cry j 2 epitope <400> SEQUENCE: 211 Gln Phe Ala Lys Leu Thr Gly Phe Thr Leu Met Gly 1 5 10 <210> SEQ ID NO 212 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 212 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 213 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 213 Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 15 <210> SEQ ID NO 214 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 214 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 <210> SEQ ID NO 215 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 215 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 216 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 216 Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 15 <210> SEQ ID NO 217 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 217 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys 1 5 10 <210> SEQ ID NO 218 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 218 Thr Asn Lys Trp Glu Asp Lys 1 5 <210> SEQ ID NO 219 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 219 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys Arg 1 5 10 <210> SEQ ID NO 220 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 220 Pro Arg Leu Ser Trp His Gln Tyr Thr Lys Arg Asp Ser Arg Glu 1 5 10 15 <210> SEQ ID NO 221 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 221 Thr Val Asp Leu Ile Ser Pro Val Thr Lys Arg Ala Ser Leu Lys 1 5 10 15 <210> SEQ ID NO 222 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 222 Ala Trp Tyr Tyr Val Pro Leu Gly Thr Gln Tyr Thr Asp Ala Pro Ser 1 5 10 15 Phe Ser <210> SEQ ID NO 223

<211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 223 Asp Ala Tyr Pro Ser Gly Ala Trp Tyr Tyr Val Pro Leu Gly Thr Gln 1 5 10 15 Tyr Thr <210> SEQ ID NO 224 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 224 Asp Ile Gly Ser Glu Ser Thr Glu Asp Gln Ala Met Glu Asp Ile Lys 1 5 10 15 Gln Met <210> SEQ ID NO 225 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 225 Glu Asp Ile Lys Gln Met 1 5 <210> SEQ ID NO 226 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 226 Glu Pro Met Ile Gly Val Asn Gln Glu Leu Ala Tyr 1 5 10 <210> SEQ ID NO 227 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 227 Glu Pro Met Ile Gly Val Asn Gln Glu Leu Ala Tyr Phe Tyr Pro Glu 1 5 10 15 Leu Phe <210> SEQ ID NO 228 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 228 Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met Cys Glu Ala Leu 1 5 10 15 Gln <210> SEQ ID NO 229 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 229 Ser Gln Leu Glu Arg Ala Asn Leu Arg Pro Cys Glu Gln His Leu Met 1 5 10 15 <210> SEQ ID NO 230 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 230 Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn 1 5 10 15 <210> SEQ ID NO 231 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 231 Ile Phe Ser Gly Asn Met Asn Ile Lys Leu Lys Met Pro Met Tyr Ile 1 5 10 15 Ala Gly Tyr Lys 20 <210> SEQ ID NO 232 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 232 Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr Phe Asp Gly Arg Gly 1 5 10 15 Ala Gln Val Tyr 20 <210> SEQ ID NO 233 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 233 Leu Gly His Asp Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr 1 5 10 15 Val Ala Phe Asn 20 <210> SEQ ID NO 234 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Cry j 1 precursor epitope <400> SEQUENCE: 234 Ser Gly Lys Tyr Glu Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe 1 5 10 15 Asn Val Glu <210> SEQ ID NO 235 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 235 Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys 1 5 10 <210> SEQ ID NO 236 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 236 Gly Leu Phe Gly Arg Lys Thr Gly Ser Val Ala 1 5 10 <210> SEQ ID NO 237 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 237 Lys Ile Gly Pro Glu Leu His Gly Leu 1 5 <210> SEQ ID NO 238 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 238 Leu Lys Ala Gly Glu Gly Asn Lys Ile Gly Pro Glu 1 5 10 <210> SEQ ID NO 239 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 239 Leu Lys Lys Pro Lys Asp Arg Asn Asp Leu Ile 1 5 10

<210> SEQ ID NO 240 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 allergen epitope <400> SEQUENCE: 240 Gly Leu Glu Ile Asp Val Pro Gly Ile Asp Thr Asn Ala Cys His Phe 1 5 10 15 Val Lys <210> SEQ ID NO 241 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 allergen epitope <400> SEQUENCE: 241 Pro Gly Ile Asp Thr Asn Ala Cys His Phe Val Lys Cys Pro Leu Val 1 5 10 15 Lys Gly Gln Gln 20 <210> SEQ ID NO 242 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 242 Arg Phe Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn 1 5 10 15 Lys Ile Arg <210> SEQ ID NO 243 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 243 Ala Val Asn Ile Val Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr 1 5 10 15 <210> SEQ ID NO 244 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 244 Phe Ala Gly Lys Asp Leu Glu Ser Ile Lys Gly Thr Ala Pro Phe Glu 1 5 10 15 Thr His Ala Asn 20 <210> SEQ ID NO 245 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 245 Gly Thr Ala Pro Phe Glu Thr His Ala Asn Arg 1 5 10 <210> SEQ ID NO 246 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi globin Ctt 3-1 epitope <400> SEQUENCE: 246 Lys Gly Thr Ala Pro Phe Glu Thr His Ala Asn Arg Ile Val Gly Phe 1 5 10 15 Phe Ser Lys Ile Ile 20 <210> SEQ ID NO 247 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 247 Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr Leu 1 5 10 15 Asp Thr Phe Phe Gly 20 <210> SEQ ID NO 248 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 248 Phe Ala Gly Lys Asp Leu Glu Ser Ile Lys Gly Thr Ala Pro Phe Glu 1 5 10 15 Ile His Ala Asn 20 <210> SEQ ID NO 249 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 249 Val Asn Thr Phe Val Ala Ser His Lys Pro Arg Gly Val Thr His Asp 1 5 10 15 Gln Leu Asn Asn Phe 20 <210> SEQ ID NO 250 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 250 Ala Asp Pro Ser Ile Met Ala Lys 1 5 <210> SEQ ID NO 251 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 251 Ala Asp Pro Ser Ile Met Ala Lys Phe Thr Gln Phe Ala Gly Lys Asp 1 5 10 15 Leu Glu Ser Ile Lys 20 <210> SEQ ID NO 252 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 252 Ala Glu Ala Ala Trp 1 5 <210> SEQ ID NO 253 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 253 Ala Glu Ala Ala Trp Gly Ala Thr Leu Asp Thr Phe Phe Gly Met Ile 1 5 10 15 Phe Ser Lys Met 20 <210> SEQ ID NO 254 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 254 Ala Gly Phe Val Ser Tyr Met Lys 1 5 <210> SEQ ID NO 255 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phaseolus vulgaris Glycine-rich cell wall structural protein 1.8 precursor epitope <400> SEQUENCE: 255 Gly Gly Tyr Gly Asp Gly Gly Ala His Gly Gly Gly Tyr Gly Gly 1 5 10 15

<210> SEQ ID NO 256 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 256 Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser 1 5 10 15 <210> SEQ ID NO 257 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 257 Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile Lys Ala Gly 1 5 10 15 <210> SEQ ID NO 258 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 258 Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile 1 5 10 15 <210> SEQ ID NO 259 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 259 Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asn 1 5 10 15 <210> SEQ ID NO 260 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Group V allergen Phl p 5 epitope <400> SEQUENCE: 260 Pro Lys Gly Gly Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser 1 5 10 15 <210> SEQ ID NO 261 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens KIAA1224 protein epitope <400> SEQUENCE: 261 Asp Leu Glu Ser Tyr Leu Gln Leu Asn Cys Glu Arg Gly Thr Trp Arg 1 5 10 15 <210> SEQ ID NO 262 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Lep D 2 precursor epitope <400> SEQUENCE: 262 Lys Gly Glu Ala Leu Asp Phe Asn Tyr Gly Met Thr Ile Pro Ala 1 5 10 15 <210> SEQ ID NO 263 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 263 Ala Gly Leu Pro Gly Lys Cys Gly Val Asn Ile Pro 1 5 10 <210> SEQ ID NO 264 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 264 Ala Lys Gly Ile Ala Gly Leu Asn Pro Asn Leu Ala 1 5 10 <210> SEQ ID NO 265 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 265 Cys Gly Val Asn Ile Pro Tyr Lys Ile Ser Pro Ser 1 5 10 <210> SEQ ID NO 266 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 266 Cys Lys Gly Val Arg Ala Val Asn Asp Ala Ser Arg 1 5 10 <210> SEQ ID NO 267 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana lipid transfer protein precursor epitope <400> SEQUENCE: 267 Cys Val Leu Tyr Leu Lys Asn Gly Gly Val Leu Pro 1 5 10 <210> SEQ ID NO 268 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Lipocalin 1 (tear prealbumin) epitope <400> SEQUENCE: 268 Lys Pro Val Arg Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn 1 5 10 15 <210> SEQ ID NO 269 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 269 Glu Phe Asn Thr Glu Phe Thr Ile His Ala Asp Lys Asn Asn Leu 1 5 10 15 <210> SEQ ID NO 270 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 270 Phe Thr Ile His Ala Asp Lys Asn Asn Leu Lys Met His Met Asp 1 5 10 15 <210> SEQ ID NO 271 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mag3 epitope <400> SEQUENCE: 271 Lys Met His Met Asp Phe Pro Asn Val Phe Gln Ala Asp Leu Thr 1 5 10 15 <210> SEQ ID NO 272 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 272 Ala Leu Phe Lys Ala Leu Glu Ala Tyr Leu Ile Ala Asn 1 5 10 <210> SEQ ID NO 273 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 273 Asp Ala Val Val Pro Glu Glu Asn Ile Lys Tyr Ala 1 5 10 <210> SEQ ID NO 274

<211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 274 Asp Ile Leu Leu Gly Phe Ile Glu Ser Ile Glu Asn 1 5 10 <210> SEQ ID NO 275 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 275 Gly Gly Ser Ile Cys Lys Thr Thr Ala Ile Phe His 1 5 10 <210> SEQ ID NO 276 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apium graveolens Major allergen Api g 1 epitope <400> SEQUENCE: 276 Gly Val Gln Thr His Val Leu Glu Leu Thr Ser Ser 1 5 10 <210> SEQ ID NO 277 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 precursor epitope <400> SEQUENCE: 277 Phe Gly Asn Arg Pro Thr Met Glu Ala Val Gly Ala Tyr Asp Val 1 5 10 15 <210> SEQ ID NO 278 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 precursor epitope <400> SEQUENCE: 278 Met Glu Ala Val Gly Ala Tyr Asp Val Ile Val Asn Gly Asp Lys 1 5 10 15 <210> SEQ ID NO 279 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Canis lupus familiaris Major allergen Can f 1 precursor epitope <400> SEQUENCE: 279 Ala Leu Glu Asp Phe Arg Glu Phe Ser Arg Ala Lys Gly Leu Asn Gln 1 5 10 15 <210> SEQ ID NO 280 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Canis lupus familiaris Major allergen Can f 1 precursor epitope <400> SEQUENCE: 280 Asp Gln Glu Val Pro Glu Lys Pro Asp Ser Val Thr Pro Met Ile Leu 1 5 10 15 <210> SEQ ID NO 281 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 281 Ala Gly Lys Glu Lys Ala Ala Gly Leu Phe Lys Ala 1 5 10 <210> SEQ ID NO 282 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 282 Ala Gly Leu Phe Lys Ala Val Glu Ala Tyr Leu Leu 1 5 10 <210> SEQ ID NO 283 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 283 Ala Pro Gln His Phe Thr Ser Ala Glu Asn Leu Glu 1 5 10 <210> SEQ ID NO 284 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 284 Ala Arg Leu Phe Lys Ser Phe Val Leu Asp Ala Asp 1 5 10 <210> SEQ ID NO 285 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana major allergen Cor a 1.0401 epitope <400> SEQUENCE: 285 Glu Ile Asp His Ala Asn Phe Lys Tyr Cys Tyr Ser 1 5 10 <210> SEQ ID NO 286 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Daucus carota Major allergen Dau c 1 epitope <400> SEQUENCE: 286 Ala Leu Phe Lys Ala Ile Glu Ala Tyr Leu Ile Ala Asn 1 5 10 <210> SEQ ID NO 287 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 287 Asp Gly Tyr Asn Val Phe Arg Ile Ser Glu Phe Glu Asn Asp Glu His 1 5 10 15 <210> SEQ ID NO 288 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 288 Asp Lys Asp Arg Pro Phe Gln Leu Phe Glu Phe Tyr Ala Arg Glu Pro 1 5 10 15 <210> SEQ ID NO 289 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 289 Asp Leu Thr Lys Ile Asp Arg Cys Phe Gln Leu Arg Gly Asn Gly Val 1 5 10 15 <210> SEQ ID NO 290 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 290 Asp Arg Pro Phe Gln Leu Phe Glu Phe Tyr Ala Arg Glu Pro Asp Val 1 5 10 15 <210> SEQ ID NO 291

<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Equus caballus Major allergen Equ c 1 precursor epitope <400> SEQUENCE: 291 Asp Val Ser Pro Glu Ile Lys Glu Glu Phe Val Lys Ile Val Gln Lys 1 5 10 15 <210> SEQ ID NO 292 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 292 Glu Asn Ala Arg Ile Leu Lys Asn Cys Val Asp Ala Lys Met Thr Glu 1 5 10 15 Glu <210> SEQ ID NO 293 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 293 Arg Asp Val Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu 1 5 10 15 Gln <210> SEQ ID NO 294 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I epitope <400> SEQUENCE: 294 Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala 1 5 10 15 Leu <210> SEQ ID NO 295 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 295 Asp Val Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln 1 5 10 15 Val <210> SEQ ID NO 296 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 296 Glu Ile Cys Pro Ala Val Lys Arg Asp Val Asp Leu Phe Leu Thr Gly 1 5 10 15 Thr <210> SEQ ID NO 297 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 297 Glu Gln Val Ala Gln Tyr Lys Ala Leu Pro Val Val Leu Glu Asn Ala 1 5 10 15 <210> SEQ ID NO 298 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 298 Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys Asn Cys 1 5 10 15 Val <210> SEQ ID NO 299 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 299 Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln 1 5 10 15 Tyr <210> SEQ ID NO 300 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 300 Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys Ile Tyr Thr Ser Pro Leu 1 5 10 15 <210> SEQ ID NO 301 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 301 Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys 1 5 10 15 <210> SEQ ID NO 302 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica Major allergen Mal d 1 epitope <400> SEQUENCE: 302 Gly Leu Phe Lys Leu Ile Glu Ser Tyr Leu Lys Asp His Pro Asp 1 5 10 15 <210> SEQ ID NO 303 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus avium Major allergen Pru av 1 epitope <400> SEQUENCE: 303 Asn Leu Phe Lys Leu Ile Glu Thr Tyr Leu Lys Gly His Pro Asp 1 5 10 15 <210> SEQ ID NO 304 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 304 Ala Ala Pro Ala Glu Gly Glu Lys Pro Ala Glu Glu Glu Lys Pro Ile 1 5 10 15 Thr Glu Ala Ala 20 <210> SEQ ID NO 305 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 305 Ala Glu Glu Glu Lys Pro Ile Thr Glu Ala Ala Glu Thr Ala Thr Thr 1 5 10 15 Glu Val Pro Val 20 <210> SEQ ID NO 306 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 306 Ala Pro Ala Glu Pro Glu Ala Pro Ala Pro Glu Thr Glu Lys Ala Glu 1 5 10 15 Glu Val Glu Lys

20 <210> SEQ ID NO 307 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 307 Ala Pro Glu Ala Asp Gln Thr Thr Pro Glu Glu Lys Pro Ala Glu Pro 1 5 10 15 Glu Pro Val Ala 20 <210> SEQ ID NO 308 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 308 Ala Ser Glu Gln Glu Thr Ala Asp Ala Thr Pro Glu Lys Glu Glu Pro 1 5 10 15 Thr Ala Ala Pro 20 <210> SEQ ID NO 309 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope <400> SEQUENCE: 309 Tyr Ala Tyr Val Ala Arg Glu Gln Ser Cys Arg 1 5 10 <210> SEQ ID NO 310 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope <400> SEQUENCE: 310 Ala Leu Ala Gln Thr His Thr Ala Ile Ala Val Ile Ile Gly Ile Lys 1 5 10 15 Asp Leu Asp <210> SEQ ID NO 311 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 311 Glu Asp Ile Pro Gln Pro Pro Val Ser Gln Phe His Ile Gln Gly Gln 1 5 10 15 Val Tyr Cys Asp Thr Cys Arg Ala Gly Phe Ile Thr Glu Leu Ser Glu 20 25 30 Phe Ile Pro 35 <210> SEQ ID NO 312 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 312 Gly Ala Ser Leu Arg Leu Gln Cys Lys Asp Lys Glu Asn Gly Asp Val 1 5 10 15 Thr Phe Thr Glu Val Gly Tyr Thr Arg Ala Glu Gly Leu Tyr Ser 20 25 30 <210> SEQ ID NO 313 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 313 Gly Thr Thr Arg Thr Val Asn Pro Leu Gly Phe Phe Lys Lys Glu Ala 1 5 10 15 Leu Pro Lys Cys Ala Gln Val Tyr Asn Lys Leu Gly Met Tyr Pro Pro 20 25 30 Asn Met <210> SEQ ID NO 314 <211> LENGTH: 53 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 314 Leu Val Glu Arg Asp His Lys Asn Glu Phe Cys Glu Ile Thr Leu Ile 1 5 10 15 Ser Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp Ala 20 25 30 Lys Pro Ser Leu Lys Phe Lys Leu Asn Thr Val Asn Gly Thr Thr Arg 35 40 45 Thr Val Asn Pro Leu 50 <210> SEQ ID NO 315 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 315 Met Leu Val Glu Arg Asp His Lys Asn Glu Phe Cys Glu Ile Thr Leu 1 5 10 15 Ile Ser Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp 20 25 30 Ala <210> SEQ ID NO 316 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 316 Ala Gly Gly Ser Pro Ser Pro Pro Ala Asp Gly Gly 1 5 10 <210> SEQ ID NO 317 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 317 Ala Gly Ser Lys Leu Cys Glu Lys Thr Ser Lys Thr 1 5 10 <210> SEQ ID NO 318 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 318 Cys Asp Lys Lys Cys Ile Glu Trp Glu Lys Ala Gln 1 5 10 <210> SEQ ID NO 319 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 319 Asp Gly Gly Ser Pro Pro Pro Pro Ala Asp Gly Gly 1 5 10 <210> SEQ ID NO 320 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Artemisia vulgaris Major pollen allergen Art v 1 precursor epitope <400> SEQUENCE: 320 Glu Lys Thr Ser Lys Thr Tyr Ser Gly Lys Cys Asp 1 5 10 <210> SEQ ID NO 321 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A

epitope> SEQUENCE: 321 Ala Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly 1 5 10 <210> SEQ ID NO 322 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 322 Ala Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly Asp Asn Leu 1 5 10 15 <210> SEQ ID NO 323 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 323 Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu 1 5 10 <210> SEQ ID NO 324 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 324 Ala Phe Ile Leu Asp Gly Asp Asn Leu Phe Pro Lys Val Ala Pro Gln 1 5 10 15 Ala Ile Ser Ser Val 20 <210> SEQ ID NO 325 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 325 Ala Ile Ser Ser Val Glu Asn Ile Glu Gly Asn Gly 1 5 10 <210> SEQ ID NO 326 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 326 Glu Thr Leu Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser 1 5 10 15 <210> SEQ ID NO 327 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-F/ I epitope <400> SEQUENCE: 327 Gly Glu Thr Leu Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser 1 5 10 15 <210> SEQ ID NO 328 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 328 Ala Asn Asn Asn Tyr Asp Pro Trp Ser Ile Tyr Ala Ile Gly Gly Ser 1 5 10 15 Ser Asn Pro Thr 20 <210> SEQ ID NO 329 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 329 Ala Ser Thr Gly Val Thr Ile Ser Asn Asn His Phe Phe Asn His His 1 5 10 15 Lys Val Met Leu 20 <210> SEQ ID NO 330 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 330 Cys Ala Asn Trp Val Trp Arg Ser Thr Gln Asp Ser Phe Asn Asn Gly 1 5 10 15 Ala Tyr Phe Val 20 <210> SEQ ID NO 331 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 331 Asp Ala Ile Thr Met Arg Asn Val Thr Asp Val Trp Ile Asp His Asn 1 5 10 15 Ser Leu Ser Asp 20 <210> SEQ ID NO 332 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 332 Asp Ala Asn Trp Asp Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val 1 5 10 15 Gly Phe Gly Ser 20 <210> SEQ ID NO 333 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 333 Ala Ile Gly Asp Lys Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asn 1 5 10 15 Lys Trp Leu Glu 20 <210> SEQ ID NO 334 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 334 Cys Tyr Glu Ile Lys Cys Lys Glu Pro Val Glu Cys Ser Gly Glu Pro 1 5 10 15 Val Leu Val Lys 20 <210> SEQ ID NO 335 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 335 Asp His Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys Pro Pro Phe 1 5 10 15 Asp Gly Met Thr 20 <210> SEQ ID NO 336 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope

<400> SEQUENCE: 336 Glu Gly Gly Ala His Leu Val Gln Asp Asp Val Ile Pro Ala Asn Trp 1 5 10 15 Lys Pro Asp Thr 20 <210> SEQ ID NO 337 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon Major pollen allergen Cyn d 1 epitope <400> SEQUENCE: 337 Phe Lys Asp Gly Leu Gly Cys Gly Ala Cys Tyr Glu Ile Lys Cys Lys 1 5 10 15 Glu Pro Val Glu 20 <210> SEQ ID NO 338 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 338 Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr Gln Pro Phe Pro Lys 1 5 10 15 <210> SEQ ID NO 339 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 339 Met Leu Leu Arg Lys Tyr Gly Ile Ala Ala Glu Asn Val Ile Asp 1 5 10 15 <210> SEQ ID NO 340 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Major pollen allergen Phl p 4 precursor epitope <400> SEQUENCE: 340 Asn Ser Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr 1 5 10 15 <210> SEQ ID NO 341 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 341 Ala Ser Asn Lys Arg Glu Lys Ile Glu Glu Asn Gly Ser Met Arg Val 1 5 10 15 Phe Met Gln His 20 <210> SEQ ID NO 342 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 342 Asp Ile Lys Glu Lys Phe Ala Lys Leu Cys Glu Ala His Gly Ile Thr 1 5 10 15 Arg Asp Asn Ile 20 <210> SEQ ID NO 343 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 343 Glu Glu Ala Ser Ser Thr Arg Gly Asn Leu Asp Val Ala Lys Leu Asn 1 5 10 15 Gly Asp Trp Phe 20 <210> SEQ ID NO 344 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 344 Glu Glu Asn Gly Ser Met Arg Val Phe Met Gln His Ile Asp Val Leu 1 5 10 15 Glu Asn Ser Leu 20 <210> SEQ ID NO 345 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Major urinary protein precursor epitope <400> SEQUENCE: 345 Glu Asn Ser Leu Gly Phe Lys Phe Arg Ile Lys Glu Asn Gly Glu Cys 1 5 10 15 Arg Glu Leu Tyr 20 <210> SEQ ID NO 346 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 346 Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys Ser Glu 1 5 10 15 Asn Val Val Val Thr 20 <210> SEQ ID NO 347 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 347 Asp Asn Gly Val Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile Arg 1 5 10 15 Asp <210> SEQ ID NO 348 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 348 Glu Ala Leu Phe Asp Ala Asn Gln Asn Thr Lys Thr Ala Lys Ile Glu 1 5 10 15 Ile Lys Ala Ser Leu 20 <210> SEQ ID NO 349 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 349 Gln Tyr Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys 1 5 10 15 Ser Glu Asn Val Val Val Thr Val Lys Leu Ile Gly Asp Asn Gly Val 20 25 30 Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile Arg Asp 35 40 45 <210> SEQ ID NO 350 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 350 Thr Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Leu Asp Gly Leu Glu 1 5 10 15 Ile Asp Val <210> SEQ ID NO 351 <211> LENGTH: 14

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 351 Ala Ser Ile Asp Gly Leu Gly Val Asp Val Pro Gly Ile Asp 1 5 10 <210> SEQ ID NO 352 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 352 Phe Glu Ala Val Gln Asn Thr Lys Thr Ala Lys Ile Glu Ile Lys 1 5 10 15 <210> SEQ ID NO 353 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 epitope <400> SEQUENCE: 353 Arg Gly Lys Pro Pro Gln Leu Glu Ala Val Phe Glu Ala Val Gln Asn 1 5 10 15 Thr <210> SEQ ID NO 354 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 354 Cys His Gly Ser Glu Pro Cys Ile Ile His Arg Gly Lys Pro Phe 1 5 10 15 <210> SEQ ID NO 355 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 355 Cys Pro Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn 1 5 10 15 Val Pro Lys Ile Ala Pro Lys Ser Glu Asn Val 20 25 <210> SEQ ID NO 356 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 356 Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys Ser Glu 1 5 10 15 Asn Val Val Val Thr Val Lys Val Met Gly 20 25 <210> SEQ ID NO 357 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 357 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys 1 5 10 15 <210> SEQ ID NO 358 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 358 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys Val 1 5 10 15 Leu Val Pro Gly 20 <210> SEQ ID NO 359 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope <400> SEQUENCE: 359 Cys His Gly Ser Glu Pro Cys Ile Ile His Arg Gly Lys Pro Phe 1 5 10 15 <210> SEQ ID NO 360 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 360 Asp His Gly Val Met Ala Cys Gly Thr Val His Gly Gln Val Glu 1 5 10 15 <210> SEQ ID NO 361 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 361 Gly Cys Lys Phe Ile Lys Cys Pro Val Lys Lys Gly Glu Ala Leu 1 5 10 15 <210> SEQ ID NO 362 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 362 Gly Glu Lys Met Thr Leu Glu Ala Lys Phe Ala Ala Asn Gln Asp 1 5 10 15 <210> SEQ ID NO 363 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 363 Gly Glu Val Thr Glu Leu Asp Ile Thr Gly Cys Ser Gly Asp Thr 1 5 10 15 <210> SEQ ID NO 364 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 364 Gly Lys Met Thr Phe Lys Asp Cys Gly His Gly Glu Val Thr Glu 1 5 10 15 <210> SEQ ID NO 365 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Neurofilament heavy polypeptide (NF-H) (Neurofilament triplet H protein) (200 kDa neurofilament protein) epitope <400> SEQUENCE: 365 Tyr Gln Glu Ala Ile Gln Gln Leu Asp Ala Glu Leu Arg Asn Thr Lys 1 5 10 15 <210> SEQ ID NO 366 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 366 Ala Ala Ala Leu Pro Gly Lys Cys Gly Val 1 5 10 <210> SEQ ID NO 367

<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 367 Ala Cys Cys Asn Gly Ile Arg Asn Val Asn 1 5 10 <210> SEQ ID NO 368 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 368 Ala Pro Cys Ile Pro Tyr Val Arg Gly Gly 1 5 10 <210> SEQ ID NO 369 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 369 Ile Arg Asn Val Asn Asn Leu Ala Arg Thr 1 5 10 <210> SEQ ID NO 370 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 370 Ile Ser Ala Ser Thr Asn Cys Ala Thr Val Lys 1 5 10 <210> SEQ ID NO 371 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 371 Asn Leu Ala Arg Thr Thr Pro Asp Arg Gln 1 5 10 <210> SEQ ID NO 372 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 372 Cys Phe Asp Val Phe Lys Glu Leu Lys Val 1 5 10 <210> SEQ ID NO 373 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 373 Gly Ser Ile Gly Ala Ala Ser Met Glu Phe 1 5 10 <210> SEQ ID NO 374 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 374 Ile Gly Leu Phe Arg Val Ala Ser Met Ala Ser Glu Lys Met Lys Ile 1 5 10 15 Leu Glu <210> SEQ ID NO 375 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 375 Ile Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val 1 5 10 15 Ser Pro <210> SEQ ID NO 376 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 376 Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gly Ala Lys 1 5 10 <210> SEQ ID NO 377 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 377 Ala Glu Val Asp Cys Ser Arg Phe Pro Asn Ala Thr Asp Lys 1 5 10 <210> SEQ ID NO 378 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 378 Ala Thr Asp Lys Glu Gly Lys Asp Val Leu Val Cys Asn Lys 1 5 10 <210> SEQ ID NO 379 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 379 Ala Val Val Glu Ser Asn Gly Thr Leu Thr Leu Ser His Phe Gly Lys 1 5 10 15 Cys <210> SEQ ID NO 380 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 380 Cys Leu Leu Cys Ala Tyr Ser Ile Glu Phe Gly Thr Asn Ile Ser Lys 1 5 10 15 <210> SEQ ID NO 381 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 381 Asp Asn Glu Cys Leu Leu Cys Ala His Lys Val Glu Gln Gly Ala Ser 1 5 10 15 Val Asp Lys Arg 20 <210> SEQ ID NO 382 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata pectate lyase epitope <400> SEQUENCE: 382 Gly His Ser Asp Glu Leu Thr Ser Asp Lys Ser Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 383 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Zinnia violacea Pectate lyase precursor epitope <400> SEQUENCE: 383 Gly His Ser Asp Ser Tyr Thr Gln Asp Lys Asn Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 384 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 384

Asp Gly Arg Thr Ile Ile Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr 1 5 10 15 His Ala Val Asn Ile 20 <210> SEQ ID NO 385 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 385 Asp Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly 1 5 10 15 Cys Gly Ser <210> SEQ ID NO 386 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 386 Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser 1 5 10 15 Ala Tyr Leu <210> SEQ ID NO 387 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 387 Ile Arg Glu Ala Leu Thr Gln Thr His Thr Ala Ile Ala Val Ile Ile 1 5 10 15 Gly Ile Lys Asp Leu 20 <210> SEQ ID NO 388 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Peptidase 1 precursor (Major mite fecal allergen Der f 1) (Allergen Der f I) epitope <400> SEQUENCE: 388 Ile Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 1 5 10 15 Ala Ala Thr <210> SEQ ID NO 389 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 389 Phe Arg His Tyr Asp Gly Arg Thr Ile Met Gln His Asp Asn Gly Tyr 1 5 10 15 Gln Pro Asn <210> SEQ ID NO 390 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 390 Gly Arg Thr Ile Met Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His 1 5 10 15 Ala Val Asn <210> SEQ ID NO 391 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 391 His Ala Val Asn Ile Val Gly Tyr Gly Asn Thr Gln Gly Val Asp Tyr 1 5 10 15 Trp Ile Val <210> SEQ ID NO 392 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 392 Asn Lys Ile Arg Gln Ala Leu Thr Gln Thr His Thr Ala Val Ala Val 1 5 10 15 Ile Ile Gly <210> SEQ ID NO 393 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Euroglyphus maynei Peptidase 1 precursor (Mite group 1 allergen Eur m 1) (Allergen Eur m I) epitope <400> SEQUENCE: 393 Pro Tyr Val Ala Arg Glu Gln Ser Cys His Arg Pro Asn Ala Gln Arg 1 5 10 15 Tyr Gly Leu <210> SEQ ID NO 394 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 394 Ala Val Gln Val Thr Phe Thr Val Gln Lys Gly Ser Asp Pro Lys 1 5 10 15 <210> SEQ ID NO 395 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 395 Glu Glu Trp Glu Pro Leu Thr Lys Lys Gly Asn Val Trp Glu Val 1 5 10 15 <210> SEQ ID NO 396 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 396 Phe Thr Val Gln Lys Gly Ser Asp Pro Lys Lys Leu Val Leu Asp 1 5 10 15 <210> SEQ ID NO 397 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 397 Phe Thr Val Gln Lys Gly Ser Asp Pro Lys Lys Leu Val Leu Asn 1 5 10 15 <210> SEQ ID NO 398 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Phl p 3 allergen epitope <400> SEQUENCE: 398 Gly Ser Asp Pro Lys Lys Leu Val Leu Asp Ile Lys Tyr Thr Arg 1 5 10 15 <210> SEQ ID NO 399 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 399 Cys Asp Cys Asp Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala 1 5 10 15 <210> SEQ ID NO 400 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 400 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys

1 5 10 <210> SEQ ID NO 401 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 401 Cys Arg Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu 1 5 10 15 <210> SEQ ID NO 402 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 402 Asp Thr Ile Ser Ser Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile 1 5 10 15 Asp Thr <210> SEQ ID NO 403 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 403 Glu Arg Thr Glu Gly Arg Cys Leu His Tyr Thr Val Asp Lys Ser Lys 1 5 10 15 Pro Lys <210> SEQ ID NO 404 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Spiroplasma citri plectrovirus spv1-r8a2b orf 14 transmembrane protein epitope <400> SEQUENCE: 404 His Val Ile Glu Val Gln Gln Ile Asn Ser Glu Arg Ser Trp Phe Phe 1 5 10 15 <210> SEQ ID NO 405 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 405 Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly 1 5 10 15 Cys Gly Asn Thr 20 <210> SEQ ID NO 406 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 406 Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val 1 5 10 15 Asp Lys Ala Pro 20 <210> SEQ ID NO 407 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 407 Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser 1 5 10 15 Tyr Ser Ala Lys 20 <210> SEQ ID NO 408 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 408 Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr 1 5 10 15 Val Asp Gly Asp 20 <210> SEQ ID NO 409 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 409 Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys Gly Ser Asn 1 5 10 15 Pro Asn Tyr Leu 20 <210> SEQ ID NO 410 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.1 precursor epitope <400> SEQUENCE: 410 Gly Ala Gly Asp Glu Asn Ile Glu Asp Arg Gly Met Leu Ala Thr Val 1 5 10 15 <210> SEQ ID NO 411 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.1 precursor epitope <400> SEQUENCE: 411 Gly Ala Gly Asp Glu Asn Ile Glu Asp Arg Gly Met Leu Ala Thr Val 1 5 10 15 <210> SEQ ID NO 412 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 412 Gly Ala Ser Asp Thr His Phe Gln Asp Leu Lys Met His Val Thr Leu 1 5 10 15 <210> SEQ ID NO 413 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 413 Gly Ala Ser Asp Thr His Phe Gln Asp Leu Lys Met His Val Thr Leu 1 5 10 15 <210> SEQ ID NO 414 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 414 Glu Glu Ala Tyr His Ala Cys Asp Ile Lys Asp 1 5 10 <210> SEQ ID NO 415 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 415 Gly Lys Val Tyr Leu Val Gly Gly Pro Glu Leu Gly Gly Trp Lys 1 5 10 15 <210> SEQ ID NO 416 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 416 Leu Gly Gly Trp Lys Leu Gln Ser Asp Pro Arg Ala Tyr Ala Leu 1 5 10 15 <210> SEQ ID NO 417 <211> LENGTH: 15

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 417 Pro Gly Gly Pro Asp Arg Phe Thr Leu Leu Thr Pro Gly Ser His 1 5 10 15 <210> SEQ ID NO 418 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 418 Ala Tyr Cys Cys Ser Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val 1 5 10 15 <210> SEQ ID NO 419 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 419 Cys Gly Glu Lys Arg Ala Tyr Cys Cys Ser Asp Pro Gly Arg Tyr Cys 1 5 10 15 Pro Trp Gln Val 20 <210> SEQ ID NO 420 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 420 Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val Val Cys Tyr Glu Ser Ser 1 5 10 15 Glu <210> SEQ ID NO 421 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 421 Asp Pro Gly Arg Tyr Cys Pro Trp Gln Val Val Cys Tyr Glu Ser Ser 1 5 10 15 Glu Ile Cys Ser 20 <210> SEQ ID NO 422 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 422 Gly Asn Val Cys Gly Glu Lys Arg Ala Tyr Cys Cys Ser Asp Pro 1 5 10 15 <210> SEQ ID NO 423 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 423 Leu Val Pro Cys Ala Trp Ala Gly Asn Val Cys Gly Glu Lys Arg 1 5 10 15 <210> SEQ ID NO 424 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 424 Leu Val Pro Cys Ala Trp Ala Gly Asn Val Cys Gly Glu Lys Arg Ala 1 5 10 15 Tyr Cys Cys Ser 20 <210> SEQ ID NO 425 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 5 epitope <400> SEQUENCE: 425 Val Cys Tyr Glu Ser Ser Glu Ile Cys Ser Lys Lys Cys Gly Lys 1 5 10 15 <210> SEQ ID NO 426 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 426 Cys Gly Lys Val Gly Lys Tyr Cys Cys Ser Pro Ile Gly Lys Tyr Cys 1 5 10 15 Val Cys Tyr Asp 20 <210> SEQ ID NO 427 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 427 Asp Asp Gly Leu Cys Tyr Glu Gly Thr Asn Cys Gly Lys Val Gly Lys 1 5 10 15 Tyr Cys Cys Ser 20 <210> SEQ ID NO 428 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 428 Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile 1 5 10 <210> SEQ ID NO 429 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 429 Pro Ile Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile 1 5 10 <210> SEQ ID NO 430 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 430 Pro Ile Gly Lys Tyr Cys Val Cys Tyr Asp Ser Lys Ala Ile Cys Asn 1 5 10 15 Lys Asn Cys Thr 20 <210> SEQ ID NO 431 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia trifida Pollen allergen Amb t 5 precursor epitope <400> SEQUENCE: 431 Val Cys Tyr Asp Ser Lys Ala Ile Cys Asn Lys Asn Cys Thr 1 5 10 <210> SEQ ID NO 432 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula pollen allergen Bet v 1 epitope <400> SEQUENCE: 432 His Glu Val Lys Ala Glu Gln Val Lys Ala Thr Lys Glu Met Gly 1 5 10 15

<210> SEQ ID NO 433 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 433 Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala Ser 1 5 10 15 Asn Lys Ala Phe 20 <210> SEQ ID NO 434 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 434 Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn 1 5 10 15 Asp Ala Ile Lys 20 <210> SEQ ID NO 435 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 435 Ala Ala Val Asp Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala 1 5 10 15 Ala Tyr Lys Leu 20 <210> SEQ ID NO 436 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 436 Ala Glu Glu Val Lys Ala Thr Pro Ala Gly Glu Leu Gln Val Ile Asp 1 5 10 15 Lys Val Asp Ala 20 <210> SEQ ID NO 437 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 437 Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp 1 5 10 15 Lys Phe Thr Val 20 <210> SEQ ID NO 438 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 438 Ala Phe Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Asn Val Arg Ser 1 5 10 15 Ala Gly Glu Leu 20 <210> SEQ ID NO 439 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 439 Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro 1 5 10 15 Asp Asp Thr Lys 20 <210> SEQ ID NO 440 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 440 Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp 1 5 10 15 Asn Gly Gly Ala 20 <210> SEQ ID NO 441 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 441 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala 1 5 10 15 Lys Lys Gly Glu 20 <210> SEQ ID NO 442 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 1 precursor epitope <400> SEQUENCE: 442 Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala 1 5 10 <210> SEQ ID NO 443 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 443 Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr Gln Ala Gln Lys Ala 1 5 10 15 Gly Lys Pro Ala 20 <210> SEQ ID NO 444 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 444 Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Ser 1 5 10 15 Ala Phe Asn Lys 20 <210> SEQ ID NO 445 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 445 Ala Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys 1 5 10 15 Gly Leu Leu Ala 20 <210> SEQ ID NO 446 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 446 Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser Ala Ala Lys 1 5 10 15 Ala Pro Gly Leu 20 <210> SEQ ID NO 447 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 447 Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Glu Val Lys Tyr Ala Val

1 5 10 15 Phe Glu Ala Ala 20 <210> SEQ ID NO 448 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 448 Ala Cys Ser Gly Glu Pro Val Val Val His Ile Thr 1 5 10 <210> SEQ ID NO 449 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 449 Ala Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp 1 5 10 <210> SEQ ID NO 450 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 450 Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val Lys 1 5 10 <210> SEQ ID NO 451 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 451 Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala 1 5 10 <210> SEQ ID NO 452 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 epitope <400> SEQUENCE: 452 Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly 1 5 10 <210> SEQ ID NO 453 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 453 Phe Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser 1 5 10 <210> SEQ ID NO 454 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 454 Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ala 1 5 10 <210> SEQ ID NO 455 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 455 Glu Leu Lys Glu Ser Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro 1 5 10 15 <210> SEQ ID NO 456 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 456 Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe 1 5 10 15 <210> SEQ ID NO 457 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 457 Phe Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser Gly Glu Pro 1 5 10 15 <210> SEQ ID NO 458 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 458 Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly 1 5 10 15 <210> SEQ ID NO 459 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 11 epitope <400> SEQUENCE: 459 Arg Tyr Ala Asn Pro Ile Ala Phe Phe Arg Lys Glu Pro Leu Lys 1 5 10 15 <210> SEQ ID NO 460 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 460 Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly 1 5 10 15 <210> SEQ ID NO 461 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 461 Glu Trp Val Ala Met Thr Lys Gly Glu Gly Gly Val Trp Thr Phe 1 5 10 15 <210> SEQ ID NO 462 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 462 Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe 1 5 10 15 <210> SEQ ID NO 463 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 463 Lys Asn Val Phe Asp Asp Val Val Pro Glu Lys Tyr Thr Ile Gly 1 5 10 15 <210> SEQ ID NO 464 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 2 epitope <400> SEQUENCE: 464 Leu Gln Gly Pro Phe Asn Phe Arg Phe Leu Thr Glu Lys Gly Met 1 5 10 15 <210> SEQ ID NO 465 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope

<400> SEQUENCE: 465 Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp Tyr Val Tyr Glu Pro 1 5 10 15 <210> SEQ ID NO 466 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 466 Phe Pro Lys Glu Val Trp Glu Gln Ile Phe Ser Thr Trp Leu Leu 1 5 10 15 <210> SEQ ID NO 467 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 467 Phe Val His Leu Gly His Arg Asp Asn Ile Glu Asp Asp Leu Leu 1 5 10 15 <210> SEQ ID NO 468 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 468 Gly Ile Val Val Ala Trp Lys Val Arg Leu Leu Pro Val Pro Pro 1 5 10 15 <210> SEQ ID NO 469 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 4 epitope <400> SEQUENCE: 469 Asn Arg Asn Asn Thr Phe Lys Pro Phe Ala Glu Tyr Lys Ser Asp 1 5 10 15 <210> SEQ ID NO 470 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5a epitope <400> SEQUENCE: 470 Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys 1 5 10 <210> SEQ ID NO 471 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5a epitope <400> SEQUENCE: 471 Asn Ala Gly Phe Lys Ala Ala Leu Ala Gly Ala Gly Val Gln Pro Ala 1 5 10 15 Asp Lys Tyr <210> SEQ ID NO 472 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 472 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 1 5 10 15 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala 20 25 <210> SEQ ID NO 473 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 473 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 1 5 10 15 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala 20 25 30 Ala <210> SEQ ID NO 474 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 474 Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala Ala Asp Lys Phe Lys 1 5 10 15 Thr Phe Glu <210> SEQ ID NO 475 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 475 Ala Lys Phe Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val 1 5 10 15 Ile Ala Gly Ala Leu Glu Val His Ala Val Lys 20 25 <210> SEQ ID NO 476 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 5b precursor epitope <400> SEQUENCE: 476 Ala Met Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala 1 5 10 15 Thr Val Ala <210> SEQ ID NO 477 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 477 Ala Arg Trp Lys Asn Ser Lys Ile Trp Leu Gln Phe Ala Gln Leu Thr 1 5 10 15 Asp Phe Asn Leu 20 <210> SEQ ID NO 478 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 478 Ala Val Leu Leu Val Pro Ala Asn Lys Lys Phe Phe Val Asn Asn Leu 1 5 10 15 Val Phe Arg Gly 20 <210> SEQ ID NO 479 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 479 Asp Gly Thr Ile Val Ala Gln Pro Asp Pro Ala Arg Trp Lys Asn Ser 1 5 10 15 Lys Ile Trp Leu 20 <210> SEQ ID NO 480 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 480 Phe Phe Val Asn Asn Leu Val Phe Arg Gly Pro Cys Gln Pro His Leu 1 5 10 15 Ser Phe Lys Val 20 <210> SEQ ID NO 481 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:

<223> OTHER INFORMATION: Chamaecyparis obtusa Polygalacturonase epitope <400> SEQUENCE: 481 Phe Gly Glu Cys Glu Gly Val Lys Ile Gln Gly Leu Lys Ile Lys Ala 1 5 10 15 Pro Arg Asp Ser 20 <210> SEQ ID NO 482 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 482 Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp 1 5 10 15 <210> SEQ ID NO 483 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 483 Ala Cys Lys Lys Pro Ser Ala Met Leu Leu Val Pro Gly Asn Lys 1 5 10 15 <210> SEQ ID NO 484 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 484 Ala Ile Lys Phe Asp Phe Ser Thr Gly Leu Ile Ile Gln Gly Leu 1 5 10 15 <210> SEQ ID NO 485 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 485 Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp 1 5 10 15 <210> SEQ ID NO 486 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 486 Ala Asn Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn 1 5 10 15 <210> SEQ ID NO 487 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arabidopsis thaliana Probable pectate lyase 18 precursor epitope <400> SEQUENCE: 487 Gly His Ser Asp Thr Tyr Ser Arg Asp Lys Asn Met Gln Val Thr Ile 1 5 10 15 <210> SEQ ID NO 488 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Profilin-2/4 epitope <400> SEQUENCE: 488 Leu Gly His Asp Gly Thr Val Trp Ala Gln Ser Ala Asp Phe Pro 1 5 10 15 <210> SEQ ID NO 489 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 489 Asp Glu Tyr Cys Ser Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 1 5 10 15 Ser Gly Glu Gly 20 <210> SEQ ID NO 490 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 490 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln 20 <210> SEQ ID NO 491 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 491 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln Trp Gly Trp Cys Gly Ser Thr Asp Glu Tyr Cys Ser 20 25 30 Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 35 40 <210> SEQ ID NO 492 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 492 Lys Leu Cys Pro Asn Asn Leu Cys Cys Ser Gln Trp Gly Trp Cys Gly 1 5 10 15 Ser Thr Asp Glu 20 <210> SEQ ID NO 493 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 493 Asn Gly Gly Leu Asp Leu Asp Val Asn Val Phe Arg Gln Leu Asp Thr 1 5 10 15 Asp Gly Lys Gly 20 <210> SEQ ID NO 494 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 494 Gly Lys Cys Gly Val Ser Ile Pro Tyr Lys 1 5 10 <210> SEQ ID NO 495 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 495 Ile Thr Cys Gly Gln Val Ser Ser Ser Leu 1 5 10 <210> SEQ ID NO 496 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 496 Ser Ile Pro Tyr Lys Ile Ser Ala Ser Thr 1 5 10 <210> SEQ ID NO 497 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 497 Asp Arg Gln Ala Ala Cys Asn Cys Leu Lys Gln Leu Ser Ala Ser 1 5 10 15 <210> SEQ ID NO 498

<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 498 Val Asn Pro Asn Asn Ala Ala Ala Leu Pro Gly Lys Cys Gly Val 1 5 10 15 <210> SEQ ID NO 499 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arabidopsis thaliana Putative pectate lyase 17 precursor epitope <400> SEQUENCE: 499 Gly His Asn Asp Asn Phe Val Lys Asp Val Lys Met Lys Val Thr Val 1 5 10 15 <210> SEQ ID NO 500 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens RAD51-like 1 isoform 1 epitope <400> SEQUENCE: 500 Thr Arg Leu Ile Leu Gln Tyr Leu Asp Ser Glu Arg Arg Gln Ile Leu 1 5 10 15 <210> SEQ ID NO 501 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 501 Asp Pro Gly Pro Ala Arg Val Ile Tyr Thr Tyr Pro Asn Lys Val Phe 1 5 10 15 <210> SEQ ID NO 502 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 502 Ala Thr Trp Thr Cys Ile Asn Gln Gln Leu Asn Pro Lys Thr Asn Lys 1 5 10 15 Trp Glu Asp Lys 20 <210> SEQ ID NO 503 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 503 His Tyr Leu Leu Glu Phe Pro Thr Phe Pro Asp Gly His Asp Tyr Lys 1 5 10 15 Phe Asp Ser Lys 20 <210> SEQ ID NO 504 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 504 Lys Phe Asp Ser Lys Lys Pro Lys Glu Asp Pro Gly Pro Ala Arg Val 1 5 10 15 Ile Tyr Thr Tyr 20 <210> SEQ ID NO 505 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 505 Leu Ile Lys Gly Arg Thr Pro Ile Lys Phe Gly Lys Ala Asp Cys Asp 1 5 10 15 Arg Pro Pro Lys 20 <210> SEQ ID NO 506 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 506 Ser Tyr Pro His Trp Phe Thr Asn Gly Tyr Asp Gly Asn Gly Lys Leu 1 5 10 15 Ile Lys Gly Arg 20 <210> SEQ ID NO 507 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 507 Ala Glu Asp Glu Asp Asn Gln Gln Gly Gln Gly Glu Gly Leu Lys Tyr 1 5 10 15 Leu Gly Phe <210> SEQ ID NO 508 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 508 Phe Ser Asn Val Tyr Leu Phe Ala Lys Asp Lys Ser Gly Pro Leu Gln 1 5 10 15 Pro Gly Val <210> SEQ ID NO 509 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 509 Lys Phe Val Asp Ser Thr Val Val Ala Ser Val Thr Ile Ile Asp Arg 1 5 10 15 Ser Leu Pro <210> SEQ ID NO 510 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 510 Gln Pro Gly Val Asp Ile Ile Glu Gly Pro Val Lys Asn Val Ala Val 1 5 10 15 Pro Leu Tyr <210> SEQ ID NO 511 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 511 Arg Ser Leu Pro Pro Ile Val Lys Asp Ala Ser Ile Gln Val Val Ser 1 5 10 15 Ala Ile Arg <210> SEQ ID NO 512 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 512 Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn Thr Leu 1 5 10 15 Cys <210> SEQ ID NO 513 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:

<223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 513 Glu Lys Asp Ala Ile Pro Glu Asn Leu Pro Pro Leu Thr Ala Asp Phe 1 5 10 15 Ala Glu Asp Lys 20 <210> SEQ ID NO 514 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 514 Glu Ser His Ala Gly Cys Glu Lys Ser 1 5 <210> SEQ ID NO 515 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 515 His Pro Glu Tyr Ala Val Ser Val Leu Leu 1 5 10 <210> SEQ ID NO 516 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 516 Leu Ser Leu Ile Leu Asn Arg Leu Cys 1 5 <210> SEQ ID NO 517 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 517 Asp Phe Val Arg Ala Ala Gly Val Tyr Ala Val Asp 1 5 10 <210> SEQ ID NO 518 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 518 Lys Tyr Leu Asp Phe Val Arg Ala Ala Gly Val Tyr 1 5 10 <210> SEQ ID NO 519 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 519 Asn Val Val Lys Thr Val Val Thr Pro Val Tyr Tyr 1 5 10 <210> SEQ ID NO 520 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 520 Pro Arg Ile Val Leu Asp Val Ala Ser Ser Val Phe 1 5 10 <210> SEQ ID NO 521 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 521 Gln Gly Tyr Arg Val Ser Ser Tyr Leu Pro Leu Leu 1 5 10 <210> SEQ ID NO 522 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Stress-induced protein SAM22 epitope <400> SEQUENCE: 522 Ala Leu Phe Lys Ala Ile Glu Ala Tyr Leu Leu Ala His Pro Asp 1 5 10 15 <210> SEQ ID NO 523 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 523 Ala Phe Asn Val Glu Asn Gly Asn Ala Thr Pro Gln Leu Thr Lys 1 5 10 15 <210> SEQ ID NO 524 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 524 Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr Ala Ile Gly Gly 1 5 10 15 <210> SEQ ID NO 525 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 525 Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe Asn 1 5 10 15 <210> SEQ ID NO 526 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 526 Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr Gly Leu Val His Val 1 5 10 15 <210> SEQ ID NO 527 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 527 Cys Ser Asn Trp Val Trp Gln Ser Thr Gln Asp Val Phe Tyr Asn 1 5 10 15 <210> SEQ ID NO 528 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 528 Ala Asp Phe Ser Asn Tyr Gly Ala Val Val Asp Val Tyr Ala Pro Gly 1 5 10 15 Lys Asp Ile Thr 20 <210> SEQ ID NO 529 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 529 Ala Lys Gly Val Ser Leu Val Ala Val Lys Val Leu Asp Cys Asp Gly 1 5 10 15 Ser Gly Ser Asn 20 <210> SEQ ID NO 530 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 530 Ala Ser Asn Gln Ala Ala Lys Ala Ile Ser Asp Ala Gly Ile Phe Met 1 5 10 15

Ala Val Ala Ala 20 <210> SEQ ID NO 531 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 531 Asp Cys Asn Gly His Gly Thr His Val Ala Gly Thr Val Gly Gly Thr 1 5 10 15 Lys Tyr Gly Leu 20 <210> SEQ ID NO 532 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 532 Asp Pro Ser Ala Gly Lys Gly Val Thr Ala Tyr Ile Ile Asp Thr Gly 1 5 10 15 Ile Asp Ile Asp 20 <210> SEQ ID NO 533 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 533 Ala Cys Lys Tyr Gly Ser Leu Lys Pro Asn Cys Gly 1 5 10 <210> SEQ ID NO 534 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 534 Cys Asn Tyr Gly Pro Ser Gly Asn Phe Met Asn Glu 1 5 10 <210> SEQ ID NO 535 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 535 Asp Val Ala Lys Tyr Gln Val Gly Gln Asn Val Ala 1 5 10 <210> SEQ ID NO 536 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 536 Glu Lys Trp His Lys His Tyr Leu Val Cys Asn Tyr 1 5 10 <210> SEQ ID NO 537 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Vespula vulgaris Venom allergen 5 precursor epitope <400> SEQUENCE: 537 Glu Leu Ala Tyr Val Ala Gln Val Trp Ala Asn Gln 1 5 10 <210> SEQ ID NO 538 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana 11S globulin-like protein epitope <400> SEQUENCE: 538 Ala Phe Gln Ile Ser Arg Glu Glu Ala Arg Arg Leu Lys Tyr Asn 1 5 10 15 <210> SEQ ID NO 539 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Carya illinoinensis 11S legumin protein epitope <400> SEQUENCE: 539 Glu Glu Ser Gln Arg Gln Ser Gln Gln Gly Gln Arg 1 5 10 <210> SEQ ID NO 540 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin epitope <400> SEQUENCE: 540 Asp Ala His Gln Pro Thr Arg Arg Val Arg Lys Gly Asp Val Val Ala 1 5 10 15 Leu Pro <210> SEQ ID NO 541 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin seed storage protein 1 precursor (Legumin-like protein 1) epitope <400> SEQUENCE: 541 Phe Lys Gln Asn Val Asn Arg Pro Ser Arg Ala Asp 1 5 10 <210> SEQ ID NO 542 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum 13S globulin seed storage protein 3 precursor (Legumin-like protein 3) (Allergen Fag e 1) epitope <400> SEQUENCE: 542 Asp Ile Ser Thr Lys Glu Ala Phe Arg Leu Lys Asn 1 5 10 <210> SEQ ID NO 543 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale 2s albumin epitope <400> SEQUENCE: 543 Cys Gln Arg Gln Phe Glu Glu Gln Gln Arg Phe Arg 1 5 10 <210> SEQ ID NO 544 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Sesamum indicum 2S seed storage protein 1 epitope <400> SEQUENCE: 544 His Phe Arg Glu Cys Cys Asn Glu Ile Arg 1 5 10 <210> SEQ ID NO 545 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Sesamum indicum 2S seed storage protein 1 precursor epitope <400> SEQUENCE: 545 Cys Met Gln Trp Met Arg Ser Met Arg Gly 1 5 10 <210> SEQ ID NO 546 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bertholletia excelsa 2S sulfur-rich seed storage protein precursor (Allergen Ber e 1) epitope <400> SEQUENCE: 546 Cys Arg Cys Glu Gly Leu Arg Met Met Met Met Arg Met Gln 1 5 10 <210> SEQ ID NO 547 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 52 kDa Ro protein epitope <400> SEQUENCE: 547

Leu Glu Lys Asp Glu Arg Glu Gln Leu Arg Ile Leu Gly Glu Lys Glu 1 5 10 15 Ala Lys Leu Ala Gln Gln Ser Gln Ala Leu Gln Glu Leu Ile Ser Glu 20 25 30 Leu Asp Arg Arg Cys His Ser Ser 35 40 <210> SEQ ID NO 548 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 52-kD SS-A/Ro autoantigen epitope <400> SEQUENCE: 548 Gln Glu Lys Leu Gln Val Ala Leu Gly Glu 1 5 10 <210> SEQ ID NO 549 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 5-hydroxytryptamine (serotonin) receptor 4 epitope <400> SEQUENCE: 549 Gly Ile Ile Asp Leu Ile Glu Lys Arg Lys Phe Asn Gln Asn Ser Asn 1 5 10 15 Ser Thr Tyr Cys Val 20 <210> SEQ ID NO 550 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60 kDa heat shock protein, mitochondrial precursor epitope <400> SEQUENCE: 550 Asp Gly Val Ala Val Leu Lys Val Gly Gly 1 5 10 <210> SEQ ID NO 551 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60 kDa SS-A/Ro ribonucleoprotein epitope <400> SEQUENCE: 551 Glu Leu Tyr Lys Glu Lys Ala Leu Ser Val Glu Thr Glu Lys Leu Leu 1 5 10 15 Lys Tyr Leu Glu Ala Val 20 <210> SEQ ID NO 552 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60S acidic ribosomal protein P0 epitope <400> SEQUENCE: 552 Ala Lys Val Glu Ala Lys Glu Glu Ser Glu Glu Ser Asp Glu Asp Met 1 5 10 15 Gly Phe Gly Leu Phe Asp 20 <210> SEQ ID NO 553 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 60S acidic ribosomal protein P2 epitope <400> SEQUENCE: 553 Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 <210> SEQ ID NO 554 <211> LENGTH: 50 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 64 Kd autoantigen epitope <400> SEQUENCE: 554 Ala Thr Lys Lys Glu Glu Glu Lys Lys Gly Gly Asp Arg Asn Thr Gly 1 5 10 15 Leu Ser Arg Asp Lys Asp Lys Lys Arg Glu Glu Met Lys Glu Val Ala 20 25 30 Lys Lys Glu Asp Asp Glu Lys Val Lys Gly Glu Arg Arg Asn Thr Asp 35 40 45 Thr Arg 50 <210> SEQ ID NO 555 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens 65 kDa heat shock protein epitope <400> SEQUENCE: 555 Ala Leu Leu Arg Cys Ile Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn 1 5 10 15 Glu Asp Cys <210> SEQ ID NO 556 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Acetylcholine receptor subunit alpha precursor epitope <400> SEQUENCE: 556 Ala Ile Asn Pro Glu Ser Asp Gln Pro Asp Leu Ser Asn Phe 1 5 10 <210> SEQ ID NO 557 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon acidic Cyn d 1 isoallergen isoform 1 precursor epitope <400> SEQUENCE: 557 Gln Asp Asp Val Ile Pro Glu Asp Trp Lys Pro Asp Thr Val Tyr Lys 1 5 10 15 Ser Lys Ile Gln Phe 20 <210> SEQ ID NO 558 <211> LENGTH: 50 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cynodon dactylon acidic Cyn d 1 isoallergen isoform 3 precursor epitope <400> SEQUENCE: 558 Glu Glu Asp Lys Leu Arg Lys Ala Gly Glu Leu Met Leu Gln Phe Arg 1 5 10 15 Arg Val Lys Cys Glu Tyr Pro Ser Asp Thr Lys Ile Thr Phe His Val 20 25 30 Glu Lys Gly Ser Ser Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr Ala 35 40 45 Ala Gly 50 <210> SEQ ID NO 559 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P0) epitope <400> SEQUENCE: 559 Ala Ala Ala Ala Ala Pro Ala Lys 1 5 <210> SEQ ID NO 560 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P1) epitope <400> SEQUENCE: 560 Glu Ser Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 15 <210> SEQ ID NO 561 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens acidic ribosomal phosphoprotein (P2) epitope <400> SEQUENCE: 561 Ala Pro Ala Ala Gly Ser Ala Pro Ala Ala Ala Glu Glu Lys Lys 1 5 10 15 <210> SEQ ID NO 562 <211> LENGTH: 16 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Adrenergic, beta-2-, receptor, surface epitope <400> SEQUENCE: 562 His Trp Tyr Arg Ala Thr His Gln Glu Ala Ile Asn Cys Tyr Ala Asn 1 5 10 15 <210> SEQ ID NO 563 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Alanyl-tRNA synthetase, cytoplasmic epitope <400> SEQUENCE: 563 Phe Ile Asp Glu Pro Arg Arg Arg Pro Ile 1 5 10 <210> SEQ ID NO 564 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus albumin epitope <400> SEQUENCE: 564 Pro Val Glu Ser Lys Val Thr 1 5 <210> SEQ ID NO 565 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia Albumin seed storage protein epitope <400> SEQUENCE: 565 Gly Leu Arg Gly Glu Glu Met Glu Glu Met Val Gln Ser 1 5 10 <210> SEQ ID NO 566 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus alcohol dehydrogenase epitope <400> SEQUENCE: 566 Ala Val Asn Gly Asp Trp Pro Leu Pro Thr Lys Leu Pro Leu Val Gly 1 5 10 15 Gly His <210> SEQ ID NO 567 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penicillium chrysogenum alkaline serine protease epitope <400> SEQUENCE: 567 Ala Asn Val Val Gln Arg Asn Ala Pro Ser Trp Gly Leu Ser Arg Ile 1 5 10 15 Ser Ser Lys Lys Ser Gly Ala Thr Asp Tyr Val Tyr Asp Ser Thr Ala 20 25 30 Gly Glu Gly Ile Val 35 <210> SEQ ID NO 568 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen epitope <400> SEQUENCE: 568 Asp Asp Gln Cys Gln Arg Gln Leu Gln Arg 1 5 10 <210> SEQ ID NO 569 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale allergen Ana o 2 epitope <400> SEQUENCE: 569 Glu Glu Ser Glu Asp Glu Lys Arg Arg Trp Gly Gln Arg Asp Asn 1 5 10 15 <210> SEQ ID NO 570 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Allergen Ara h 1, clone P41B precursor epitope <400> SEQUENCE: 570 Ala Lys Ser Ser Pro Tyr Gln Lys Lys Thr 1 5 10 <210> SEQ ID NO 571 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen Arah3/Arah4 epitope <400> SEQUENCE: 571 Ala Gly Val Ala Leu Ser Arg Leu Val Leu Arg Arg Asn Ala Leu 1 5 10 15 <210> SEQ ID NO 572 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea allergen Arah6 epitope <400> SEQUENCE: 572 Asp Arg Gln Met Val Gln His Phe Lys Arg 1 5 10 <210> SEQ ID NO 573 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Periplaneta americana Allergen Cr-PI epitope <400> SEQUENCE: 573 Ile Pro Lys Gly Lys Lys Gly Gly Gln Ala Tyr 1 5 10 <210> SEQ ID NO 574 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus allergen I/a; Asp f I/a epitope <400> SEQUENCE: 574 Ile Asn Gln Gln Leu Asn Pro Lys 1 5 <210> SEQ ID NO 575 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Allergen II epitope <400> SEQUENCE: 575 Asp Arg Leu Gln Gly Arg Gln Gln Glu Gln 1 5 10 <210> SEQ ID NO 576 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lens culinaris allergen Len c 1.0101 epitope <400> SEQUENCE: 576 Ala Ile Asn Ala Ser Ser Asp Leu Asn Leu Ile Gly Phe Gly Ile 1 5 10 15 <210> SEQ ID NO 577 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Allergen Mag epitope <400> SEQUENCE: 577 Asp Val Glu Leu Ser Leu Arg Ser Ser Asp Ile Ala 1 5 10 <210> SEQ ID NO 578 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penicillium chrysogenum Allergen Pen n 18 epitope <400> SEQUENCE: 578 Ala His Ile Lys Lys Ser Lys Lys Gly Asp Lys Lys Phe Lys Gly Ser 1 5 10 15 Val Ala Asn Met Ser Leu Gly Gly Gly Ser Ser Arg Thr Leu Asp 20 25 30 <210> SEQ ID NO 579 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Sinapis alba Allergen Sin a 1 epitope <400> SEQUENCE: 579 Gln Gly Pro His Val Ile Ser Arg Ile Tyr Gln Thr Ala Thr 1 5 10 <210> SEQ ID NO 580 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ziziphus mauritiana allergen Ziz m 1 epitope <400> SEQUENCE: 580 Lys Thr Asn Tyr Ser Ser Ser Ile Ile Leu Glu Tyr 1 5 10 <210> SEQ ID NO 581 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum tataricum allergenic protein epitope <400> SEQUENCE: 581 Asp Ile Ser Thr Glu Glu Ala Tyr Lys Leu Lys Asn Gly Arg Gln Glu 1 5 10 15 Val Glu Val Phe Arg Pro Phe Gln Ser Arg Tyr Glu Lys Glu Glu Glu 20 25 30 Lys Glu Arg Glu Arg 35 <210> SEQ ID NO 582 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha 2 interferon epitope <400> SEQUENCE: 582 Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser 1 5 10 <210> SEQ ID NO 583 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha S1 casein epitope <400> SEQUENCE: 583 Glu Asp Gln Ala Met Glu Asp Ile Lys Gln Met Glu Ala Glu Ser Ile 1 5 10 15 Ser Ser Ser Glu Glu Ile Val Pro Asn Ser Val Glu Gln Lys 20 25 30 <210> SEQ ID NO 584 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha/beta-gliadin A-II precursor epitope <400> SEQUENCE: 584 Gln Val Ser Phe Gln Gln Pro Gln Gln Gln 1 5 10 <210> SEQ ID NO 585 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha/beta-gliadin A-V epitope <400> SEQUENCE: 585 Leu Ala Leu Gln Thr Leu Pro Ala Met Cys 1 5 10 <210> SEQ ID NO 586 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-1 type IV collagen epitope <400> SEQUENCE: 586 Ser Arg Cys Gln Val Cys Met Arg Arg Thr 1 5 10 <210> SEQ ID NO 587 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha1A-voltage-dependent calcium channel epitope <400> SEQUENCE: 587 Glu Asp Ser Asp Glu Asp Glu Phe Gln Ile Thr Glu 1 5 10 <210> SEQ ID NO 588 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-2 type XI collagen epitope <400> SEQUENCE: 588 Gly Ser Leu Asp Ser Leu Arg Arg Glu Ile Glu Gln Met Arg Arg 1 5 10 15 <210> SEQ ID NO 589 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha2(I) collagen epitope <400> SEQUENCE: 589 Leu Pro Gly Leu Lys Gly His Asn Gly Leu Gln Gly Leu Pro Gly Leu 1 5 10 15 Ala Gly His His 20 <210> SEQ ID NO 590 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha-amylase inhibitor 0.28 precursor (CIII) (WMAI-1) epitope <400> SEQUENCE: 590 Ala Tyr Pro Asp Val 1 5 <210> SEQ ID NO 591 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Alpha-enolase epitope <400> SEQUENCE: 591 Lys Ile His Ala Arg Glu Ile Phe Asp Ser Arg Gly Asn Pro Thr Val 1 5 10 15 Glu <210> SEQ ID NO 592 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens alpha-fibrinogen precursor epitope <400> SEQUENCE: 592 Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser 1 5 10 15 <210> SEQ ID NO 593 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Alpha-gliadin epitope <400> SEQUENCE: 593 Leu Gly Gln Gly Ser Phe Arg Pro Ser Gln Gln Asn 1 5 10 <210> SEQ ID NO 594 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-lactalbumin epitope <400> SEQUENCE: 594 Lys Asp Leu Lys Gly Tyr Gly Gly Val Ser 1 5 10 <210> SEQ ID NO 595 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-lactalbumin precursor epitope <400> SEQUENCE: 595 Lys Cys Glu Val Phe Arg Glu Leu Lys Asp Leu Lys Gly Tyr 1 5 10 <210> SEQ ID NO 596 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus alpha-S1-casein epitope <400> SEQUENCE: 596

Leu Asn Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Gln Val 1 5 10 15 Phe Gly Lys Glu 20 <210> SEQ ID NO 597 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S1-casein precursor epitope <400> SEQUENCE: 597 Ala Met Glu Asp Ile Lys Gln Met Glu Ala 1 5 10 <210> SEQ ID NO 598 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Alpha-S2-casein precursor epitope <400> SEQUENCE: 598 Glu Asn Leu Cys Ser Thr Phe Cys Lys Glu 1 5 10 <210> SEQ ID NO 599 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens anti-beta-amyloid peptide immunoglobulin heavy chain variable region epitope <400> SEQUENCE: 599 Ala His Ile Trp Trp Asn Asp 1 5 <210> SEQ ID NO 600 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Aquaporin-4 epitope <400> SEQUENCE: 600 Phe Cys Pro Asp Val Glu Phe Lys Arg Arg Phe Lys Glu Ala Phe Ser 1 5 10 15 Lys Ala Ala Gln Gln Thr Lys Gly 20 <210> SEQ ID NO 601 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Ara h 2.01 allergen epitope <400> SEQUENCE: 601 Cys Cys Asn Glu Leu Asn Glu Phe Glu Asn Asn Gln Arg Cys Met 1 5 10 15 <210> SEQ ID NO 602 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ATP-dependent DNA helicase 2 subunit 2 epitope <400> SEQUENCE: 602 Glu Glu Ala Ser Gly Ser Ser Val Thr Ala Glu Glu Ala Lys Lys Phe 1 5 10 15 Leu Ala Pro Lys 20 <210> SEQ ID NO 603 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens autoantigen epitope <400> SEQUENCE: 603 Glu Ile Arg Val Arg Leu Gln Ser Ala Ser Pro Ser Thr Arg Trp Thr 1 5 10 15 Glu Leu Asp Asp Val Lys Arg Leu Leu Lys Gly Ser 20 25 <210> SEQ ID NO 604 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Band 3 anion transport protein epitope <400> SEQUENCE: 604 Leu Phe Lys Pro Pro Lys Tyr His Pro Asp Val Pro Tyr Val Lys Arg 1 5 10 15 <210> SEQ ID NO 605 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Bd 30K (34 kDa maturing seed protein) epitope <400> SEQUENCE: 605 Glu Asp Trp Gly Glu Asp Gly Tyr Ile Trp Ile Gln Arg Asn Thr 1 5 10 15 <210> SEQ ID NO 606 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Bence Jones protein HAG epitope <400> SEQUENCE: 606 Ala Trp His Gln Gln Gln Pro 1 5 <210> SEQ ID NO 607 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Bet v 4 epitope <400> SEQUENCE: 607 Phe Ala Arg Ala Asn Arg Gly Leu 1 5 <210> SEQ ID NO 608 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata beta-1, 3-glucananse epitope <400> SEQUENCE: 608 Gly Leu Phe Tyr Pro Asn Lys Gln Pro 1 5 <210> SEQ ID NO 609 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis beta-1,3-glucanase epitope <400> SEQUENCE: 609 Gly Leu Phe Phe Pro Asp Lys Arg Pro Lys Tyr Asn Leu Asn Phe 1 5 10 15 <210> SEQ ID NO 610 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea beta-1,3-glucanase-like protein epitope <400> SEQUENCE: 610 Ala Gly Arg Asn Ser Trp Asn Cys Asp Phe Ser Gln 1 5 10 <210> SEQ ID NO 611 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens beta-2-glycoprotein 1 precursor epitope <400> SEQUENCE: 611 Leu Lys Thr Pro Arg Val 1 5 <210> SEQ ID NO 612 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens beta-2-glycoprotein I epitope <400> SEQUENCE: 612 Thr Leu Arg Val Tyr Lys 1 5 <210> SEQ ID NO 613 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus beta-casein epitope <400> SEQUENCE: 613 Gln Ser Lys Val Leu Pro Val Pro Gln Lys Ala Val Pro 1 5 10

<210> SEQ ID NO 614 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-casein precursor epitope <400> SEQUENCE: 614 Asp Glu Leu Gln Asp Lys Ile His Pro Phe Ala Gln 1 5 10 <210> SEQ ID NO 615 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-lactoglobulin epitope <400> SEQUENCE: 615 Ala Gln Lys Lys Ile Ile Ala Glu Lys Thr 1 5 10 <210> SEQ ID NO 616 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Beta-lactoglobulin precursor epitope <400> SEQUENCE: 616 Ala Ala Ser Asp Ile Ser Leu Leu Asp Ala Gln Ser Ala Pro Leu Arg 1 5 10 15 <210> SEQ ID NO 617 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Botulinum neurotoxin type E epitope <400> SEQUENCE: 617 Trp Lys Ala Pro Ser Ser Pro 1 5 <210> SEQ ID NO 618 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens bullous pemphigoid antigen epitope <400> SEQUENCE: 618 Lys Ser Thr Ala Lys Asp Cys Thr Phe Lys Pro Asp Phe Glu Met Thr 1 5 10 15 Val Lys Glu <210> SEQ ID NO 619 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Bullous pemphigoid antigen 1, isoforms 1/2/3/4/5/8 epitope <400> SEQUENCE: 619 Leu Thr Asp Thr Lys Thr Gly Leu His Phe Asn Ile Asn Glu Ala Ile 1 5 10 15 Glu Gln Gly Thr 20 <210> SEQ ID NO 620 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum BW 16kDa allergen epitope <400> SEQUENCE: 620 Glu Gly Val Arg Asp Leu Lys Glu 1 5 <210> SEQ ID NO 621 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens calcium channel, alpha 1A subunit isoform 3 epitope <400> SEQUENCE: 621 Gly Asn Ile Gly Ile Asp Val Glu Asp Glu Asp Ser Asp Glu Asp Glu 1 5 10 15 Phe <210> SEQ ID NO 622 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Calpastatin epitope <400> SEQUENCE: 622 Ala Val Cys Arg Thr Ser Met Cys Ser Ile Gln Ser Ala Pro Pro 1 5 10 15 <210> SEQ ID NO 623 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Calreticulin precursor epitope <400> SEQUENCE: 623 Lys Glu Gln Phe Leu Asp Gly Asp Gly Trp Thr Ser Arg Trp Ile Glu 1 5 10 15 Ser Lys <210> SEQ ID NO 624 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ca-sensing receptor epitope <400> SEQUENCE: 624 Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp 1 5 10 <210> SEQ ID NO 625 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Caspase-8 precursor epitope <400> SEQUENCE: 625 Asp Arg Asn Gly Thr His Leu Asp Ala 1 5 <210> SEQ ID NO 626 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein A isoform a epitope <400> SEQUENCE: 626 Gly Pro Ser Arg Arg Gly Pro Ser Leu Gly Ala Ser Ser His 1 5 10 <210> SEQ ID NO 627 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein B, 80kDa epitope <400> SEQUENCE: 627 Met Gly Pro Lys Arg Arg Gln Leu Thr Phe 1 5 10 <210> SEQ ID NO 628 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens centromere protein-A epitope <400> SEQUENCE: 628 Glu Ala Pro Arg Arg Arg Ser Pro Ser Pro 1 5 10 <210> SEQ ID NO 629 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Chain A, Birch Pollen Profilin epitope <400> SEQUENCE: 629 Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu Ile Thr Gly 1 5 10 15 Ile <210> SEQ ID NO 630 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain A, Crystal Structure Of The Glycosylated Five-Domain Human Beta2-Glycoprotein I Purified From Blood Plasma epitope <400> SEQUENCE: 630 Arg Gly Gly Met Arg 1 5

<210> SEQ ID NO 631 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Chain H, Three-Dimensional Structure Of A Human Immunoglobulin With A Hinge Deletion epitope <400> SEQUENCE: 631 Ala Leu Pro Ala Pro Ile Glu 1 5 <210> SEQ ID NO 632 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens cholesterol side-chain cleavage enzyme P450scc (EC 1.14.15.67) epitope <400> SEQUENCE: 632 Phe Asp Pro Glu Asn Phe Asp Pro Thr Arg Trp Leu Ser Lys Asp Lys 1 5 10 15 Asn Ile Thr Tyr Phe Arg Asn Leu Gly Phe Gly 20 25 <210> SEQ ID NO 633 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens citrate synthase epitope <400> SEQUENCE: 633 Ala Leu Lys His Leu Pro Asn Asp Pro Met 1 5 10 <210> SEQ ID NO 634 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens claudin 11 epitope <400> SEQUENCE: 634 Ala His Arg Glu Thr 1 5 <210> SEQ ID NO 635 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Coagulation factor VIII precursor epitope <400> SEQUENCE: 635 Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr 1 5 10 <210> SEQ ID NO 636 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Oncorhynchus mykiss collagen a2(I) epitope <400> SEQUENCE: 636 Met Lys Gly Leu Arg Gly His Gly Gly Leu Gln Gly Met Pro Gly Pro 1 5 10 15 Asn Gly Pro Ser 20 <210> SEQ ID NO 637 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-1(II) chain epitope <400> SEQUENCE: 637 Ala Arg Gly Ala Gln Gly Pro Pro Gly Ala Thr Gly Phe Pro 1 5 10 <210> SEQ ID NO 638 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen alpha-1(VII) chain precursor epitope <400> SEQUENCE: 638 Gly Thr Leu His Val Val Gln Arg 1 5 <210> SEQ ID NO 639 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-1(XVII) chain epitope <400> SEQUENCE: 639 Arg Ser Ile Leu Pro Tyr Gly Asp Ser Met Asp Arg Ile Glu Lys Asp 1 5 10 15 Arg Leu Gln Gly Met Ala Pro 20 <210> SEQ ID NO 640 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Collagen alpha-3(IV) chain epitope <400> SEQUENCE: 640 Thr Ala Ile Pro Ser Cys Pro Glu Gly Thr Val Pro Leu Tyr Ser 1 5 10 15 <210> SEQ ID NO 641 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen VII epitope <400> SEQUENCE: 641 Ile Ile Trp Arg Ser Thr Gln Gly 1 5 <210> SEQ ID NO 642 <211> LENGTH: 46 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus collagen, type I, alpha 2 epitope <400> SEQUENCE: 642 Ala Pro Gly Pro Asp Gly Asn Asn Gly Ala Gln Gly Pro Pro Gly Leu 1 5 10 15 Gln Gly Val Gln Gly Gly Lys Gly Glu Gln Gly Pro Ala Gly Pro Pro 20 25 30 Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Thr Ala Gly Glu 35 40 45 <210> SEQ ID NO 643 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 epitope <400> SEQUENCE: 643 Pro Pro Gly Pro Thr Gly Ala Ser Gly 1 5 <210> SEQ ID NO 644 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 1 precursor epitope <400> SEQUENCE: 644 Ala Arg Gly Leu Thr Gly Arg Pro Gly Asp Ala 1 5 10 <210> SEQ ID NO 645 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens collagen, type II, alpha 1 isoform 2 precursor epitope <400> SEQUENCE: 645 Leu Val Gly Pro Arg Gly Glu Arg Gly Phe Pro 1 5 10 <210> SEQ ID NO 646 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Complement C1q subcomponent subunit A epitope <400> SEQUENCE: 646 Lys Gly Glu Gln Gly Glu Pro Gly Ala 1 5 <210> SEQ ID NO 647 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Condensin-2 complex subunit D3 epitope <400> SEQUENCE: 647 Pro Thr Pro Glu Thr Gly Pro Leu Gln Arg

1 5 10 <210> SEQ ID NO 648 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Conglutin-7 precursor epitope <400> SEQUENCE: 648 Ala Ala His Ala Ser Ala Arg Gln Gln Trp Glu Leu Gln Gly Asp 1 5 10 15 <210> SEQ ID NO 649 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Periplaneta americana Cr-PII allergen epitope <400> SEQUENCE: 649 Ile Arg Ser Trp Phe Gly Leu Pro 1 5 <210> SEQ ID NO 650 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cochliobolus lunatus Cytochrome c epitope <400> SEQUENCE: 650 Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys 1 5 10 <210> SEQ ID NO 651 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rattus norvegicus Cytochrome P450 3A1 epitope <400> SEQUENCE: 651 Asp Met Val Leu Asn Glu Thr Leu Arg Leu 1 5 10 <210> SEQ ID NO 652 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens cytoskeleton-associated protein 5 isoform b epitope <400> SEQUENCE: 652 Cys Gln Ala Leu Val Arg Met Leu Ala Lys Lys Pro Gly Trp Lys 1 5 10 15 <210> SEQ ID NO 653 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 2 epitope <400> SEQUENCE: 653 Ile Ala Thr His Ala Lys Ile Arg Asp 1 5 <210> SEQ ID NO 654 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Der f 7 allergen epitope <400> SEQUENCE: 654 His Ile Gly Gly Leu Ser Ile Leu Asp Pro Ile Phe Gly Val Leu 1 5 10 15 <210> SEQ ID NO 655 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 1 allergen epitope <400> SEQUENCE: 655 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val 35 40 <210> SEQ ID NO 656 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Der p 7 allergen polypeptide epitope <400> SEQUENCE: 656 His Ile Gly Gly Leu Ser Ile Leu Asp Pro Ile Phe Ala Val Leu 1 5 10 15 <210> SEQ ID NO 657 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Desmoglein-1 epitope <400> SEQUENCE: 657 Arg Glu Trp Ile Lys Phe Ala Ala Ala Cys Arg Glu 1 5 10 <210> SEQ ID NO 658 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Desmoglein-3 precursor epitope <400> SEQUENCE: 658 Arg Glu Trp Val Lys Phe Ala Lys Pro Cys Arg Glu 1 5 10 <210> SEQ ID NO 659 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoglein-3 preproprotein epitope <400> SEQUENCE: 659 Ser Gln Glu Pro Ala Gly Thr Pro Met Phe Leu Leu Ser Arg Asn Thr 1 5 10 15 Gly Glu Val Arg Thr Leu Thr Asn Ser Leu Asp Arg Glu Gln 20 25 30 <210> SEQ ID NO 660 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoplakin epitope <400> SEQUENCE: 660 Gly Asn Ser Ser Tyr Ser Tyr Ser Tyr Ser Phe Ser 1 5 10 <210> SEQ ID NO 661 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens desmoplakin isoform II epitope <400> SEQUENCE: 661 Leu Val Asp Arg Lys Thr Gly Ser Gln Tyr Asp Ile Gln Asp Ala Ile 1 5 10 15 Asp Lys Gly Leu 20 <210> SEQ ID NO 662 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens dihydrolipoamide S- acetyltransferase (E2 component of pyruvate dehydrogenase complex), isoform CRA_a epitope <400> SEQUENCE: 662 Ala Glu Ile Glu Thr Asp Lys Ala Thr Ile Gly Phe Glu Val Gln Glu 1 5 10 15 Glu Gly <210> SEQ ID NO 663 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase 1 epitope <400> SEQUENCE: 663 Gly Val Pro Ile Glu Lys Ile Tyr Asn Lys Thr Gln Arg Glu Lys Phe 1 5 10 15 Ala <210> SEQ ID NO 664 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase I epitope <400> SEQUENCE: 664

Glu Leu Asp Gly Gln Glu Tyr Val Val Glu Phe Asp Phe Leu Gly Lys 1 5 10 15 Asp Ser Ile Arg 20 <210> SEQ ID NO 665 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA topoisomerase II beta epitope <400> SEQUENCE: 665 His Pro Met Leu Pro Asn Tyr Lys Asn Phe Lys Gly Thr Ile Gln Glu 1 5 10 15 Leu Gly Gln Asn 20 <210> SEQ ID NO 666 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens DNA-directed RNA polymerase II subunit RPB1 epitope <400> SEQUENCE: 666 Tyr Ser Pro Thr Ser Pro Ser 1 5 <210> SEQ ID NO 667 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens E3 ubiquitin-protein ligase TRIM9 isoform 2 epitope <400> SEQUENCE: 667 Ala Phe Asn Lys Thr Gly Val Ser Pro Tyr Ser Lys Thr Leu Val Leu 1 5 10 15 Gln Thr Ser Glu Gly Lys Ala Leu Gln Gln Tyr Pro Ser Glu Arg Glu 20 25 30 Leu Arg Gly Ile 35 <210> SEQ ID NO 668 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Candida albicans Enolase 1 (2-phosphoglycerate dehydratase) (2-phospho-D-glycerate hydro-lyase) epitope <400> SEQUENCE: 668 Gln Ala Ala Asn Asp Ser Tyr Ala Ala Gly Trp Gly Val Met Val Ser 1 5 10 15 His Arg Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Ser Val 20 25 30 Gly Leu Arg Ser Gly Gln Ile 35 <210> SEQ ID NO 669 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens enolase 1 variant epitope <400> SEQUENCE: 669 Lys Ile His Ala Arg Glu Ile Phe Asp Ser Arg Gly Asn Pro Thr Val 1 5 10 15 <210> SEQ ID NO 670 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis ENSP-like protein epitope <400> SEQUENCE: 670 Phe Pro Leu Ile Thr Cys Cys Gly Tyr Gly Gly Lys Tyr Asn Phe Ser 1 5 10 15 Val Thr Ala Pro Cys 20 <210> SEQ ID NO 671 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens envoplakin epitope <400> SEQUENCE: 671 Ala Gly Glu Thr Lys Pro Ser Ser Ser Leu Ser Ile Gly Ser Ile Ile 1 5 10 15 Ser Lys Ser Pro 20 <210> SEQ ID NO 672 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Fagopyrum esculentum Fag e 1 epitope <400> SEQUENCE: 672 Ala Val Val Leu Lys Ala Gly Asn Glu Gly Leu Glu 1 5 10 <210> SEQ ID NO 673 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fas AMA epitope <400> SEQUENCE: 673 Cys Val Pro 1 <210> SEQ ID NO 674 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens FGA protein epitope <400> SEQUENCE: 674 Ser Arg Ala Leu Ala Arg Glu Val Asp Leu Lys Asp Tyr Glu Asp Gln 1 5 10 15 Gln Lys <210> SEQ ID NO 675 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens FGB protein epitope <400> SEQUENCE: 675 Ala Arg Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser 1 5 10 15 Leu Arg Pro Ala 20 <210> SEQ ID NO 676 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrin beta epitope <400> SEQUENCE: 676 Ala Asn Lys Tyr Gln Ile Ser Val Asn Lys Tyr Arg Gly Thr Ala Gly 1 5 10 15 Asn Ala Leu <210> SEQ ID NO 677 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen alpha chain isoform alpha preproprotein epitope <400> SEQUENCE: 677 Asp Ser Pro Gly Ser Gly Asn Ala Arg Pro Asn Asn Pro Asp Trp 1 5 10 15 <210> SEQ ID NO 678 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fibrinogen alpha chain precursor epitope <400> SEQUENCE: 678 Phe Leu Ala Glu Gly Gly Gly Val Arg Gly Pro Arg Val Val Glu Arg 1 5 10 15 His <210> SEQ ID NO 679 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen alpha chain preproprotein, isoform alpha epitope <400> SEQUENCE: 679 Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala Lys Ser Arg 1 5 10 15 Pro Val Arg Gly 20 <210> SEQ ID NO 680 <211> LENGTH: 15 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain epitope <400> SEQUENCE: 680 Pro Arg Lys Gln Cys Ser Lys Glu Asp Gly Gly Gly Trp Trp Tyr 1 5 10 15 <210> SEQ ID NO 681 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain, isoform CRA_d epitope <400> SEQUENCE: 681 Asn Glu Glu Gly Phe Phe Ser Ala Arg Gly His Arg Pro Leu Asp Lys 1 5 10 15 Lys <210> SEQ ID NO 682 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens fibrinogen beta chain, isoform CRA_i epitope <400> SEQUENCE: 682 Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly 1 5 10 15 Gly Tyr Arg Ala Arg Pro Ala Lys 20 <210> SEQ ID NO 683 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Fibronectin precursor epitope <400> SEQUENCE: 683 Leu Thr Ser Arg Pro Ala 1 5 <210> SEQ ID NO 684 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens filaggrin epitope <400> SEQUENCE: 684 Asp Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu 1 5 10 15 Gly His <210> SEQ ID NO 685 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Follistatin-related protein 1 epitope <400> SEQUENCE: 685 Leu Lys Phe Val Glu Gln Asn Glu 1 5 <210> SEQ ID NO 686 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Forkhead box protein E3 epitope <400> SEQUENCE: 686 Pro Thr Pro Ala Pro Gly Pro Gly Arg Arg 1 5 10 <210> SEQ ID NO 687 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens GAD65 autoantigen glutamic acid decarboxylase epitope <400> SEQUENCE: 687 Ala Pro Ala Met Ile Pro Pro 1 5 <210> SEQ ID NO 688 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Gamma-gliadin precursor epitope <400> SEQUENCE: 688 Leu Gln Pro Gln Gln Pro Phe Pro Gln Gln 1 5 10 <210> SEQ ID NO 689 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III epitope <400> SEQUENCE: 689 Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr Leu 1 5 10 15 Asp Thr Phe Phe Gly 20 <210> SEQ ID NO 690 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-III precursor epitope <400> SEQUENCE: 690 Gly Val Thr His Asp Gln Leu Asn Asn Phe Arg 1 5 10 <210> SEQ ID NO 691 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-IV precursor epitope <400> SEQUENCE: 691 Lys Ala His Thr Asp Phe Ala Gly Ala Glu Ala Ala Trp Gly Ala Thr 1 5 10 15 Leu Asp Ala Phe Phe Gly Met 20 <210> SEQ ID NO 692 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-VI precursor epitope <400> SEQUENCE: 692 Ile Val Ser Phe Leu Ser Glu Val Ile Ser Leu Ala Gly Ser Asp Ala 1 5 10 15 Asn Ile Pro Ala Ile Gln Asn Leu Ala Lys Glu Leu Ala Thr Ser His 20 25 30 Lys Pro Arg 35 <210> SEQ ID NO 693 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chironomus thummi thummi Globin CTT-VIII epitope <400> SEQUENCE: 693 Ile Val Gly Phe Phe Ser Glu Val Ile Gly Leu Ile Gly Asn Pro Glu 1 5 10 15 Asn Arg Pro Ala Leu Lys Thr Leu Ile Asp Gly Leu Ala Ser Ser His 20 25 30 Lys Ala Arg 35 <210> SEQ ID NO 694 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Glucan endo-1,3-beta- glucosidase, basic vacuolar isoform epitope <400> SEQUENCE: 694 Ala Trp Leu Ala Gln Phe Val Leu Pro 1 5 <210> SEQ ID NO 695 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutamate decarboxylase epitope <400> SEQUENCE: 695 Phe Arg Glu Arg Gln Ser Ser Lys Asn Leu Leu Ser Cys Glu Asn Ser 1 5 10 15 Asp Arg Asp Ala 20 <210> SEQ ID NO 696

<211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 1 epitope <400> SEQUENCE: 696 Met Ala Ser Ser Thr Pro Ser Ser Ser Ala Thr Ser Ser Asn Ala Gly 1 5 10 15 Ala Asp Pro Asn 20 <210> SEQ ID NO 697 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Glutamate decarboxylase 2 epitope <400> SEQUENCE: 697 Pro Gly Ser Gly Phe Trp Ser Phe Gly Ser Glu Asp Gly Ser Gly Asp 1 5 10 15 Ser Glu Asn <210> SEQ ID NO 698 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutamate receptor, ionotropic, N-methyl D-aspartate 2A epitope <400> SEQUENCE: 698 Ser Val Ser Tyr Asp Asp Trp Asp Tyr Ser Leu Glu Ala Arg Val 1 5 10 15 <210> SEQ ID NO 699 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens glutathione peroxidase-GI epitope <400> SEQUENCE: 699 Asn Glu His Pro Val Phe Ala Tyr Leu Lys Asp Lys Leu Pro 1 5 10 <210> SEQ ID NO 700 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, high molecular weight subunit DX5 epitope <400> SEQUENCE: 700 Ala Gln Gly Gln Gln Pro Gly Gln Gly Gln Gln Gly Gln Gln 1 5 10 <210> SEQ ID NO 701 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, high molecular weight subunit DX5 precursor epitope <400> SEQUENCE: 701 Gln Gln Pro Gly Gln 1 5 <210> SEQ ID NO 702 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Glutenin, low molecular weight subunit precursor epitope <400> SEQUENCE: 702 Gln Gln Gln Pro Pro 1 5 <210> SEQ ID NO 703 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phaseolus vulgaris Glycine-rich cell wall structural protein 1.8 precursor epitope <400> SEQUENCE: 703 Gly Gly Tyr Gly Asp Gly Gly Ala His Gly Gly Gly Tyr Gly Gly 1 5 10 15 <210> SEQ ID NO 704 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea Glycinin epitope <400> SEQUENCE: 704 Ala Leu Ser Arg Leu Val Leu Arg Arg Asn Ala Leu Arg Arg Pro 1 5 10 15 <210> SEQ ID NO 705 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Glycinin G1 precursor epitope <400> SEQUENCE: 705 Gly Ala Ile Val Thr Val Lys Gly Gly Leu Ser Val Ile 1 5 10 <210> SEQ ID NO 706 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Glycinin G2 precursor epitope <400> SEQUENCE: 706 Ala Leu Ser Arg Cys Thr Leu Asn Arg Asn Ala Leu Arg Arg Pro 1 5 10 15 <210> SEQ ID NO 707 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Holcus lanatus group V allergen epitope <400> SEQUENCE: 707 Ala Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr Phe Glu Ala Ala 1 5 10 15 <210> SEQ ID NO 708 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Gu protein epitope <400> SEQUENCE: 708 Ile Asp Ala Pro Lys Pro Lys Lys Met Lys Lys Glu Lys Glu Met Asn 1 5 10 15 Gly Glu Thr Arg Glu Lys Ser Pro Lys Leu Lys Asn Gly Phe Pro His 20 25 30 Pro Glu Pro Asp Cys Asn 35 <210> SEQ ID NO 709 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens H1 histone family, member 0 epitope <400> SEQUENCE: 709 Lys Glu Ile Lys Lys Val Ala Thr Pro Lys Lys Ala Ser Lys Pro Lys 1 5 10 15 Lys <210> SEQ ID NO 710 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens heat shock 60kDa protein 1 (chaperonin) epitope <400> SEQUENCE: 710 Ala Tyr Ala Lys Asp Val Lys Phe Gly Ala Asp Ala 1 5 10 <210> SEQ ID NO 711 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Heat shock protein HSP 90-beta epitope <400> SEQUENCE: 711 Gly Leu Glu Leu Pro Glu 1 5 <210> SEQ ID NO 712 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens high mobility group protein 17 epitope <400> SEQUENCE: 712 Lys Lys Ala Pro Ala Lys Lys Gly Glu Lys Val Pro Lys Gly Lys 1 5 10 15 <210> SEQ ID NO 713

<211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens High mobility group protein B1 epitope <400> SEQUENCE: 713 Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val Lys Ala Glu 1 5 10 15 Lys Ser Lys Lys Lys Lys 20 <210> SEQ ID NO 714 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens high-mobility group box 2 epitope <400> SEQUENCE: 714 Phe Glu Asp Met Ala Lys Ser Asp Lys Ala Arg Tyr Asp Arg Glu 1 5 10 15 <210> SEQ ID NO 715 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histidyl-tRNA synthetase, cytoplasmic epitope <400> SEQUENCE: 715 Ala Glu Arg Ala Ala Leu Glu Glu Leu Val Lys Leu Gln Gly Glu Arg 1 5 10 15 Val Arg Gly Leu Lys Gln Gln Lys Ala Ser Ala Glu Leu Ile Glu Glu 20 25 30 Glu Val Ala Lys Leu Leu Lys Leu Lys Ala Gln 35 40 <210> SEQ ID NO 716 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H1.4 epitope <400> SEQUENCE: 716 Ser Glu Thr Ala Pro Ala Ala Pro Ala Ala Pro Ala Pro Ala Glu Lys 1 5 10 15 <210> SEQ ID NO 717 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histone H1b epitope <400> SEQUENCE: 717 Lys Pro Lys Ala Ala Lys Pro Lys Lys Ala Ala Ala Lys Lys Lys 1 5 10 15 <210> SEQ ID NO 718 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H2A.Z epitope <400> SEQUENCE: 718 Gly Lys Ala Lys Thr Lys Ala Val Ser Arg Ser Gln Arg Ala Gly Leu 1 5 10 15 Gln Phe Pro Val 20 <210> SEQ ID NO 719 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens histone H3 epitope <400> SEQUENCE: 719 Leu Pro Phe Gln Arg Leu Val Arg Glu Ile Ala Gln Asp Phe Lys 1 5 10 15 <210> SEQ ID NO 720 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Histone H3-like centromeric protein A epitope <400> SEQUENCE: 720 Lys Pro Glu Ala Pro Arg Arg Arg Ser Pro 1 5 10 <210> SEQ ID NO 721 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA class I histocompatibility antigen, B-27 alpha chain precursor epitope <400> SEQUENCE: 721 Lys Ala Lys Ala Gln Thr Asp Arg 1 5 <210> SEQ ID NO 722 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-B27 epitope <400> SEQUENCE: 722 Ala Lys Ala Gln Thr Asp Arg Glu Asp Leu Arg Thr Leu Leu Arg Tyr 1 5 10 15 <210> SEQ ID NO 723 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HLA-DR3 epitope <400> SEQUENCE: 723 Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln 1 5 10 15 Lys Arg Gly Arg 20 <210> SEQ ID NO 724 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HMG-17 epitope <400> SEQUENCE: 724 Asp Gly Lys Ala Lys Val Lys Asp Glu Pro Gln Arg Arg Ser Ala 1 5 10 15 <210> SEQ ID NO 725 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens HNRNPA2B1 protein epitope <400> SEQUENCE: 725 Glu Thr Thr Glu Glu Ser Leu Arg Asn Tyr Tyr Glu Gln 1 5 10 <210> SEQ ID NO 726 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens hypothetical protein epitope <400> SEQUENCE: 726 Ala Asn Glu Asp Ala Ala Gln Gly Ile Ala Asn Trp Asp Ala Val Gln 1 5 10 15 Asp Ile Ala Asn Glu Asp Gly Phe His Gly Ile Asp Ile Glu Asp Ala 20 25 30 Ala Gln Gly 35 <210> SEQ ID NO 727 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Oryza sativa Japonica Group hypothetical protein epitope <400> SEQUENCE: 727 Ala Phe Asn His Phe Gly Ile Gln Leu Val Gln Arg 1 5 10 <210> SEQ ID NO 728 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig alpha-1 chain C region epitope <400> SEQUENCE: 728 Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr 1 5 10 15 Pro Ser Pro Ser 20 <210> SEQ ID NO 729 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig gamma-1 chain C region epitope <400> SEQUENCE: 729 Lys Phe Asn Trp Tyr Val Asp

1 5 <210> SEQ ID NO 730 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig gamma-3 chain C region epitope <400> SEQUENCE: 730 Asp Gly Ser Phe Phe Leu Tyr 1 5 <210> SEQ ID NO 731 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig heavy chain V-III region (ART) epitope <400> SEQUENCE: 731 Cys Ser Val Met His Glu Gly 1 5 <210> SEQ ID NO 732 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig lambda chain V-II region MGC epitope <400> SEQUENCE: 732 Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr 1 5 10 15 <210> SEQ ID NO 733 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ig L-chain V-region epitope <400> SEQUENCE: 733 Ala Pro Ser Val Thr Leu Phe 1 5 <210> SEQ ID NO 734 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Immunoglobulin heavy chain epitope <400> SEQUENCE: 734 Asp Lys Ser Arg Trp Gln Glu 1 5 <210> SEQ ID NO 735 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens immunoglobulin light chain epitope <400> SEQUENCE: 735 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 1 5 10 15 <210> SEQ ID NO 736 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens immunoglobulin light chain variable region epitope <400> SEQUENCE: 736 Ala Gly Glu Lys Val Thr Met 1 5 <210> SEQ ID NO 737 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Insulin precursor epitope <400> SEQUENCE: 737 Thr Ser Ile 1 <210> SEQ ID NO 738 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Integrin alpha-6 epitope <400> SEQUENCE: 738 Leu Lys Arg Asp Met Lys Ser Ala His Leu Leu Pro Glu His 1 5 10 <210> SEQ ID NO 739 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Integrin beta-3 precursor epitope <400> SEQUENCE: 739 Cys Ala Pro Glu Ser Ile Glu Phe Pro Val Ser Glu Ala Arg Val Leu 1 5 10 15 Glu Asp <210> SEQ ID NO 740 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon alpha 2 epitope <400> SEQUENCE: 740 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr 1 5 10 <210> SEQ ID NO 741 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon alpha A epitope <400> SEQUENCE: 741 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile 1 5 10 <210> SEQ ID NO 742 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon beta precursor epitope <400> SEQUENCE: 742 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr 1 5 10 <210> SEQ ID NO 743 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens interferon-alpha 2 epitope <400> SEQUENCE: 743 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser 1 5 10 <210> SEQ ID NO 744 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Islet amyloid polypeptide precursor epitope <400> SEQUENCE: 744 Met Gly Ile Leu Lys Leu Gln Val Phe Leu Ile Val Leu Ser Val Ala 1 5 10 15 Leu Asn His Leu Lys Ala Thr Pro Ile Glu Ser His Gln Val Glu Lys 20 25 30 Arg Lys Cys Asn Thr 35 <210> SEQ ID NO 745 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Kappa-casein precursor epitope <400> SEQUENCE: 745 Ala Lys Tyr Ile Pro Ile Gln Tyr Val Leu Ser Arg Tyr Pro 1 5 10 <210> SEQ ID NO 746 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ku antigen epitope <400> SEQUENCE: 746 Arg Gly Asp Gly Pro Phe Arg Leu Gly Gly 1 5 10 <210> SEQ ID NO 747 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens leukotriene B4 receptor 2 epitope

<400> SEQUENCE: 747 Gly Arg Gly Asn Gly Asp Pro Gly Gly Gly Met Glu Lys Asp Gly 1 5 10 15 <210> SEQ ID NO 748 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens liver histone H1e epitope <400> SEQUENCE: 748 Ile Lys Lys Val Ala Thr Pro Lys Lys Ala Ser Pro Lys Lys 1 5 10 <210> SEQ ID NO 749 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Lupus La protein epitope <400> SEQUENCE: 749 Ala Gln Pro Gly Ser Gly Lys Gly Lys Val Gln Phe Gln Gly Lys Lys 1 5 10 15 Thr Lys Phe Ala Ser Asp Asp 20 <210> SEQ ID NO 750 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens lymphocyte activation gene 3 protein precursor epitope <400> SEQUENCE: 750 Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu Ala Pro Gly Pro His 1 5 10 15 Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro Arg Arg Tyr 20 25 30 <210> SEQ ID NO 751 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens m3 muscarinic cholinergic receptor epitope <400> SEQUENCE: 751 Glu Pro Thr Ile Thr Phe Gly Thr Ala Ile 1 5 10 <210> SEQ ID NO 752 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Alternaria alternata Major allergen Alt a 1 precursor epitope <400> SEQUENCE: 752 Ala Asp Pro Val Thr Thr Glu Gly Asp Tyr Val Val Lys Ile Ser Glu 1 5 10 15 Phe Tyr Gly Arg 20 <210> SEQ ID NO 753 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anisakis simplex Major allergen Ani s 1 epitope <400> SEQUENCE: 753 Cys Lys Met Pro Asp Arg Gly Ala Cys Ala Leu Gly Lys Lys Pro 1 5 10 15 <210> SEQ ID NO 754 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 1 epitope <400> SEQUENCE: 754 Leu Asn Pro Lys Thr Asn Lys Trp Glu Asp Lys Arg Tyr 1 5 10 <210> SEQ ID NO 755 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Major allergen Asp f 2 epitope <400> SEQUENCE: 755 Ala His Ile Leu Arg Trp Gly Asn Glu Ser 1 5 10 <210> SEQ ID NO 756 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus major allergen beta-lactoglobulin epitope <400> SEQUENCE: 756 Leu Gln Lys Trp Glu Asn Asp Glu Cys Ala Gln Lys Lys Ile Ile Ala 1 5 10 15 Glu Lys Thr Lys 20 <210> SEQ ID NO 757 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 1 precursor epitope <400> SEQUENCE: 757 Asp Ala Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser 1 5 10 <210> SEQ ID NO 758 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus Major allergen I polypeptide chain 2 precursor epitope <400> SEQUENCE: 758 Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Gln Asp Cys Tyr 1 5 10 <210> SEQ ID NO 759 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Felis catus major allergen I, polypeptide chain 1 epitope <400> SEQUENCE: 759 Leu Leu Asp Lys Ile Tyr Thr Ser Pro Leu Cys 1 5 10 <210> SEQ ID NO 760 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Turbo cornutus major allergen Tur c1 - Turbo cornutus epitope <400> SEQUENCE: 760 Leu Glu Asp Glu Leu Leu Ala Glu Lys Glu Lys Tyr Lys Ala Ile Ser 1 5 10 15 Asp Glu Leu Asp Gln Thr Phe Ala Glu Leu Ala Gly Tyr 20 25 <210> SEQ ID NO 761 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus major house dust allergen epitope <400> SEQUENCE: 761 Leu Ala His Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val 1 5 10 15 Asp Cys Ala Ser Gln His Gly Cys His 20 25 <210> SEQ ID NO 762 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Major latex allergen Hev b 5 epitope <400> SEQUENCE: 762 Ala Pro Pro Ala Ser Glu Gln Glu Thr 1 5 <210> SEQ ID NO 763 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Major mite fecal allergen Der p 1 epitope

<400> SEQUENCE: 763 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Pro Gln Arg Tyr Cys Arg His 35 40 <210> SEQ ID NO 764 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Major pollen allergen epitope <400> SEQUENCE: 764 Phe Thr Glu Val Gly Tyr Thr Arg Ala Glu Gly Leu 1 5 10 <210> SEQ ID NO 765 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Major pollen allergen Bet v 1-A epitope <400> SEQUENCE: 765 Asp Gly Asp Asn Leu Phe Pro Lys Val Ala 1 5 10 <210> SEQ ID NO 766 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Chamaecyparis obtusa Major pollen allergen Cha o 1 precursor epitope <400> SEQUENCE: 766 Trp Arg Ser Thr Gln Asp Ser Phe Asn Asn Gly 1 5 10 <210> SEQ ID NO 767 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Corylus avellana Major pollen allergen Cor a 1 epitope <400> SEQUENCE: 767 Tyr Val Leu Asp Gly Asp Lys Leu Leu Pro Lys Val Ala Pro Gln Ala 1 5 10 15 Leu <210> SEQ ID NO 768 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Holcus lanatus Major pollen allergen Hol l 1 precursor epitope <400> SEQUENCE: 768 Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp 1 5 10 15 Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp 20 25 <210> SEQ ID NO 769 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juniperus ashei Major pollen allergen Jun a 1 precursor epitope <400> SEQUENCE: 769 Ala Phe Asn Gln Phe Gly Pro Asn Ala Gly Gln Arg 1 5 10 <210> SEQ ID NO 770 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea major pollen allergen Ole e 1 epitope <400> SEQUENCE: 770 Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu Gly Trp Val Lys 1 5 10 15 Pro Ser Leu Lys Phe Ile Leu Asn Thr Val Asn Gly Thr Thr Arg Thr 20 25 30 Val Asn <210> SEQ ID NO 771 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica mal d 3 epitope <400> SEQUENCE: 771 Arg Thr Thr Ala Asp Arg Gln Thr Ala 1 5 <210> SEQ ID NO 772 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MBP protein epitope <400> SEQUENCE: 772 Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15 <210> SEQ ID NO 773 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens melanin-concentrating hormone receptor 1, isoform CRA_a epitope <400> SEQUENCE: 773 Ala Glu His Ala Ser Arg Met Ser Val Leu Arg Ala Lys Pro Met Ser 1 5 10 15 Asn Ser Gln Arg Leu Leu Leu Leu Ser Pro Gly Ser Pro Pro 20 25 30 <210> SEQ ID NO 774 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Melanocyte protein Pmel 17 precursor epitope <400> SEQUENCE: 774 Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr Pro Gly Gln Ala Pro 1 5 10 15 <210> SEQ ID NO 775 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC classII HLA-DRB1 epitope <400> SEQUENCE: 775 Glu Gln Arg Arg Ala Ala 1 5 <210> SEQ ID NO 776 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens MHC HLA-DR1-beta epitope <400> SEQUENCE: 776 Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln 1 5 10 15 Arg Arg Ala Ala 20 <210> SEQ ID NO 777 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Blomia tropicalis Mite allergen Blo t 5 epitope <400> SEQUENCE: 777 Glu Glu Ala Gln Thr Leu Ser Lys Ile Leu Leu Lys Asp Leu Lys Glu 1 5 10 15 <210> SEQ ID NO 778 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides farinae Mite group 2 allergen Der f 2 precursor epitope <400> SEQUENCE: 778 Asp Pro Cys Ile Ile 1 5 <210> SEQ ID NO 779 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Mite group 2 allergen Der p 2 precursor epitope

<400> SEQUENCE: 779 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys 1 5 10 15 <210> SEQ ID NO 780 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lepidoglyphus destructor Mite group 2 allergen Lep d 2 precursor epitope <400> SEQUENCE: 780 Ala Ala Asn Gln Asp Thr Ala Lys Val Thr Ile Lys Val Leu Ala Lys 1 5 10 15 Val Ala Gly Thr Thr Ile Gln Val Pro Gly Leu Glu Thr Asp Gly Cys 20 25 30 Lys <210> SEQ ID NO 781 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum monomeric alpha-amylase inhibitor epitope <400> SEQUENCE: 781 Ala Ala Ser Val Pro Glu 1 5 <210> SEQ ID NO 782 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Muscarinic acetylcholine receptor M1 epitope <400> SEQUENCE: 782 Gln Tyr Leu Val Gly Glu Arg Thr Val Leu Ala Gly Gln Cys Tyr Ile 1 5 10 15 Gln Phe Leu Ser Gln 20 <210> SEQ ID NO 783 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin associated glycoprotein epitope <400> SEQUENCE: 783 Asp Ser Tyr Thr Leu Thr Glu Glu Leu Ala Tyr Ala Glu Ile Arg Val 1 5 10 15 Lys <210> SEQ ID NO 784 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin basic protein epitope <400> SEQUENCE: 784 Ile Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys 1 5 10 <210> SEQ ID NO 785 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin oligodendrocyte glycoprotein epitope <400> SEQUENCE: 785 Ala Leu Val Gly Asp Glu Val Glu Leu Pro Cys Arg Ile Ser Pro Gly 1 5 10 15 Lys Asn Ala Thr Gly Met Glu Leu Gly Trp 20 25 <210> SEQ ID NO 786 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin oligodendrocyte glycoprotein isoform alpha6 precursor epitope <400> SEQUENCE: 786 His Arg Thr Phe Glu 1 5 <210> SEQ ID NO 787 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens myelin proteolipid protein epitope <400> SEQUENCE: 787 Ala Asp Ala Arg Met 1 5 <210> SEQ ID NO 788 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-associated glycoprotein precursor epitope <400> SEQUENCE: 788 Gly His Trp Gly Ala Trp Met Pro Ser Ser Ile Ser Ala Phe Glu Gly 1 5 10 15 Thr Cys Val Ser Ile 20 <210> SEQ ID NO 789 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myelin-oligodendrocyte glycoprotein precursor epitope <400> SEQUENCE: 789 Gly Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val 1 5 10 15 Gly Asp Glu Val Glu Leu Pro Cys Arg Ile 20 25 <210> SEQ ID NO 790 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myeloblastin precursor epitope <400> SEQUENCE: 790 Ala His Arg Pro Pro Ser Pro Ala 1 5 <210> SEQ ID NO 791 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myeloperoxidase epitope <400> SEQUENCE: 791 Gly Ser Ala Ser Pro Met Glu Leu Leu Ser 1 5 10 <210> SEQ ID NO 792 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Myosin-11 epitope <400> SEQUENCE: 792 Ala Leu Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Thr Gln 1 5 10 15 Gln Glu Leu Arg 20 <210> SEQ ID NO 793 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Neurofilament heavy polypeptide (NF-H) (Neurofilament triplet H protein) (200 kDa neurofilament protein) epitope <400> SEQUENCE: 793 Ala Lys Ser Pro Glu Lys Ala Lys 1 5 <210> SEQ ID NO 794 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens nicotinic acetylcholine receptor alpha subunit|AChR alpha subunit epitope <400> SEQUENCE: 794 Glu Val Asn Gln Ile Val Thr Thr Asn Val Arg Leu Lys Gln Gln Trp 1 5 10 15 <210> SEQ ID NO 795 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Non-histone chromosomal protein HMG-17 epitope

<400> SEQUENCE: 795 Val Lys Asp Glu Pro Gln Arg Arg Ser Ala 1 5 10 <210> SEQ ID NO 796 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus armeniaca Non-specific lipid-transfer protein 1 epitope <400> SEQUENCE: 796 Val Asn Pro Asn Asn Ala Ala Ala Leu 1 5 <210> SEQ ID NO 797 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus armeniaca Non-specific lipid-transfer protein 1 (LTP 1) (Major allergen Pru ar 3) epitope <400> SEQUENCE: 797 Leu Ala Arg Thr Thr Pro Asp Arg Arg Thr Ala Cys Asn Cys Leu 1 5 10 15 <210> SEQ ID NO 798 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus domestica Non-specific lipid-transfer protein 1 (LTP 1) (Major allergen Pru d 3) epitope <400> SEQUENCE: 798 Leu Ala Arg Thr Thr Ala Asp Arg Arg Ala Ala Cys Asn Cys Leu Lys 1 5 10 15 Gln Leu <210> SEQ ID NO 799 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Malus x domestica Non-specific lipid-transfer protein precursor (LTP) (Allergen Mal d 3) epitope <400> SEQUENCE: 799 Ala Asp Arg Gln Thr Ala Cys Asn Cys Leu Lys Asn Leu Ala Gly 1 5 10 15 <210> SEQ ID NO 800 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens NR2 subunit NMDA receptor epitope <400> SEQUENCE: 800 Asp Trp Glu Tyr Ser Val Trp Leu Ser Asn 1 5 10 <210> SEQ ID NO 801 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens nuclear autoantigen Sp-100 isoform 1 epitope <400> SEQUENCE: 801 Glu Val Phe Ile Ser Ala Pro Arg 1 5 <210> SEQ ID NO 802 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Ole e 1 protein epitope <400> SEQUENCE: 802 Glu Asp Val Pro Gln Pro Pro Val Ser Gln Phe His 1 5 10 <210> SEQ ID NO 803 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Olea europaea Ole e 1.0102 protein epitope <400> SEQUENCE: 803 Glu Asp Val Pro Gln Pro Pro Val Ser Gln Phe His Ile Gln Gly Gln 1 5 10 15 Val Tyr Cys Asp Thr Cys Arg Ala Gly 20 25 <210> SEQ ID NO 804 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Omega gliadin storage protein epitope <400> SEQUENCE: 804 Gln Gln Pro Gln Gln Ser Phe Pro Gln Gln 1 5 10 <210> SEQ ID NO 805 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum omega-5 gliadin epitope <400> SEQUENCE: 805 Gln Gln Phe His Gln Gln Gln 1 5 <210> SEQ ID NO 806 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Oryzin precursor epitope <400> SEQUENCE: 806 Ala Ser Asn Thr Ser Pro Ala Ser Ala Pro Asn Ala Leu Thr Val Ala 1 5 10 15 Ala Ile Asn Lys Ser Asn Ala Arg Ala Ser Phe Ser Asn Tyr Gly Ser 20 25 30 Val Val Asp 35 <210> SEQ ID NO 807 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovalbumin epitope <400> SEQUENCE: 807 Cys Phe Asp Val Phe Lys Glu Leu Lys 1 5 <210> SEQ ID NO 808 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid epitope <400> SEQUENCE: 808 Cys Asn Phe Cys Asn Ala Val Val Glu Ser 1 5 10 <210> SEQ ID NO 809 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Ovomucoid precursor epitope <400> SEQUENCE: 809 Ala Glu Val Asp Cys Ser Arg Phe Pro Asn Ala Thr Asp Lys 1 5 10 <210> SEQ ID NO 810 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max P34 probable thiol protease precursor epitope <400> SEQUENCE: 810 Ala Ser Trp Asp Trp Arg Lys Lys Gly Val 1 5 10 <210> SEQ ID NO 811 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max P34 probable thiol protease precursor; Gly m 1 epitope <400> SEQUENCE: 811 Pro Gln Glu Phe Ser Lys Lys Thr Tyr Gln 1 5 10 <210> SEQ ID NO 812 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens p70 autoantigen epitope <400> SEQUENCE: 812

Glu Ala Leu Thr Lys His Phe Gln Asp 1 5 <210> SEQ ID NO 813 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens PADI-H protein epitope <400> SEQUENCE: 813 Lys Ala Ala Ser Gly Ser Thr Gly Asp Gln Lys Val Gln Ile Ser Tyr 1 5 10 15 Tyr Gly Pro Lys 20 <210> SEQ ID NO 814 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Par j epitope <400> SEQUENCE: 814 Gly Thr Ser Ser Cys Arg Leu Val Pro 1 5 <210> SEQ ID NO 815 <211> LENGTH: 47 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Blomia tropicalis Paramyosin epitope <400> SEQUENCE: 815 Glu Lys Leu Arg Asp Gln Lys Glu Ala Leu Ala Arg Glu Asn Lys Lys 1 5 10 15 Leu Ala Asp Asp Leu Ala Glu Ala Lys Ser Gln Leu Asn Asp Ala His 20 25 30 Arg Arg Ile His Glu Gln Glu Ile Glu Ile Lys Arg Leu Glu Asn 35 40 45 <210> SEQ ID NO 816 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gadus morhua callarias Parvalbumin beta epitope <400> SEQUENCE: 816 Ala Ala Glu Ala Ala Cys Phe Lys 1 5 <210> SEQ ID NO 817 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Salmo salar parvalbumin like 1 epitope <400> SEQUENCE: 817 Ala Asp Ile Lys Thr Ala Leu Glu Ala Arg Lys Ala Ala Asp Thr 1 5 10 15 <210> SEQ ID NO 818 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juniperus ashei Pathogenesis-related protein precursor epitope <400> SEQUENCE: 818 Ala Asp Ile Asn Ala Val Cys Pro Ser Glu Leu Lys 1 5 10 <210> SEQ ID NO 819 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Nicotiana tabacum Pectate lyase epitope <400> SEQUENCE: 819 Ala Tyr Asn His Phe Gly Lys Arg Leu Asp Gln Arg 1 5 10 <210> SEQ ID NO 820 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Musa acuminata AAA Group pectate lyase 2 epitope <400> SEQUENCE: 820 Ala Phe Asn His Phe Gly Glu Gly Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 821 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Farfantepenaeus aztecus Pen a 1 allergen epitope <400> SEQUENCE: 821 Ala Asn Ile Gln Leu Val Glu Lys Asp Lys Ala Leu Ser Asn Ala 1 5 10 15 <210> SEQ ID NO 822 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Dermatophagoides pteronyssinus Peptidase 1 precursor (Major mite fecal allergen Der p 1) (Allergen Der p I) epitope <400> SEQUENCE: 822 Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile 1 5 10 15 Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu 20 25 30 Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val 35 40 <210> SEQ ID NO 823 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens pericentriolar material 1 protein epitope <400> SEQUENCE: 823 Lys Asp Cys 1 <210> SEQ ID NO 824 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Periplakin epitope <400> SEQUENCE: 824 Ile His Asp Arg Lys Ser Gly Lys Lys Phe Ser Ile Glu Glu Ala Leu 1 5 10 15 Gln Ser Gly Arg 20 <210> SEQ ID NO 825 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Apis mellifera Phospholipase A2 precursor epitope <400> SEQUENCE: 825 Leu Ile Asp Thr Lys Cys Tyr Lys Leu Glu His Pro Val Thr Gly Cys 1 5 10 15 Gly Glu Arg Thr Glu Gly Arg Cys Leu His Tyr Thr Val Asp Lys Ser 20 25 30 Lys Pro Lys Val Tyr Gln Trp Phe Asp Leu Arg Lys Tyr 35 40 45 <210> SEQ ID NO 826 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Myrmecia pilosula Pilosulin-1 precursor (Major allergen Myr p 1) (Myr p I) epitope <400> SEQUENCE: 826 Lys Glu Ala Ile Pro Met Ala Val Glu Met Ala Lys Ser Gln 1 5 10 <210> SEQ ID NO 827 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens plasma protease C1 inhibitor precursor epitope <400> SEQUENCE: 827 Ala Ser Ala Ile Ser Val Ala Arg 1 5 <210> SEQ ID NO 828 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens platelet glycoprotein IIIa epitope <400> SEQUENCE: 828 Arg Ala Arg Ala Lys Trp 1 5

<210> SEQ ID NO 829 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens plexin domain containing 1, isoform CRA_b epitope <400> SEQUENCE: 829 Asn Cys Ser Trp Cys His Val Leu Gln Arg Cys Ser 1 5 10 <210> SEQ ID NO 830 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens PM/Scl 100kD nucleolar protein epitope <400> SEQUENCE: 830 Cys Ile Ala Ala Lys Lys Ile Lys Gln Ser Val Gly Asn Lys Ser 1 5 10 15 <210> SEQ ID NO 831 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula Polcalcin Bet v 4 epitope <400> SEQUENCE: 831 Phe Gly Arg Ala Asn Arg Gly Leu 1 5 <210> SEQ ID NO 832 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Polcalcin Phl p 7 (Calcium- binding pollen allergen Phl p 7) (P7) epitope <400> SEQUENCE: 832 Ala Asp Asp Met Glu Arg Ile Phe Lys Arg Phe Asp Thr Asn Gly Asp 1 5 10 15 Gly Lys Ile Ser Leu Ser Glu Leu Thr Asp Ala Leu Arg Thr Leu Gly 20 25 30 Ser Thr Ser Ala 35 <210> SEQ ID NO 833 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne pollen allergen epitope <400> SEQUENCE: 833 Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp 1 5 10 15 Lys Ala Asp Thr Ser Tyr Ser Ala Lys 20 25 <210> SEQ ID NO 834 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 1.4 epitope <400> SEQUENCE: 834 Ala Phe Asn Lys Phe Thr Asp Asn Val Asp Gln Arg 1 5 10 <210> SEQ ID NO 835 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia Pollen allergen Amb a 2 precursor epitope <400> SEQUENCE: 835 Met Pro Arg Cys Arg Phe Gly Phe 1 5 <210> SEQ ID NO 836 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Ambrosia artemisiifolia var. elatior Pollen allergen Amb a 3 epitope <400> SEQUENCE: 836 Cys Asp Ile Lys Asp Pro Ile Arg Leu Glu Pro Gly Gly Pro Asp 1 5 10 15 <210> SEQ ID NO 837 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Betula pendula pollen allergen Bet v 1 epitope <400> SEQUENCE: 837 Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu Leu 1 5 10 15 Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn 20 25 30 <210> SEQ ID NO 838 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poa pratensis Pollen allergen KBG 60 precursor epitope <400> SEQUENCE: 838 Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala Ser 1 5 10 15 Asn Lys Ala Phe 20 <210> SEQ ID NO 839 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 2-A (Lol p II-A) epitope <400> SEQUENCE: 839 Glu Lys Gly Met Arg Asn Val Phe Asp Asp Val Val Pro Ala Asp Phe 1 5 10 15 Lys Val Gly Thr Thr Tyr Lys Pro Glu 20 25 <210> SEQ ID NO 840 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p 3 (Lol p III) epitope <400> SEQUENCE: 840 Lys Gly Gly Met Lys Asn Val Phe Asp Glu Val Ile Pro Thr Ala Phe 1 5 10 15 Thr Val Gly Lys Thr Tyr Thr Pro Glu Tyr Asn 20 25 <210> SEQ ID NO 841 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Lolium perenne Pollen allergen Lol p VA precursor epitope <400> SEQUENCE: 841 Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp 1 5 10 <210> SEQ ID NO 842 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense Pollen allergen Phl p 1 precursor epitope <400> SEQUENCE: 842 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ala Met 1 5 10 15 <210> SEQ ID NO 843 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Zea mays pollen allergen Phl p 11 epitope <400> SEQUENCE: 843 Arg Asp Arg Ala Arg Val Pro Leu 1 5 <210> SEQ ID NO 844 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Phleum pratense pollen allergen Phl pI epitope <400> SEQUENCE: 844 Ile Pro Lys Val Pro Pro Gly Pro Asn Ile Thr Ala 1 5 10 <210> SEQ ID NO 845

<211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Polygalacturonase precursor epitope <400> SEQUENCE: 845 Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg Asp 1 5 10 15 Arg Pro Thr Ala 20 <210> SEQ ID NO 846 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein epitope <400> SEQUENCE: 846 Gln Glu Thr Cys Gly Thr Met Val Arg Ala Leu Met Pro Cys Leu Pro 1 5 10 15 Phe Val Gln Gly Lys Glu Lys Glu Pro Ser Lys Gly Cys Cys 20 25 30 <210> SEQ ID NO 847 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein 2 epitope <400> SEQUENCE: 847 Ala Glu Val Pro Lys Lys Cys Asp Ile Lys 1 5 10 <210> SEQ ID NO 848 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Parietaria judaica Probable non-specific lipid- transfer protein 2 precursor epitope <400> SEQUENCE: 848 Glu Ala Cys Gly Lys Val Val Gln Asp Ile Met Pro Cys Leu His Phe 1 5 10 15 Val Lys Gly Glu Glu Lys Glu Pro Ser Lys Glu Cys Cys Ser 20 25 30 <210> SEQ ID NO 849 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Solanum lycopersicum Probable pectate lyase P59 epitope <400> SEQUENCE: 849 Ala Phe Asn His Phe Gly Lys Arg Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 850 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens profilaggrin epitope <400> SEQUENCE: 850 Gly Gly Gln Gly Ser Arg His Gln Gln Ala Arg 1 5 10 <210> SEQ ID NO 851 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cucumis melo profilin epitope <400> SEQUENCE: 851 Ala Phe Arg Leu Glu Glu Ile Ala Ala Ile 1 5 10 <210> SEQ ID NO 852 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Glycine max Profilin-1 epitope <400> SEQUENCE: 852 Trp Ala Gln Ser Thr Asp Phe Pro Gln Phe Lys Pro Glu Glu Ile Thr 1 5 10 15 Ala Ile Met Asn Asp Phe Asn Glu Pro Gly Ser Leu Ala Pro Thr Gly 20 25 30 Leu Tyr Leu Gly Gly Thr Lys Tyr Met Val Ile Gln Gly Glu Pro Gly 35 40 45 Ala Val Ile Arg Gly Lys Lys Gly 50 55 <210> SEQ ID NO 853 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Pro-hevein precursor epitope <400> SEQUENCE: 853 Glu Gln Cys Gly Arg Gln Ala Gly Gly Lys Leu Cys Pro Asn Asn Leu 1 5 10 15 Cys Cys Ser Gln Trp Gly Trp Cys Gly Ser Thr Asp Glu Tyr Cys Ser 20 25 30 Pro Asp His Asn Cys Gln Ser Asn Cys Lys Asp 35 40 <210> SEQ ID NO 854 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Proliferating cell nuclear antigen epitope <400> SEQUENCE: 854 Leu Lys Tyr Tyr Leu Ala Pro Lys Ile Glu Asp Glu Glu Gly Ser 1 5 10 15 <210> SEQ ID NO 855 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Proline-rich transmembrane protein 2 epitope <400> SEQUENCE: 855 His Ser Glu Ala Glu Thr Gly Pro Pro 1 5 <210> SEQ ID NO 856 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki), isoform CRA_a epitope <400> SEQUENCE: 856 Leu Asp Gly Pro Thr Tyr Lys Arg Arg Leu Asp Glu Cys Glu Glu 1 5 10 15 <210> SEQ ID NO 857 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens protein tyrosine phosphatase-like autoantigen epitope <400> SEQUENCE: 857 Gly Ala His Gly Asp Thr Thr Pro Glu Tyr Gln Asp Leu 1 5 10 <210> SEQ ID NO 858 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens protein-arginine deiminase type-4 epitope <400> SEQUENCE: 858 Ala Phe Phe Pro Asn Met Val Asn Met Leu Val Leu Gly Lys His Leu 1 5 10 15 Gly Ile Pro Lys 20 <210> SEQ ID NO 859 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens proteinase 3 epitope <400> SEQUENCE: 859 Cys Ala Thr Arg Leu Phe Pro Asp Phe Phe Thr Arg Val Ala Leu 1 5 10 15 <210> SEQ ID NO 860 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus persica pru p 1 epitope <400> SEQUENCE: 860 Gly Lys Cys Gly Val Ser Ile Pro Tyr Lys

1 5 10 <210> SEQ ID NO 861 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus dulcis prunin 1 precursor epitope <400> SEQUENCE: 861 Glu Glu Ser Gln Gln Ser Ser Gln Gln Gly Arg Gln Gln Glu Gln 1 5 10 15 <210> SEQ ID NO 862 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Prunus dulcis prunin 2 precursor epitope <400> SEQUENCE: 862 Asp Ser Gln Pro Gln Gln Phe Gln Gln Gln Gln Gln Gln Gln Gln 1 5 10 15 <210> SEQ ID NO 863 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hesperocyparis arizonica putative allergen Cup a 1 epitope <400> SEQUENCE: 863 Trp Arg Phe Thr Arg Asp Ala Phe Thr Asn Gly 1 5 10 <210> SEQ ID NO 864 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Putative HTLV-1-related endogenous sequence (p25) epitope <400> SEQUENCE: 864 Pro Thr Arg Ala Pro Ser Gly Pro Arg Pro Pro 1 5 10 <210> SEQ ID NO 865 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Putative small nuclear ribonucleoprotein polypeptide E-like protein 1 epitope <400> SEQUENCE: 865 Glu Ile His Ser Lys Thr Lys Ser 1 5 <210> SEQ ID NO 866 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor tyrosine-protein kinase rbB-2 precursor epitope <400> SEQUENCE: 866 Pro Glu Ser Phe Asp Gly Asp Pro Ala Ser Asn Thr Ala Pro Leu Gln 1 5 10 15 Pro Glu <210> SEQ ID NO 867 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Receptor-type tyrosine-protein phosphatase-like N precursor epitope <400> SEQUENCE: 867 Lys Glu Arg Leu Ala Ala Leu Gly Pro Glu Gly Ala His 1 5 10 <210> SEQ ID NO 868 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens recombinant IgG2 heavy chain epitope <400> SEQUENCE: 868 Glu Pro Gln Val Val Thr Leu Pro Pro Ser Arg 1 5 10 <210> SEQ ID NO 869 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Replication protein A 32 kDa subunit epitope <400> SEQUENCE: 869 Arg Ser Phe Gln Asn Lys Lys Ser Leu Val Ala Phe Lys Ile Met Pro 1 5 10 15 Leu Glu Asp Met 20 <210> SEQ ID NO 870 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Ribonuclease mitogillin precursor epitope <400> SEQUENCE: 870 Phe Pro Thr Phe Pro Asp Gly His Asp Tyr 1 5 10 <210> SEQ ID NO 871 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ribosomal protein L7 epitope <400> SEQUENCE: 871 Glu Leu Lys Ile Lys Arg Leu Arg Lys Lys Phe Ala Gln Lys Met Leu 1 5 10 15 Arg Lys Ala Arg Arg Lys Leu 20 <210> SEQ ID NO 872 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens ribosomal protein P2 epitope <400> SEQUENCE: 872 Ser Glu Glu Ser Asp Asp Asp Met Gly Phe Gly Leu Phe Asp 1 5 10 <210> SEQ ID NO 873 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Mangifera indica ripening-related pectate lyase epitope <400> SEQUENCE: 873 Ala Tyr Asn His Phe Gly Glu Gly Leu Ile Gln Arg 1 5 10 <210> SEQ ID NO 874 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse)), isoform CRA_c epitope <400> SEQUENCE: 874 Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 1 5 10 15 Gly Gly Gly Ser Ser 20 <210> SEQ ID NO 875 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Ro ribonucleoprotein epitope <400> SEQUENCE: 875 Asp Gly Tyr Val Trp Gln Val Thr Asp Met Asn Arg Leu His Arg Phe 1 5 10 15 Leu Cys Phe Gly Ser 20 <210> SEQ ID NO 876 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Rubber elongation factor protein epitope <400> SEQUENCE: 876 Ala Glu Asp Glu Asp Asn Gln Gln Gly Gln 1 5 10 <210> SEQ ID NO 877 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens S-arrestin epitope

<400> SEQUENCE: 877 Phe Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val 1 5 10 <210> SEQ ID NO 878 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia seed storage protein epitope <400> SEQUENCE: 878 Asp Asp Asn Gly Leu Glu Glu Thr Ile Cys Thr Leu Arg Leu Arg 1 5 10 15 <210> SEQ ID NO 879 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Arachis hypogaea seed storage protein SSP2 epitope <400> SEQUENCE: 879 Cys Gly Leu Arg Ala Pro Gln Arg Cys Asp Leu Asp Val Glu Ser 1 5 10 15 <210> SEQ ID NO 880 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 epitope <400> SEQUENCE: 880 Arg Pro Asn Ala Thr Tyr Ser Leu 1 5 <210> SEQ ID NO 881 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gallus gallus Serum albumin epitope <400> SEQUENCE: 881 Gln Ser Arg Ala Thr Leu Gly Ile 1 5 <210> SEQ ID NO 882 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Bos taurus Serum albumin precursor epitope <400> SEQUENCE: 882 Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn Thr Leu 1 5 10 15 Cys <210> SEQ ID NO 883 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein epitope <400> SEQUENCE: 883 Pro Pro Pro Gly Ile Arg Gly Pro 1 5 <210> SEQ ID NO 884 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein B' epitope <400> SEQUENCE: 884 Pro Pro Pro Gly Met Arg Gly Pro 1 5 <210> SEQ ID NO 885 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein D1 polypeptide epitope <400> SEQUENCE: 885 Lys Met Thr Leu Lys Asn Arg Glu Pro Val Gln Leu Glu Thr Leu Ser 1 5 10 15 Ile Arg Gly Asn Arg Ile Arg Tyr 20 <210> SEQ ID NO 886 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein D2 isoform 1 epitope <400> SEQUENCE: 886 Gly Lys Lys Lys Ser Lys Pro Val Asn Lys Asp Arg Tyr Ile Ser Lys 1 5 10 15 Met Phe Leu Arg Gly Asp Ser 20 <210> SEQ ID NO 887 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein F epitope <400> SEQUENCE: 887 Glu Glu Glu Glu Asp Gly Glu Met 1 5 <210> SEQ ID NO 888 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein G epitope <400> SEQUENCE: 888 Trp Ser Lys Ala His Pro Pro Glu 1 5 <210> SEQ ID NO 889 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide A epitope <400> SEQUENCE: 889 Ala Met Lys Ile Ser Phe Ala Lys Lys 1 5 <210> SEQ ID NO 890 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide B epitope <400> SEQUENCE: 890 Pro Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 891 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide B/B' isoform B epitope <400> SEQUENCE: 891 Met Gly Arg Gly Ala Pro Pro Pro Gly Met Met Gly 1 5 10 <210> SEQ ID NO 892 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide C, isoform CRA_b epitope <400> SEQUENCE: 892 Ala Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 893 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide D3 epitope <400> SEQUENCE: 893 Ala Ala Arg Gly Arg Gly Arg Gly Met Gly Arg Gly Asn Ile Phe 1 5 10 15 <210> SEQ ID NO 894 <211> LENGTH: 12

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens small nuclear ribonucleoprotein polypeptide N variant epitope <400> SEQUENCE: 894 Val Gly Arg Ala Thr Pro Pro Pro Gly Ile Met Ala 1 5 10 <210> SEQ ID NO 895 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein Sm D1 epitope <400> SEQUENCE: 895 Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg 1 5 10 15 Gly Arg Gly Gly Pro Arg Arg 20 <210> SEQ ID NO 896 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein Sm D2 epitope <400> SEQUENCE: 896 Glu Glu Leu Gln Lys Arg Glu Glu 1 5 <210> SEQ ID NO 897 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Small nuclear ribonucleoprotein- associated proteins B and B' epitope <400> SEQUENCE: 897 Arg Gly Val Gly Gly Pro Ser Gln 1 5 <210> SEQ ID NO 898 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Hevea brasiliensis Small rubber particle protein epitope <400> SEQUENCE: 898 Ala Glu Glu Val Glu Glu Glu Arg Leu Lys 1 5 10 <210> SEQ ID NO 899 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Smoothelin epitope <400> SEQUENCE: 899 Gly Ser Thr Met Met Gln Thr Lys Thr Phe Ser Ser Ser Ser Ser Ser 1 5 10 15 Lys Lys Met Gly 20 <210> SEQ ID NO 900 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens snRNP polypeptide B epitope <400> SEQUENCE: 900 Pro Pro Gly Met Arg Pro Pro Met Gly Pro Met Gly Ile Pro Pro 1 5 10 15 <210> SEQ ID NO 901 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens spectrin, alpha, non-erythrocytic 1 (alpha-fodrin), isoform CRA_e epitope <400> SEQUENCE: 901 Phe Gln Phe Phe Gln Arg Asp Ala Glu Glu Leu Glu Lys Trp 1 5 10 <210> SEQ ID NO 902 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens steroid 17-alpha-hydroxylase/17,20 lyase epitope <400> SEQUENCE: 902 Glu Val Pro Asp Asp Gly Gln Leu Pro Ser Leu Glu Gly Ile Pro Lys 1 5 10 15 Val Val Phe Leu Ile Asp Ser Phe Lys Val Lys Ile Lys Val Arg Gln 20 25 30 Ala Trp Arg Glu Ala Gln Ala Glu Gly Ser Thr 35 40 <210> SEQ ID NO 903 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Sucrase-isomaltase, intestinal epitope <400> SEQUENCE: 903 Asp Phe Thr Tyr Asp Gln Val Ala Phe Asn Gly Leu Pro Gln Phe 1 5 10 15 <210> SEQ ID NO 904 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Cryptomeria japonica Sugi basic protein precursor epitope <400> SEQUENCE: 904 Asp Ala Leu Thr Leu Arg Thr Ala Thr Asn Ile Trp 1 5 10 <210> SEQ ID NO 905 <211> LENGTH: 48 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Aspergillus fumigatus Superoxide dismutase epitope <400> SEQUENCE: 905 Tyr Thr Leu Pro Pro Leu Pro Tyr Pro Tyr Asp Ala Leu Gln Pro Tyr 1 5 10 15 Ile Ser Gln Gln Ile Met Glu Leu His His Lys Lys His His Gln Thr 20 25 30 Tyr Val Asn Gly Leu Asn Ala Ala Leu Glu Ala Gln Lys Lys Ala Ala 35 40 45 <210> SEQ ID NO 906 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T cell receptor beta variable 20 epitope <400> SEQUENCE: 906 Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe 1 5 10 <210> SEQ ID NO 907 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T cell receptor beta variable 5 epitope <400> SEQUENCE: 907 Ala Leu Gly Gln Gly Pro Gln Phe Ile Phe Gln Tyr Tyr Glu Glu Glu 1 5 10 15 Glu Arg <210> SEQ ID NO 908 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Tax1-binding protein 1 epitope <400> SEQUENCE: 908 Glu Phe Lys Lys Arg Phe Ser Asp Ala Thr Ser Lys Ala His Gln 1 5 10 15 <210> SEQ ID NO 909 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain epitope <400> SEQUENCE: 909 Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu 1 5 10 15 <210> SEQ ID NO 910

<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain C region epitope <400> SEQUENCE: 910 Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln Val 1 5 10 15 <210> SEQ ID NO 911 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta chain V region YT35 epitope <400> SEQUENCE: 911 Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr 1 5 10 15 <210> SEQ ID NO 912 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens T-cell receptor beta-chain (V1-D- J-C) precursor epitope <400> SEQUENCE: 912 Ser Pro Arg Ser Gly Asp Leu Ser Val Tyr 1 5 10 <210> SEQ ID NO 913 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TCR V-beta 6.1 epitope <400> SEQUENCE: 913 Leu Gly Gln Gly Pro Glu Phe Leu Ile Tyr Phe Gln Gly Thr Gly Ala 1 5 10 15 Ala Asp Asp Ser Gly 20 <210> SEQ ID NO 914 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TCR V-beta 6.3 epitope <400> SEQUENCE: 914 Asp Pro Ile Ser Gly His Val Ser Leu Phe 1 5 10 <210> SEQ ID NO 915 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyroglobulin epitope <400> SEQUENCE: 915 Pro Pro Ala Arg Ala Leu Lys Arg Ser Leu Trp Val Glu Val Asp Leu 1 5 10 15 Leu Ile Gly Ser 20 <210> SEQ ID NO 916 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyroid peroxidase epitope <400> SEQUENCE: 916 Gly Leu Pro Arg Leu Glu Thr Pro Ala Asp Leu Ser Thr Ala Ile Ala 1 5 10 15 Ser Arg Ser <210> SEQ ID NO 917 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens thyroid stimulating hormone receptor epitope <400> SEQUENCE: 917 Glu Ile Ile Gly Phe Gly Gln Glu Leu Lys Asn Pro Gln Glu Glu 1 5 10 15 <210> SEQ ID NO 918 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens thyroid stimulating hormone receptor variant epitope <400> SEQUENCE: 918 Glu Glu Gln Glu Asp Glu Ile Ile Gly Phe Gly Gln Glu Leu Lys Asn 1 5 10 15 <210> SEQ ID NO 919 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Thyrotropin receptor epitope <400> SEQUENCE: 919 Gly Gln Glu Leu Lys Asn Pro Gln Glu Glu Thr Leu Gln Ala Phe Asp 1 5 10 15 Ser His Tyr Asp 20 <210> SEQ ID NO 920 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens transaldolase 1 epitope <400> SEQUENCE: 920 Ala Ala Ala Gln Met Pro Ala Tyr Gln Glu Leu Val Glu Glu Ala 1 5 10 15 <210> SEQ ID NO 921 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Trichophyton rubrum Tri r 2 allergen epitope <400> SEQUENCE: 921 Asp Cys Asn Gly His Gly Thr His Val Ala Gly Thr Val Gly Gly Thr 1 5 10 15 Lys Tyr Gly Leu 20 <210> SEQ ID NO 922 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens trinucleotide repeat containing 6A, isoform CRA_b epitope <400> SEQUENCE: 922 Ala Phe Leu Ser Val Asp His Leu Gly Gly Gly Gly Glu Ser Met 1 5 10 15 <210> SEQ ID NO 923 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens trinucleotide repeat containing 6A, isoform CRA_c epitope <400> SEQUENCE: 923 Trp Gly Ser Ser Ser Val Gly Pro Gln Ala Leu Ser Lys Ser Gly 1 5 10 15 <210> SEQ ID NO 924 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tripartite motif-containing 67 epitope <400> SEQUENCE: 924 Leu Gly Gly Gly Ala Gly Gly Gly Gly Asp His Ala Asp Lys Leu Ser 1 5 10 15 Leu Tyr Ser Glu Thr Asp Ser Gly Tyr Gly Ser Tyr Thr Pro Ser Leu 20 25 30 Lys Ser Pro Asn 35 <210> SEQ ID NO 925 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum Triticum aestivum proteins epitope <400> SEQUENCE: 925 Leu Pro Gln Gln Gln Ile Pro Gln Gln Pro 1 5 10 <210> SEQ ID NO 926 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Penaeus tropomyosin epitope <400> SEQUENCE: 926

Phe Leu Ala Glu Glu Ala Asp Arg Lys 1 5 <210> SEQ ID NO 927 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens TSHR protein epitope <400> SEQUENCE: 927 Cys His Gln Glu Glu Asp Phe Arg Val Thr Cys Lys Asp Ile Gln Arg 1 5 10 15 Ile Pro Ser Leu 20 <210> SEQ ID NO 928 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tubulin beta-6 chain epitope <400> SEQUENCE: 928 Ala Ala Cys Asp Pro Arg His Gly Arg Tyr Leu Thr Val Ala 1 5 10 <210> SEQ ID NO 929 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens tumor necrosis factor ligand superfamily member 6 epitope <400> SEQUENCE: 929 Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu 1 5 10 <210> SEQ ID NO 930 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Paralichthys olivaceus type 1 collagen alpha 2 epitope <400> SEQUENCE: 930 Met Lys Gly Leu Arg Gly His Pro Gly Leu Gln Gly Met Pro Gly Pro 1 5 10 15 Ser Gly Pro Ser 20 <210> SEQ ID NO 931 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Triticum aestivum type 1 non-specific lipid transfer protein precursor epitope <400> SEQUENCE: 931 Ala Arg Gly Thr Pro Leu Lys Cys Gly Val 1 5 10 <210> SEQ ID NO 932 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa epitope <400> SEQUENCE: 932 Glu Arg Lys Arg Arg 1 5 <210> SEQ ID NO 933 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein A epitope <400> SEQUENCE: 933 Ala Gly Ala Ala Arg Asp Ala Leu Gln Gly Phe Lys Ile Thr Gln Asn 1 5 10 15 Asn Ala Met Lys Ile Ser Phe Ala Lys Lys 20 25 <210> SEQ ID NO 934 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens U1 small nuclear ribonucleoprotein C epitope <400> SEQUENCE: 934 Pro Ala Pro Gly Met Arg Pro Pro 1 5 <210> SEQ ID NO 935 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anisakis simplex UA3-recognized allergen epitope <400> SEQUENCE: 935 Met Cys Gln Cys Val Gln Lys Tyr Gly Thr Glu Phe Cys Lys Lys Arg 1 5 10 15 Leu Ala <210> SEQ ID NO 936 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens unnamed protein product epitope <400> SEQUENCE: 936 Ala Phe Gln Gln Gly Lys Ile Pro Pro 1 5 <210> SEQ ID NO 937 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans nigra vicilin seed storage protein epitope <400> SEQUENCE: 937 Ser Phe Glu Asp Gln Gly Arg Arg 1 5 <210> SEQ ID NO 938 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Anacardium occidentale Vicilin-like protein epitope <400> SEQUENCE: 938 Ala Ile Met Gly Pro Pro Thr Lys Phe Ser Phe Ser Leu Phe Leu 1 5 10 15 <210> SEQ ID NO 939 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Juglans regia vicilin-like protein precursor epitope <400> SEQUENCE: 939 Asp Gln Arg Ser Gln Glu Glu Arg Glu Arg 1 5 10 <210> SEQ ID NO 940 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens Vimentin epitope <400> SEQUENCE: 940 Arg Leu Arg Ser Ser Val Pro Gly Val Arg Leu Leu Gln Asp Ser Val 1 5 10 15 Asp Phe Ser Leu 20 <210> SEQ ID NO 941 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens von Willebrand factor epitope <400> SEQUENCE: 941 His Cys Gln Ile Cys His Cys Asp Val Val Asn Leu Thr Cys Glu 1 5 10 15 <210> SEQ ID NO 942 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens von Willebrand factor-cleaving protease precursor epitope <400> SEQUENCE: 942 Pro Ser His Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala 1 5 10 15 Val Ser Ser Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro Pro 20 25 30 Ser Pro Gly Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg 35 40 45

<210> SEQ ID NO 943 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Homo sapiens XRCC4 protein epitope <400> SEQUENCE: 943 Val Ser Lys Asp Asp Ser Ile Ile Ser Ser Leu Asp Val Thr Asp 1 5 10 15

Claims

1. A composition comprising: (i) a first population of synthetic nanocarriers coupled to an immunosuppressant, and (ii) an APC presentable antigen.

2-26. (canceled)

27. A dosage form comprising the composition of claim 1.

28. A method comprising administering the dosage form of claim 27 to a subject.

29-37. (canceled)

38. A composition as defined in claim 1 for use in therapy or prophylaxis.

39-43. (canceled)

44. Use of a composition as defined in claim 1 for the manufacture of a medicament.